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ABSTRACT 
 
The aim of this thesis was to investigate the role of outpatient hysteroscopy in modern 
gynaecological care by conducting a series of systematic reviews and meta-analyses to 
examine how the procedure can be optimised to reduce pain and by performing a cost 
effectiveness analysis.  
 
The systematic reviews concluded that women undergoing outpatient hysteroscopy should 
take simple analgesia beforehand and that the hysteroscopist should adopt a vaginoscopic 
approach using a small diameter, rigid hysteroscope and normal saline as the distension 
medium. If dilatation of the cervix is required this should be done under a paracervical block. 
These findings were incorporated into a clinical guideline and the quality of the evidence that 
the reviews provided was assessed using the SIGN and GRADE methods. A comparison of 
the assessments found that they gave varying estimates of the quality of evidence and that 
neither offered a perfect solution to the assessment of evidence quality when writing clinical 
guidance. 
 
The economic analysis found that initial testing with outpatient hysteroscopy was the most 
cost-effective testing strategy for investigation of heavy menstrual bleeding when compared 
to other diagnostic tests, regardless of a woman’s wish for future fertility or prior treatment 
with a levonorgestrel intrauterine system.  
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CHAPTER 1 
 
THESIS OVERVIEW AND OBJECTIVES 
 
In recent years the ‘classical’ inpatient hysteroscopy, which allows gynaecologists to visualise the 
lining of the womb has evolved into a diagnostic and therapeutic outpatient procedure. The Royal 
College of Obstetricians and Gynaecologists (RCOG) has published standards of care stating that 
‘outpatient-based diagnostic services should be available in the community and hospital setting, 
including operative procedures for carefully selected cases’(1). For this to be possible, outpatient 
hysteroscopy (OPH) needs to be acceptable to patients and to be cost-effective when compared to 
alternative outpatient diagnostic testing strategies such as transvaginal ultrasound scan (TVS) and 
global endometrial biopsy (EBx). 
 
The aim of this thesis was to investigate the role of outpatient hysteroscopy in modern 
gynaecological care. There are two themes within the thesis. The first examines how outpatient 
hysteroscopy can be optimised using systematic reviews. A clinical guideline was then produced 
to recommend ‘best-practice’ for outpatient hysteroscopy. The quality of the evidence behind the 
guideline was then graded and examined using two guideline methods.  
 
The second theme within the thesis looks at the cost-effectiveness of outpatient hysteroscopy and 
other diagnostic tests in the investigation of heavy menstrual bleeding. The aim of this analysis is 
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to determine the most cost-effective diagnostic strategy for investigating women who present to 
secondary care with HMB. 
 
Project objectives 
 
The thesis objectives are as follows: 
 to examine different aspects of outpatient hysteroscopy and perform systematic reviews to 
determine how best they can be adapted to make the procedure as tolerable as possible for 
patients. 
 to use the data from the systematic reviews to write a ‘Green-top’ style guideline and a 
compare the evidence gradings produced with those allocated by the GRADE guideline 
process. 
 to examine strategies for investigating HMB to see if outpatient hysteroscopy is a cost-
effective option when compared to other outpatient diagnostic tests.  
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CHAPTER 2 
 
INTRODUCTION TO A SERIES OF SYSTEMATIC REVIEWS 
AND META-ANALYSES WHICH INVESTIGATE PAIN 
REDUCTION IN OUTPATIENT HYSTEROSCOPY 
 
Diagnostic and operative outpatient hysteroscopy is feasible, safe and acceptable to women (2-5), 
however, the outpatient setting can present many challenges, with the conscious patient being less 
forgiving of induced discomfort (6). To examine how outpatient hysteroscopy can be optimised 
to reduce pain, different aspects of the procedure can be examined and the available alternative 
options evaluated.  For example, is using normal saline as a distension medium less painful than 
using carbon dioxide? What method of anaesthetising the cervix is the least painful? Can the 
procedure be performed without passing a vaginal speculum?  
 
The obvious method of controlling pain is to use pharmaceuticals, whether they are anaesthetics 
or analgesics. Pain from the body of the uterus is relayed by T12 to L2 nerve roots which are not 
accessible vaginally (7) and thus cannot be anaesthetised, however the splanchnic plexus nerves 
(S2-S4) (7) which sense pain from the cervix and lower uterus can be anaesthetised by 
administering local anaesthetic to the cervix. Vasovagal reactions during outpatient hysteroscopy 
are reported to occur in 20% of women in the general population (8). Nerve stimulation during 
passage of instruments through the cervical canal has been suggested as the cause of vasovagal 
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episodes. It has been theorised that blocking the nerves with local anaesthetic may reduce the 
incidence of attacks (9-11) but there is also a study which has shown conflicting results (12). 
Individual studies examining the effect of local anaesthetics are often imprecise and hence 
provide contradictory results (13). Local anaesthetic can be applied as an injection directly into 
the body of the cervix (intracervical or direct cervical block) or to the surrounding tissues 
(paracervical block), or topically to the uterine cavity (transcervical application) or the ectocervix 
(topical application), these methods are shown in Figure 2.1.  
 
Figure 2.1 Diagram showing the different methods of local anaesthetic administration for 
outpatient hysteroscopy 
 
A recent review (14) examined the use of paracervical injection for cervical dilatation and uterine 
interventions in a variety of obstetric and gynaecological procedures, however, there is no 
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comprehensive review evaluating comparative effectiveness of  the whole range of local 
anaesthetic modalities for specific procedures.  
 
Analgesics block pain receptors and prevent pain signals being relayed to the central nervous 
system. They can be administered before, during or after procedures to reduce pain. Opiate and 
non-steroidal inflammatory drugs (NSAID’s) have been used to reduce pain during outpatient 
hysteroscopy as has conscious sedation (6), however no guidance exists on use of analgesics for 
outpatient hysteroscopy, resulting in eclectic practice.  
 
A compromise between general anaesthesia and analgesics might be to use conscious sedation 
(i.e. depression of the central nervous system enabling treatment to be carried out, but during 
which verbal contact with the patient is maintained’ (15)) which is widely used in endoscopic 
procedures of the gastrointestinal system and in dentistry to make unpleasant interventions more 
acceptable but it is less commonly employed in outpatient hysteroscopy. The Royal College of 
Anaesthetists has issued guidance on the safe use of conscious sedation by other medical 
specialties, recommending that a designated trained staff member be responsible for monitoring 
the patient throughout the sedation and that resuscitation facilities be available (15). This has 
obvious cost implications on staffing, equipment and recovery areas. To justify these costs there 
would need to be a large added benefit of using conscious sedation over less compromising 
medication.  
 
A final group of drugs which may alleviate discomfort during outpatient hysteroscopy are those 
which can dilate the cervix and potentially aid the passage of the hysteroscope into the uterine 
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cavity.  Hysteroscopy is traditionally an inpatient procedure that requires dilatation of the cervix 
so that large diameter instruments can be passed into the uterine cavity. Blind mechanical 
dilatation risks perforation of the uterus, especially where the cervical canal provides more 
resistance i.e. postmenopausal or nulliparous women or those who have had previous cervical 
surgery or caesarean section (16;17). Studies examining the use of pharmaceutical 
(antiprogestogens, prostaglandins) and mechanical (laminaria) dilatation of the cervix prior to 
inpatient hysteroscopy under general anaesthesia have produced conflicting results regarding 
their effect on dilatation and trauma during the procedure (18-22).  
 
Prostaglandins are commonly used in gynaecology for inducing dilatation of the cervix for 
termination of pregnancy and for removing retained products of conception (23). The natural 
progression from this has been for clinicians to use prostaglandins in non-pregnant women to 
dilate the cervix and ease access to the uterine cavity for transcervical procedures (24). However, 
the evidence is unclear as to whether the dilatory effect is apparent in a non-pregnant cervix and 
prostaglandins have unpleasant side effects (nausea, vomiting and excessive bleeding) (25). 
Similarly antiprogestogens have also been used to soften the cervix (26) as well as dilatory 
materials which when inserted into the cervical canal absorb water and cause a mechanical 
dilatation (18;27;28). Again these methods have associated side effects .Thus any benefit may 
become outweighed by the associated adverse effects. The technological advances that have 
resulted in miniaturisation of endoscopic instruments have done away with the need for routine, 
painful cervical dilatation. However, a significant minority of women undergoing an outpatient 
procedure will require cervical dilatation with the risks of excessive pain and potential trauma to 
the genital tract. 
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As well as investigating pharmaceuticals that can play a role in pain there are technical aspects of 
the outpatient hysteroscopy procedure that can be adapted to be less painful. The first method 
explored is vaginoscopy, also known as the ‘no-touch’ technique which is an alternative method 
for performing hysteroscopy without the need for a vaginal speculum to view the cervix (29) or 
cervical instrumentation to grasp and steady it (6). The hysteroscope is inserted into the vagina 
which is distended with the selected medium, the external cervical os identified and the 
hysteroscope steered into the cervical canal so that the hysteroscopy can be performed. 
Distension of the vagina to aid identification of the cervix can be facilitated by a Trendelenburg 
tilt and manual closure of the labia minora. Individual papers have suggested that use of the 
vaginoscopic technique is feasible and may reduce the pain of outpatient hysteroscopy (30-33) 
but no clear, collated summaries of evidence exist.  
 
Once the cervix is traversed and the cavity entered a distending medium needs to be instilled to 
visualise the uterine cavity. A variety of fluid (normal saline, water, sorbitol, dextran and glycine 
(34-37)) and gaseous (carbon dioxide (38;39)) media have been used. As with any hollow 
viscous, distension of the uterine cavity causes pain (irritation of T10 –L2 nerve roots). 
Moreover, spilling of distension medium into the abdominal cavity can be associated with 
phrenic (C3-5) nerve irritation and referred pain to the shoulder tip and cervical manipulation 
may cause vagal stimulation resulting in fainting episodes (6). Image quality is an important 
consideration and may vary according to medium used.  
 
The final technical aspect of the procedure to explore is the type of hysteroscope used for the 
procedure. Flexible endoscopes are used to investigate the gastrointestinal and respiratory tracts 
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as they allow the operator to negotiate the convoluted anatomy. Flexible hysteroscopes are able to 
exploit this advantage when negotiating the cervical canal and viewing the cornuae (40). Studies 
have shown that outpatient flexible hysteroscopy is well tolerated (41;42) so this technique was 
compared to outpatient hysteroscopy using rigid hysteroscopes. 
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CHAPTER 3 
 
METHODS FOR THE SEVEN SYSTEMATIC REVIEWS AND 
META-ANALYSES WHICH INVESTIGATE PAIN REDUCTION 
IN OUTPATIENT HYSTEROSCOPY 
 
Topics for investigation 
 
Seven different aspects of outpatient hysteroscopy were evaluated: 
1. the use of local anaesthesia 
2. the use of analgesics 
3. the use of conscious sedation 
4. the use of cervical preparation 
5. the vaginoscopic approach 
6. different distension media 
7. the type of hysteroscope 
All of the systematic reviews were conducted prospectively, devising a protocol based upon 
widely documented methods (43;44). 
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Data Sources, Searches and Study Selection 
 
A comprehensive literature search was conducted for each of the seven topics to identify relevant 
studies. The databases searched included Medline (from 1950 to September 2008), EMBASE 
(from 1980 to September 2008), CINAHL (from 1981 to September 2008) and the Cochrane 
library. The search terms used are shown in Table 3.1 and the full search strategies are shown in 
Appendix 1. There were no limits or filters placed on the searches to ensure maximal sensitivity.  
The reference sections of selected original articles were checked for relevant papers that had not 
already been retrieved by the database searches. The contents lists from two specialist journals 
(Gynaecological Surgery and The Journal of Minimally Invasive Gynecology) from November 
1993 until 2008 were scrutinised for relevant studies.  
 
The titles and abstracts from the electronic literature searches were reviewed in duplicate (see 
acknowledgements). The citations were selected if they appeared to fulfil the selection criteria. 
The selection criteria for each systematic review are shown in Table 3.1. 
 
The complete manuscripts of selected citations were then reviewed in full to reach the final 
decision on inclusion or exclusion.  Studies were excluded if numerical data assessing pain were 
not presented explicitly (e.g. some papers displayed results graphically such that the mean pain 
scores could only be estimated from the graph and given this ambiguity were excluded from 
further analysis). An attempt was made to contact authors for missing data but in some instances 
this was not possible (11) and in others no reply was received (45-47). When duplicate data were 
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published, only the most up to date, larger series were included. Any disagreements about study 
eligibility were resolved by consensus. Inter-rater agreement for study selection was assessed 
using the kappa statistic (48)
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Table 3.1. Search terms and selection criteria for the seven systematic reviews and meta-analyses which investigate pain 
reduction in outpatient hysteroscopy 
Topic Search terms Study selection criteria 
 
 Medline, 
EMBASE, 
CINAHL 
 
Cochrane Library Population Intervention Outcome Study Design 
Local anaesthesia ‘hysteroscopy’, 
‘vaginoscopy’, 
‘local anaesthetic’ 
and associated 
Medical Subject 
Headings 
‘hysteroscopy’, 
‘anaesthetic’ 
Women 
undergoing 
diagnostic or 
operative 
hysteroscopy in the 
outpatient setting 
i.e. without general 
anaesthesia 
Use of local 
anaesthetic for pain 
relief during the 
procedure (e.g. 
intracervical block, 
paracervical block, 
local anaesthetic 
instilled into the 
cavity or applied to 
the ectocervix - see 
figure 2.1), 
compared to no 
intervention, 
placebo, oral 
analgesics or 
conscious sedation. 
 
Assessment of pain 
(primary outcome) 
and vasovagal 
episodes 
(secondary 
outcome) 
associated with the 
procedure 
Randomised 
controlled trials 
Analgesia ‘hysteroscopy’, 
‘vaginoscopy’, 
‘analges*and 
associated Medical 
Subject Headings  
‘hysteroscopy’, 
‘analgesia’ 
As above. Use of analgesics 
for pain relief 
during the 
procedure 
compared to no 
intervention or 
placebo. 
 
Assessment of pain 
associated with the 
procedure (primary 
outcome) and 
medication side 
effects (secondary 
outcome). 
Randomised 
controlled trials 
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Table 3.1 continued 
Topic Search terms Study selection criteria 
 
 Medline, 
EMBASE, 
CINAHL 
 
Cochrane Library Population Intervention Outcome Study Design 
Conscious sedation ‘hysteroscopy’, 
‘vaginoscopy’, 
‘conscious 
sedation’, 
‘sedative’, 
‘sedati*’, ‘pain’ 
and associated 
Medical Subject 
Headings 
‘hysteroscopy’, 
‘sedation’ 
As above Use of conscious 
sedation for pain 
relief during the 
procedure 
compared to no 
intervention or 
placebo. 
Assessment of pain 
associated with the 
procedure (primary 
outcome) and 
medication side 
effects (secondary 
outcome). 
Randomised 
controlled trials 
 
Cervical 
preparation 
 
‘hysteroscopy’, 
‘vaginoscopy’, 
‘cervical ripening’, 
’laminaria’, 
’progest*’, 
‘prostaglandin’, 
‘oestrogen’ 
‘cervical 
preparation’ and 
associated Medical 
Subject Headings 
 
‘hysteroscopy’, 
‘cervical’ 
 
As above 
 
Use of cervical 
preparation prior to 
the procedure, 
compared to no 
intervention, or 
placebo. 
 
 
Assessment of pain 
associated with the 
procedure. 
 
Randomised 
controlled trials 
 
Vaginoscopic 
approach 
 
‘hysteroscopy’, 
‘vaginoscopy’, 
‘vaginoscop*’, ‘no-
touch’ and 
associated Medical 
Subject Headings  
 
‘hysteroscopy’, 
‘vaginoscopy’, 
‘vaginoscopic’, 
‘no-touch’ 
 
As above 
 
Comparison of the 
vaginoscopic 
technique versus 
hysteroscopy using 
a vaginal 
speculum. 
 
Assessment of pain 
associated with the 
procedure  and 
feasibility 
(secondary 
outcome). 
 
Randomised 
controlled trials 
* is used in the search terms to identify all possible suffixes e.g. analges* will identify analgesia, analgesic, and analgesics  
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Table 3.1 continued      
Topic Search terms Study selection criteria 
 
 Medline, 
EMBASE, 
CINAHL 
 
Cochrane Library Population Intervention Outcome Study Design 
 
Distension media 
 
‘hysteroscopy’, 
‘vaginoscopy’, 
‘vaginoscop*’, 
‘(uter* AND 
disten*)’, 
‘distension media’, 
‘sodium chloride’, 
‘normal saline’, 
carbon dioxide’, 
‘dextran’, 
‘mannitol’ and 
associated Medical 
Subject Headings 
 
‘hysteroscopy’, 
‘distension’ 
 
As above 
 
Comparison of the 
use of carbon 
dioxide versus 
another distending 
medium for the 
outpatient 
hysteroscopy. 
 
Assessment of pain 
associated with the 
procedure. 
 
 
Randomised 
controlled trials 
 
Type of 
hysteroscope 
 
‘hysteroscopy’, 
‘vaginoscopy’, 
‘flexible’, ‘rigid’, 
‘pain’ and 
associated Medical 
Subject Headings 
 
 
‘hysteroscopy’, 
‘flexible’, ‘rigid’ 
 
As above 
 
Comparison of the 
use of flexible 
versus rigid 
hysteroscope 
 
Assessment of pain 
associated with the 
procedure. 
 
 
Randomised 
controlled trials 
* is used in the search terms to identify all possible suffixes e.g. analges* will identify analgesia, analgesic, and analgesics 
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Data extraction 
 
For each systematic review data were extracted from the selected studies using a piloted data 
extraction form (see Appendix 2 for an example). Data were extracted independently by two 
reviewers.  Data were collected from each trial for study quality (the confidence that the trial 
design, conduct, and analysis has minimized or avoided biases in its treatment comparisons) (49), 
the intervention, technical aspects of the outpatient hysteroscopy, assessment of pain and for the 
relevant secondary outcomes (feasibility, vasovagal episodes, effectiveness, side-effects).  
 
Jadad’s scoring method (Appendix 3) which allowed a quality score on a 5-point scale to be 
calculated (50;51) was used to assess the quality of the selected studies in the systematic reviews 
of local anaesthetic, analgesia, conscious sedation and cervical preparation. Papers that scored 
more than three points were considered to be of high quality.  For the systematic reviews of 
vaginoscopy, distension media and type of hysteroscope the scoring system was adapted to allow 
for the fact that blinding would not have been possible in the studies. 
 
Further information regarding the seven different topics reviewed is detailed in the sections 
below.  
 
Local anaesthetic 
Table 3.2 shows the quality assessment of the studies selected for use in the systematic review of 
the use of local anaesthetic for outpatient hysteroscopy. 
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Table 3.2. Methodological quality assessment of the studies included in the systematic 
review of use of local anaesthetic for outpatient hysteroscopy 
Study Randomised ±1 Double 
blind? 
±1 Withdrawals  
and dropouts 
Total Quality (>3 = 
high) 
 
Al-sunaidi(52) 1 1 0 0 1 3 
 
Low 
 
Bellati(53) 1 0 0 0 1 2 
 
Low 
 
Broadbent(54) 1 1 1 1 1 5 
 
High 
 
Cicinelli 1997 (9) 1 1 1 1 1 5 
 
High 
 
Cicinelli 1998 (10) 1 1 1 1 1 5 
 
High 
 
Costello(55) 1 1 1 1 1 5 
 
High 
 
Davies (56) 1 1 1 1 1 5 
 
High 
 
Esteve (57) 1 0 1 1 1 4 High 
Finikiotis (58) 1 -1 0 0 1 1 Low 
 
Giorda (59) 1 1 0 0 1 3 
 
Low 
 
Guida (60) 1 1 0 0 1 3 
 
Low 
 
Kabli (61) 1 1 0 0 1 3 
 
Low 
 
Lau 1999(12) 1 1 1 1 1 5 
 
High 
 
Lau 2000 (62) 1 1 1 1 1 5 
 
High 
 
Makris (63)
 
1 0 0 0 1 2 
 
Low 
 
Sagiv (33) 1 1 0 0 1 3 Low 
 
Shankar(64) 1 1 0 0 1 3 Low 
Soriano(65) 1 1 1 1 1 5 
 
High 
 
Vercellini (66) 1 1 0 0 1 3 
 
Low 
 
Wong (67) 1 1 1 1 1 5 
 
High 
        
See Appendix 3 for explanation of scoring method. 
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Studies varied in how pain was assessed.  Some studies gave an overall pain score for the 
procedure. Others scored each of the steps separately (i.e. tenaculum application, administration 
of anaesthetic or placebo, insertion of the scope, inspection of uterine cavity, during the biopsy 
and at intervals after the end of the procedure). When an overall pain score was given, this was 
used for the meta-analysis but when the individual steps were scored, and no overall score was 
given, the score relating to inspection of the uterine cavity was deemed most appropriate to use 
rather than the scores for other aspects of the procedure (e.g. cervical dilatation, endometrial 
biopsy). When scores were only given after the procedure, the most immediate score was used. 
Vasovagal reactions during outpatient hysteroscopy are reported to occur in 20% of women in the 
general population (8). Parasympathetic nerve stimulation during passage of instruments through 
the cervical canal has been suggested as the cause of vasovagal episodes. To examine the 
incidence of vasovagal episodes in relation to use of local anaesthetics, data were extracted as 2 x 
2 contingency tables (occurrence versus non-occurrence). 
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Analgesia 
Table 3.3 shows the quality assessment of studies that were selected for use in the systematic 
review of analgesia for pain control during outpatient hysteroscopy. 
 
Table 3.3 Methodological quality assessment of the studies included in the systematic 
review analgesia for pain control during outpatient hysteroscopy  
Study Randomised ±1 Double 
blind? 
±1 Withdrawals  
and dropouts 
Total Quality (>3 = high) 
 
Bellati (53) 1 0 0 0 1 2 
 
Low 
 
Caligiani (68) 1 0 0 0 1 2 
 
Low 
 
Floris (45) 1 1 1 1 1 5 
 
High 
 
Lin (69) 1 1 0 0 1 3 
 
Low 
 
Nagele (46) 1 0 1 1 1 4 
 
High 
 
Tam (70) 1 1 1 1 1 5 
 
High 
See Appendix 3 for explanation of scoring method. 
 
Again, studies varied in how pain was assessed so the same rules were applied to this review as 
for the local anaesthetic review (see page 17). 
 
Side effects are an important consideration when administering drugs and it must be established 
whether the benefit of the medication outweighs any adverse effects experienced by the patient, 
hence the incidence of reported side effects was collected. 
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Conscious sedation 
Only one study was selected from the abstracts of studies which looked at the use of conscious 
sedation for outpatient hysteroscopy. This was assessed as a low quality study (see Table 3.4). 
 
Table 3.4 Methodological quality assessment of the studies included in the systematic 
review of conscious sedation for pain control during outpatient hysteroscopy  
Study Randomised ±1 Double 
blind? 
±1 Withdrawals  
and dropouts 
Total Quality (>3 = high) 
Guida (60) 1 1 0 0 1 3 Low 
See Appendix 3 for explanation of scoring method. 
 
Cervical preparation 
The quality assessment of the studies selected for the systematic review of cervical preparation is 
detailed in .Table 3.5. 
 
Table 3.5 Methodological quality assessment of the studies included in the systematic 
review of the effect of cervical preparation on pain during outpatient hysteroscopy  
Study Randomised ±1 
Double 
blind? 
±1 
Withdrawals  and 
dropouts 
Total 
 
Quality (>3 = high) 
Atay (71) 1 0 0 0 1 2 Low 
Ben-Chetrit (72) 1 1 1 1 1 5 High 
Da Costa (73) 1 1 1 1 1 5 High 
Singh (74) 1 1 0 0 1 3 Low 
Valente (75) 1 1 1 1 1 5 High 
Waddell (76) 1 1 1 1 1 5 High 
        
See Appendix 3 for explanation of scoring method. 
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Data regarding pain were reported in an inconsistent manner so were collected for the most 
appropriate time point reported. When an overall pain score was given, this was used but when 
the individual steps were scored, and no overall score was given, the score relating to inspection 
of the uterine cavity was deemed most appropriate to use rather than the scores for other aspects 
of the procedure (e.g. cervical dilatation, endometrial biopsy).  When scores were only given 
after the procedure, the most immediate score was used. The evidence is unclear as to whether 
the dilatory effect of prostaglandins is apparent in a non-pregnant cervix, moreover, any potential 
benefit has to be weighed against unpleasant side effects (nausea, vomiting, excessive bleeding) 
and the costs associated with prostaglandin use. Therefore data regarding the effect on dilatation 
and the presence of side effects were collected in 2 x 2 contingency tables. 
 
Vaginoscopy  
The quality assessment of the data for the systematic review of the vaginoscopic technique is 
shown in Table 3.6. 
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Table 3.6 Methodological quality assessment of the studies included in the systematic 
review of the effect on pain of the vaginoscopic approach to outpatient hysteroscopy 
Study 
 
Randomisation 
sequence
a 
 
Allocation 
Concealment
b 
Follow-up
c
 Total Adequate
 
Almeida (77)
 
 
Adequate Inadequate 100% 2 
Garbin (31)
 
 
Adequate Inadequate 100% 2 
Guida (78)
 
 
Adequate Adequate 100% 3 
Paschopoulos (79)
 
 
Not reported Not reported 100% 1 
Sagiv (33)
 
 
Adequate Not reported 100% 2 
Sharma (32) 
 
Adequate Inadequate 100% 2 
aRandomisation adequate if computer generated random number sequence. 
b Concealment considered adequate if third party e.g. nursing staff. Inadequate if sealed envelopes used. 
c If the total number of patients entering the trial are accounted for in follow-up it was considered 100%. This is because if the 
patients have not had the procedure they would be unable to contribute to the results but the authors are able to explain why data 
are missing for these patients. 
 
The rules regarding pain score data were applied as in the previous reviews. Data regarding 
feasibility of the procedure were extracted as 2 x 2 contingency tables (successful versus failed 
procedures).  
 
Distension media 
The quality assessment of the data for the systematic review of distension media is shown in 
Table 3.7 
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Table 3.7. Methodological quality assessment of the studies included in the systematic 
review of the effect of the distension medium used on pain during outpatient hysteroscopy. 
Study 
 
Randomisation 
sequence
a 
Allocation 
concealment
b 
Follow-up
c
 Total Adequate
 
 
Brusco (80) 
 
 
Inadequate 
 
Inadequate 
 
100% 
 
1 
Lavitola (81) 
 
Adequate Adequate 100% 3 
Litta (82) 
 
Inadequate Inadequate 100% 1 
Nagele (83) 
 
Inadequate Inadequate 100% 1 
Paschopoulos (35) 
 
Inadequate Inadequate 100% 1 
Shankar (64) 
 
Inadequate Inadequate 100% 1 
 
aRandomisation adequate if computer generated random number sequence. 
b Concealment considered adequate if third party e.g. nursing staff. Inadequate if sealed envelopes used. 
c If the total number of patients entering the trial are accounted for in follow-up it was considered 100%. This is because if the 
patients have not had the procedure they would be unable to contribute to the results but the authors are able to explain why data 
are missing for these patients. 
 
The majority of studies gave an overall pain score for the procedure. One scored the steps 
separately (i.e. insertion of the endoscope, inspection of the uterine cavity, during endometrial 
biopsy and at intervals after the end of the procedure) so the score relating to inspection of the 
uterine cavity was used as it seemed the most appropriate. 
 
Data were collected regarding image quality as this may be adversely affected by the type of 
distension medium used. Normal saline has a higher refractive index than air which causes 
magnification and reduces the visual field (35). Carbon dioxide does not create a lavage and so 
blood, mucus and bubbles may obscure the image. The different mechanisms of administration 
(insufflators for carbon dioxide and pressure bags for normal saline) may affect the length of the 
procedure which prompted the collection of data regarding procedural time. Data regarding 
shoulder tip pain (a common side effect of gas insufflations caused by gas leaking from the 
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fallopian tubes and irritating the phrenic nerve) and vasovagal episodes (a common side effect of 
hysteroscopy) were also extracted. 
 
Type of hysteroscope 
The quality assessment of the data for the systematic review of flexible versus rigid 
hysteroscopes is shown in Table 3.8. 
 
Table 3.8. Methodological quality assessment of the studies included in the systematic 
review of the effect on pain of the type of hysteroscope used for outpatient hysteroscopy 
Study 
 
Randomisation 
sequence
a 
Allocation 
Concealment
b 
Blinding
c 
Follow-up
d
 Total 
Adequate
 
 
Baxter (84) 
 
 
Adequate 
 
Not reported 
 
Single blind 
 
100% 
 
3 
Unfried (85) 
 
Adequate Not reported Not reported 100% 2 
aRandomisation adequate if computer generated random number sequence. 
b Concealment considered adequate if third party e.g. nursing staff. Inadequate if sealed envelopes used. 
c If the total number of patients entering the trial are accounted for in follow-up it was considered 100%. This is because if the 
patients have not had the procedure they would be unable to contribute to the results but the authors are able to explain why data 
are missing for these patients. 
 
Pain data were collected and data regarding failed procedures were collected in 2x2 contingency 
tables. 
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Data Synthesis 
 
Meta-analysis of pain data was conducted in the systematic reviews of local anaesthetic, 
distension media and use of the vaginoscopic approach. The standardised mean difference (SMD) 
was used because it allowed comparison of outcome data from studies using different scales to 
quantify pain (43). Heterogeneity was assessed by examining forest plots and the I
2 
statistic, 
which if greater than 75% suggests considerable heterogeneity (43). Studies were weighted by 
the inverse of the variance and random effects models were used as standard as they give 
conservative estimates of effect (43). This method was also used to assess the secondary outcome 
of procedure time in the systematic review of distension media. Data assessing pain with the use 
of analgesics, conscious sedation, cervical preparation and type of hysteroscope were not suitable 
for meta-analysis.  
 
Meta-analysis was possible for secondary outcomes in the systematic reviews of local 
anaesthetic, cervical preparation, vaginoscopy and distension media. For dichotomous outcomes 
the Peto method was used due to a low incidence of outcome events in the studies (86). Analyses 
were performed using RevMan software (87). 
 
In the systematic review of local anaesthesia, subgroup meta-analysis was performed for data 
grouped according to method of local anaesthetic administration (intracervical, paracervical, 
transcervical and topical) because it was felt that the different methods were not directly 
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comparable. Meta-regression analysis (88) was then used to explore if one of the four types of 
local anaesthetic techniques was superior. Meta-regression was performed using Stata (89). 
 
Subgroup analysis was not performed in the six other systematic reviews. 
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CHAPTER 4 
 
RESULTS OF THE SEVEN SYSTEMATIC REVIEWS AND 
META-ANALYSES WHICH INVESTIGATE PAIN REDUCTION 
IN OUTPATIENT HYSTEROSCOPY 
 
Results of the systematic review and meta-analysis of local anaesthesia for 
pain control during outpatient hysteroscopy 
 
Study Selection, Details and Quality 
The literature search yielded 245 citations. Reviewing the reference lists yielded two further 
citations. Of these, 20 studies were considered eligible for inclusion in the review (Figure 4.1).  
The inter-rater reliability for the study selection was very good (kappa=0.9). Details of the study 
populations, intervention, outcome assessment and data reporting are shown in Tables 4.1a- 4.1c. 
The quality of the studies varied with deficiencies in randomisation and blinding (Figure 4.2). 
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Figure 4.1 Study selection process for systematic review of local anaesthetic for pain relief 
during outpatient hysteroscopy 
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Of the 20 selected studies, 18 reported data comparing local anaesthetic to placebo or nothing. 
One of these studies also reported data for a third randomised group of patients who received 
opiate analgesia (tramadol) (53). Of the remaining two studies, one compared use of local 
anaesthetic to conscious sedation (midazolam) (60) and the other compared different local 
anaesthetic regimens (paracervical injection versus uterosacral ligament injection) (58). 
 
Of the 18 papers reporting data for pain relief, three were excluded from meta-analysis; two 
because data were reported as the median value (56) or the mean but without standard deviation 
or standard error (63) precluding calculation of the SMD and another because of differences in 
intervention between the groups in addition to the use of local anaesthetic (33). The majority of 
the papers used continuous visual analogue scales (VAS) to assess pain, other studies used 
ordinal numerical or descriptive scales (Tables 4.1a-4.1c). 
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Tables 4.1a-c Characteristics of the studies included in the systematic review of use of local anaesthetic during outpatient 
hysteroscopy, subgrouped according to distension media. 
 
Table 4.1a Studies using carbon dioxide as the distension medium 
Study 
 
Participants
 
Intervention
 
Comparison Outcome measure Data reported 
 
Bellati (53) 
(Study written 
in Italian, 
abstract in 
English also) 
 
 
Women undergoing diagnostic 
out-patient hysteroscopy and 
endometrial biopsy. 
 
Intracervical injection of 
4ml 2% mepivicaine, 5 
minutes before the 
procedure. N=40 
 
2 groups: 
1. Tramadol 
100mg i.m. 50 
mins pre-
procedure. 
N=40 
2. Nil. N=40 
 
Ordinal score 0-20 during 
the hysteroscopy. 
 
 
 
 
Mean and 
Standard 
deviation 
calculated from 
raw data. 
Broadbent
 
(54)
 
Women undergoing diagnostic 
out-patient hysteroscopy for 
abnormal uterine bleeding. 
Exclusions: patients who were 
unable to tolerate the procedure. 
Intracervical injection of 
10ml 1% lignocaine with 
1:200,000 adrenaline, at 
least 5 minutes before 
the procedure. N=49 
Intracervical injection 
with 10ml 0.9% saline, at 
least 5 minutes before 
the procedure. N=48 
Pain defined by selecting a 
category from none, mild, 
moderate and severe. Graded 
before, during, immediately 
and 30min after the 
procedure.  
 
Mean and 
Standard 
deviation 
calculated by 
assigning a 
numerical value 
to the groups. 
Cicinelli 1997 
(9)
 
Post-menopausal women 
undergoing diagnostic 
hysteroscopy and endometrial 
biopsy because of endometrial 
bleeding. 
2ml 2% mepivicaine 
injected transcervically 
through the os into the 
uterine cavity 5 minutes 
before the procedure. 
N=40 
 
2ml 0.9% saline injected 
transcervically through 
the os into the uterine 
cavity 5 minutes before 
the procedure. N=40 
VAS 0-20 completed before, 
during and 15 minutes after 
the procedure and during the 
endometrial biopsy. 
 
 
Mean and 
standard 
deviation 
reported. 
Cicinelli 1998 
(10)
 
Post-menopausal women 
undergoing diagnostic 
hysteroscopy and endometrial 
biopsy because of endometrial 
bleeding. 
 
Paracervical block of 
10ml 1.5% mepivicaine 
10minutes before the 
procedure. N=36 
Paracervical injection of 
10ml 0.9% saline 
10minutes before the 
procedure. N=36 
VAS 0-20 completed before, 
during and 15 minutes after 
the procedure and during the 
endometrial biopsy. 
Mean and 
standard 
deviation 
reported. 
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Table 4.1a continued    
Study 
 
Participants
 
Intervention
 
Comparison Outcome measure Data reported 
Costello (55)
 
Women referred for out-patient 
hysteroscopy 
Scope passed into 
cervical os until ‘snug’. 
5ml 2% lignocaine was 
then injected through the 
operating channel of the 
scope. 2 minutes then 
passed before the 
procedure continued. 
N=49 
 
Scope passed into 
cervical os until ‘snug’. 
5ml 0.9% saline was then 
injected through the 
operating channel of the 
scope. 2 minutes then 
passed before the 
procedure continued. 
N=50 
VAS 0-10cm to score pain 
during the procedure. 
 
 
Mean and 
standard 
deviation 
reported. 
Davies (56)
 
Women requiring out-patient 
hysteroscopy. 
Exclusions: known sensitivity to 
lignocaine, epilepsy, significantly 
impaired respiratory or cardiac 
function, liver disease, treatment 
with tricyclic antidepressants or 
monoamine oxidase inhibitors. 
 
10% lignocaine sprayed 
onto the endocervix and 
through the cervical os 
into the uterine cavity, 10 
sprays in total. N=60 
Placebo sprayed onto the 
endocervix and through 
the cervical os into the 
uterine cavity, 10 sprays 
in total. N=60 
VAS 10cm to score pain as 
the tenaculum was applied, 
the nozzle of the spray 
inserted into the canal, 
insertion of the scope, 
during the procedure, during 
the biopsy and 5 minutes 
after the end of the 
procedure. 
 
Median VAS and 
interquartile 
ranges reported.  
Esteve (57)
 
Women attending for out-patient 
hysteroscopy. 
Intracervical injection of 
8ml 2% lignocaine. 
N=34 
Intracervical injection of 
8ml 0.9% saline. N=28 
VAS 0-10 cm to score pain 
during the hysteroscopy, 
during the biopsy, at the end 
of the procedure and 30 
minutes after the end of the 
procedure. 
 
Mean and 
standard 
deviation 
reported. 
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Table 4.1a continued     
Study 
 
Participants
 
Intervention
 
Comparison Outcome measure Data reported 
Giorda (59)
 
All post-menopausal women 
referred for diagnostic out-patient 
hysteroscopy. 
Exclusions: patient refused to 
partake, allergy to anaesthesia, 
previous hysteroscopy, and 
previous severe vagal reaction to 
a blind endometrial biopsy. 
Paracervical injection of 
20ml 1% mepivicaine at 
least 5 minutes before 
the procedure. 
Hysteroscopy performed 
with a 5mm diameter 
scope. N=121 
2 groups: 
1. No paracervical 
injection. 
Hysteroscopy 
performed with 
a 5mm scope. 
2. No paracervical 
injection. 
Hysteroscopy 
performed with 
a 3.5mm 
diameter scope. 
N=119 
 
Visual numerical rating 
scale ranging from 0 to 10 to 
score pain during the 
procedure only (patients 
who received a paracervical 
block were asked to discount 
the pain from the injection 
from their assessment.) 
Mean reported. 
Standard 
deviation 
calculated from 
standard error. 
Lau 1999 (12)
 
Women undergoing diagnostic 
outpatient hysteroscopy for 
abnormal uterine bleeding. 
Paracervical injection of 
10ml 2% lignocaine 5 
minutes before the 
procedure. 
N=49 
Paracervical injection of 
10ml 0.9% saline 5 
minutes before the 
procedure. 
N=50 
VAS 10cm used to score the 
pain when the tenaculum 
was applied, after the 
paracervical injection, at 
hysteroscopy insertion, 
during hysteroscopy, after 
endometrial biopsy and 30 
minutes after the procedure. 
 
Mean and 
standard 
deviation 
reported. 
Lau 2000 (62)
 
Women scheduled for diagnostic 
outpatient hysteroscopy. 
5ml 2% lignocaine 
instilled transcervically 
into the uterine cavity. 
N=45 
5ml 0.9% saline instilled 
transcervically into the 
uterine cavity. N=44 
VAS 10cm used to score the 
pain when the tenaculum 
was applied, after the 
paracervical injection, at 
hysteroscopy insertion, 
during hysteroscopy, after 
endometrial biopsy and 30 
minutes after the procedure. 
 
Mean and 
standard 
deviation 
reported. 
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Table 4.1a continued     
Study 
 
Participants
 
Intervention
 
Comparison Outcome measure Data reported 
Makris (63)
 
Women undergoing diagnostic 
outpatient hysteroscopy ± 
endometrial biopsy. 
Intracervical injection of 
1-3ml 3% mepivicaine, 3 
minutes before the 
procedure. N=100 
Intracervical injection of 
1-3ml 0.9% saline, 3 
minutes before the 
procedure. N=100 
Ordinal scale 0-10. Patients 
asked to rate pain 
experienced during 
hysteroscopy and at 30 and 
60 minutes after the 
procedure by circling one of 
the numbers. 
 
Mean reported. 
Unable to 
calculate 
standard 
deviation. 
Wong (67)
 
Women referred for investigation 
of abnormal uterine bleeding or 
suspected endometrial pathology. 
Exclusions: women who spoke a 
dialect (study carried out in 
China) or had other 
communication problems. 
4ml of 2% lignocaine 
rubbed over the cervix 
for 20 seconds 
immediately before the 
hysteroscopy. N=250 
4ml of KY Jelly 
(Johnson and Johnson 
Medical, UK) rubbed 
over the cervix for 20 
seconds immediately 
before the hysteroscopy. 
N=250 
Patients asked to grade the 
severity of pain at 1 minute 
intervals using the PPI scale. 
The mean pain score, peak 
pain score and overall pain 
score were all calculated as 
were mean pain scores for 
each of the individual steps 
of the procedure. 
Mean and 
standard 
deviation 
reported. 
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Table 4.1b. Studies using normal saline as the distension medium 
Study 
 
Participants
 
Intervention
 
Comparison Outcome measure Data reported 
Al-sunaidi (52)
 
Women undergoing diagnostic out-
patient hysteroscopy for evaluation of 
uterine cavity. 
Exclusions: women needing operative 
hysteroscopy under GA, positive 
Chlamydia culture, pregnancy or 
allergy to local anaesthetic. 
 
Intracervical injection 
of 2ml 0.5% 
bupivacaine and 
paracervical injection 
of 8ml 0.5% 
bupivacaine, 5 minutes 
before the procedure. 
N=42 
Intracervical 
injection of 2ml 
0.5% bupivacaine, 5 
minutes before the 
procedure. N=42 
VAS 0-10, completed 
during the procedure 
and at 10, 30 and 60 
minutes post 
procedure. 
 
 
Mean and standard 
deviation reported. 
Guida (60)
 
Women undergoing operative out-
patient hysteroscopy for surgically 
treatable lesions associated with 
infertility or abnormal uterine 
bleeding. 
 
Paracervical injection 
of 10ml 1% 
mepivicaine. N=82 
Conscious sedation 
with o.5mg atropine 
i.v., 0.25mg fentanyl 
i.v. and 2mg 
midazolam i.v. N=84  
5cm VAS used during, 
immediately after, 15 
and 60 minutes after 
and 24 and 72 hours 
after the procedure. 
Mean and standard 
deviation reported. 
Kabli (61)
 
Infertile women undergoing 
outpatient hysteroscopy. 
Exclusions: women needing operative 
hysteroscopy under GA, positive 
Chlamydia culture, pregnancy or 
allergy to local anaesthetic. 
Intracervical injection 
of 2ml 1% lignocaine 
and distension media 
with 18ml lignocaine 
per 250ml saline. N=42 
Intracervical 
injection of 2ml 1% 
lignocaine. N=36 
VAS 0-10 used to 
score pain after the 
hysteroscopy, after 
endometrial biopsy and 
at 10, 30 and 60 
minutes after the 
procedure. 
Mean and standard 
deviation reported. 
 
Sagiv (33)
 
 
Women undergoing diagnostic 
outpatient hysteroscopy. 
 
Intracervical injection 
of 10ml 3% 
mepivicaine. N=47 
 
Vaginoscopy 
(procedure 
performed without a 
speculum or 
anaesthesia). N=83 
 
VAS 0-10cm used to 
score the pain 
immediately and 15 
minutes after the 
hysteroscopy. 
 
Mean and standard 
deviation reported. 
 
Shankar (64)
 
 
Women with abnormal uterine 
bleeding referred by their general 
practitioner for diagnostic outpatient 
hysteroscopy. 
Exclusions: unable to visualize the 
cervix or severe cervical stenosis. 
 
Distension media 
containing 40ml 2% 
lignocaine per 500ml 
0.9% saline. N=100 
 
Distension media of 
0.9% saline only. 
N=100 
 
Pain scored with VAS 
0-10, and PPI. 
 
 
 
Mean and standard 
deviation reported. 
     
34 
 
Table 4.1b continued     
Study 
 
Participants
 
Intervention
 
Comparison Outcome measure Data reported 
 
Soriano (65)
 
 
Women undergoing diagnostic 
hysteroscopy for abnormal uterine 
bleeding or infertility. 
Exclusions: menorrhagia at the time 
of the procedure, sensitivity to 
lignocaine, epilepsy, significantly 
impaired respiratory or cardiac 
function and active liver disease. 
 
 
5% lignocaine sprayed 
onto the endocervix 
and into the cervical 
canal, (3 sprays in 
total) 5 minutes before 
the procedure. N=62 
 
Placebo sprayed on 
the endocervix and 
into the cervical 
canal, (3 sprays in 
total) 5 minutes 
before the procedure. 
N=56 
 
VAS 0-10cm to score 
pain experienced 
during the procedure. 
 
Mean and standard 
deviation reported. 
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Table 4.1c Studies using other distension media 
Study 
 
Participants
 
Intervention
 
Comparison Outcome measure Data reported 
 
Studies using 1.5% glycine as the distension medium 
 
Vercellini (66)
 
 
Premenopausal (FSH <30mIU/ml) 
non-pregnant (negative β-hCG test) 
women referred for investigation of 
excessive uterine bleeding of ≥ 3 
months duration. 
Exclusion: genital infection, previous 
cervical surgery or hysteroscopy, 
severe cardiac disease and known 
sensitivity to local anaesthetics. 
 
 
Paracervical injection 
of 1% mepivicaine 
more than 5 minutes 
before the procedure. 
N=87 
 
No anaesthesia. 
N=90 
 
10 point visual analogue 
scale used to score pain 
during the hysteroscopy and 
the endometrial biopsy.  
 
Mean and standard 
deviation reported. 
Distension medium not stated 
 
Finikiotis (58)
 
 
 
Patients referred from general 
practitioners and from other 
gynaecologists for the investigation 
of a variety of gynaecological 
complaints. 
 
Paracervical injection 
of 16-20ml 1% 
lignocaine. N=60 
 
Uterosacral 
injection of 2ml 
2% lignocaine 
with 1:80,000 
adrenaline. N=60 
 
VAS 0-10cm to score pain 
during the procedure. 
Reported as the number of 
patient selecting VAS 
between 0 and 3.3, 3.4 and 
6.3 and 6.4 to 10.0. 
 
 
Mean and standard 
deviation 
calculated using 
the mean value of 
each category. 
 
NB. For consistency the group receiving local anaesthetic (or a combination of anaesthetics) are considered as the intervention group even if that was not the case in the original 
study. 
GA= general anaesthetic, VAS= visual analogue scale, i.m.= intra muscular, i.v.= intra vascular, HR= heart rate, BP= blood pressure, PPI= Present pain intensity scale (verbal 
descriptors of pain ranked from 0-5 on a numeric scale).
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Figure 4.2 Jadad Quality Assessment of Studies Using Local Anaesthetic for Out-patient 
Hysteroscopy 
 
 
Results were reported as mean or median pain scores, but for the one study using a descriptive 
scale (54), numerical values were applied to each category (none=1, mild=2, moderate=3 and 
severe=4) and used to calculate the mean scores and standard deviations (90). One study reported 
raw patient data (53) from which the mean and standard deviation were calculated (90). The 
populations in the two studies (53;54) for which the mean and standard deviation were calculated 
were sufficiently large for them to be approximated to a normal distribution according to central 
limit theorem (91).  Another study reported the standard error (59) which was converted into the 
standard deviation (92). 
 
37 
 
Nine of the selected studies had data on vasovagal episodes. Four of the studies reported 
vasovagal attacks according to a strict definition based upon heart rate, blood pressure and 
symptoms (9;10;12;62), four of them reported vasovagal symptoms (e.g. faintness, nausea, 
pallor) (59;60;63;64) and one reported a vasovagal attack in the complications but did not give 
any a-priori definition of symptoms or signs (65). 
 
Effect of local anaesthetic on pain 
Meta-analysis of 15 studies showed that the use of local anaesthetic reduced the amount of pain 
experienced during outpatient hysteroscopy (SMD = -0.54, 95%CI -0.86 to -0.23, I
2 
= 91%) 
(Figure 4.3). Meta-analysis of the studies sub-grouped according to quality found that both the 
poor and the high quality studies demonstrated a significant benefit of using local anaesthetic for 
outpatient hysteroscopy (SMD = -0.77, 95%CI -1.45 to -0.08, I
2 
= 95% and SMD = -0.43, 95%CI 
-0.73 to- 0.12, I
2 
= 83% respectively) (Figure 4.3).  
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Figure 4.3 Forest plot showing the results of meta-analysis of studies that examine the use of 
local anaesthetic for reducing pain during out-patient hysteroscopy. Results overall and 
sub-grouped according to method of administration and quality.  
 
 
When divided into subgroups there were three studies examining intracervical injection 
(53;54;57), five which used paracervical injection, (10;12;52;59;66), five that used transcervical 
application (topical into the uterine cavity) (9;55;61;62;64) and two that applied the anaesthetic 
topically (topical to the cervix only) (65;67).  
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The use of an intracervical injection of local anaesthetic significantly reduced pain during out-
patient hysteroscopy (SMD = -0.36, 95%CI -0.61 to -0.10, I
2 
= 0%) (Figure 4.3). This finding 
however, contrasted with a single study included in the review but not in the meta-analysis 
because of insufficient data (63), which found no significant effect of intracervical local 
anaesthetic on pain relief for out-patient hysteroscopy. To examine this conflicting result, a 
sensitivity analysis was performed excluding from the meta-analysis the study where categorical 
data had been transformed (54). No significant reduction in pain was observed with intracervical 
injection (SMD =-0.35, 95% CI -0.82 to 0.12, I
2 
=48%) (Figure 4.4). 
 
Figure 4.4 Forest plot showing the results of meta-analysis of studies that examine the use of 
intracervical injection without the study whose data were transformed 
 
 
The use of paracervical injection was associated with a significant reduction of pain during out-
patient hysteroscopy (SMD = -1.28, 95%CI -2.22 to -0.38, I
2 
=97%) (Figure 4.3).  
 
The use of topically administered local anaesthetic did not ameliorate pain during outpatient 
hysteroscopy. Specifically, transcervical local anaesthetic was not found to significantly reduce 
the amount of pain experienced during hysteroscopy (SMD= -0.11, 95%CI -0.31 to 0.10, I
2 
=27%) (Figure 4.3). Similarly, there was no significant alleviation of pain when local anaesthetic 
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was applied topically to the cervix (SMD = -0.32, 95%CI -0.97 to 0.33, I
2 
= 90%) (Figure 4.3), 
although meta-analysis demonstrated substantial heterogeneity. A further study included in the 
review that could not be used for the meta-analysis because it reported median VAS scores, 
showed no significant difference between topical cervical local anaesthetic and placebo for the 
hysteroscopy, but it did show a significant reduction in pain in the local anaesthetic group during 
application of a cervical tenaculum (p=0.005) (56).  
 
A further meta-analysis was performed to compare injectable administration of local anaesthetic 
(intracervical and paracervical) against topical application (transcervical to uterine cavity and 
topical to the cervix).  This showed a benefit of using injectable local anaesthetics (SMD = -0.92, 
95% CI -1.51 to -0.33, I
2 
= 94%) but not topical ones (SMD =-0.17, 95%CI -0.38 to 0.03, I
2 
= 
62%). (Figure 4.5). Meta-regression analysis showed that paracervical injection was significantly 
more effective than the other anaesthetic modalities in reducing the pain of diagnostic outpatient 
hysteroscopy (p = 0.048). 
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Figure 4.5 Forest plot showing the results of meta-analysis of studies that examine the use 
anaesthetics sub-grouped into injectable and topical application 
 
 
A single study compared two methods of cervical block (58) and found no significant difference 
in pain between a paracervical and an uterosacral ligament local block p<0.65. Two studies 
compared local anaesthetic to other medication (53;60). The first compared intracervical local 
anaesthetic to a control group (data used in meta-analysis) and to intramuscular injection of 
100mg tramadol. Tramadol was significantly better at reducing the amount of pain experienced 
during hysteroscopy (p=0.001) compared to intracervical block (53). The second study compared 
paracervical injection of local anaesthetic to the use of conscious sedation for operative 
hysteroscopy and found no significant difference in the pain experienced between the two groups 
(60). 
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Effect on vasovagal episodes 
There was no significant difference in the incidence of vasovagal episodes between local 
anaesthetic and control (nil, normal saline, placebo, conscious sedation) groups p=0.09 (Figure 
4.6), regardless of how a vasovagal reaction was defined. 
 
Figure 4.6 Forest plot showing the results of meta-analysis examining the incidence of 
vasovagal episodes in studies examining the use of local anaesthetic for out-patient 
hysteroscopy  
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Results of the systematic review of analgesia for pain control during outpatient 
hysteroscopy  
 
Study Selection, Details and Quality 
The analgesia literature search yielded 185 citations. Of these, 6 studies were considered eligible 
for inclusion in the review (Figure 4.7).  The inter-rater reliability for the study selection was 
good (kappa 0.67). 
 
Figure 4.7 Study selection process for the systematic reviews of the effect of analgesia on 
pain during outpatient hysteroscopy. 
 
 
Details of the study populations, intervention, outcome assessment and data reporting are shown 
in Table 4.2. 
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Table 4.2. Characteristics of the selected studies included in the systematic reviews of analgesia for pain control during 
outpatient hysteroscopy 
Study 
 
Participants
 
Intervention
 
Comparison Outcome measure Data 
reported 
 
Bellati (53) 
 
(Study 
written in 
Italian, 
abstract in 
English also)
 
 
Women undergoing 
diagnostic out-patient 
hysteroscopy and 
endometrial biopsy. 
 
2 groups: 
1. Tramadol 100mg i.m. 50 
mins pre-procedure.    N= 
40 
2. Nil. N=40. 
Rigid 5mm hysteroscope and carbon 
dioxide for distension. 
 
Intracervical injection of 4ml 
2% mepivicaine, 5 minutes 
before hysteroscopy with a 
rigid 5mm hysteroscope and 
carbon dioxide for 
distension. N=40  
 
Rigid 5mm hysteroscope and 
carbon dioxide for 
distension. 
 
 
Ordinal score 0-20 
during the hysteroscopy. 
 
 
 
 
Mean and 
Standard 
deviation 
calculated 
from raw 
data. 
 
Caligiani (68) 
 
(Study 
written in 
Italian, 
abstract in 
English also)
 
 
Women undergoing 
diagnostic out-patient 
hysteroscopy and 
endometrial biopsy to 
investigate post-
menopausal bleeding. 
 
Intracervical injection of 4ml 3% 
mepivicaine, 5 minutes before the 
procedure and ketorolac 30mg i.m. and 
atropine 0.5mg i.m. 45 minutes before 
the procedure. Hysteroscopy not 
described. N=12. 
 
Intracervical injection of 4ml 
3% mepivicaine, 5 minutes 
before the procedure and 
atropine 0.5mg i.m. 45 
minutes before the 
procedure.  Hysteroscopy 
not described. N=12. 
 
VAS 0-10cm to score 
pain at insertion of the 
speculum, during the 
hysteroscopy, during 
endometrial biopsy and 5 
minutes after the end of 
the procedure. 
 
Mean and 
standard 
error. 
 
Floris (45)
 
 
Perimenopausal women 
undergoing outpatient 
diagnostic hysteroscopy 
and endometrial biopsy. 
Exclusions: known 
uterine malformation, 
previous uterine 
surgery. 
 
Tramadol 100mg i.v. over 20 minutes, 
followed 30 minutes later by the 
outpatient hysteroscopy with a 2.9mm, 
rigid, 30 degree fore-oblique 
hysteroscope using carbon dioxide as the 
distension medium.   N = 25. 
 
Placebo infusion i.v. over 20 
minutes, followed 30 
minutes later by the 
outpatient hysteroscopy  
with a 2.9mm, rigid, 30 
degree fore-oblique 
hysteroscope using carbon 
dioxide as the distension 
medium.    N = 25. 
 
 
VAS 0-10cm to score 
pain during and 15 
minutes after the end of 
the procedure. 
ACTH and cortisol levels 
were also assayed from 
blood samples pre and 
post procedure. 
 
 
Mean 
reported 
graphically, 
no values 
given. 
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Table 4.2 continued     
Study 
 
Participants
 
Intervention
 
Comparison Outcome measure Data 
reported 
 
Lin (69)
 
 
Pre- and post-
menopausal women 
undergoing outpatient 
hysteroscopy to 
investigate abnormal 
bleeding, infertility and 
suspected intracavity 
lesion. 
 
Buprenorphine 0.2mg sublingually, 40 
minutes before the hysteroscopy, which 
was performed a 3.1mm flexible 
hysteroscope, using 5% dextrose as the 
distension medium. N= 80. 
 
Placebo tablet, sublingually, 
40 minutes before the 
hysteroscopy, which was 
performed with a 3.1mm 
flexible hysteroscope, using 
5% dextrose as the 
distension medium. N=84. 
 
VAS 0-10cm to score the 
worst pain experienced 
during the procedure. 
 
Mean and 
standard 
deviation. 
 
Nagele (46)
 
 
Pre- and post-
menopausal women 
undergoing outpatient 
hysteroscopy. 
Exclusions: sensitivity 
to NSAID’s and 
prostaglandin synthesis 
inhibitors, medication 
that interacts with 
NSAID’s, inflammatory 
bowel disease, 
porphyria and those 
unable to consent. 
 
Mefenamic acid 500mg orally, 1 hour 
pre-procedure. Hysteroscopy with 4mm, 
rigid, 30 degree fore-oblique 
hysteroscope with a 5mm sheath using 
carbon dioxide as the distension medium. 
N= 49. 
 
Placebo orally, 1 hour pre-
procedure.  Hysteroscopy 
with 4mm, rigid, 30 degree 
fore-oblique hysteroscope 
with a 5mm sheath using 
carbon dioxide as the 
distension medium. N- 46. 
 
Women asked to score 
the worst pain 
experienced during the 
hysteroscopy and at 30 
and 60 minutes after the 
procedure using a 4 point 
ordinal scale (0=none, 
1=mild, 2=moderate, 
3=severe). 
 
No values 
given for pain 
during the 
procedure, 
results 
expressed 
graphically. 
Pain after the 
procedure 
reported as 
medians with 
interquartile 
ranges 
 
Tam (70)
 
Pre- and post-
menopausal women 
undergoing outpatient 
diagnostic 
hysteroscopy. 
Diclofenac 50mg, orally, 1-2 hours pre-
procedure. Hysteroscopy with 2.7mm, 
rigid, 25 degree fore-oblique 
hysteroscope with a 5mm sheath and 
carbon dioxide for distension. N=92. 
Placebo tablet, orally, 1-2 
hours pre-procedure. 
Hysteroscopy with 2.7mm, 
rigid, 25 degree fore-oblique 
hysteroscope with a 5mm 
sheath and carbon dioxide 
for distension. N=89. 
VAS (length not stated) 
to score pain before the 
procedure, when 
tenaculum applied, 
insertion of 
hysteroscope, 
examination of the 
uterine cavity, after 
biopsy and 30 minutes 
post procedure. 
 
Mean and 
standard 
deviation. 
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The quality of the studies varied with deficiencies in randomisation and blinding (Figure 4.8). 
 
Figure 4.8. Methodological quality assessment of studies using analgesia  for outpatient 
hysteroscopy 
 
 
Of the 6 selected analgesia studies, three examined the use of opiate drugs (45;53;69) and three 
examined non-steroidal anti-inflammatory drugs (NSAIDs) (46;68;70). All six studies examined 
diagnostic outpatient hysteroscopy. Four studies reported data comparing analgesia to placebo 
(45;46;69;70), one compared ketorolac and intracervical block to intracervical block alone (68) 
and the final study compared tramadol to intracervical block (53). Two of the selected studies 
reported their data graphically without any specific numerical values (45;46); the authors were 
contacted to try and obtain the values but no replies were received. Four of the papers used 
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continuous visual analogue scales (VAS) to assess pain, and two used ordinal numerical or 
descriptive scales (Table 4.2).  
 
Effect of analgesics on pain 
Meta-analysis was not performed as the studies used different drugs, in different doses, making 
them non-comparable. When divided into medication subgroups, there were three studies 
examining the use of opiate analgesics (45;53;69) and three which studied NSAID’s (46;68;70). 
Two of the opiate studies examined the use of 100mg tramadol administered approximately 50 
minutes before the outpatient hysteroscopy, one study giving it intramuscularly (53) and the 
second giving it as an intravenous infusion (45). The first study found that the women who had 
received tramadol had significantly less pain at the end of the procedure than women in the 
intracervical block group and the women who received no medication ( p =0.001 and p<0.001 
respectively) (53). Although this was a low quality study the result was supported by those from 
the second, high quality study that reported significantly lower pain scores in the tramadol group 
when compared to placebo  both during (p<0.012) and 15 minutes after ( p<0.008) the procedure 
(45). The third opiate study examined the use of sublingual buprenorphine 0.2mg, 40 minutes 
before the procedure, versus placebo. There was no significant pain reduction with the use of 
buprenorphine overall and when stratified for menopausal status and parity (69).  
 
The three NSAID studies all examined different drugs. The first, high quality study compared the 
use of 500mg of oral mefenamic acid, one hour prior to the procedure, to placebo. It found that 
mefenamic acid did not significantly reduce the pain of the hysteroscopy, however it did 
significantly reduce the pain experienced at 30 minutes (p<0.01) and 60 minutes (p<0.05) post-
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procedure. The second high quality study examined oral diclofenac 50mg, given one to two hours 
before the procedure (70).  Pain was assessed at a number of points during the procedure (see 
Table 4.2) but no significant difference between the intervention and control groups was found (p 
values not reported) (70). The final NSAID study was low quality. It assessed the use of oral 
ketorolac 30mg with an intracervical block compared to intracervical block alone and found that 
the addition of ketorolac significantly reduced pain at all stages of the procedure (no p values 
reported) (68). 
 
Side effects 
Two of the opiate studies reported side effects (45;70). The tramadol study found no significant 
difference between the groups in incidence of nausea, vomiting or bradycardia (45). Conversely, 
in the buprenorphine study there was a high incidence of adverse effects (nausea, vomiting, 
drowsiness) in the intervention group (38.8%) and none in the control group (69).  
 
The diclofenac study was the only NSAID study to report side effects (70). Two patients (2.2%) 
in the diclofenac group reported side effects (one reported epigastric pain and one reported a 
rash) which were mild and self-limiting (70).  
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Results of the systematic review of conscious sedation for pain control during 
outpatient hysteroscopy  
 
Study Selection, Details and Quality 
The conscious sedation literature review yielded 39 citations with just one being eligible for 
inclusion in the review (Figure 4.9).  
 
Figure 4.9 Study selection process for the systematic reviews of the effect of conscious 
sedation on pain during outpatient hysteroscopy 
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There was complete agreement between the reviewers and so the kappa score was 1. According 
to the Jadad quality assessment this paper was of low quality, however this was due to the study 
not scoring any points for blinding. It would be very difficult to blind conscious sedation versus 
intracervical injection and so blinding was removed as a quality consideration. The paper 
received full marks for randomisation and follow-up of withdrawals and dropouts, thus was 
ultimately deemed to be of high quality. 
 
The conscious sedation study (60) compared midazolam to a paracervical anaesthetic block for 
operative outpatient hysteroscopy using a bipolar electrode. A VAS marked with pain 
descriptions was used to evaluate the pain experienced and the results were reported as means 
and standard deviations. The trial examined the use of conscious sedation immediately before 
operative outpatient hysteroscopy (polypectomy, myomectomy, septoplasty and adhesiolysis) 
using the Versapoint™ bipolar electrosurgical system (Gynecare, Ethicon Inc. Menlo Park, CA, 
USA). It compared 0.25 mg of fentanyl i.v., 0.5 mg of atropine and 2mg of midazolam, to 
paracervical anaesthesia with 10mL 1% mepivicaine hydrochloride without sedation. There were 
no significant differences between local anaesthesia and conscious sedation in terms of pain 
control during the procedure, postoperative pain, side effects or patient satisfaction (60). 
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Results of the systematic review of the effect of cervical preparation on pain 
during outpatient hysteroscopy 
 
Study Selection, Details and Quality 
The literature search yielded 585 citations. Of these, six studies were considered eligible for 
inclusion in the review (Figure 4.10) (71-76).  The inter-rater reliability for the study selection 
was very good (kappa=0.86).  
Figure 4.10 Study selection process for the systematic review of the effect of cervical 
preparation on pain during outpatient hysteroscopy 
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Four of the six papers were deemed to be of high quality (72;73;75;76) (Table 4.3). Details of the 
study populations, intervention, outcome assessment and data reporting are shown in Table 4.3.  
A single study (72) examined the use of oral mifepristone for cervical dilatation in 
premenopausal women given 30 hours pre-procedure. The five remaining studies examined the 
use of vaginal misoprostol administered between four and 24 hours before the hysteroscopy. The 
dose used was 400µg in all but one study (73) which used 200µg. Two studies used only 
premenopausal women (71;75), one, only postmenopausal women (73) and the remaining two a 
combination of both (74;76) . All studies reported results for pain and five  (71-74;76) reported 
results for cervical dilatation. One paper used an ordinal scale from zero to ten to assess pain (71) 
whilst the other studies all used continuous visual analogue scales (VAS).  
 
Results were reported in a variety of ways (see Table 4.3) that could not be compared, making 
meta-analysis impossible. Cervical dilatation was assessed in different ways (adequate if scope 
passes into os, need for dilatation, force needed to dilate) and so the results were once again 
unsuitable for meta-analysis. Gastrointestinal side effects were reported by two studies (75;76), 
bleeding by four studies (71;74-76), cervical lacerations by three studies (71;73;76) and failed 
procedures by three studies (72;73;75). These results were meta-analysed.  
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Table 4.3. Methods, interventions and results for the studies included in the systematic review of the effect of cervical 
preparation on pain during outpatient hysteroscopy 
 Antiprogestogen Prostaglandins 
 
 Premenopausal Premenopausal Postmenopausal Pre and postmenopausal 
 
 Ben Chetrit (72) 
 
Atay (71) Valente (75) Da Costa (73) Singh (74) Waddell (76) 
 
Intervention 
 
Mifepristone 
200mg PO 30 
hours pre 
hysteroscopy 
 
Misoprostol 400µg 
PV 4 hours pre 
hysteroscopy 
 
 
Misoprostol 
400µg PV 6 
hours pre 
hysteroscopy 
 
 
Misoprostol 200µg 
PV 8 hours pre 
hysteroscopy 
 
Misoprostol 400µg 
PV 4-6 hours pre 
hysteroscopy 
 
Misoprostol 400µg PV 12-24 
hours pre hysteroscopy 
Control method Placebo Placebo 
 
Placebo Placebo Nil Placebo 
Number in 
intervention 
group vs. 
control group 
28 vs. 30 22 vs. 21 20 vs. 24 60 vs. 60 50 vs. 50 (only 8 
postmenopausal 
women in the 
intervention group 
and 1 in the 
control group). 
 
50 vs. 51 
Routine use of 
cervical 
dilatation 
No If 7mm resectoscope 
sheath or 6 Hegar not 
easily passed into the 
cervical canal. 
 
No No No Yes 
Hysteroscope 
size 
2.9mm rigid 
hysteroscope 
4mm rigid 
hysteroscope with 
30° fore oblique lens 
for diagnostic and 
7mm resectoscope 
for operative 
 
4mm 
hysteroscope 
with 30° fore 
oblique lens 
4mm rigid 
hysteroscope with 
30° fore oblique 
lens and 5mm 
sheath 
4mm rigid 
hysteroscope with 
30° fore oblique 
lens 
4mm rigid hysteroscope with 30° 
fore oblique lens and 5.5mm 
sheath 
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Table 4.3 continued      
 
 
Ben Chetrit (72) Atay (71) Valente (75) Da Costa (73) Singh (74) Waddell (76) 
Quality High Low 
 
High High Low High 
Operative or 
Diagnostic 
Diagnostic Suggests all  
operative but not 
clear.  
 
Diagnostic Diagnostic Diagnostic Diagnostic 
Method of 
assessing 
cervical 
dilatation 
Dilatation 
measured using 
Hegar dilators 
before 
administration of 
mifepristone and 
when patient 
returned for 
hysteroscopy.  The 
change in Hegar is 
reported as mean 
(standard 
deviation). 
 
Adequate if 7mm 
hysteroscope 
sheath or Hegar 6 
dilator passes into 
cervical canal. 
Number assessed 
adequate in each 
group.  
Not reported. Need for 
dilatation. 
Percentages. 
Need for 
dilatation. Number 
(percentage). 
Force needed to dilate at 3, 4, 5 
and 6mm measured with dilators 
attached to a tonometer. Mean 
(standard deviation). 
Dilatation in 
intervention 
group vs. 
control group 
1.28 (1.4) Hegar 
vs. 1.06 (1.4) 
Hegar 
p=0.50 
20 vs. 6 adequate 
p<0.001 
 17.2  vs. 20.3% 
p=0.66 
15 (30%) vs. 11 
(22%) p=0.36 
3mm= 1.7 (1.7)vs. 1.8 (2.1) 
p=0.82 
4mm= 2.6 (3.5) vs. 3.0 (4.5) p= 
0.86 
5mm= 4.3 (6.0) vs. 4.0 (3.1) p= 
0.21 
6mm= 5.0 (4.2) vs. 7.5 (5.9) p= 
0.02 
Scores separated into pre and 
postmenopausal are all non-
significant (p>0.05) 
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Table 4.3 continued      
 
 
Ben Chetrit (72) Atay (71) Valente (75) Da Costa (73) Singh (74) Waddell (76) 
Method of pain 
assessment 
100mm VAS Score from 0-10 
(0= no pain, 10= 
worst menstrual 
pain). 
0-10cm VAS 
with faces  
symbolising the 
amount of pain. 
 
VAS (length not 
reported but 
assumed to be 
10cm). 
10cm VAS Sliding visual analogue scale of 1 
to 100. 
Timing of pain 
assessment 
Pain as 
hysteroscope 
passes through the 
cervical os. Mean 
(standard 
deviation). 
Pain during 
cervical dilatation. 
Mean (range). 
Pain during the 
hysteroscopy, 
biopsy and after 
the hysteroscopy. 
Number 
(percentage), 
selecting between 
0-5 and 6-10 
 
Pain as scope 
passes through 
internal cervical 
os, as the cervix is 
clamped and the 
biopsy is taken. 
Median. 
Pain at the end of 
the procedure. 
Median (standard 
deviation). 
Pain assessed during assessment 
of cervical dilatation at baseline 
(before administration of 
misoprostol) and after cervix 
dilated to 6mm before 
hysteroscopy. 
Mean (standard deviation). 
Pain score in 
intervention 
group vs. 
control group 
33.4mm (23.5)vs. 
37.0mm (30.0) 
p=0.60 
5.1 (4-10) vs. 9.3 
(6-10) p<0.05 
Selecting 0-5: 7 
(53.8%) vs. 11 
(47.8%) 
 
Selecting 6-10: 6 
(46.2%) vs. 12 
(52.2%)  
 
p=0.72 
During procedure 
medians:  
5 vs. 7, p=0.02  
 
Comparing 
number in group 
selecting Vas>6 : 
Clamping p = 
0.507 
Hysteroscopy 
p=0.0132 
Endometrial 
biopsy p= 0.5919  
 
Presence of pain: 
Clamping p = 0.74 
Hysteroscopy 
p=0.32 
Endometrial 
biopsy p= 0.19  
 
4.5cm (2.0) vs. 
5.0cm (1.8) p=0.03 
42.1 (23.1) vs. 57.2 (24.9), p= 
0.004 
 
If adjusted for baseline pain: 43.2 
(3.7) vs. 55.5 (3.4), p= 0.01 
 
Premenopausal:  
Overall p = 0.56 or if adjusted for 
baseline pain p= 0.77 
 
Postmenopausal: 
Overall p=0.004 or if adjusted for 
baseline pain p= 0.006 
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Effect of cervical preparation on pain 
Premenopausal women 
Mifepristone given 30 hours before hysteroscopy did not reduce the pain of the outpatient 
procedure for pre-menopausal women (p=0.60) (72) (Table 4.3). 
 
Two studies examined the use of misoprostol 400µg given vaginally before the hysteroscopy 
to premenopausal women. The drugs were administered 4 hours before in one of the studies 
(71) and 6 hours before in the other (75). The low quality study (71) found that pain during 
cervical dilatation was significantly reduced after the use of prostaglandin compared to 
placebo (p<0.05) however the other study which, was considered to be high quality (75), 
found no significant reduction in pain during the hysteroscopy with the use of misoprostol (p= 
0.72) (Table 4.3). 
 
Postmenopausal women 
One study (73) examined the use of misoprostol 200µg given vaginally 8 hours before the 
hysteroscopy to postmenopausal women. The median pain scores as the hysteroscope passed 
through the cervical os were five in the intervention group and seven in the placebo group 
(p=0.02). When the pain severity was assessed by comparing the number of patients scoring 
more than six on the VAS (i.e. considerable pain)  there were significantly fewer in the 
intervention group (p=0.0132). However no significant difference between the groups was 
identified when assessing the presence of pain during clamping of the cervix (p= 0.74), during 
the examination (p= 0.32) or during the endometrial biopsy (p=0.19) (Table 4.3). 
 
Pre- and postmenopausal women 
Two studies included pre- and post-menopausal women in their study populations (74;76).  
One of these studies gave misoprostol 400µg vaginally four to six hours before the 
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hysteroscopy (74) and found that pain at the end of the procedure was significantly less in the 
intervention group when compared to no medication (p=0.03). This was judged to be a low 
quality study due to the lack of blinding. The second study gave the same dose of misoprostol 
twelve to twenty-four hours before the procedure and assessed pain after the cervix was 
dilated to 6mm (76). Pain was found to be significantly less in the misoprostol group 
(p=0.004 and when adjusted for baseline pain score p=0.01). This study subgrouped the 
patients according to menopausal status and found that there was a significant reduction in 
pain for postmenopausal women given misoprostol (p= 0.004 and when adjusted for baseline 
scores p=0.006) but not for premenopausal women (p=0.56, and when adjusted for baseline 
scores p=0.77). This was a high quality study (Table 4.3). 
 
Effect of cervical preparation on dilatation of the cervix 
Five studies evaluated the effect of cervical priming with antiprogestogens or prostaglandins 
on cervical dilatation. No significant differences were seen between priming and placebo as 
regards the need for or degree of cervical dilatation. The only significant results were for the 
amount of force required to dilate the cervix above 6mm in a mixed pre and postmenopausal 
population (76) and the number of premenopausal women requiring dilatation above 6mm 
(p=0.001) (71) (Table 4.3). 
 
Side effects 
No significant differences in the prevalence of gastrointestinal side effects, unscheduled 
vaginal bleeding, cervical laceration or failed procedures were found (Figure 4.11). 
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Figure 4.11 Forest plots showing the results of meta-analysis of adverse effects and failed 
procedures when prostaglandins are given prior to outpatient hysteroscopy  
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Results of the systematic review of the effect on pain of the vaginoscopic 
approach to outpatient hysteroscopy 
 
Study Selection, Details and Quality 
The literature search yielded 1167 citations. Of these, 6 studies (31-33;77-79) were 
considered eligible for inclusion in the review (Figure 4.12). The inter-rater reliability for the 
study selection was very good (=0.81). 
 
Figure 4.12 Study selection process for systematic review of the effect on pain of the 
vaginoscopic approach to outpatient hysteroscopy. 
 
 
 
Potentially relevant citations 
identified and screened for 
retrieval 
 
Medline, EMBASE and CINAHL 
1157 
Cochrane Library 10 
 
Total n = 1167 
Publications selected for 
appraisal 
 
n = 6 
Citations excluded 
 
Inappropriate population, 
intervention or outcome measure 
n=1060 
Duplicates n= 88 
 
Total n = 1048 
 
Publications excluded 
 
Not randomized controlled trial n 
=11 
Duplicates n = 2 
 
Total n =13  
 
Citations retrieved for more 
detailed evaluation 
 
Total n = 19 
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Details of the study populations, intervention, outcome assessment and data reporting are 
shown in Table 4.4. The quality of the studies was high but with deficiencies in allocation 
concealment (Figure 4.13).  
 
Figure 4.13 Methodological Quality Assessment of Studies Examining the effect of the 
vaginoscopic approach on pain during outpatient hysteroscopy 
 
 
All six papers (31-33;77-79) used a visual analogue scale (VAS) to assess the patients’ level 
of pain. Of the six papers reporting data for pain experience three reported means and 
standard deviations (31;33;77), two reported medians (32;78) and one reported the pain in 
categories (79). The data reported as median pain scores could not be used to calculate the 
SMD, so were excluded from the analysis. For data reported categorically, the midpoint of 
each category and the number of people selecting that category were used to calculate the 
mean and standard deviation. 
0% 20% 40% 60% 80% 100%
Follow-up >90%
Randomisation sequence
Allocation concealment
Adequate
Inadequate
Unreported
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Table 4.4. Characteristics of the selected studies included in the systematic review of the effect of the vaginoscopic approach on pain 
during outpatient hysteroscopy 
Study 
 
Participants
 
Intervention
 
Comparison Outcome measure Data reported 
Almeida (77)
 Pre- and post-menopausal 
women undergoing diagnostic 
outpatient hysteroscopy. 
Exclusions: pelvic 
inflammatory disease, 
pregnancy, uterine perforation 
within the last 30 days, active 
uterine bleeding and use of 
hormonal vaginal cream. 
Patients positioned in lithotomy, 
vagina cleaned and the rigid, 
2.7mm (3.7mm with the sheath) 
hysteroscope introduced into the 
vagina. Holding the labia minora 
together the vagina was distended 
with normal saline and the 
hysteroscope steered into the 
external cervical os and along the 
canal into the uterine cavity. The 
hysteroscopy then continued as 
normal. Endometrial biopsies were 
also taken without the use of a 
speculum. 
N =91. 
 
Patients positioned in lithotomy, 
Collins speculum inserted, 
vagina and cervix cleaned and 
the cervix grasped with a 
tenaculum. The rigid, 2.7mm 
(3.7mm with sheath) 
hysteroscope was then inserted 
into the external cervical canal 
and advanced into the uterine 
cavity which was then distended 
with carbon dioxide. The 
hysteroscopy then continued as 
normal and endometrial biopsies 
were taken. N=93. 
VAS 0-10 with five 
faces drawn above the 
line indicating the 
amount of pain. Scored 
during the procedure 
and 5, 10, 15 and 20 
minutes afterwards. 
Mean and 
standard 
deviation 
reported. 
Garbin (31)
 Pre- and post-menopausal 
women undergoing diagnostic 
outpatient hysteroscopy. 
Exclusions: age < 18 years, 
current genital infection, 
refusal to participate.  
Vagina cleaned and the rigid, 
2.7mm (3.5mm with the sheath) 
hysteroscope introduced into the 
vagina, which was distended with 
normal saline so that the 
hysteroscope could be steered into 
the external cervical os and along 
the canal into the uterine cavity. 
The hysteroscopy then continued as 
normal.  
N =200. 
Speculum inserted, vagina and 
cervix cleaned and the cervix 
grasped with a tenaculum. The 
rigid, 2.7mm (3.5mm with 
sheath) hysteroscope was then 
inserted into the external 
cervical canal and advanced into 
the uterine cavity, using normal 
saline as the distension medium. 
The hysteroscopy then 
continued as normal. N=200. 
 
VAS 0-10cm, pain 
rated immediately after 
the procedure. 
Mean and 
standard 
deviation and 
median and range 
reported. 
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Table 4.4 continued     
Study 
 
Participants
 
Intervention
 
Comparison Outcome measure Data reported 
 
Guida (78)
 
 
Pre- and post-menopausal 
women undergoing diagnostic 
outpatient hysteroscopy. 
Exclusions: active genital tract 
infection, cervical cancer, 
heavy bleeding, severe 
cardiovascular disease and 
suspected pregnancy.  
 
Rigid, 3.5mm minihysteroscope 
introduced into the vagina, which 
was distended with normal saline 
so that the hysteroscope could be 
steered into the external cervical os 
and along the canal into the uterine 
cavity. The hysteroscopy then 
continued as normal. Endometrial 
biopsies were taken when 
indicated. 
N =145. 
 
Speculum inserted in to the 
vagina and if necessary the 
cervix was grasped with a 
tenaculum. The 3.5mm 
minihysteroscope was then 
inserted into the external 
cervical canal and advanced into 
the uterine cavity, using normal 
saline as the distension medium. 
The hysteroscopy then 
continued as normal.  
Endometrial biopsies were taken 
when indicated. N=145. 
 
 
VAS 0-5cm marked 
no, slight, tolerable, 
severe and intolerable 
pain. Asked to rate pain 
at introduction of the 
hysteroscope or 
speculum into the 
vagina, progression 
through the cervical 
canal, inspection of the 
cavity and during the 
endometrial biopsy. 
 
Median and 95% 
confidence 
intervals. 
Paschopoulos (79)
 Pre- and post-menopausal 
women undergoing diagnostic 
outpatient hysteroscopy. 
Rigid, 3.5mm hysteroscope 
introduced into the vagina. Holding 
the labia minora together the vagina 
was distended with normal saline 
and the hysteroscope steered into 
the external cervical os and along 
the canal into the uterine cavity. 
The hysteroscopy then continued as 
normal. 
N=98. 
 
Conventional hysteroscopy. 
N=99. 
VAS 0-10cm Divided into 
groups scoring 
<3, 3 – 5, >5. 
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Table 4.4 continued     
Study 
 
Participants
 
Intervention
 
Comparison Outcome measure Data reported 
Sagiv (33)
 Pre- and post-menopausal 
women undergoing diagnostic 
outpatient hysteroscopy. 
Patients positioned in lithotomy, 
vagina cleaned and the rigid, 
3.7mm hysteroscope introduced 
into the vagina which was then 
distended with normal saline and 
the hysteroscope steered into the 
external cervical os and along the 
canal into the uterine cavity. The 
hysteroscopy then continued as 
normal. Endometrial biopsies were 
performed as necessary. 
N=83. 
 
Traditional hysteroscopy using a 
rigid, 3.7mm hysteroscope and 
normal saline, with an 
intracervical injection of local 
anaesthetic. 
N=47. 
VAS 0-10cm used to 
score the pain 
immediately and 15 
minutes after the 
hysteroscopy. 
 
Mean and 
standard 
deviation 
reported. 
Sharma (32)
 Pre- and post-menopausal 
women undergoing diagnostic 
outpatient hysteroscopy. 
Rigid, 3.5mm or 5mm hysteroscope 
introduced into the vagina, which 
was distended with normal saline 
so that the hysteroscope could be 
steered into the external cervical os 
and along the canal into the uterine 
cavity. The hysteroscopy then 
continued as normal. Endometrial 
biopsies were taken when 
indicated. 
N =60. 
Speculum inserted in to the 
vagina and the cervix was 
grasped with forceps. Cervical 
canal dilated if necessary and 
local anaesthetic given if 
requested by the patient. Either 
a 3.5mm or 5mm rigid 
hysteroscope was then inserted 
into the external cervical canal 
and advanced into the uterine 
cavity, using normal saline as 
the distension medium. The 
hysteroscopy then continued as 
normal.  Endometrial biopsies 
were taken when indicated 
N=60. 
 
VAS 0-10cm, rated at 
insertion of 
hysteroscope, 
inspection of cavity, 
insertion of speculum, 
administration of local 
anaesthetic, 
endometrial biopsy, at 
the end of the 
procedure and 30mins 
after the procedure. 
Medians and 
ranges. 
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Five papers reported data on the feasibility of the vaginoscopic procedure versus the 
traditional hysteroscopy (31-33;77;78). Feasibility was assessed using the number of failed 
procedures (i.e. failure to adequately visualise the uterine cavity) in each of the study arms.  
 
Effect of vaginoscopy on pain 
Meta-analysis of four studies showed that in the outpatient setting, the use of the vaginoscopic 
approach to hysteroscopy was less painful than using the traditional technique with a vaginal 
speculum (SMD -0.44, 95%CI -0.65 to -0.22, I
2 
= 58%) (Figure 4.14).  
 
Figure 4.14 Forest plot showing the results of meta-analysis of studies that examine the 
use of a vaginoscopic approach to outpatient hysteroscopy 
 
 
One of these studies was considered ‘poor’ quality (79) as it only met one of the three quality 
criteria. When this study was excluded from meta-analysis, the magnitude of reduction in pain 
favouring vaginoscopy was not significantly altered and results were more homogenous 
(SMD -0.52, 95%CI -0.71 to -0.33, I
2 
= 30%) (Figure 4.15). Neither of the two papers 
included in the systematic review that could not be included in the meta-analysis (32;78) 
reported any significant differences in the mean pain scores between the vaginoscopic and the 
traditional hysteroscopy groups. However one of the studies (78) found that the 95% 
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confidence interval in the vaginoscopic group was significantly lower than in the traditional 
hysteroscopy group (p<0.05).  
 
Figure 4.15 Forest plot showing the results of meta-analysis of the high quality studies 
that examine the use of a vaginoscopic approach to outpatient hysteroscopy 
 
 
Feasibility 
There was no significant difference in the number of failed procedures between the 
vaginoscopic and traditional approaches to hysteroscopy p=0.38 (Figure 4.16). 
 
Figure 4.16 Forest plot showing the results of meta-analysis of the studies that report 
feasibility of the vaginoscopic approach to outpatient hysteroscopy 
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Results of the systematic review of the effect of distension media on pain 
during outpatient hysteroscopy  
 
Study Selection, Details and Quality 
The literature search yielded 703 citations; twenty were retrieved for further evaluation. 
Eleven studies were rejected because they did not meet the inclusion criteria (34;36-38;60;93-
98)  and two were rejected as duplicates (64;93). The seven remaining studies were selected 
as eligible for inclusion in the review (35;60;64;80-83); however it became apparent that two 
of these papers may have reported the same study (81;99). The authors were contacted to 
confirm this, however no answer was received. To prevent probable duplication of data only 
the earliest published paper was used (81) resulting in six papers being eligible for the review 
(Figure 4.17).  The inter-rater reliability for the study selection was very good (kappa=0.85). 
 
Details of the study populations, interventions, outcome assessment and data reporting are 
shown in Table 4.5. The quality of the studies was poor with only one considered to have 
adequate randomisation and concealment (81) this study was randomised by computer and so 
it was assumed that it was also concealed. 
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Figure 4.17 Study selection process for systematic review of the effect of distension 
media on pain during outpatient hysteroscopy 
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Table 4.5 Characteristics of the selected studies included in the systematic review of the effect of the distension medium used on pain 
during outpatient hysteroscopy. 
Study 
 
Participants
 
Intervention
 
Comparison Outcome measures Data reported 
Brusco (80)
 
Women attending for 
hysteroscopy at an 
artificial insemination and 
sterility clinic. 
External genitalia cleaned 
with disinfectant. Outpatient 
hysteroscopy performed with 
a 4mm rigid hysteroscope and 
a 7mm operative sheath by a 
vaginoscopic approach. 
Normal saline delivered by a 
pressure bag (at 50mmHg) 
used to distend the uterine 
cavity. A paracervical block 
was used when necessary.  
N =45. 
External genitalia cleaned with 
disinfectant. Outpatient 
hysteroscopy performed with a 
4mm rigid hysteroscope and a 
7mm operative sheath by a 
traditional approach using a 
speculum and tenaculum. 
Carbon dioxide delivered by a 
uterine insufflator at 40ml/min 
used to distend the uterine 
cavity. A paracervical block 
was used when necessary.  
N =29. 
Scale of 0-5 to score 
pain during the 
procedure. Also, 
presence of shoulder 
pain was recorded.  
Operators graded the 
quality of the image on a 
scale from 0-5 (5= good 
image quality).  
Time from introduction 
of the hysteroscope until 
the removal at the end of 
the procedure. 
 
Pain and procedure 
time reported as mean 
and standard deviation. 
Number and 
percentage of women 
experiencing shoulder 
tip pain reported. 
Image quality reported 
as percentages. 
Lavitola (81)
 
Infertile women 
undergoing diagnostic 
outpatient hysteroscopy. 
  
Vaginoscopic hysteroscopy 
with a 30 degree continuous 
flow hysteroscope, using 
normal saline as the 
distension medium introduced 
by a pressure bag at 50-
120mmHg measured by a 
manometer. An endometrial 
biopsy was taken when 
indicated.  
N =97. 
Vaginoscopic hysteroscopy 
with a 30 degree continuous 
flow hysteroscope, using 
carbon dioxide as the 
distension medium introduced 
by uterine insufflator at a 
pressure of 100mmHg. An 
endometrial biopsy was taken 
when indicated.  
N =92. 
VAS 0-10 used to score 
pain during progression 
of the scope through the 
canal, during inspection 
of the cavity, and the 
intensity of any shoulder 
pain. 
 The image quality was 
scored by the operator 
on a scale of 0-5           
(5 = excellent).  
The incidence of 
vasovagal episodes. 
 
Mean and standard 
deviation for pain and 
procedural time. 
Number and 
percentage of women 
experiencing vasovagal 
episodes and having 
examinations with 
mediocre image 
quality. 
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Table 4.5 continued     
Study 
 
Participants
 
Intervention
 
Comparison Outcome measures Data reported 
 
Litta (82)
 
 
Pre- and post-menopausal 
women undergoing 
diagnostic outpatient 
hysteroscopy. 
  
 
Speculum inserted in to the 
vagina to visualise the cervix. 
Rigid, 2.9mm, 30 degree 
hysteroscope, introduced into 
the cervical os and along the 
canal into the uterine cavity 
which was distended with 
normal saline infused by a 
100mmHg pressure bag.  
Endometrial biopsies were 
taken when indicated. 
N =214. 
 
Speculum inserted in to the 
vagina to visualise the cervix. 
Rigid, 2.9mm, 30 degree 
hysteroscope, introduced into 
the cervical os and along the 
canal into the uterine cavity 
which was distended with 
carbon dioxide administered 
by a hysterosufflator with a 
pressure of 100mmHg and 
flow rate of 40ml/min. 
Endometrial biopsies were 
taken when indicated. 
N =201. 
 
 
VAS 0-10 completed 
approximately 10 
minutes after the end of 
the procedure to rate the 
pain experienced.  
 
Procedure duration.  
 
Presence of shoulder tip 
pain. 
 
Mean and standard 
deviation for pain and 
procedural time. 
Number and 
percentage of women 
experiencing shoulder 
tip pain. 
Nagele (83)
 
Pre- and post-menopausal 
women undergoing 
diagnostic outpatient 
hysteroscopy. 
Speculum inserted in to the 
vagina. Os probed and if 
thought to be tight ,dilated 
under local anaesthesia. 
Rigid, 5.5mm , 30 degree 
hysteroscopy with normal 
saline infused by a 150-
250mmHg pressure bag. 
Targeted endometrial biopsies 
and minor surgical procedures 
were performed when 
indicated using a 7mm 
operative sheath. 
N =78.  
Speculum inserted in to the 
vagina. Os probed and if 
thought to be tight ,dilated 
under local anaesthesia .Rigid, 
5.5mm , 30 degree 
hysteroscopy with carbon 
dioxide distension media 
administered by a 
hysterosufflator at 100mmHg. 
Targeted endometrial biopsies 
and minor surgical procedures 
were performed when 
indicated using a 7mm 
operative sheath. 
N =79. 
 
Abdominal pain and 
shoulder tip pain ranked 
on a scale of 0-4. (0= no 
pain, , 4= very severe 
pain). 
 
Image quality was 
graded on a scale of 0-4 
(0= none, 1= good, 2 = 
adequate, 3= poor, 4= 
very poor). 
 
Incidence of vasovagal 
episodes. 
 
Procedure duration. 
Abdominal pain, 
shoulder pain, 
hysteroscopic vision 
and procedural time 
were all reported as 
means and standard 
deviations. The 
number of women 
experiencing shoulder 
pain and vasovagal 
episodes were also 
reported as numbers. 
The number of poor or 
very poor image 
examinations was 
reported. 
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PPI= Present pain intensity scale (verbal descriptors of pain ranked from 0-5 on a numeric scale).  VAS= visual analogue scale
Table 4.5 continued     
Study 
 
Participants
 
Intervention
 
Comparison Outcome measures Data reported 
Paschopoulos (35)
 
Women admitted for total 
abdominal hysterectomy 
who agreed to undergo 
outpatient diagnostic 
hysteroscopy 12-24 hours 
prior to surgery. 
Exclusions: suspicion of 
endometrial cancer 
Hysteroscopy performed with 
a 2.8mm, 30 degree, rigid 
hysteroscope by a 
vaginoscopic approach. 
Normal saline delivered by a 
pressure bag (40-80mmHg) 
used to distend the uterine 
cavity.   
N =35. 
Hysteroscopy performed with 
a 2.8mm, 30 degree, rigid 
hysteroscope by a 
vaginoscopic approach. 
Carbon dioxide was delivered 
by a microhysteroflator with a 
maximum pressure of 
200mmHg and a flow rate of 
25ml/min to distend the uterine 
cavity.   
N =39. 
 
Completed a 
questionnaire after the 
hysteroscopy which 
asked patients to rate 
shoulder pain and pelvic 
pain on a 4 point scale 
(0= none, 1= mild, 
2=severe, 3= pain which 
did not allow the 
procedure to continue). 
 
Number and 
percentage of women 
in each group selecting 
each of the four 
categories. Values 
were allocated to the 
categories i.e. 0, 1, 2, 3 
and calculated the 
mean and standard 
deviation. 
Shankar (64)
 
Pre- and post-menopausal 
women undergoing 
diagnostic outpatient 
hysteroscopy for abnormal 
uterine bleeding. 
Exclusions: procedure not 
feasible as unable to 
visualise the cervix or 
severe cervical stenosis. 
Speculum inserted in to the 
vagina to visualise the cervix. 
Vulsellum applied. Cervix 
dilated if necessary. Rigid, 
5.5mm (with sheath), 30 
degree hysteroscope, 
introduced into the uterine 
cavity which was distended 
with normal saline infused by 
a 150-250mmHg pressure 
bag.  Endometrial biopsies 
were taken from all patients. 
N= 100. 
 
Another saline group had 
lignocaine added to the 
distension medium. This 
group was not used in the 
analysis. N=100 
Speculum inserted in to the 
vagina to visualise the cervix. 
Vulsellum applied. Cervix 
dilated if necessary. Rigid, 
5.5mm (with sheath), 30 
degree hysteroscope, 
introduced uterine cavity 
which was distended with 
carbon dioxide, delivered by a 
hysteron-insufflator  at a 
maximum pressure of 
100mmHg with a variable flow 
rate of up to 100ml/min. 
Endometrial biopsies were 
taken from all patients. 
N= 100. 
 
Pelvic pain was scored 
with VAS 0-10, and PPI.  
 
Shoulder tip pain scored 
with VAS 0-10.  
 
The image quality was 
ranked as very 
satisfactory, satisfactory 
or unsatisfactory.  
 
 
 
 
 
 
 
 
Pelvic pain reported as 
mean and standard 
deviation.  
 
Shoulder tip pain 
reported as percentages 
with 95% confidence 
intervals. Percentages 
were converted to 
numbers. 
 
Image quality reported 
as number of 
examinations falling 
into each category. 
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Effect of distension media on pain 
All six studies reported data for pain when comparing normal saline versus carbon dioxide as 
the distension media for the procedure. Five studies used scales to collect the data (64;80-83) 
and reported them as means and standard deviations. One study reported the number of people 
selecting each of four numbered categories (0= none, 1= mild, 2=severe, 3= pain which did 
not allow the procedure to continue) (35). The category number was used as a value and the 
mean and standard deviation were calculated (90) for the pain experienced during the 
procedure. Meta-analysis showed that there was no significant difference in pain scores when 
carbon dioxide or normal saline were used as the distension medium for outpatient 
hysteroscopy (SMD= -0.05, 95% CI -0.17 to 0.07, I² = 92%) (Figure 4.18). 
 
Figure 4.18 Forest plot showing the effect of distension media on procedural pain during 
outpatient hysteroscopy 
 
 
Effect of distension media on shoulder tip pain 
Shoulder tip pain was reported by all six studies. One study used a visual analogue scale to 
assess the severity of the pain and reported a mean and standard deviation (81). The 
remaining five studies (35;64;80;82;83) reported the number of events or the percentage of 
women that experienced shoulder tip pain. If the number of events were not reported (64;82) 
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the value was calculated from the percentage. Meta-analysis of five studies found that 
shoulder tip pain was significantly reduced when using normal saline as compared to carbon 
dioxide as the distension medium (OR = 0.19, 95% CI 0.09 to 0.40, I²= 41%) (Figure 4.19). 
 
Figure 4.19 Forest plot showing the effect of distension media on shoulder tip pain 
during hysteroscopy 
 
 
Effect on vasovagal episodes 
Vasovagal reactions were specifically reported by four studies (35;81-83), one of which 
reported no vasovagal episodes (82). The two studies that didn’t report vasovagal episodes did 
report symptoms that may be attributed to vasovagal episodes (nausea, dizziness, 
hypotension) (64;80) but did not specifically state them to be vasovagal reactions. The 
number of events from the three studies (35;81;83) that stated the patients had suffered 
vasovagal episodes were used for meta-analysis and it was found that there were significantly 
fewer vasovagal episodes when using normal saline as the distension medium (OR = 0.31, 
95% CI 0.12 to 0.82, I²= 0%) (Figure 4.20). 
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Figure 4.20 Forest plot showing the effect of distension media on vasovagal episodes 
during outpatient hysteroscopy 
 
 
Effect on duration of the procedure 
Procedural time was reported by four studies (80-83) as means and standard deviations. Meta-
analysis found that outpatient hysteroscopy using normal saline was significantly shorter than 
when using carbon dioxide (SMD=-1.32, 95% CI -1.48 to -1.17, I² =98%) (Figure 4.21). 
 
Figure 4.21 Forest plot showing the effect of distension media on procedural time for 
outpatient hysteroscopy 
 
 
Effect of distension media on image quality 
Image quality was reported by four studies (64;80;81;83).  Three studies used scales with 
categories (e.g. 0= no view, 1= poor view etc.) (80;81;83) and asked the operators to select 
the appropriate number. One study used this data to calculate a mean and standard deviation 
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(83). The remaining two studies (80;81) reported the number of operators selecting from 
certain categories but did not give data for all of the categories. The final study (64) used 
unnumbered categories (very satisfactory, satisfactory, unsatisfactory) and asked the operators 
to select an appropriate one. Data for the ‘very satisfactory’ category were reported in the text 
and for the ‘unsatisfactory’ category in a table, thus allowing calculation of the number of 
operators selecting the ‘satisfactory’ category.  Data from the studies could not be meta-
analysed as they were not adequately reported and outcome assessments were not comparable. 
Three studies reported no significant difference in image quality between carbon dioxide and 
normal saline (80;81;83), however one of these studies (83) reported changing the distension 
media from carbon dioxide to normal saline in 8 (10.1%) patients. One study found a 
statistically significant increased risk of unsatisfactory view with the use of carbon dioxide 
(Relative risk (RR) =4.75, 95% CI 1.61, 16.4) attributing it to bubbles, and bleeding (64). Of 
the 19 patients who had an unsatisfactory view at hysteroscopy using carbon dioxide, 17 were 
changed to normal saline and an improved view reported in 11 (64.7%).  
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Results of the systematic review of the effect on pain of the type of 
hysteroscope used for outpatient hysteroscopy 
 
Study Selection, Details and Quality 
From 214 citations, 212 were rejected on methodological grounds or because they were 
duplicates. That left just two studies (84;85) which were selected for review (Figure 4.22).  
 
Figure 4.22 Study selection process for systematic review of the effect on pain of the type 
of hysteroscope used for outpatient hysteroscopy 
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Both selected studies were randomised controlled trials that compared flexible with rigid 
hysteroscopes, using normal saline as the distension medium. The inter-rater reliability for the 
study selection was very good (kappa=0.84). Pain scores were assessed on 10cm visual 
analogue scales in both studies. Both studies assessed pain immediately after the procedure 
(84;85) and one assessed pain during the procedure (85). The study characteristics and results 
are shown in Table 4.6.  
 
Pain during the procedure was found to be significantly less when the flexible hysteroscope 
was used (flexible median pain score 1.2, rigid median pain scores 3.1, p = 0.0001 (85)). 
Immediately after the hysteroscopy the studies reported different results, with one finding a 
significantly lower pain score when a flexible hysteroscope was used (flexible pain scores 
mean 1.8, median 1.2 versus rigid pain scores mean 4.0, median 3.6, p= 0.0001) (84) and the 
second finding no difference between pain scores (median 0 in flexible and rigid groups) (85). 
 
No vasovagal episodes occurred in the single study reporting this outcome (84). Image quality 
was assessed by the hysteroscopists and reported in both studies. One study (84) reported that 
the view was good to excellent in all examinations whereas the other study (85) reported a 
significantly better view with the use of the rigid hysteroscope (p< 0.001). There were no 
failures in the rigid hysteroscopy groups, however one of the studies (85) reported five 
failures in the flexible hysteroscopy group. This is reported as ‘(5/40) 12.5%’ in the paper, 
however there were 70 rather than 40 patients in the group which results in a 7.2% failure 
rate. One of the studies found use of a rigid hysteroscope to be significantly quicker than 
using a flexible scope (p = 0.003) (85) in contrast to the second paper which reported similar 
procedure times in both groups (flexible 5.9 minutes, rigid 6.1 minutes) (84).
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Table 4.6 Overview of the studies included in the systematic review of the effect on pain of the type of hysteroscope used for outpatient 
hysteroscopy including interventions and results 
 
 
Baxter (84)
 
Unfried (85)
 
Design 
 
Randomised controlled trial Randomised controlled trial 
Randomisation Computer generated random number sequence Computer generated random permutation list with 36 
blocks of length four 
 
Blinding Single blinded Not reported 
 
Follow-up 100% 100% 
 
No. in flexible group 40 70 
 
No. in rigid group 43 72 
 
Intervention After a vaginal examination to assess uterine size and 
position, a Cusco’s speculum was inserted and the 
cervix was visualized and cleaned. When necessary, the 
anterior lip of the cervix was grasped gently with a 
tenaculum. Occasionally a local anaesthetic block was 
used. Hysteroscopy was then performed with either a 
3mm flexible hysteroscope (Olympus Keymed, 
Southend-on Sea, UK) or a 3.3mm rigid scope, 
including sheath (Storz, Slough, UK). The distension 
medium was warmed normal saline at a pressure of up 
to 100 mmHg.  
The procedure was performed according to a standard 
protocol which is not described in the paper. Lignocaine 
spray was applied to the cervix before the hysteroscopy 
and occasionally an additional local anaesthetic block 
was used. Hysteroscopy was then performed with either 
a 3.6mm flexible hysteroscope with 100° bending 
section (Olympus HYF type P, Hamburg, Germany) or 
a 3.7mm rigid hysteroscope with a 30° fore oblique lens 
(WISAP, Munich, Germany). The distension medium 
was normal saline at a pressure of 120-200 mmHg. 
 
   
78 
 
Table 4.6 continued   
 Baxter (84) 
 
Unfried (85)
 
Method of scoring pain Analogue pain scale measuring 10 cm long, with a score 
of 0 at one end corresponding to having ‘no pain at all’ 
and 10 at the other being ‘the worst pain they have ever 
had’. Completed immediately and 30 minutes after the 
hysteroscopy. 
 
A 10cm visual analogue scale completed before the test, 
at insertion of the hysteroscope, during and immediately 
after the hysteroscopy and at endometrial biopsy. 
Pain score in flexible group During hysteroscopy- not reported 
 Immediately after- mean 1.8, median 1.2 
During hysteroscopy- Median 1.2 
Immediately after – 0 
 
Pain score in rigid group During hysteroscopy- not reported  
Immediately after- mean 4.0, median 3.6 
During hysteroscopy- Median 3.1 
Immediately after – 0 
 
P value of pain score difference During hysteroscopy- not reported 
Immediately after p= 0.0001 
During hysteroscopy- p<0.001  
Immediately after- p= NS 
 
Vasovagal episodes in flexible group 0 Not reported 
 
Vasovagal episodes in rigid group 0 Not reported 
 
Failures in flexible group 0 5 (7.2%) –reported as 12.5% in the paper. 
 
Failures in rigid group 0 0 
 
Quality of image in flexible group Excellent to good 66% excellent to good 
 
Quality of image in rigid group Excellent to good 100% excellent to good 
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CHAPTER 5 
 
DISCUSSION REGARDING THE RESULTS OF THE 
SYSTEMATIC REVIEWS AND META-ANALYSES WHICH 
INVESTIGATE PAIN REDUCTION IN OUTPATIENT 
HYSTEROSCOPY 
 
Principal findings of the reviews 
 
The systematic review of local anaesthetic found that pain is reduced during outpatient 
hysteroscopy with paracervical and intracervical injections of anaesthetic but not with 
transcervical and topical application. Paracervical injection appears to be the most effective 
method of administering local anaesthetic for the procedure. Local anaesthetic did not 
significantly reduce the incidence of vasovagal attacks during outpatient hysteroscopy but 
there was a beneficial trend.  
 
The analgesia systematic review found that opiates may reduce the pain of outpatient 
hysteroscopy during the procedure but not without significant side effects, although some of 
the symptoms experienced (nausea, vomiting, dizziness) could be attributed to the procedure. 
In one study the side effects attributed to buprenorphine caused high rates of patient 
dissatisfaction, demonstrating the importance of considering whether the benefit of pain relief 
outweighs medication side effects. A study, examining mefenamic acid found a significant 
reduction in post-operative pain at 30 and 60 minutes. 
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Conscious sedation with midazolam was found to be as effective as intracervical local 
anaesthetic for reducing pain during outpatient hysteroscopy. Sedation requires regular 
monitoring and may be associated with inadvertent overdose, requiring reversal. 
Hysteroscopists will be experienced in administering an intracervical block but will have far 
less experience in the use of conscious sedation and are unlikely to feel confident to manage 
the sedation without an anaesthetist or a second clinician. Additionally, ambulatory 
gynaecologists who perform colposcopy are already familiar with techniques for anesthetising 
the cervix when taking biopsies. Thus to ensure patient safety and reduce the number of 
trained staff required, alternatives to conscious sedation should be used for outpatient 
hysteroscopy. 
 
The studies used in the systematic review of cervical preparation examined different drug 
doses and administration times and assessed pain at different time points. Similarly, 
effectiveness of cervical priming was assessed in a variety of ways. This heterogeneity made 
meta-analysis unfeasible and interpretation of the results problematic. However the following 
conclusions were drawn from the results. Mifepristone given before hysteroscopy does not 
have any significant effect on the pain experienced during the procedure or dilatation of the 
cervix in premenopausal women. Cervical priming with prostaglandins is beneficial in 
reducing pain when dilating the cervix beyond 6mm but this is likely to be greater in 
postmenopausal women. Pain on inserting the hysteroscope and during the hysteroscopy is 
reduced when using large diameter hysteroscopic systems (4mm endoscopes with 5.5mm 
sheath) but miniaturisation of the instruments used in the outpatient setting means that there is 
rarely any need to dilate the cervix above six millimetres thus these findings are, in the most,  
clinically irrelevant.  It was demonstrated that prostaglandins do not have significant adverse 
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effects when compared to placebo and do not increase the number of failed procedures, 
however the negligible benefit means that the routine use of cervical priming prior to 
outpatient hysteroscopy cannot be recommend. 
 
The review of vaginoscopy for outpatient hysteroscopy found that the vaginoscopic approach 
to hysteroscopy significantly reduces the pain experienced by patients during the procedure. 
The vaginoscopic technique is successful as demonstrated by the majority of hysteroscopies 
being completed successfully (83-98%) and there being no significant difference in the 
number of failed procedures between groups of patients undergoing a vaginoscopic 
hysteroscopy and a traditional outpatient hysteroscopy using a vaginal speculum. However 
whilst a reduction in pain is clearly advantageous in outpatient procedures to optimise 
acceptability to patients, the review did not demonstrate any improvement in procedural 
feasibility (i.e. successful completion of hysteroscopy) as a consequence of minimising 
discomfort. 
 
There is no significant difference in pain experienced between carbon dioxide and normal 
saline when used as the distension medium for outpatient hysteroscopy. However, meta-
analysis found that vasovagal episodes, shoulder tip pain and procedural time were all 
significantly reduced when using normal saline. Image quality may be better with normal 
saline as it causes a lavage and so prevents blood and bubbles obscuring the view.  
 
Flexible hysteroscopy causes less pain than rigid hysteroscopy in the outpatient setting. Rigid 
hysteroscopy may provide a better image, resulting in fewer failed procedures and be quicker 
to perform although these results were not consistently reported. Mean pain scores were low 
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with both types of hysteroscope (≤4) and so without further qualitative assessment it is 
difficult to assess the clinical relevance of the lower pain score associated with flexible 
hysteroscopy, especially when procedure times may be more prolonged (85) and more likely 
to fail (85) with a non-rigid endoscope. Whilst the current review did not evaluate test 
accuracy, the superior image quality with rigid hysteroscopy reported in one study (85) may 
further offset any clinical advantage of a less painful procedure using a flexible instrument.   
 
Strengths and limitations of the reviews 
 
Many aspects of the reviews support their results being valid. Firstly, clinically focused 
questions were formulated. Comprehensive searches were then performed which 
encompassed multiple online databases as well as searching of the reference sections of 
relevant studies. The searches were not restricted to the English language and broad search 
terms were used to avoid making the question too specific to be adequately sensitive. 
Unpublished data were not sought and therefore there is a risk of publication bias. Data were 
restricted by the study design to randomised controlled trials to minimise selection bias. 
Excepting the review of local anaesthesia, all of the reviews contained small numbers of 
studies which limits the conclusions. However, although there was paucity of studies the 
reviews did contain the totality of published, randomised data.  Meta-analysis was not always 
possible making it difficult to draw conclusions for the examined elements of hysteroscopy in 
some of the reviews. 
 
For the systematic review of local anaesthetic the studies were sub-grouped according to 
quality to examine for the overall heterogeneity. Heterogeneity was reduced in the high 
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quality sub-group, but I
2 
was still 83%. Meta-analysis of the high quality studies found a 
significant reduction in pain with the use of local anaesthetic, a finding which was consistent 
with and thus supportive of the overall findings. Intracervical injection of local anaesthetic 
was associated with a significant reduction in pain during outpatient hysteroscopy, but the 
strength of this finding is limited. This is because a sensitivity analysis excluding a study in 
which categorical data had been transformed, demonstrated no beneficial effect of 
intracervical injection, although this finding was associated with increased heterogeneity.  
Reasons for heterogeneity could not be examined in the method of administration sub-groups 
due to the paucity of studies.  
 
Out-patient hysteroscopy is a multi-faceted procedure and so there are many factors that 
contribute towards pain. These can be categorised into patient factors (e.g. menopausal status, 
reason for hysteroscopy) and procedural factors (e.g. the type of distension media, use of a 
speculum, use of a rigid or flexible hysteroscope). The small number of studies in the review 
of local anaesthesia meant that there were not enough data to sub-group the patients according 
to menopausal status and indication for hysteroscopy. Confounding due to procedural factors 
should be eradicated on the basis of the study designs being restricted to randomised 
controlled trials in this review.  
 
There were further limitations in the study of the cervical preparation, mainly due to the 
heterogeneity of the studies. Although the majority of studies gave 400µg misoprostol (71;74-
76) the administration times varied between the studies from four, to twenty-four hours before 
the procedure. One study used mifepristone as a priming agent (72) and so was incomparable 
with the other five studies The studies varied in the timing of pain assessment with some 
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assessing pain during cervical dilatation whilst others assessed pain during or after the 
procedure. Similarly, cervical dilatation was assessed in a non-uniform manner, some studies 
assessing the force needed to dilate and others assessing change in dilatation from baseline or 
dilatation pre-procedure.  The study populations differed so that conclusions regarding 
menopausal status and the use of cervical priming agents were limited. 
 
Only the abstract was available for one of the studies included in the vaginoscopy systematic 
review (79) and only limited information about the study method was available hence it was 
graded as low quality. However, the five remaining RCT’s were all considered to be of high 
quality. All of the studies used a tenaculum in the ‘traditional’ hysteroscopy arm and thus it 
was not assessed whether there was a significant pain reduction when there is no cervical 
instrumentation. Whilst all studies included in the review compared vaginoscopy with a 
traditional approach to hysteroscopy utilising a vaginal speculum, there were some minor 
procedural differences between the studies (e.g. use of intracervical local anaesthetic (33), 
varying distension media between the arms of the study (77)), however heterogeneity was low 
in all analyses, showing consistency of findings across studies in favour of vaginoscopy. 
Effectiveness of the procedure in sub-groups of patients (e.g. pre- versus post-menopausal, 
nulliparous versus parous) could not be assessed as all of the studies included mixed 
populations. There were no studies which used flexible hysteroscopes for vaginoscopy or that 
compared vaginoscopy to flexible hysteroscopy. 
 
There was considerable heterogeneity (I
2 
=92%) in the meta-analysis of procedural pain when 
comparing distension media for outpatient hysteroscopy. Because the random effects model 
gives more weight to small studies, one small study (80) with an outlying result was excluded 
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to explore heterogeneity. As well as being small this study used a vaginoscopic approach 
(without a speculum and tenaculum) in the normal saline group and a traditional approach 
with a speculum in the carbon dioxide group and so had more than one variable. Analysis 
without this study reduced the heterogeneity to 82% but still produced a non-significant result 
overall (SMD = 0.06, 95% CI -0.24 to 0.37). No causes for heterogeneity were identified but 
may be attributable to the small number of studies used for the meta-analysis.  
 
Heterogeneity was also high in the meta-analysis of procedural time (I
2 
=98%), again this was 
difficult to explain. All of the studies in this analysis found individual significant results in 
favour of the use of normal saline, which were in keeping with the meta-analysis result. In 
contrast, heterogeneity was low in the meta-analyses exploring vasovagal episodes and 
shoulder tip pain. A weakness of this distension media review is that it only contains six 
studies, five of which were assessed to be of low quality due to inadequate randomisation and 
concealment and two of which have small populations. However, as already mentioned, these 
data reflect the totality of the published trials in this area.  Although statistically significant 
results were found it was not possible to assess whether they were clinically significant. 
 
Comparison with other studies 
 
The systematic reviews that examine local anaesthetic, vaginoscopy, cervical preparation and 
distension media have been published in peer reviewed journals (100-103) since this thesis 
was undertaken. Prior to that there were no published systematic reviews that addressed 
methods to relieve pain during outpatient or office hysteroscopy.  The conclusions of these 
reviews were unique in having been drawn from the available primary studies.  
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A Cochrane review had assessed the use of paracervical injection for a variety of obstetric and 
gynaecological procedures including hysteroscopy, endometrial biopsy, fractional curettage, 
vacuum aspiration, suction termination of pregnancy or evacuation of retained products of 
conception and bimanual removal of retained placenta (14). Only three studies involving 
hysteroscopy were included in the review and only two in the meta-analysis so their 
conclusion that the use of paracervical injection does not reduce the pain of ‘uterine 
intervention’ cannot be applied specifically to hysteroscopy. The meta-analysis of 
paracervical injection in this systematic review contains five studies assessing paracervical 
anaesthesia in hysteroscopy and so has greater power, adding weight to the findings. 
Moreover, intracervical and topical administration of local anaesthesia is more commonly 
practised in ambulatory hysteroscopy than paracervical approaches (6). The systematic review 
of local anaesthesia described in this dissertation assesses all routes of local anaesthetic 
administration thereby providing relevant guidance to clinicians for one of the most 
commonly practised interventions in gynaecology. Similarly, a Cochrane review published in 
2012 examined analgesics and local anaesthetics (104) but did not separate the anaesthetics 
according to method of administration. This review agreed that local anaesthetics were 
successful at reducing pain during outpatient hysteroscopy but by failing to look at method of 
administration it is difficult to make clinical inferences and decide how to administer the 
anaesthetic for maximum effect. In fact, the review of local anaesthetic in this thesis was able 
to demonstrate that the topical methods of administration do not have any benefit in pain 
reduction and thus provide clinically useful information.  
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The Cochrane review of local anaesthetics and analgesia (104) concluded that there was 
insufficient evidence for the use of analgesics prior to outpatient hysteroscopy which is in 
keeping with the review conducted for this thesis. A review that assessed the use of analgesia 
for hysterosalpingogram (HSG) found that when using analgesia versus placebo there was no 
benefit of using the analgesia during the procedure, however there was a benefit 30 minutes 
post-procedure (105). This is in keeping with the results of the outpatient analgesia review 
and although it refers to a different procedure, HSG is an outpatient test which also involves 
distension of the uterus in a similar way to hysteroscopy.  
 
A systematic review of the use of paracervical local anaesthesia for cervical dilatation and 
uterine intervention (14) assessed conscious sedation versus cervical block for hysteroscopy 
and bimanual removal of placenta and found there to be no difference in pain between the 
sedated patients and those receiving local anaesthetic. This is in keeping with the findings of 
the only study retrieved in the review of conscious sedation. 
 
A review that examined the use of misoprostol prior to hysteroscopy (studies examining 
procedures under general anaesthetic and in the office) (24) found that misoprostol given to 
premenopausal women reduced the need for cervical dilatation as well as the incidence of 
cervical laceration. However, vaginal bleeding, abdominal cramping and fever were 
significantly increased in the misoprostol groups.  No significant difference was found 
between the control and intervention groups in postmenopausal women. These results conflict 
with the findings of the review of cervical preparation for outpatient hysteroscopy, mainly 
because the majority of the studies examined were assessing the use of misoprostol for 
inpatient hysteroscopy which routinely requires cervical dilatation because of the use of larger 
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instruments. Secondly as most of the patients were anaesthetised the review was unable to 
assess pain during the procedure. The systematic review of cervical dilatation for outpatient 
hysteroscopy was only able to meta-analyse a small number of studies to assess the adverse 
effect of prostaglandins and thus the result may underestimate their true incidence. 
 
Two recent systematic reviews have examined the use of misoprostol given prior to 
hysteroscopy (106;107). The first examined the benefits and harms of misoprostol given prior 
to operative hysteroscopy with hysteroscopes of greater than 9mm in diameter. These 
procedures were not carried out in the outpatient setting but despite the use of much larger 
hysteroscopes, there was still no benefit of using misoprostol for dilatation of the cervix or in 
reducing complications. Similarly to the review by Crane et al. (24), side effects were 
significantly increased in the group of women who had taken misoprostol. This is not in 
keeping with the results found in this thesis as discussed above. The second review (107) 
investigated the feasibility of using misoprostol to facilitate the passage of the hysteroscope 
and the side effects associated with the medication. Pain during the hysteroscopy was not 
assessed. Studies that included inpatient and outpatient procedures were included, resulting in 
17 studies being eligible. However, this will have caused heterogeneity as the size of 
hysteroscopes used will vary. The authors do not discuss this. This review found that 
misoprostol significantly reduced the need for cervical dilatation in the total population but 
when the women were analysed according to menopausal status there was no significant 
difference for either pre or postmenopausal women. The difference found for women overall 
may have been driven by the studies which used large hysteroscopes and although the 
differences were statistically significant they may not be clinically significant. Once again, the 
presence of side effects was significantly increased in the misoprostol group. The authors 
89 
 
concluded that there was not enough evidence to recommend routine use of misoprostol prior 
to hysteroscopy.  
 
A large case series of five thousand patients found that carbon dioxide and normal saline were 
both feasible distending media, with no difference in success rate but that there were 
significantly more vasovagal episodes and shoulder tip pain when carbon dioxide was used 
(93). This is in keeping with the findings of the distension media review.  
 
Clinical implications of the reviews 
 
Injectable, preferably paracervical, administration of local anaesthetic should be used for out-
patient hysteroscopy to reduce the amount of pain that women experience. Topical application 
of local anaesthetic does not reduce the pain of the hysteroscopy but should be used when 
applying a tenaculum to the cervix. Only one study examined the use of local anaesthetic for 
operative hysteroscopy (60) and therefore the results do not adequately address the benefit of 
local anaesthetic in this variation of the procedure.   
 
Although these conclusions show a benefit of using local anaesthetic, data reviewing the 
harms could not be reviewed. This is because harms were not explicitly reported by the 
majority of studies except when referring to symptoms caused by vagal stimulation 
(hypotension, bradycardia, nausea, vomiting etc.) although it is possible that similar 
symptoms may arise from intravasation of injected local anaesthetic. Therefore side effects 
resulting from the use of local anaesthetic for outpatient hysteroscopy are likely to be 
underestimated. For example, the time taken to perform the block prolongs the procedure and 
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the pain scores may not take into account the pain experienced during injection of local 
anaesthetic, in itself a painful procedure. In fact it was found in one study that a vaginoscopic 
approach to hysteroscopy was significantly less painful than having the procedure done 
traditionally using a vaginal speculum and a local anaesthetic block (33).  
 
Good pain control is important to ensure an efficient outpatient ‘ambulatory’ hysteroscopy 
service with rapid discharge and high levels of patient satisfaction (6;108). When prescribing 
analgesia non-steroidal anti-inflammatories should be preferred to opioids as they have fewer 
side effects but should be avoided in certain patient groups (asthmatics, history of peptic 
ulceration, allergy).  
 
For investigation of the gastrointestinal tract, which cannot be anaesthetised and may require 
quashing of the gag reflex, conscious sedation is an invaluable resource.  However, conscious 
sedation requires an experienced clinician to monitor the degree of sedation and possibly 
reverse the medication (15) and this is an unfamiliar entity to the gynaecologist. As there is no 
benefit of conscious sedation over paracervical block (a technique familiar to the 
hysteroscopist and administrable by them) it would seem that conscious sedation should be 
avoided for outpatient hysteroscopy. 
 
The review of cervical preparation suggests that routine use of prostaglandins prior to 
outpatient hysteroscopy would not provide a clinically significant change in dilatation or pain 
and although no significant adverse effects were found, other systematic reviews of their use 
suggest that this may have been underestimated. A further clinical consideration is the added 
cost of using cervical preparations. As well as the cost of the drugs there may be increased 
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costs related to the added intervention, such as extra clinic appointments and management of 
adverse effects. There may need to be a facility for administering the vaginal drugs, especially 
in elderly women.  Whether they are admitted for the prostaglandin and stay until the 
procedure or they go home between, there will be significant inconvenience for the patient 
and a possible impact on hospital beds. The final consideration is patient acceptability. 
Patients may prefer to have a short period of discomfort during the procedure, rather than 
abdominal cramping and vaginal bleeding for hours beforehand.  
 
The findings that vaginoscopy is associated with significantly reduced procedural pain and 
comparable feasibility, compared with traditional speculum assisted and cervical 
instrumentation approaches to office hysteroscopy have clinical implications for clinical 
practice. Outpatient hysteroscopy is a common diagnostic and increasingly therapeutic 
intervention (e.g. polypectomy, sterilisation) and vaginoscopy is not widely taught or 
practised (6). The findings of this review however, strongly support vaginoscopic outpatient 
hysteroscopy as the technique of choice. Although it was not examined by this review, it is 
proposed that the vaginoscopic approach allows greater intracavity manoeuvrability of the 
hysteroscope as there is no restriction on external movement caused by the presence of a 
vaginal speculum. This is particularly advantageous in certain patient groups (e.g. restricted 
hip abduction / flexion, inability to lie supine due to respiratory disease, obesity, enlarged or 
acutely flexed uteri) and when access to the tubal ostia is required, for example, during 
hysteroscopic sterilisation (109). In addition, nulliparous women, those who have not been 
sexually active, have atrophy of the genital tract or who find intimate examinations distressing 
are likely to find the vaginoscopic approach more acceptable as it obviates the need for 
stretching the vagina by a bivalve speculum. Traditional hysteroscopy, with a vaginal 
92 
 
speculum and possibly cervical instrumentation, will still be necessary in the minority of 
cases where visualisation of the cervical canal is difficult (e.g. deficient intravaginal cervix, 
previous cone biopsy) or cervical stenosis is encountered.  A vaginal speculum is also 
required when a global endometrial biopsy is indicated although there are new developments 
in global hysteroscopic endometrial sampling (110). Adopting a first-line approach of 
vaginoscopy allows visualisation of the uterine cavity with a subsequent recourse to either 
directed hysteroscopic biopsy or global ‘blind’ office sampling of the endometrium.  
 
Normal saline and carbon dioxide are both suitable for outpatient hysteroscopy, as pain 
experienced during the diagnostic procedure is comparable between media. However, normal 
saline is the distension medium of choice in the office setting because it is associated with 
significantly fewer vasovagal episodes and incidences of shoulder tip pain. Furthermore, 
distension of the uterine cavity with normal saline as opposed to carbon dioxide results in a 
quicker hysteroscopic procedure, which is especially advantageous in conscious patients 
undergoing an invasive test. Although image quality could not adequately be assessed two of 
the studies reported changing from carbon dioxide to normal saline when the image was poor 
or obscured by blood (64;83) thus suggesting that normal saline is a more practical medium 
and can cause an improvement in view over carbon dioxide. A further consideration is the 
specialist equipment that is required to use carbon dioxide to distend the uterus. A 
hysterosufflator is required to control insufflation of carbon dioxide into the uterus however 
normal saline can be administered simply with a giving set and gravity or a pressure bag, 
although this can result in leakage of fluid and a more ‘messy’ procedure, compared with 
carbon dioxide. This review did not examine cost-effectiveness of the distension media but 
the increased duration of the procedure and capital outlay for specialist equipment associated 
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with the use of carbon dioxide, for no apparent benefit over normal saline, may not support 
the routine use of carbon dioxide in an outpatient setting from an economic perspective. A 
final, important consideration when choosing distension medium refers to the increasing use 
of therapeutic procedures in outpatient hysteroscopy. These procedures include the use of 
bipolar electrosurgery (6;111) for removing fibroids, polyps, synechiae (112) and septae 
(113;114) which require a conducting liquid medium (i.e. normal saline). Moreover, other 
office interventional procedures using mechanical equipment (115) or where there is a 
likelihood of endometrial fragmentation, necessitate the use of a liquid distension medium to 
maintain visualisation by clearing both blood and debris. Thus performing a diagnostic 
hysteroscopy with normal saline will negate the need to change distending medium should a 
subsequent operative procedure be required (i.e. the ‘see and treat’ ethos). 
 
The review of hysteroscope type was not able to address the differences between the types of 
scope with regards to cost and maintenance. It has been reported that flexible hysteroscopes 
are approximately twice as expensive to purchase (40;116) as rigid hysteroscopes and more 
expensive to sterilise and maintain (116). The clinical implications of this review are that 
when purchasing hysteroscopes, clinicians should consider the advantage of flexible 
hysteroscopy as regards to reduced procedural pain against the potential disadvantages of 
procedure duration, feasibility and cost. 
 
Unanswered questions and future research 
 
These reviews have implications for future research. They highlight the need for large trials 
comparing how the different hysteroscopic techniques (e.g. vaginoscopy versus a traditional 
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hysteroscopy with or without local anaesthesia, type of distension media, use of a flexible or 
rigid scope, cervical preparation etc.) affect pain, feasibility and the incidence of vasovagal 
episodes during outpatient hysteroscopy. Such trials should explicitly define and standardise 
the procedure and systematically examine acceptability and quality of life, in addition to 
alleviation of pain. These qualitative outcomes can then be correlated with pain scores to see 
if any reported reduction in pain during outpatient hysteroscopy is actually clinically 
meaningful. Is the pain that women feel during a hysteroscopy enough to warrant the use of 
anaesthetic? It may cause a significant reduction in the amount of pain experienced, however 
in the majority of studies the mean pain scores felt in the intervention and control groups 
showed little variation and tended to be low anyway. Then it must be considered that case 
selection is important when assessing who will benefit the most from the use of local 
anaesthetic. Parous, pre-menopausal women are less likely to benefit as it is presumed that 
they have less narrowing of the cervical canal, whereas nulliparous post-menopausal women 
who will almost certainly have a degree of cervical stenosis may benefit greatly.  The results 
from these reviews cannot quantify this benefit. It may be that altering different aspects of the 
procedure (e.g. vaginoscopy, warming liquid distension media, distension pressures etc.) can 
reduce the pain significantly without having to use local anaesthetic injection. There are 
obvious cost implications (for equipment and medication, as well as reducing the number of 
people seen in clinic) of using local anaesthetic for every patient who undergoes an outpatient 
hysteroscopy.  
 
Research trials should also evaluate administration of local anaesthetic, analgesics and 
hysteroscopic technique in operative outpatient hysteroscopic surgery, which is becoming 
increasingly prevalent with technological advances in endoscopic instrumentation 
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(6;117;118). The timing of administration needs to be assessed as well as the different 
available drugs and doses and the incidence of adverse effects. It would be prudent to assess 
the benefit of simple analgesics regimens (e.g. paracetamol or ibuprofen) self-administered by 
the patient prior to attending for their examination. The use of ‘rescue analgesia’ once the 
patient has left the hospital may be indicative of the medium term benefit of analgesics and 
this information could also be collected along with qualitative data referring to the patient 
experience and rates of satisfaction.  Additionally, the role of simply administered, short 
acting inhalational sedation (e.g. Entonox
TM 
- nitrous oxide with oxygen) should be examined 
with randomised studies, particularly for therapeutic outpatient hysteroscopic procedures. 
 
It is during blind dilatation of the cervix that perforation of the uterus is most likely to occur. 
There are subgroups of women (previous caesarean section, nulliparous, postmenopausal, 
previous loop biopsy) who more often need dilatation of the cervix to facilitate passage of the 
hysteroscope. A well designed clinical trial should concentrate on these subgroups to assess 
whether the use of prostaglandins provides a clinically significant reduction in pain, reduces 
the need for dilatation and incidence of genital tract trauma and whether these benefits 
outweigh the potential harms (bleeding, laceration, abdominal cramping, fever). As well as 
focussing on certain populations the study should use miniature hysteroscopes to make the 
results clinically relevant to modern practice. If positive results were found, further research 
would be needed to determine optimum dose and timing of administration of the 
prostaglandins.  
 
Large trials are needed to compare vaginoscopy to traditional hysteroscopy using both rigid 
and flexible hysteroscopes. Such trials should explicitly define and standardise the procedure 
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and systematically examine acceptability and quality of life, in addition to alleviation of pain, 
the risk of ascending infection and the incidence of vasovagal episodes. In addition, studies 
need to look a priori at patient factors, such as parity, menopausal status, previous cervical 
biopsy or caesarean section and body mass index to identify patient sub-groups in whom the 
vaginoscopic procedure is less likely to succeed.   
 
An economic analysis should be performed to analyse whether there is any true discrepancy 
regarding cost when different distension media or flexible or rigid hysteroscopes are used for 
outpatient hysteroscopy.  Personal experience is that the majority of clinicians within the UK 
are using normal saline and rigid hysteroscopes and it would be interesting to examine the 
reasons for this with qualitative research. 
 
Summary 
 
The ideal outpatient hysteroscopy would be pain free. However this is impossible and so the 
utmost should be done to minimise pain. The seven systematic reviews conducted suggest that 
in order to optimise success and minimise pain, women undergoing outpatient hysteroscopy 
should take simple analgesia a short time prior to the procedure and the hysteroscopist should 
adopt a vaginoscopic approach using a small diameter, rigid hysteroscope and normal saline 
as the distension medium. If dilatation of the cervix is required, this should be done under a 
paracervical block. The use of cervical preparation and conscious sedation should not be 
routinely used.  
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CHAPTER 6 
 
EVIDENCE QUALITY IN CLINICAL GUIDELINES: A 
COMPARISON OF TWO METHODS 
 
In the 21
st
 century we no longer practice medicine based on our own experience and 
prejudices but try to find real evidence that our practice is not only beneficial but that it does 
not harm and is cost-effective. This process is called evidence based medicine and should be 
the foundation of modern medical care.  
 
Guidelines and protocols are developed using evidence relevant to their topics and this should 
be critically appraised during development. The Royal College of Obstetricians and 
Gynaecologists use the SIGN methodology (119;120) for their clinical, Green-top guidelines, 
which are used to inform practice in Obstetrics and Gynaecology throughout the UK and 
internationally. 
 
‘Quality of evidence’ has been defined as ‘reflecting the extent to which confidence in the 
estimate of an effect is adequate to support recommendations’ (121). Guidelines report the 
quality of the evidence used when formulating recommendations so that clinicians can decide 
how reliable the recommendation might be. Unfortunately, different organisations use 
different methods of grading the quality of evidence which can make interpretation difficult 
(122), particularly if multiple guidelines are being considered. In view of this, the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) working group have 
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developed the GRADE system which is intended as a common, sensible and transparent 
approach to grading the quality of evidence (123) for use in clinical guidelines. The GRADE 
format (122) claims to make it easier for users to assess the judgments behind 
recommendations by tabulating the evidence. 
 
Using the systematic reviews of outpatient hysteroscopy presented in this thesis, a guideline 
was written for the British Society of Gynaecological Endoscopists (BSGE) in the format of 
an RCOG Green-top guideline, entitled ‘Best Practice in Outpatient Hysteroscopy’. This 
guideline has since been published by the RCOG as a formal Green-top guideline (124) and is 
available to clinicians in the UK and abroad (Appendix 4). To investigate how the evidence 
quality would have been graded if the GRADE method was used, evidence profiles were 
created for the outcomes from the outpatient hysteroscopy reviews and compared to the 
gradings in the original guideline.  
 
This chapter examines how assessment of the quality of evidence differs between the GRADE 
and SIGN guideline methods and discusses whether the GRADE method offers significant 
advantages that might benefit the RCOG Green-top guidance. 
 
Methods for comparing SIGN and GRADE for assessing quality of evidence 
 
Using the seven systematic reviews of outpatient hysteroscopy (described in previous 
chapters), a guideline was written entitled ‘Best Practice in Outpatient Hysteroscopy’ on 
behalf of the British Society of Gynaecological Endoscopists (BSGE). The guideline was 
developed with two NHS consultants and used the RCOG methods of guideline development 
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(119) which grades the quality of evidence and recommendations using the Scottish 
Intercollegiate Guideline Network (SIGN) model (125) (Table 6.1). The final guideline was 
published as a greentop guideline by the RCOG in association with the BSGE. The full 
guideline can be reviewed in Appendix 4 
Table 6.1 SIGN method for classification of evidence for clinical guidelines (120) 
Classification of evidence levels 
1++ High-quality meta-analyses, systematic reviews of randomised controlled 
trials or randomised controlled trials with a very low risk of bias 
1+ Well-conducted meta-analyses, systematic reviews of randomised 
controlled trials or randomised controlled trials with a low risk of bias 
1- Meta-analyses, systematic reviews of randomised controlled trials or 
randomised controlled trials with a high risk of bias 
2++ High-quality systematic reviews of case–control or cohort studies or high-
quality case–control or cohort studies with a very low risk of confounding, 
bias or chance and a high probability that the relationship is causal 
2+ Well-conducted case–control or cohort studies with a low risk of 
confounding, bias or chance and a moderate probability that the 
relationship is causal 
2- Case–control or cohort studies with a high risk of confounding, bias or 
chance and a significant risk that the relationship is not causal. 
3 Non-analytical studies, e.g. case reports, case series 
4 Expert opinion 
  
Grades of Recommendation 
 
A At least one meta-analysis, systematic reviews or RCT rated as 1++, and 
directly applicable to the target population; or A systematic review of  
RCTs or a body of evidence consisting principally of studies rated as 1+, 
directly applicable to the target population and demonstrating overall 
consistency of results. 
B A body of evidence including studies rated as 2++ directly applicable to 
the target population, and demonstrating overall consistency of results; or 
extrapolated evidence from studies rated as 1++ or 1+ 
C A body of evidence including studies rated as 2+ directly applicable to the 
target population, and demonstrating overall consistency of results; or 
extrapolated evidence from studies rated as 2++ 
D Evidence level 3 or 4; or extrapolated evidence from studies rated as 2+ 
 
 
Recommended best practice based on the clinical experience of the 
guideline development group 
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On reviewing Table 6.1 it is clear that by using the SIGN classification method, even the most 
poorly conducted randomised controlled trial (RCT) can at worst be classified as 1- and any 
recommendations that arise from this evidence will be graded as an A or B. Similarly, a 
rigorous observational study can at best be judged as 2++ and recommendations arising from 
it classified as C level evidence. This system puts the emphasis on trial design and not on trial 
quality.  
 
The GRADE guideline method examines eight determinants of quality; five which can lead to 
downgrading of evidence ( limitations of the study design, inconsistency, indirectness, 
imprecision and  publication bias) and three which can lead to upgrading of the evidence 
(strong association,  evidence of a dose-response gradient and possible dilution due to 
confounding). Randomised controlled trials start as high quality and are downgraded as 
appropriate and observational studies start as low quality and are upgraded as appropriate. 
The results of this evaluation are then tabulated as GRADE evidence profiles. The studies 
within the meta-analysis or the individual study that provides the evidence for 
recommendations must be evaluated for each of the outcomes and a decision made whether 
there is enough concern to downgrade the quality of the evidence. The hysteroscopy guideline 
only used randomised controlled trials and so in this evaluation the emphasis was on 
downgrading.  
 
’Limitations of the study design’ relates to the methodology of the studies and downgrades 
the quality if there are concerns about randomisation method, allocation concealment, 
blinding, reporting of pre-stated outcomes and loss to follow-up or inappropriate analysis (e.g. 
not analysed as intention to treat). When ‘inconsistency’ is considered, studies are 
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downgraded if there is heterogeneity that cannot be explained or if the point estimates vary 
widely with little overlap of the confidence intervals. When the systematic review or studies 
assess a different population, use surrogate outcomes or comparisons are not head-to-head, 
the evidence should be downgraded for ‘indirectness’. ’Imprecision’ considers the size of the 
study population to assess whether it is adequate to answer the point in question and examines 
the width of confidence intervals to assess if the clinical action would differ if the true point 
estimate lies at the upper or lower limit of the confidence interval. The final criterion for 
downgrading is ‘publication bias ‘which is likely if there are only a few small studies, 
duplicate publications or the studies are unrepresentative (all in English, all find a significant 
effect).  Studies can be upgraded if there is a strong association (relative risk greater than 2 or 
less than 0.5), if there is evidence of a dose-response gradient or if the presence of 
confounding factors may have diluted the perceived result. However, it is recommended that 
studies with limitations are not upgraded. 
 
To examine how the quality of evidence in the hysteroscopy guideline would be graded if the 
GRADE system was used evidence profiles were drawn for each of the recommendations in 
the hysteroscopy guideline, that had been directly drawn from the systematic reviews 
(chapters 2-5) using GradeProfiler (126). The GRADE tables are displayed in Appendix 5 
with the recommendations and quality gradings from the original guideline. Each profile was 
made up of a number of elements which addressed different aspects of the clinical question 
e.g. when asking which type of distension media to use, five elements were investigated, (i) 
pain, (ii) shoulder tip pain, (iii) vasovagal episodes, (iv) procedure time and (v) unsatisfactory 
view. This GRADE table is displayed below as an example (Table 6.2)
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Table 6.2 GRADE evidence table examining the evidence for using different types of distension medium for outpatient hysteroscopy 
 
Quality assessment No of patients Effect 
Quality Importance 
No of 
studies 
Design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Normal 
saline 
Carbon 
dioxide 
Relative 
(95% CI) 
Absolute 
Pain score (Better indicated by lower values) 
6 randomised 
trials 
very 
serious
1
 
serious
2
 no serious 
indirectness 
no serious 
imprecision 
none 540 569 - SMD 0.34 higher (0.12 
lower to 0.8 higher) 
 
VERY 
LOW 
CRITICAL 
Shoulder tip pain 
5 randomised 
trials 
very 
serious
1
 
no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 9/472  
(1.9%) 
55/448  
(12.3%) 
OR 0.19 (0.09 
to 0.4) 
97 fewer per 1000 (from 
70 fewer to 110 fewer) 
 
LOW 
CRITICAL 
Vasovagal episodes 
3 randomised 
trials 
very 
serious
1
 
no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
reporting bias
3
 5/210  
(2.4%) 
18/210  
(8.6%) 
OR 0.31 (0.12 
to 0.82) 
57 fewer per 1000 (from 
14 fewer to 75 fewer) 
 
VERY 
LOW 
IMPORTANT 
Procedure time (Better indicated by lower values) 
4 randomised 
trials 
very 
serious
1
 
no serious 
inconsistency
4
 
no serious 
indirectness 
no serious 
imprecision 
none 434 401 - SMD 1.32 lower (1.48 to 
1.17 lower) 
 
LOW 
IMPORTANT 
Unsatisfactory hysteroscopic view  
1 randomised 
trials 
very 
serious
1
 
no serious 
inconsistency 
no serious 
indirectness 
serious
5
 reporting bias
6
 4/100  
(4%) 
19/100  
(19%) 
RR 4.75 (1.61 
to 16.4) 
712 more per 1000 (from 
116 more to 1000 more) 
 
VERY 
LOW 
CRITICAL 
1 Poor randomisation methods (quasi-randomised in some cases) and lack of allocation concealment in most studies. Neither patient nor operator was blinded but this would not be possible. 
2 High heterogeneity that cannot be explained by differences in technique. 
3 Outcome reported in just three of the six identified trials. 
4 High heterogeneity but all studies in favour of normal saline and heterogeneity can be explained by the two studies that don't using a speculum showing the largest effect size. 
5 Single study therefore imprecise. 
6 This is the only study that reports a difference.
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The importance of each aspect was determined by clinicians and not patients; however this 
judgment does not contribute to the assessment of evidence quality and therefore was not felt 
to be a significant omission. A score was then allocated to the quality assessment in its 
GRADE and SIGN forms, with the highest quality rating awarded four points and the lowest 
(see Table 6.3), one point. The difference between the two methods could then be quantified. 
 
Table 6.3 Score allocated to the quality of evidence gradings as determined by SIGN and 
GRADE 
Score SIGN GRADE 
4 A High 
3 B Moderate 
2 C Low 
1 D Very low 
 
To investigate which of the five aspects of the GRADE method (study limitations, 
indirectness, inconsistency, imprecision and publication bias) were most often chosen as 
reasons to downgrade the quality of the evidence, points were allocated to each aspect in the 
GRADE evidence profiles as detailed in Table 6.4.  When there was ‘no risk’ of bias the score 
allocated was ‘0’, When there was ‘serious risk’ of bias a score of ‘1’ was allocated and if 
there was ‘very serious’ risk of bias a score of ‘2’ was given. The aspect ‘publication bias’ 
can only be downgraded to ‘serious’ and so in this category a score of ‘2’ was not possible. 
There were 37 elements examined using evidence profiles and so the maximum point 
allocation for each aspect was 74 (37 x 2), except for ‘publication bias’, which was just 37. 
  
104 
 
Table 6.4 Scores applied to the downgrading aspects of the GRADE profile elements 
GRADE aspect 
 
Risk Score 
 
Study limitations 
 
No serious risk 
Serious 
Very serious 
 
0 
1 
2 
 
Inconsistency 
 
As for ‘study limitations’ 
 
Indirectness 
 
As for ‘study limitations’ 
 
Imprecision 
 
As for ‘study limitations’ 
 
Publication bias 
 
Undetected 
Strongly suspected 
 
0 
1 
 
Results of the comparison of SIGN and GRADE for assessing quality of 
evidence 
 
The differences between the allocated quality scores for the evidence behind each 
recommendation were plotted graphically (Figure 6.1). 
Figure 6.1. Quality rating according to SIGN and GRADE methodology and the 
difference between the two scores. 
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Eleven of the recommendations from the SIGN guideline were converted into GRADE 
evidence profile tables with 37 elements. Figure 6.1 above shows the points allocated to each 
recommendation by SIGN and GRADE. It then shows the value when the GRADE rating is 
subtracted from the SIGN rating to show the difference between the two methods. A positive 
results shows that SIGN estimates the quality as higher than GRADE, a result of zero shows 
that the assessment was the same in both systems and a negative result shows that GRADE 
assessed the evidence quality as higher than SIGN.  The figure illustrates that SIGN has a 
tendency to grade evidence as higher quality than GRADE because all of the 
recommendations were allocated a positive results when the scores were subtracted. None of 
the recommendations were assessed as being the same level of quality by both of the 
guidelines. The points difference ranged from one to three points. 
 
Figure 6.2. Reasons for downgrading the quality of evidence for guideline 
recommendations when using the GRADE system. 
 
 
Figure 6.2 shows the contribution of each quality aspect to downgrading of the evidence. It 
gives an overview of the quality of the evidence used throughout the guideline. It is clear that 
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the most common reasons for downgrading evidence were ‘study limitations’,’ imprecision’ 
and ‘publication bias’. This is consistent with studies which have small populations and are 
poorly conducted and also reflects the paucity of data available. However, Figure 6.2 also 
suggests that the studies addressed the right questions and were reasonably homogenous as 
‘indirectness’ and ‘inconsistency’ were rarely selected as reasons to downgrade the evidence.  
Evidence for all recommendations was downgraded and so upgrading was not appropriate.  
 
Discussion of the comparison of SIGN and GRADE for assessing quality of 
evidence 
 
Guidelines need to make clear recommendations. If the recommendations are open to 
interpretation they become unfit for purpose and rather than guiding practice can cause 
confusion and hesitancy. However, these recommendations can only be based upon the 
available evidence and it is important that the quality of the evidence is taken into account 
when making recommendations about health care. This evaluation of two different systems of 
assessing available evidence to formulate guideline recommendations showed that the 
GRADE and SIGN methods produced varying estimates of the quality of evidence. This may 
not be surprising given that the systems adopt different methodologies. The GRADE 
approach aims to demonstrate the available evidence in a transparent fashion that allows the 
users of the guideline to understand why recommendations are afforded their weight. In 
contrast the SIGN guideline system uses an alternative method of grading the quality of 
recommendations which is based on the hierarchy of published data, with systematic reviews 
and meta-analysis at the top, followed by randomised controlled trials and then observational 
studies.  
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Guideline developers have focused upon the quality of available evidence to inform 
recommendations but other considerations need to be taken into account especially as often 
the evidence available is of poor quality. These factors include the potential for an 
intervention to cause harm and its cost. For example, if we have an intervention that is cheap 
and unlikely to be harmful, we may recommend its use (if there is no better alternative) even 
if the quality of the studies showing benefit are of poor quality. However, if the intervention 
had the potential to cause significant harm or was prohibitively expensive we would be 
unlikely to recommend it. Thus, it is clear that when formulating recommendations from the 
available evidence, the benefits and harms of the intervention need to be taken into account in 
addition to the quality of the evidence.  
 
The GRADE method considers these additional aspects when making recommendations but 
they do not form part of the quality of evidence judgment.  SIGN rates quality according to 
study design with little consideration of the outcomes or publication bias. This is a simple 
system in which the user identifies the trial design and decides if there is any risk of bias. 
Although this method is subjective the classifications system dictates that all 
recommendations from RCT’s or meta-analysis of RCT’s will receive a high quality grading 
of A or B even if there is a high risk of bias. Conversely, GRADE focuses less on study type 
and considers multiple aspects of the available data when assessing quality. It is designed to 
be standardised and systematic (121;127;128) implying that if different people were presented 
with the same body of evidence and asked to produce GRADE evidence tables they would all 
come to  the same conclusions regarding quality. However, a Spanish group examined the 
introduction of the GRADE system into oncology guidelines and looked at how different 
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groups of clinicians rated the same evidence. For the same aspect of care, three groups rated 
the body of evidence as ‘low’ quality, nine as ‘moderate’ quality and three as ‘high’ quality 
(129). This casts doubt about the reproducibility of the GRADE system and is likely to be due 
to factors inherent to the process.  
 
The GRADE system is complicated (130) and time-consuming (128) because users must 
consider multiple aspects during their quality assessment, each of which is open to some 
degree of subjectivity. How does one decide whether the limitation identified is downgraded 
to ‘serious’ or ‘very serious’? This is probably based on the individual’s prior knowledge and 
experience of working with clinical studies. Users need to have some academic training to 
understand the concepts behind each of the quality categories. Whilst most clinicians 
understand different methods of randomisation and what is meant by ‘allocation 
concealment’, when it comes to the more complicated criteria which require assessment of the 
statistics or indicators of heterogeneity it is understandable that many would feel out of their 
depth. Secondly, these judgments are also affected by the user’s expectations of trial design 
and quality. Whilst an academic would prefer that the most rigorous methods are used at all 
times, a clinician might recognises that the practicalities of running a study dictate that the 
ideal methods cannot always be used if they are not pragmatic and would have jeopardised 
trial recruitment. In these cases the clinician may feel that the best methods for the studies in 
question were selected and  that downgrading is not warranted, whilst the academic may 
decide to downgrade to ‘very serious’ risks of bias. In the SIGN method this subjectivity will 
only downgrade the quality of the recommendations to a B at worst but in the GRADE 
system, if this subjectivity is present in multiple aspects of the quality assessment the data 
could easily be assessed as high / moderate quality by one assessor and low / very by another.  
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Thus a criticism that could be justifiably levelled at the GRADE system is that it appears to 
have been developed by academics for academics. If the increased complexity of GRADE 
compared to other methods results in clinical guideline developers failing to understand the 
process clearly (131) then this will limit GRADE from achieving the objective of being 
standardised. One potential solution is to produce alternative methods of data display to make 
guidelines more user friendly for clinicians, who are ultimately the end users. Clinicians may 
find the guidance less confusing and easier to assimilate if only the outcome of the quality 
assessment was presented to them but they understood that this judgment was made after a 
rigorous assessment, using the GRADE methodology. Thus, the intimidating GRADE 
evidence profile tables, displaying cumbersome volumes of data (132) along with the 
rationale for upgrading or downgrading evidence quality could be dispensed with.. This 
would be reminiscent of the SIGN guidelines which display the result of quality assessment 
but don’t explain the reasoning for reducing (-) or increasing (++) the quality within the text. 
However, as already discussed, the SIGN classification, which uses numbers and letters, does 
not reliably convey the quality of evidence. Graphical representation of the GRADE evidence 
profiles may prove more useful than the tables as it allows clinicians to quickly interpret the 
data and make a judgment at a glance, without having to read lots of text (133). In addition 
graphical display enables quick and easy comparison of the data quality for competing 
strategies. Graphical display of GRADE data using radar charts and traffic light systems have 
been suggested (132;134) although they are yet to be validated. 
 
The current study is a comparison of two methods for assessing evidence quality for just one 
guideline. Future research should assess other guidelines in a similar way to evaluate whether 
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GRADE is indeed associated with more conservative grading of evidence quality and whether 
the magnitude of differences are similar to the current study . If this is the case, then research 
addressing the clinical significance of using the GRADE system upon existing 
recommendations would be needed. In addition further research should examine how 
clinicians interpret quality gradings when they are displayed in different formats, including 
tables, diagrams and codes. 
 
In summary, when comparing the GRADE and SIGN methods for grading the quality of the 
evidence used in the guideline for ‘Best Practice in Outpatient Hysteroscopy’ the two 
different systems produced varying estimates of the quality of evidence. Furthermore, 
GRADE appeared to rate the evidence less highly than SIGN. It is evident from this 
assessment that neither GRADE nor SIGN offer a perfect solution to the assessment of 
evidence quality when it comes to writing clinical guidance. Whilst SIGN may be too 
simplistic and under or overestimate quality, GRADE is too complex which results in it being 
used incorrectly and the judgments not being reproducible. The GRADE system in its current 
form may need to be adapted so that results are displayed in a more user-friendly style, 
possibly by the incorporation of diagrams to present the evidence quality. A hybrid system 
which uses GRADE to assess the quality but displays only the result of the quality assessment 
in the guideline may prove to be the most manageable form of guidance for clinicians. 
Furthermore, high quality evidence is far from ubiquitous, and so the benefits, harms and 
costs of interventions should also have an influence upon the degree of evidence quality 
required in order to make a particular recommendation.   
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CHAPTER 7 
 
INTRODUCTION TO THE ECONOMIC ANALYSIS OF 
DIAGNOSTIC STRATEGIES FOR THE INVESTIGATION OF 
HEAVY MENSTRUAL BLEEDING 
 
The following economic analysis forms a small part of a report that was written for the 
National Institute for Health Research, Health Technology Assessment programme. The 
report investigated the cost-effectiveness of diagnostic tests in the management of all types of 
abnormal uterine bleeding. It is due to be published in late 2013. 
 
Heavy Menstrual Bleeding 
 
HMB affects 1 in 5 women of reproductive age, with 5% of women aged 30-49 consulting 
their General Practitioner each year because of the condition and accounting for a third of all 
gynaecology referrals (135). The overall prevalence of HMB in England and Wales has been 
estimated at 1.5 million women (136). The number and cost of consultations and treatments 
impose substantial demands on health service resources (137;138). Moreover, HMB can cause 
significant distress to women by affecting their performance at work as well as their social 
activities, and imposes a substantial adverse impact upon health-related quality of life 
(HRQL) (139-141).  The National Institute for Clinical Excellence in their 2007 guideline into 
the management of heavy menstrual bleeding (HMB) recommended the condition be defined 
as “excessive menstrual blood loss which interferes with the woman’s physical, emotional, 
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social and material quality of life, and which can occur alone or in combination with other 
symptoms” (142). This clinical definition is the most useful one as using objective 
measurement, with loss of > 80 ml of blood per cycle considered definitive of HMB (143), is 
impractical. More applicable semi-objective measurement, using pictorial blood loss 
assessment of sanitary ware (144;145) as a surrogate for objective measurement, has been 
tried but the correlation between objective and semi-objective quantification  has been 
questioned (144). In any case, objective quantification of menstrual loss does not correlate in 
many cases with a woman’s subjective complaint of HMB (146-148).  
 
Causes of heavy menstrual bleeding 
 
Heavy menstrual bleeding has been reported to be caused by a variety of underlying 
pathologies (142). However, whilst many conditions have been linked to HMB, in practice 
most cases are attributed to fibroids, endometrial pathology or dysfunctional uterine bleeding 
(DUB) and subsequent treatment is dictated by the presence or absence of these conditions 
(Table 7.1). 
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Table 7.1 Causes of heavy menstrual bleeding 
Cause 
 
 Definition 
Dysfunctional uterine bleeding  The occurrence of irregular or excessive uterine bleeding in the 
absence of identifiable organic pathology (142). 
 
Uterine fibroids   Smooth-muscle tumours of the uterus, generally benign 
(>99%). They vary in size from millimetres to tens of 
centimetres, and are associated with heavy periods, pressure 
symptoms and occasionally pain. They are responsive to 
oestrogen and progesterone, so tend to shrink after the 
menopause (142). 
 
Endometrial pathology: 
 Polyps 
 
 
 
 
 Hyperplasia 
 
 
 
 
 Cancer 
  
Focal outgrowths within the uterine cavity, containing a 
variable amount of glands, stroma and blood vessels which 
influence their macroscopic appearance. Usually benign with 
less than 1% frankly malignant (6). 
 
Endometrial hyperplasia is a proliferation of endometrial glands 
with structural abnormalities and crowding. If the nuclei exhibit 
cytological atypia the hyperplasia is classified as atypical (149) 
and is considered pre-malignant. 
 
Well-differentiated carcinoma is distinguished from atypical 
hyperplasia by the presence of endometrial stromal invasion 
(149). Both conditions are rare in premenopausal women. 
 
 
Diagnosis of heavy menstrual bleeding 
The current National Institute for Health and Clinical Excellence (NICE) guideline advocates 
full gynaecological examination and taking a full blood count to exclude anaemia (142). This 
guideline (142) recognises the need for diagnostic tests to evaluate the uterus, namely 
endometrial biopsy, ultrasound scan and hysteroscopy in specific cases. These tests are 
described in Table 7.2. 
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Table 7.2 Description of currently used tests for the diagnosis of uterine pathology 
Test  Description (adapted from CG44 NICE 
Heavy Menstrual Bleeding Guideline 
2007 (142)) 
 Capability 
   
Tests primarily for detecting structural abnormalities   
Transvaginal 
Ultrasound 
(TVS) 
 
 A method of imaging the genital tract in 
women using high-frequency sound waves 
that bounce off body structures to create a 
picture on a screen. The ultrasound 
transducer is inserted directly into the 
vagina so that it closer to pelvic structures 
than with the conventional transabdominal 
technique. 
 Diagnoses 
endometrial, focal 
intracavity (polyps, 
submucous 
fibroids) 
myometrial and 
adnexal pathology  
Saline infusion 
ultrasound 
 
 This is an extension of transvaginal 
ultrasound. Prior to the ultrasound, saline is 
injected into the uterine cavity to distend it 
and provide better visualisation of the 
anatomic structures within it by providing a 
liquid-solid interface. 
 As for TVS but 
with enhanced 
diagnosis of focal 
intracavity 
pathology 
Outpatient 
hysteroscopy 
 A hysteroscopy is an examination of the 
inside of the uterus using an endoscope. The 
hysteroscope is carefully passed through the 
vagina and cervix and into the uterine cavity 
to allow direct visualisation. During the 
procedure a biopsy may be taken for 
examination.  
 
 Diagnoses 
endometrial and 
focal intracavity 
pathology 
 
Tests primarily for detecting histological abnormalities 
 
  
Endometrial 
biopsy  
 
 
 A sample of endometrial tissue is obtained 
blindly using a sampler which is passed 
through the cervix and uses suction to obtain 
the tissue. This can then be histologically 
examined 
 Diagnoses 
endometrial 
pathology at a 
histological level. 
Dilatation and 
curettage  
 
 A procedure performed under general 
anaesthetic in which the cervix is 
mechanically dilated and a curette is 
introduced into the uterine cavity to scrape 
away a sample of endometrial tissue. 
 
 As for endometrial 
biopsy 
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Current diagnostic pathways for heavy menstrual bleeding 
It is only in the last 25 or so years, that evaluation of the uterine cavity in women with HMB 
symptoms has moved on from dilatation of the cervix and curettage of the endometrium lining 
from the uterine cavity (D&C). This test is now used only in exceptional circumstances as it 
requires general anaesthesia and has been superseded by outpatient endometrial biopsy, which 
obtains endometrial tissue samples for histological analysis in a convenient outpatient setting 
without the need for anaesthesia (150;151). Moreover, the development of high resolution 
transvaginal ultrasound (TVS) has allowed female pelvic structures, including the uterus, to 
be visualised. The ‘inside’ of the uterus i.e. the uterine cavity, cannot normally be seen 
without effecting distension using a fluid or gaseous medium to separate the opposing walls 
of the uterus. This potential limitation of TVS has been overcome by the advent of saline 
infusion sonography (SIS) (152-154) and outpatient hysteroscopy. These tests, described in 
Table 7.2, provide different, albeit overlapping information and diagnostic accuracy varies 
according to the particular pathology under scrutiny.  NICE guidance from 2007 recognised 
that “…particular investigative methods were better for identifying certain types of pathology 
than others.” 
 
Thus, the availability of different, easy to use, miniature and increasingly portable ‘bed side’ 
tests has created uncertainty as to how best to employ them. This is particularly true in HMB 
where different aetiologies need to be considered and the preceding clinical history, and more 
often than not the examination too, are unable to predict causation with accuracy. As a result 
current testing is eclectic, depending upon the preferences of individual clinicians and the 
availability of services locally. 
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Literature review of cost-effectiveness studies for the diagnostic work up of 
heavy menstrual bleeding  
 
A systematic search was performed of Medline and Embase electronic bibliographic 
databases using the terms ‘heavy menstrual bleeding’ and ‘cost-effectiveness’ along with their 
MeSH terms. 350 articles were identified once duplicates had been removed. Three relevant 
economic evaluations of diagnostic tests used for evaluating HMB were identified. One 
evaluation took place alongside an RCT (155) and the other two were economic modelling 
studies (142;156).  
 
Cost-effectiveness was examined in a RCT conducted between 1999-2001 in Scotland 
comparing three outpatient diagnostic tests (outpatient biopsy, ultrasound and hysteroscopy) 
for the evaluation of  abnormal uterine bleeding (AUB) in certain test combinations (155). 
Women were split into high, moderate and low risk groups for endometrial cancer. Resource 
use tended to be higher in the moderate- and low-risk women, because of the need to manage 
their persistent abnormal bleeding symptoms. Minimal difference in cost-effectiveness was 
found between investigation options in the high-risk group (postmenopausal), with the option 
involving hysteroscopy being marginally better than ultrasound (£88/woman, compared with 
the other options). The most cost-effective investigation in the moderate-risk group was 
biopsy alone (saving £128–212/ woman better) and in the low-risk group ultrasound (£74–
452/woman better).  
 
The mixed population of women with AUB, i.e. women of reproductive age with HMB and 
postmenopausal women with unexpected vaginal bleeding, limits clinical inferences because 
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the aim of investigation of women with PMB is to exclude endometrial cancer whereas in pre-
menopausal women it is to optimise management of benign pathology. The authors of this 
RCT (155) highlight this themselves by stating “…in future research into the evaluation and 
management of AUB, postmenopausal women should be studied separately from 
premenopausal women with menstrual bleeding problems”. Furthermore, the primary end-
point defining ‘effectiveness’ was based upon the premise that a satisfactory diagnosis must 
have been reached once no further investigation had been carried out, as identified by 
retrospective case note review. Clearly such an indirect assumption of effective diagnosis, 
whilst expedient, is unlikely to be a reliable or valid measure of effectiveness and does not 
take account of patient-centred outcomes (e.g. satisfaction, reduction in bleeding, survival 
etc.).  
 
As well as economic data from effectiveness studies, an alternative approach to assessment of 
cost-effectiveness of diagnostic testing is to employ decision-analytic modelling. Two 
economic evaluations of diagnostic testing in HMB using decision analytic modelling have 
been published (142;156). The first of these analyses was conducted from the perspective of 
the Dutch Health Care system and compared the percentage of patients treated successfully 
and the cost of six strategies for the evaluation of HMB: (0) hormonal treatment, (I) treatment 
of all patients with balloon ablation, (II) TVS and therapeutic hysteroscopy, (III) TVS, SIS 
and therapeutic hysteroscopy, (IV) SIS and therapeutic hysteroscopy, and (V) diagnostic 
hysteroscopy and therapeutic hysteroscopy. Hormonal treatment was considered to be the 
reference strategy to which the five strategies were compared. The study found that the 
strategy starting with SIS (IV) and the strategy with diagnostic hysteroscopy (V) revealed the 
highest number of patients treated successfully for HMB. However, the diagnostic strategy 
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based upon initial evaluation with SIS was the most cost-effective strategy for successful 
treatment of HMB, especially when the prevalence of intracavity pathology (polyps, 
submucous fibroids) was high. Study weaknesses limit to some degree the validity and 
stability of these findings. These included problems with construction of the decision model 
(limited pathologies were taken into account e.g. diagnosis of intramural fibroids and 
endometrial disease were not considered), the use of outmoded treatments (e.g. use of long 
term systemic progestogen) and overlooked ambulatory outpatient based treatment.  Failure 
rates of testing were unaccounted for, the precision and quality of data sources used for 
estimating test accuracy were questionable and the definition of therapeutic effectiveness was 
unclear. The findings of the analysis were sensitive to changes in the key assumptions and so 
the robustness of the results is questionable.  
 
The other decision-analytic model was developed to examine the cost- effectiveness of three 
imaging techniques; TVS, SIS and hysteroscopy from an NHS perspective (142). The model 
showed that TVS was more accurate and less costly than either SIS or hysteroscopy. For a 
cohort of 1000 women examined for the presence of structural abnormalities, ultrasound 
generated 810 correct diagnoses at a cost of £107,490 compared with 735 correct diagnoses at 
a cost of £145,110 using saline infusion sonography and 696 correct diagnoses at a cost of 
£209,720 using hysteroscopy. Although the economic analysis was conducted from an NHS 
perspective, the general applicability of the model is limited due to its simplistic construction. 
Women were assumed to have one of two health states: ‘no intrauterine pathology’, or ‘any 
intrauterine pathology’ and the outcome measure chosen was ‘correct diagnosis’. This was a 
pragmatic choice given the scope of the guideline (142) such that it was not possible to 
construct a model designed to take into account the range of pathologies under consideration 
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for HMB, and the associated range of treatment pathways. The impact on cost-effectiveness 
of women falsely diagnosed was not considered (the model did not follow women beyond an 
initial diagnosis) so that the model does not reflect the true longer term costs and outcomes 
associated with each diagnostic method. Moreover, diagnosis was restricted to one test, 
whereas this does not reflect contemporary practice where multiple testing is likely, either 
conducted simultaneously or conditional on previous test results. 
 
The relative dearth of comprehensive diagnostic cost-effectiveness data in women with HMB 
reflects the complexity of care pathways (i.e. the varied outpatient tests available, the range of 
uterine pathologies) and the relatively recent introduction of minimally invasive, ‘ambulatory’ 
or ‘outpatient’ treatments. 
 
Current treatment of heavy menstrual bleeding 
 
Medical therapy 
According to the recent NICE guideline on HMB, medical treatments should be considered 
where (i) structural and histological abnormalities of the uterus have been excluded; (ii) for 
fibroids < 3 cm in diameter which do not appear to distort the cavity of the uterus or (iii) 
where future fertility is required (142). The first line recommended medical treatment by 
NICE is the levonorgestrel-releasing intrauterine system (LNG-IUS or Mirena®, Bayer 
Healthcare Pharmaceuticals, Pittsburg, PA, USA) which is an effective non-surgical treatment 
for HMB, is reversible, contraceptive and fertility sparing. In the majority of cases, the device 
is fitted easily within a few minutes in the outpatient setting. Endometrial proliferation is 
suppressed as a result of local release of the synthetic progestogen levonorgestrel (LNG) and 
120 
 
this leads to a reduction in estimated menstrual blood loss of up to 96% by 12 months, with 
up to 44% of users reporting amenorrhoea, (157;158) at a cost which is a third of that for 
hysterectomy (159). However, the LNG-IUS can lead to troublesome break through bleeding 
and vaginal discharge in some women, causing early discontinuation of the device. The LNG-
IUS works effectively in a relatively normal sized uterus (<11cm sound length) without 
distortion by focal pathology (160) i.e. in DUB or the presence of small uterine fibroids (<12 
week uterine size) which do not encroach into the uterine cavity (161). Local release of 
progestogen can also reverse endometrial hyperplasia without atypia (162;163). Thus the 
LNG-IUS is applicable for most aetiologies of HMB with the exception of focal pathologies 
distorting the uterine cavity, large uterine fibroids (>12 weeks size) or in the presence of 
atypical hyperplasia or endometrial cancer. 
 
Surgical treatment 
Long-term medical treatment with the LNG-IUS is unsuccessful or unacceptable in many 
cases and surgical alternatives may be required (164). Traditional surgical treatment of HMB 
refractory to medical intervention has been with hysterectomy, but now removal of the uterus 
is generally restricted to women where conservative, uterine sparing surgical procedures have 
been unsuccessful or in the presence of large fibroids, atypical hyperplasia and endometrial 
cancer. Endometrial ablation is a technique where a semi-automated device is placed in the 
uterine cavity and thermal energy is applied to the endometrium and superficial myometrium 
to achieve a uniform, global and permanent destruction of the endometrial lining, thereby 
inducing amenorrhea or substantially reducing menstrual blood loss (6). Various modalities 
are available including fluid filled thermal balloons, free circulating warmed saline, bipolar 
radiofrequency ablative systems and cryotherapy. Prior to the automated techniques, 
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endometrial ablation was performed with a resectoscope, however this technique is now used 
in rare circumstances, having been replaced by the safer and cheaper (165) second generation 
methods. Endometrial ablation is recommended as a second line treatment when fertility is 
not desired and medical treatment has failed in DUB but can also be used in the presence of 
uterine fibroids when there is a relatively normal sized and shaped uterine cavity. 
Hysteroscopic resection of focal intracavity lesions including polyps (166;167) and 
submucous fibroids (111;168-171) has been shown to improve HMB symptoms found in 
association with these pathologies. Hysteroscopic removal is standard practice in the UK 
(172) and in the case of polyps can usually be achieved in the outpatient setting (173-176). 
The procedures involve the use of electrosurgical cutting electrodes placed down a small 
operative working channel in the hysteroscope or a formal hysteroscopic resectoscope using a 
larger loop electrode.  
In the presence of significant fibroids associated with an estimated uterine size of >12 weeks, 
and when retention of fertility is not required, hysterectomy is usually recommended. Uterine 
artery embolisation (UAE), is a less invasive, uterine sparing, interventional radiological 
intervention (177). This procedure is normally restricted to women with medical or surgical 
risk factors for open surgery. Myomectomy (removal of fibroids with conservation of the 
uterus) is sometimes offered but as it is as invasive as hysterectomy but less effective (178), 
the technique is generally reserved for women wanting to retain their fertility or to improve 
fecundity in those women with subfertility associated with a large fibroid uterus. 
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Defining treatment success in heavy menstrual bleeding 
Menstruation is normal for women of reproductive age and so defining ‘successful treatment’ 
can be problematic. The primary aim of treating HMB is not to eradicate bleeding altogether, 
although some interventions do induce amenorrhoea, but to ameliorate bleeding symptoms to 
a tolerable level. As already discussed, objective measurement of reduction in menstrual 
bleeding is impractical and lacks relevance. Many studies have tried to measure the impact of 
interventions upon patient’s quality of life and / or satisfaction with treatment outcome. 
 
Health related quality of life 
Generic health related quality of life measures have been used, but many have not been 
validated for use in HMB and fail to capture the cyclical nature of the symptom (179;180). In 
addition, they lack sensitivity as most women suffering with HMB are otherwise healthy and 
can continue to function in most generic health domains during menstruation (140;141). 
Condition-specific measures have been developed for HMB but either only assess surgical 
interventions (181) (as opposed to medical ones) or have been infrequently used which has 
limited a full assessment of their inherent psychometric qualities (182).   
 
Satisfaction 
Patient satisfaction is widely used as a primary outcome measure in studies of treatments for 
HMB and guidelines (136;142;183;184). Satisfaction is a subjective concept and represents 
the extent to which a service meets the users’ expectations. A variety of questions and scales 
have been used to elicit satisfaction with treatment in HMB studies but this lack of uniformity 
has precluded meta-analysis of data across studies (136;166). Furthermore, the validity of 
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current patient satisfaction measures is questionable in light of the lack of published studies 
examining their development and application in HMB.  
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CHAPTER 8 
 
METHODS FOR THE ECONOMIC ANALYSIS OF 
DIAGNOSTIC STRATEGIES FOR THE INVESTIGATION OF 
HEAVY MENSTRUAL BLEEDING 
 
Construction of the decision model 
 
A clinically informed cost effectiveness model was drawn as a decision tree using Treeage 
software (185) to reflect current service provision for the diagnostic work up of women 
presenting with heavy menstrual bleeding. The tree was constructed to examine the 
effectiveness of different diagnostic testing strategies for women referred to secondary care 
by their general practitioner. The tests evaluated were transvaginal ultrasound (TVS), saline 
infusion sonography (SIS), global endometrial biopsy (EBx) and outpatient hysteroscopy 
(OPH). The tree structure was informed by clinical input. As there is no consensus regarding 
how best to investigate women with HMB, initial investigation utilising all tests either alone 
or in combination were included in the model. Therefore the tree consisted of the four tests 
available deployed in isolation or in various clinically relevant combinations following initial 
presentation. The need for any additional subsequent tests was conditional upon the preceding 
test result(s). This resulted in the formation of eleven clinically relevant, alternative testing 
strategies. In addition, two scenarios were developed where testing was dispensed with and 
treatment of HMB instituted immediately regardless of diagnosis. The treatments chosen were 
the most effective medical treatment (the levonorgestrel intrauterine system (LNG-IUS)) and 
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surgical treatment (hysterectomy). This allowed comparison of  the various approaches to 
diagnostic work up with the option of ‘no investigation’. In view of the fact that NICE 
guidance (142) recommends the use of the LNG-IUS as first line treatment in HMB, this arm 
was used as the base-case scenario to compare all other strategies against. An incremental 
approach was used for reporting the results. Thus, in total there were 13 different scenarios 
evaluated in the decision model (eleven testing and two treatment alone strategies) which are 
listed below: 
   
1. LNG-IUS alone 
2. Hysterectomy alone 
3. Outpatient hysteroscopy 
4. Transvaginal scan 
5. Endometrial biopsy 
6. Saline infusion sonography 
7. Outpatient hysteroscopy and endometrial biopsy 
8. Transvaginal scan and endometrial biopsy 
9. Saline infusion sonography and endometrial biopsy 
10. Outpatient hysteroscopy and saline infusion sonography 
11. Outpatient hysteroscopy and transvaginal scan 
12. Saline infusion sonography, outpatient hysteroscopy and endometrial biopsy 
13. Transvaginal scan, outpatient hysteroscopy and endometrial biopsy 
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Structure of the model 
 
A series of decision trees evaluating various testing strategies for HMB were developed to 
represent alternative decision options and their possible consequences. The trees explicitly 
illustrate the patient pathway from suspected pathology underlying the clinical presentation 
through to the outcome of testing, distinguishing between correct and incorrect diagnosis. 
Then, conditional on the accuracy of the diagnostic testing strategy, the outcome of treatment 
for HMB was analysed at one year post initial presentation.  Disease prevalence, diagnostic 
test accuracy, treatment effectiveness along with associated costs was used to populate the 
relevant branches of the decision tree. The basic tree structure is illustrated in (Figure 8.1). 
The thirteen trees representing the diagnostic testing options for HMB are detailed in 
Appendix 6, however the trees themselves are too large to display completely so a branch of 
one tree has been expanded as an example and a table has been included which details the 
data from the remaining branches of the tree.  
 
Deterministic results were obtained using point estimates of the parameters to estimate the 
expected cost, outcome (satisfaction) and incremental cost-effectiveness (additional cost per 
extra patient satisfied). The stability of the results was then tested through sensitivity analysis.  
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Figure 8.1 Example decision tree for evaluating the cost-effectiveness of diagnostic 
testing in heavy menstrual bleeding 
 
Clinical assumptions 
The following section details the main clinical assumptions required to develop the economic 
model. Senior gynaecologists (see Acknowledgments) who were selected based upon their 
reputation and experience, were surveyed to ensure that the model structure and clinical 
inputs reflected contemporary practice. The clinicians were contacted by email, as well as 
telephone and face-to face interview. Initial correspondence concerned the structure of the 
model and clinical management. The size of the model precluded it from being presented as a 
whole, so only scenarios which appeared contentious were presented to the clinicians, asking 
how they would manage the patients. When starting to populate the tree with data  it became 
clear that not all values could be identified from the literature. This was particularly true for 
‘satisfaction’ values after inappropriate treatments (for example, women with large fibroid 
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uteri being treated with the levonorgestrel intrauterine system or endometrial ablation) 
because these scenarios only arise when women are unknowingly treated with unsuitable 
medications or procedures, hence the numbers are small and the data are not collected. In the 
absence of a consensus view, the opinion of the majority was adopted or when data were 
concerned the median values were used. Inevitably not all clinicians responded to all 
questions. 
 
Demographics, pathologies and treatments 
It was assumed that women presenting with HMB had a mean age of 45 years and no wish for 
future fertility. Forty-five years was selected for two reasons. Firstly,  NICE recommends that 
endometrial biopsy should not be performed routinely for women with HMB before this age 
(142) as prevalence of endometrial premalignant or malignant disease is low. Secondly 
because HMB is most prevalent in parous women over 40 years, most of whom have 
completed their families  (186) and are then eligible for all potential treatment options (the 
desire for current or future fertility restricts treatment options in HMB i.e. avoidance of 
hormonal contraceptive medical treatments or the surgical interventions endometrial ablation 
or hysterectomy).  
 
All women were assumed to have been referred from primary care and to have not previously 
been seen for testing or treatment in secondary care. A single underlying aetiology was 
assumed to be causative and concurrent pathologies were not considered. This assumption is 
in keeping with the majority of HMB cases (142) and prevented unnecessary model 
complexity.  
 
129 
 
The premise was that optimal treatment of HMB is dependent upon correctly diagnosing the 
underlying cause so that appropriate, tailored treatment is arranged. The model was 
constructed based upon the true underlying diagnosis. The true diagnosis was assumed to fall 
within one of the following categories; 
 
Intrauterine resectable pathology (endometrial polyps, submucous fibroids) 
Fibroid uterus <12 weeks size (intramural and subserosal fibroids only) 
Fibroid uterus >12 weeks size (intramural and subserosal fibroids only) 
Endometrial disease (complex endometrial hyperplasia or endometrial hyperplasia 
with atypia or cancer) 
Dysfunctional uterine bleeding 
 
When choosing the pathology categories, it was decided that endometrial polyps and 
submucous fibroids should be grouped together as they are treated in the same way i.e. 
hysteroscopic resection of focal lesions. The majority of polyps were assumed to be treated in 
the outpatient setting (174;187;188) whereas the majority of submucous (intracavity) fibroids 
were assumed to be treated under general anaesthesia (169;170), 70% of which also required 
pharmaceutical endometrial down regulation with gonadatrophin releasing analogues (GnRH-
a) for three months prior to surgery following outpatient diagnosis. Only 70% were pre-
treated with GnRH-a because not all women would require or tolerate pre-treatment and not 
all gynaecologists use it.  A minority of women would undergo hysteroscopy and D&C under 
general anaesthesia because the planned outpatient testing was unsuccessful.  In these 
circumstances, where a polyp or submucous fibroid was detected at hysteroscopy and D&C, it 
was assumed that the focal lesion would be treated simultaneously; in the case of a 
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submucous fibroid this meant that GnRH-a pre-preparation of the endometrium would not 
have been used. 
 
Intramural (confined to the myometrium) and subserosal (extending beyond the myometrium 
to distort the serosal surface of the uterus) fibroids were grouped according to size. This was 
because smaller fibroids, which do not substantially distort the shape of the uterine cavity or 
increase the uterine size beyond the equivalent size of a 12 week gravid uterus (the size at 
which the uterus becomes palpable abdominally), do not contraindicate the use of LNG-IUS 
or endometrial ablation (EA) (189-191); treatments which are successful in the majority of 
women (184;192-194). Thus the presence of small fibroids without cavity encroachment is, in 
practice, treated the same way as those women diagnosed with DUB (i.e. no identified 
structural uterine pathology).  
 
In contrast, large fibroids increasing the uterine size beyond 12 weeks size, tend to be treated 
with invasive surgical interventions (abdominal hysterectomy or laparotomic myomectomy) 
as the LNG-IUS and minimally invasive surgery (EA or hysteroscopic resection of focal 
lesions) are either contra-indicated due to cavity size or ineffective (189;190).  An alternative, 
less invasive radiological intervention for large uterine fibroids is uterine artery embolisation 
(UAE) but a randomised controlled trial of UAE and hysterectomy (195) has found no 
statistically significant differences between them in terms of satisfaction and effectiveness. 
Furthermore, hysterectomy is the gold standard definitive treatment and is more widely 
available than UAE therefore it was chosen as the treatment for fibroid uteri beyond 12 weeks 
size.     
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The majority of women with HMB have a benign, functional endometrium. However, over 
proliferation of the endometrium can lead to endometrial hyperplasia, which in the minority 
of cases (<5%) if left untreated, can result in the development of endometrial cancer (149). 
Endometrial cancer is rare in pre-menopausal women, but hyperplasia is not infrequently 
encountered as the result of anovulation and a relative excess of unopposed oestrogen 
stimulating the endometrium. Histological assessment of the endometrium is the only way to 
reliably diagnose endometrial hyperplasia and cancer and so EBx is mandatory where 
suspected. Endometrial hyperplasia is treated hormonally with progestogens either delivered 
systemically or more often now locally by fitting a LNG-IUS. Hysterectomy is recommended 
where the hyperplastic process does not respond to progestogen treatment or in the presence 
of cytological atypia. This is because the likelihood of developing malignant disease is 
increased to around 25% in the presence of atypia (149). Endometrial cancer is generally 
treated with hysterectomy with or without radiotherapy depending upon the stage and type of 
cancer. Over 70% of endometrial cancers are diagnosed early and are confined to the uterus 
so can be cured by timely hysterectomy (196). Given the rarity of malignant endometrial 
disease in pre-menopausal women it was assumed that when endometrial cancer was 
encountered it would be a well differentiated FIGO stage 1a endometrioid cancer, treated by 
hysterectomy alone. 
 
Dysfunctional uterine bleeding, although not a distinct pathology, is a diagnosis of exclusion 
and the recommended first line medical treatment is the LNG-IUS (142). This was therefore 
the chosen treatment in the model for DUB. 
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Setting and decision making 
The clinical setting was assumed to be an efficient, contemporary ‘one-stop or ‘see and treat’ 
service run by a consultant gynaecologist. This setting meant that the expertise and 
infrastructure were available to perform all stipulated tests at the same visit and that 
therapeutic management could be implemented without unnecessary delay. When outpatient 
treatment was indicated, such as fitting of a LNG-IUS or hysteroscopic removal of a uterine 
polyp, then this was done at that visit. Interventions that required a general anaesthetic in a 
formal theatre setting (e.g. hysterectomy, endometrial ablations) were scheduled for a later 
date.  
 
The results of all imaging tests would be available in real time to the senior clinician 
performing the test. However, in the case of EBx, the result would be delayed whilst the 
tissue sample was prepared, analysed and reported by the pathologist. Therefore when an EBx 
was performed because endometrial disease was suspected, any treatment or treatment plan 
could not be instigated immediately. However, when a testing strategy involved the initial use 
of endometrial biopsy in combination with OPH which showed a probable benign cause for 
HMB (normal appearance i.e. DUB or a focal lesions seen i.e. polyp or submucous fibroid), 
treatment would be initiated at that first appointment. If endometrial disease was then 
unexpectedly diagnosed once the biopsy result became available, an alternative treatment 
would be instigated at a further appointment if it was felt to be more a more appropriate 
treatment option.  
 
Imaging tests (OPH, TVS and SIS) (197-199) can discriminate to some degree between 
normal and abnormal endometria, but are unable to accurately differentiate between 
histological subtypes of abnormal endometria; complex hyperplasia, complex hyperplasia 
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with cytological atypia or cancer (198;200). In keeping with clinical practice (opinion of 
expert panel), when imaging tests diagnose an abnormal endometrium it was felt by the panel 
of gynaecologists that no clinician would treat these suspected endometrial conditions without 
a histological tissue diagnosis. Therefore, a confirmatory histopathological test was performed 
if abnormal endometria were suspected by imaging; EBx will provide a result in 91% (151) of 
women but the remaining 9% would need to undergo formal D&C under a general anaesthetic 
as a day case because of failed procedures, non-diagnostic samples or patient preference. 
Therefore the cost for a confirmatory test was a composite value calculated as 91% of the cost 
of EBx plus 9% of the cost of D&C.  
 
Formal hysteroscopy D&C under general anaesthesia, was considered a second line 
diagnostic test and was restricted, for consistency, to the minority of women where initial 
diagnostic testing was unsuccessful i.e. failure to complete the test.  
 
Combination testing strategies and discordant results 
When combinations of tests were used, the overall testing strategy was considered successful 
only if all tests were completed successfully. Failure of one or both tests was considered a 
failure of the testing strategy. This assumption seemed reasonable on clinical grounds and 
from a modelling point of view because success of one test in a dual testing strategy would 
simply replicate the analysis for the respective single test strategy in the model, rendering it 
redundant. 
 
When a testing strategy involved more than one test applied simultaneously, the decision trees 
for each test were combined (appearing in series within the trees) to provide the additional 
information associated with combined testing. The final diagnoses were based upon the 
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results from the combination of tests. Tests in agreement presented no uncertainty, but where 
test results were modelled as being discordant, the panel of gynaecologists were asked to 
recommend the favoured diagnosis. 
 
False diagnoses 
Table 8.1 lists the false negative diagnoses which were considered plausible for true 
pathologies according to testing modality. The rationale underpinning the assumptions is also 
described. 
 
Treatment failure 
Following diagnosis, the most suitable treatment was arranged (Table 8.2). Only one 
treatment was considered for each diagnosis. As HMB is cyclical and patients would expect a 
delay in symptom relief with the LNG-IUS and EA, outcomes could not be assessed for at 
least six months. It was assumed that dissatisfied women would attend their general 
practitioner (GP) and be referred back to secondary care to be reviewed by a gynaecologist, 
who would undertake a further specific, second-line treatment (Table 8.2). The exception to 
this strategy was dissatisfaction after initial treatment with hysterectomy because no further 
treatment is possible in the absence of a uterus. These women were assumed to attend their 
GP for a consultation only. Women that remained dissatisfied following a second treatment 
were assumed to receive ‘rescue treatment’ consisting of a GP visit, a further hospital 
gynaecology outpatient appointment and a total abdominal hysterectomy (unless 
hysterectomy had been performed already in which case they were assumed to attend their GP 
for a consultation only). Patients were assumed to undergo the first two treatments within a 12 
month period.   
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Table 8.1 False diagnoses according to testing modality 
True pathology 
 
 False  diagnoses   Rationale (Clinical consensus)  
     
Transvaginal ultrasound   
Intrauterine polyp or submucous fibroid   Fibroids < 12 weeks 
Endometrial Disease 
DUB 
 Focal pathology can be easily missed by 2D imaging 
without cavity distension. Endometrial polyps can appear 
cystic and thus be mistaken for endometrial disease. A 
small fibroid encroaching into the endometrial cavity 
(submucous fibroid) could be erroneously considered 
intramural forming part of a small fibroid uterus.  
     
Fibroid uterus <12 weeks size  Polyp / SMF 
Endometrial Disease 
DUB 
 Intramural fibroids may be wrongly diagnosed as 
submucosal. Small fibroids could be missed and a 
thickened, functional endometrium could appear 
hyperplastic. 
     
Fibroid uterus >12 weeks size  Polyp / SMF 
Fibroids < 12 weeks 
 Large fibroids would be rarely overlooked entirely, but it 
is possible to underestimate their size or incorrectly 
classify fibroid location 
     
Endometrial disease  Polyp / SMF 
Fibroids < 12 weeks 
DUB 
 A thickened hyperplastic or cancerous endometrium 
could be misdiagnosed as containing a polyp. Small 
fibroids may be incorrectly identified within the 
myometrium. The endometrium may appear to be 
normal. 
     
Dysfunctional uterine bleeding  Polyp / SMF 
Fibroids < 12 weeks 
Endometrial disease 
 A normal, thickened endometrium could be considered 
falsely to be some form of endometrial disease 
(hyperplasia or cancer) or focal lesion (e.g. folds of 
normal endometrium mistaken for a polyp). Small 
fibroids may be incorrectly identified within the 
myometrium. 
     
136 
 
Table 8.1 continued     
True pathology 
 
 False  diagnoses   Rationale (Clinical consensus)  
     
Saline infusion sonography   
Intrauterine polyp or submucous fibroid   Fibroids < 12 weeks 
Endometrial disease 
DUB 
 Focal pathologies could be missed on imaging, but this 
will occur less compared to TVS because of cavity 
distension with fluid. A small fibroid encroaching into 
the endometrial cavity (submucous fibroid) could be 
erroneously considered intramural forming part of a 
small fibroid uterus. Cystic looking polyps may be 
mistaken for endometrial hyperplasia. 
     
Fibroid uterus <12 weeks size  Polyp / SMF 
Endometrial Disease 
DUB 
 As for transvaginal ultrasound... 
     
Fibroid uterus >12 weeks size  Polyp / SMF 
Fibroids < 12 weeks 
 As for transvaginal ultrasound... 
     
Endometrial disease  Polyp / SMF 
Fibroids < 12 weeks 
DUB 
 As for transvaginal ultrasound.. 
     
Dysfunctional uterine bleeding  Polyp / SMF 
Fibroids <12 weeks 
Endometrial disease 
 As for transvaginal ultrasound.. 
     
Outpatient hysteroscopy     
Intrauterine polyp or submucous fibroid   Endometrial disease 
DUB 
 Focal pathologies could be missed on imaging, but this 
will occur less compared to TVS because of cavity 
distension with fluid. OPH cannot visualise the 
myometrium and so, in contrast to TVS and SIS, 
presence of fibroids cannot be falsely diagnosed. Polyps 
may be mistakenly diagnosed as endometrial disease. 
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Table 8.1 continued     
True pathology 
 
 False  diagnoses   Rationale (Clinical consensus)  
     
Fibroid uterus <12 weeks size  Polyp / SMF 
Endometrial disease 
 The myometrium is not visualised by OPH and preceding 
clinical examination is not sensitive enough to identify 
small fibroids. Thus, at OPH a normal cavity would be 
found in the presence of the true pathology (small 
intramural fibroids). Possible false diagnoses would be 
when normal, functional thickened endometrium is 
considered falsely to be some form of endometrial 
disease (hyperplasia or cancer) or focal lesion (e.g. folds 
of normal endometrium mistaken for a polyp). 
     
Fibroid uterus >12 weeks size  Polyps / SMF 
Endometrial disease 
 Large fibroids would be missed at OPH because the 
myometrium is not visualised, although the majority 
would be detected on preceding clinical examination*. 
At OPH a normal cavity would be found in the presence 
of the true pathology (large intramural fibroids). Possible 
false diagnoses would be when normal, functional 
thickened endometrium is considered falsely to be 
endometrial disease (hyperplasia or cancer) or a focal 
lesion (e.g. folds of normal endometrium mistaken for a 
polyp). 
     
Endometrial disease  Polyp / SMF 
DUB 
 A thickened hyperplastic or cancerous endometrium 
could appear normal or as a polyp. 
     
Dysfunctional uterine bleeding  Polyp / SMF 
Endometrial disease 
 A normal, thickened endometrium could be considered 
falsely to be endometrial disease (hyperplasia or cancer) 
or a focal lesion (e.g. folds of normal endometrium 
mistaken for a polyp especially in the secretory phase of 
the menstrual cycle). 
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Table 8.1 continued     
True pathology 
 
 False  diagnoses   Rationale (Clinical consensus)  
     
Endometrial biopsy   
Intrauterine polyp or submucous fibroid   Endometrial disease (hyperplasia but not 
cancer) 
DUB 
 Endometrial polyp tissue could be mistaken for normal 
or complex endometrial hyperplasia but it would be 
extremely unlikely to erroneously diagnose a polyp as 
endometrial cancer. The focal lesion may be missed by 
the biopsy.  
     
Fibroid uterus <12 weeks size  Polyp / SMF 
Endometrial disease (hyperplasia not cancer) 
 Cystic pieces of endometrium could be mistaken for 
endometrial polyps. Fibroids can distort the uterine 
cavity and compact areas of endometrium. If these areas 
are sampled they can be mistaken for complex 
endometrial hyperplasia  
     
Fibroid uterus >12 weeks size  Polyps / SMF  
Endometrial disease (hyperplasia not cancer) 
 As for small fibroids above 
     
Endometrial disease  Polyp / SMF 
DUB 
 Polyp or DUB were considered the only plausible false 
diagnoses 
     
Dysfunctional uterine bleeding  Polyp / SMF  An endometrial polyp or submucous fibroid were 
considered the only possible false diagnoses. It was felt 
to be extremely unlikely to mistakenly diagnose any 
endometrial disease from a normal sample.  
*Note that it was assumed that a bimanual gynaecological examination took place in all women with HMB immediately pre-testing. Expert consensus was that this examination would allow the 
detection of a large fibroid uterus >12 week. A competent gynaecological examination would normally detect a large fibroid pelvic mass, but in some instances (e.g. poor patient tolerance, 
obesity) clinical examination would be less reliable so that the examination would be a false negative. This was assumed to occur in 20% of cases. In the absence of large fibroids, clinical 
examination was considered unable to discriminate between any of the other potential pathologies and so examination outcomes were dichotomous; i.e. either large fibroids > 12 weeks or 
‘normal’. As regards false positive diagnosis, it was felt that a small fibroid uterus < 12 weeks could be mistaken for large fibroid uterus > 12 weeks, OPH= outpatient hysteroscopy; TVS = 
transvaginal scan; SIS= saline infusion sonography; SMF= submucous fibroid; DUB= dysfunctional uterine bleeding.  
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Table 8.2 First and second line treatments for heavy menstrual bleeding according to 
underlying diagnosis in women with no desire to retain fertility 
Diagnosis Treatment 1 Treatment 2 (only 
performed if patient ‘not 
satisfied’ with treatment 1) 
   
Endometrial polyp Outpatient polypectomy Levonorgestrel intrauterine 
system 
Submucous fibroid Transcervical resection of fibroid Levonorgestrel intrauterine 
system 
Fibroids <12 weeks 
size 
Levonorgestrel intrauterine 
system 
Endometrial ablation 
Fibroids >12 weeks 
size 
Total abdominal hysterectomy GP visit 
Complex hyperplasia Levonorgestrel intrauterine 
system 
Total abdominal hysterectomy 
Complex hyperplasia 
with atypia / 
Endometrial Cancer 
Total abdominal hysterectomy GP visit 
Dysfunctional uterine 
bleeding 
Levonorgestrel intrauterine 
system 
Endometrial ablation 
GP= general practitioner 
 
Adaptations of the base case tree to assess alternative clinical scenarios 
 
Women being managed during multiple clinic visits 
The base case tree was designed to reflect a contemporary ‘one-stop’ clinic to ensure that the 
results remain relevant and do not quickly become outdated as services evolve. However, this 
approach has not yet been widely adopted across the UK. Traditionally women referred to a 
gynaecologist would be reviewed in a general outpatient clinic before any investigation or 
treatment was instigated. The patient would have their history taken and be examined and 
then the clinician would plan appropriate tests and send the patient away to have these done at 
a later date. Weeks or even months later the patient would be seen again in clinic with the 
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results of those investigations and then the clinician would initiate treatment. The model was 
adapted to represent the ‘traditional’ multi-stop care model. 
 
In this analysis all tests were performed at separate appointments except for endometrial 
biopsy which would be taken at the initial consultant appointment. Transvaginal scan and 
saline infusion sonography were assumed to be performed in the ultrasound department at a 
later date with the patients having a follow-up appointment to review the results. Outpatient 
hysteroscopy required a further consultant appointment for the hysteroscopic assessment. If 
polyps were diagnosed, whether by scan or hysteroscopy, patients required a further 
hysteroscopy appointment for removal. Submucous fibroids were removed under general 
anaesthesia and treatment with the LNG-IUS, hysterectomy and endometrial ablation were 
performed as in the base case tree. 
 
Women refractory to LNG-IUS treatment 
Alternative analysis was performed by adapting the model to fit with the scenario that all 
women referred to secondary care had already received treatment with a LNG-IUS in primary 
care but whose symptoms had not resolved. This was to reflect current NICE guidance which 
recommends that women receive a LNG-IUS in a primary care setting as first-line treatment 
for HMB (142) and only attend secondary care if their symptoms are refractory or structural 
abnormality is expected. The prevalence of disease changed within this tree as it was assumed 
that patients treated appropriately with the LNG-IUS (DUB, endometrial hyperplasia, fibroids 
<12 weeks size) would be less likely to be referred to secondary care than women who were 
being treated inappropriately (fibroids > 12 weeks size, polyps, SMF’s, endometrial cancer) 
because their symptoms would be more likely to have resolved. Satisfaction rates for 
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treatment of each of the pathologies were used to re-calculate the disease prevalence. LNG-
IUS was no longer a possible treatment within this tree as women had previously failed to 
respond to it. The exception to this rule was for women who were dissatisfied following 
removal of a polyp or SMF as they now had a ‘normal’ uterine cavity, where as previously 
there had been a structural abnormality compromising the effectiveness of the LNG-IUS. 
These women received a LNG-IUS as their second treatment following removal of focal 
pathology. Endometrial ablation became the first treatment to be offered to women who were 
thought to have a ‘normal’ uterine cavity and if this failed, hysterectomy was offered as the 
next treatment option. Given that patients already have a LNG-IUS in situ when they attend 
secondary care in this scenario the tree was adjusted so that the comparative strategy was ‘no 
further treatment’ to represent patients coming to clinic but not having any further treatment 
i.e. woman attending the clinic but ultimately deciding to continue with the LNG-IUS. 
 
Women wishing to retain their fertility 
The base case analysis was revised to reflect a population who wished to maintain their future 
fertility. This meant that endometrial ablation and hysterectomy were no longer possible 
treatments, except in the case of endometrial cancer when hysterectomy was still selected as 
the treatment of choice. Myomectomy and uterine artery embolisation (UAE) were introduced 
as possible treatments in this tree as they are far more likely to be offered to women who wish 
to have children than women who have completed their families. Myomectomy was assumed 
to be selected over UAE by 80% of women as it is thought to improve fertility to a greater 
extent than UAE (201). Following UAE or myomectomy patients who were ‘not satisfied’ 
with their treatment were offered the other treatment. Hysterectomy was not offered as a 
treatment for any benign cause of HMB and women who remained ‘not satisfied’ after two 
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treatments, or after one if no fertility preserving treatment could be offered, received a GP 
visit and a new gynaecology outpatient appointment as ‘rescue treatment’. 
 
Clinical data collection 
 
All literature derived data were obtained following systematic searches.  
 
Accuracy data came from published systematic reviews and meta-analyses when possible, 
followed by data derived from primary, well conducted test accuracy studies.  
For treatment data, systematic quantitative reviews using individual patient data (IPD) were 
considered as the highest level of data, followed by systematic reviews of study level data. 
Randomised controlled trials were acknowledged as the third step down the hierarchy, 
followed by large comparative cohort studies and then uncontrolled observational series. 
Prospectively collected data from studies with large populations were considered superior to 
small studies and those with retrospectively collected data. When possible data from a purely 
premenopausal population were used, however occasionally data came from studies of AUB 
incorporating both pre- and postmenopausal women. When possible these data were stratified 
by menopausal status. 
 
Disease prevalence 
For prevalence of disease underlying HMB symptoms a gold standard test was selected for 
confirmation of diagnosis (Table 8.3) A systematic literature review was then performed to 
estimate the prevalence of pathologies as estimated by the gold standard confirmatory test. 
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Table 8.3 Gold standard diagnostic tests for uterine pathology 
Pathology 
 
Confirmatory test 
Polyps 
 
Outpatient hysteroscopy 
Submucous fibroids  
 
Outpatient hysteroscopy 
Uterine fibroids < 12 weeks 
 
Pelvic ultrasound 
Uterine fibroids > 12 weeks 
 
Pelvic ultrasound 
Endometrial disease 
 
Histological sampling 
Dysfunctional uterine bleeding 
 
Diagnosis of exclusion 
The searches for prevalence are reported in Appendix 7.1-7.4. As dysfunctional uterine 
bleeding is a diagnosis of exclusion a diagnostic test was not used as one of the search terms. 
The prevalence of each diagnosis was determined from published studies, using systematic 
reviews when possible. Seven quality criteria were used to assess the quality of identified 
studies (see Table 8.4) with a score from one to three being awarded for each criterion giving 
a maximum score of 21.Data from the highest scoring papers were used to populate the 
decision model. 
Table 8.4 Quality criteria for disease prevalence studies 
Criterion Points awarded 
 3  2 1 
Data collection 
 
Prospective Retrospective Not clear 
Consecutive patients 
 
Yes No Not  reported 
Population size 
 
>500 100-500 <100 
Menopausal status Premenopausal Mixed but >50% 
premenopausal 
Postmenopausal 
Data collection All have the gold 
standard test 
Selection prior to 
gold standard test 
Inferior test 
Proportion having the 
gold standard test 
>90%  <90% 
Pathology clearly defined 
 
Clear definition Unclear definition No definition 
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Data regarding the prevalence of fibroids (intramural and subserosal) were taken from a 
database of 473 women with HMB, held at Birmingham Women’s Hospital (BWH) in the 
absence of a better quality published data set.  
 
Data regarding the prevalence of DUB were often not specified within studies in contrast to 
organic pathologies. As the overall prevalence of disease must add up to 1 (100%) in the 
economic model it was decided that the prevalence of DUB (which is a diagnosis of 
exclusion) would be altered to become the remaining proportion once the prevalence of other 
pathologies had been estimated. The impact of this manipulation was tested with sensitivity 
analyses. 
 
Test success and accuracy  
To identify diagnostic data regarding the feasibility and accuracy of the tests under evaluation 
broad search terms were used for the literature searches to ensure a high level of sensitivity. If 
searches retrieved a large number of studies they were restricted to review articles only. In the 
case of searches for SIS, the search was qualified by the population under scrutiny because 
preliminary, broad searches were retrieving a large number of articles which evaluated the test 
in postmenopausal women and women with infertility. Duplicate articles were removed, the 
abstracts of all remaining articles were read and the full text of relevant papers retrieved based 
upon the following selection criteria: 
Population  Heavy menstrual bleeding 
Intervention  Outpatient test to evaluate the uterus (TVS, SIS, EBx, OPH) 
Outcome  Feasibility (success rate) or test accuracy for uterine pathology 
Study design  Restricted to systematic reviews if available 
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Although systematic reviews report high quality aggregated data of feasibility and/or test 
accuracy, the data reported did not always give the relevant accuracy data for all of the 
pathologies. In these circumstances restriction on study design was removed and in the 
absence of relevant primary study data, additional searches to look for data regarding the 
accuracy of the test without regard for population characteristics (heavy menstrual bleeding) 
were undertaken as were searches using specific pathologies as the population of interest. The 
quality of the studies was assessed using the criteria in Table 8.5. The highest scoring studies 
were selected. If studies were of equal quality the largest was selected and if this did not 
discriminate, blinding and interval between tests were taken into consideration. 
 
Table 8.5 Quality criteria for assessing test accuracy studies 
Criterion 
 
Explanation 
Population size 
 
>100 women 
Type of bleeding 
 
>75% with heavy menstrual bleeding 
Menopausal status 
 
>70% premenopausal 
Data collection 
 
Prospective 
Reference test 
 
Appropriate ‘gold’ standard test applied (see Table 8.3) 
Blinding Present (diagnostic test and the gold standard test are 
performed by different, blinded clinicians). 
Interval between tests 
 
Within the same menstrual cycle 
Cross tabulation 
 
Data presented in a 2x2 table 
Total 8 points max (one point awarded for each criteria present) 
 
Details of searches are given in Appendix 7.5-7.8.  An unsuccessful test was defined as failure 
of the test to provide a diagnosis. This may arise for a number of reasons such as an inability 
to pass the ultrasound probe (TVS, SIS) into the vagina, instrument the uterine cavity (SIS, 
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EBx, OPH) or because of inadequate visualisation (TVS,SIS, OPH). In the case of EBx, 
failure also included a successfully completed test but the subsequent finding of a tissue 
sample insufficient for diagnosis. 
 
Accuracy data tended to be reported as sensitivity and specificity along with their respective 
95% confidence intervals. These true positive and true negative rates were then used to 
calculate the false positive and negative rates (see Table 8.6). 
 
Table 8.6 Accuracy value calculation using sensitivity and specificity 
Accuracy value Calculation 
True positive rate Sensitivity 
True negative rate Specificity 
False positive rate 1 – specificity 
False negative rate 1 – sensitivity 
 
When data were reported as likelihood ratios, sensitivity and specificity values were derived. 
Sensitivity and specificity along with their 95% confidence intervals were calculated from 
raw data when necessary. In order to simplify the decision model, underlying pathologies 
were grouped when appropriate i.e. similar aetiologies and/or commonly associated 
treatments (see assumptions section). One problem with this approach was that accuracy data 
for these categories were often reported separately for each respective pathology. Therefore 
the figures were combined, weighting them according to the proportion of the pathology 
category they made up.  
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Taking EBx as an example test: 
Endometrial hyperplasia = 60% of the endometrial disease category  
Atypical endometrial hyperplasia / cancer = 40% of the endometrial disease category 
The sensitivity value for endometrial biopsy for hyperplasia is 0.81 
The sensitivity value for endometrial biopsy for atypia/cancer is 0.86 
Combined sensitivity is (0.6 x 0.81) + (0.4 x 0.86)  
Sensitivity = 0.83 
 
A final data manipulation was needed when tests were reported in the literature as having a 
sensitivity or specificity of 1. These perfect accuracy data were rounded down to 0.99 as 
although tests can have high predictive values, no test can be reported as completely accurate.  
 
Treatment satisfaction data 
Systematic searches of the literature were conducted to identify patient satisfaction data at one 
year post-treatment. The electronic bibliographic databases EMBASE and Medline were 
searched using search terms for the relevant treatment, combined with menorrhagia or HMB, 
and satisfaction along with their alternatives. Searches and outputs are detailed in Appendix 
7.9-7.13. 
 
For the purpose of the model, effectiveness data in terms of patient satisfaction were needed 
according to underlying pathology. Whilst treatment outcome data are reported for women 
with HMB, in some cases the underlying diagnoses were not ascertained or treatments were 
not utilised when contraindicated. However, the diagnostic model required data for treatment 
outcomes not only used appropriately but also for when false diagnoses were made on testing 
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and so suboptimal or inappropriate treatments would be applied. When this data could not be 
identified in the published literature, the panel of gynaecologists were surveyed for their 
opinions regarding the likely treatment efficacy. The median values obtained in this way were 
used as the satisfaction rate and the range of values were used for sensitivity analysis.  
 
Systematic reviews with meta-analysis were considered the highest quality data, followed by 
randomised controlled trials. When 12 month data weren’t available the data reported closest 
to twelve months were used. If the time of reporting was not stated within the study the data 
were only used when no other appropriate data had been identified. For endometrial ablation, 
data were used that exclusively examined second generation techniques (6) as first generation 
methods are now seldom used.  
 
Results of clinical data collection 
 
Disease prevalence 
Uterine polyps 
The searches for prevalence of endometrial polyps identified 845 studies (Appendix 7.1). 
Seven studies were selected and the manuscripts obtained for further analysis. The majority of 
studies were rejected because they did not report prevalence or referred to postmenopausal or 
infertile populations. The highest quality study (score 20/21) reported a uterine polyp 
prevalence of 18% (202). The range in prevalence was wide however, with the next two best 
studies reporting a prevalence of 3.7% (203) and 33.9% (204).   
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Submucous fibroids 
Searches for the prevalence of fibroids in women with heavy menstrual bleeding (Appendix 
7.2) identified 134 papers, 3 of which were selected and assessed for quality and the 
prevalence data were extracted. Papers were discarded if they did not report prevalence of 
submucous fibroids in premenopausal women and if the reference test used was not the 
selected gold standard. The two highest scoring papers reported differing values of 21.9% and 
7.4% for the prevalence of submucous fibroids (202;204) with 21.9% coming from the best 
paper (202) (quality score 18/21).  
 
The prevalence of polyps and submucous fibroids reported in the highest quality studies were 
intended for use in the decision tree. However, whilst examining papers that reported the 
accuracy of hysteroscopy a systematic review of diagnostic hysteroscopy was identified 
which reported the prevalence of polyps and submucous fibroids (205). This systematic 
review meta-analysed over 3000 procedures. The prevalence of polyps was reported as 21% 
and that of submucous fibroids as 25%. However, polyps and submucous fibroids are 
estimated to co-exist in approximately one third of women (206) and so the value for 
submucous fibroids was reduced by one third to 17% to account for this. Thus the derived 
prevalence rate used for the pathology category ‘endometrial polyps/SMF’ was 38% (0.38).  
 
Fibroids 
Two studies were identified that looked at the prevalence of intramural or subserosal fibroids 
out of 134 studies identified from the original search (Appendix 7.2). One study only 
contained 80 participants (206) and the second was a study of women being scanned for a 
variety of symptoms (pain, worry, AUB, suspected fibroids) and not just heavy menstrual 
bleeding (207). The prevalence values reported by the two studies were 57.7% and 23.5% 
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respectively. Neither study specified whether submucosal fibroids were excluded and the 
patient populations were heterogeneous, preventing meta-analysis. Both studies scored 17 for 
quality but in view of the small size of the first study (80 patients), the poorly defined 
population in the second study and the large discrepancy in the reported values, a database of 
473 women held at the BWH was consulted. This database showed that 19% (88/473) women 
had intramural fibroids less than 12 weeks size and that 6% (28/473) had fibroids greater than 
12 weeks size, thus these data were used as the prevalence values within the decision tree.  
 
Endometrial disease 
The searches for prevalence of endometrial hyperplasia (Appendix 7.3) diagnosed by 
histology samples identified 86 studies of which five were chosen for review. Two studies 
were high quality (both scoring 20/21) and reported similar values for the prevalence of 
endometrial hyperplasia without atypia (3.0% and 2.4%). One study was a retrospective 
review of histology samples (208) and the second a retrospective audit of hysteroscopy 
findings (202). The same two studies were also identified as the best from the searches for 
studies reporting the prevalence of endometrial cancer (374 studies identified, 4 assessed 
further) (Appendix 7.4). Both studies were large and contained only premenopausal women. 
Meta-analysis of these two studies was performed to calculate the prevalence data more 
precisely. Data for endometrial hyperplasia without atypia were analysed separately from data 
for endometrial hyperplasia with atypia and endometrial cancer because the clinical 
implications of diagnosis and optimal therapeutic interventions differ. Meta-analysis was 
performed by converting the values from the studies to log odds and standard errors using 
Excel (Microsoft) this data was then copied across to RevMan (Cochrane Library) and 
analysed as the generic inverse variance using random effects analysis. The output from 
RevMan is the odds, so these were copied back into Excel and converted to values to give 
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prevalence rates with 95% confidence intervals. The value calculated for prevalence of 
endometrial hyperplasia without atypia was 3% and that for endometrial hyperplasia with 
atypia or endometrial cancer as 2%. Therefore the value for ‘endometrial disease’ was the 
sum of the two, 5%. 
 
Dysfunctional Uterine Bleeding 
In all decision trees the sum of all the branches from a common stem must add to 1. It was 
inevitable that the prevalences for the five pathology groups would not add up to one as the 
data came from a variety of sources and so dysfunctional bleeding was used as the ‘buffer’ to 
make the prevalences add to one (given DUB is a diagnosis assigned after exclusion of other 
identifiable ‘organic’ pathologies). This resulted in the prevalence of DUB being set at 32%.  
A summary of the derived disease prevalences is given in Table 8.7.  
 
Table 8.7 Estimated prevalence of pathologies in heavy menstrual bleeding: Base case 
Disease Prevalence Sensitivity analysis 
(range) 
Source 
Polyps/Submucous fibroids 
 
 
0.38 0.2-0.5 (EP 
estimate) 
SR (205) 
Fibroids <12/40 
 
0.19 0.15-0.22
† 
BWH database 
Fibroids >12/40 
 
0.06 0.04-0.08
† 
BWH database 
Complex endometrial 
hyperplasia 
 
0.03 0.02-0.03
† 
Meta-analysis of two 
studies (202;208) 
Atypical hyperplasia / cancer 
 
 
0.02 0.01-0.02
† 
Meta-analysis of two 
studies (202;208) 
Endometrial disease (all 
hyperplasias and cancer) 
 
0.05 0.03-0.05
† 
Meta-analysis of two 
studies (202;208) 
Dysfunctional uterine bleeding 
 
 
0.32 Remaining 
proportion 
Remaining 
proportion used so 
that total sums to 1 
SR= systematic review;  †= 95% confidence interval; EP= expert panel 
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To calculate the prevalence of disease within the decision tree for women already treated with 
a LNG-IUS in primary care, the data were weighted by taking the proportion of women who 
would not be satisfied with a LNG-IUS for each pathology (see rates later on in this chapter) 
and dividing each by the total, so that the sum of them all came to one and became the new 
prevalences for the decision tree (Table 8.8).  
Table 8.8 Recalculated disease prevalence for HMB in women refractory to treatment 
with a LNG-IUS 
Disease Original 
prevalence 
(a) 
Proportion 
dissatisfied 
with LNG-IUS  
(b) 
Proportion 
coming to 
gynaecology  
(a x b) 
(c) 
New prevalence  
(c / total c) 
Polyps/Submucous 
fibroid 
 
0.38 0.60 0.228 0.592 
Fibroids <12/40 
 
0.19 0.17 0.032 0.083 
Fibroids >12/40 
 
0.06 0.71 0.043 0.111 
Endometrial disease 
 
0.05 0.56 0.028 0.073 
Dysfunctional uterine 
bleeding 
0.32 0.17 0.054 0.141 
Total 
  
0.3853  1.0 
LNG-IUS= levonorgestrel intrauterine system 
 
Test success   
Success data for each of the four separate tests came from systematic reviews and meta-
analysis (see Table 8.9).  
 
Outpatient hysteroscopy 
The search strategy for outpatient hysteroscopy identified three systematic reviews 
(198;199;205) from 1095 studies. Two studies reported test success (205) (198). The 
outpatient hysteroscopy value came from one of the systematic reviews (205) of diagnostic 
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hysteroscopy. This quantitative systematic review reported success data separately for all 
women having outpatient hysteroscopy and also for premenopausal women. However, the 
data for OPH included some postmenopausal women and the data for premenopausal women 
contained some women undergoing hysteroscopy as an inpatient under general anaesthesia. In 
total 2643/3158 (84%) procedures were done as outpatient hysteroscopies and only 306 
women were specified as being postmenopausal, therefore it was decided to use the success 
rate value for outpatient hysteroscopy (0.97). This value was supported by the second review 
of predominantly pre-menopausal women (71%) but included both inpatient and outpatient 
hysteroscopy.  The reported success rate in this meta-analysis was similar at 95.8% (CI 95.5-
96.1%). (198). 
 
Transvaginal ultrasound 
There were no systematic reviews of premenopausal women undergoing transvaginal 
ultrasound that reported test success rate. Only one small study of 43 women reported the 
success rate of TVS and this was 100% (209). A previously used systematic review of women 
with postmenopausal bleeding reported a mean success rate of 100% with a standard 
deviation of 2% when data from 16 studies were meta-analysed (210). The value 0.99 was 
used because no test is 100% successful; women do occasionally refuse to have the test, 
cannot tolerate it or the visualisation on imaging is too poor to make a diagnosis.  
 
Saline infusion sonography 
Searches for reviews of saline infusion sonography identified 257 studies, two of which were 
systematic reviews (197;199) which were selected for data extraction. The first systematic 
review included meta-analysis of the accuracy of saline infusion sonography in a population 
of women with abnormal uterine bleeding (>50% premenopausal) and reported that the 
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success rate of the test in premenopausal women was 94.8% with confidence intervals of 93.5 
-96.1% (197). A similar success rate of 95% reported by the second review examining SIS in 
premenopausal women supported this value (199). 
 
Endometrial biopsy 
Searches for reviews of endometrial biopsy identified two systematic reviews, one for the 
diagnosis of endometrial hyperplasia (150) and one for the diagnosis of endometrial cancer 
(151). The latter review of endometrial biopsy for diagnosis of endometrial cancer had a 
mainly postmenopausal population. Therefore the study looking at endometrial hyperplasia 
where the majority of women were premenopausal (50% were known to be premenopausal, 
25% were known to be postmenopausal and 25% unknown) was used. This study found that 
76/881 (8.6%) tests failed or were insufficient for histological diagnosis (150) and so a failure 
rate of 9% (0.09) was used. The raw data were used to calculate confidence intervals.  
 
Test combinations 
When combinations of tests were performed, the success rates of the individual tests were 
multiplied within the tree to calculate the success rate. The success rates of combined tests 
will always be worse than tests performed individually which is reflected by this 
manipulation. However it does not take into account whether the failure of one test is 
dependent upon the next, for example, if a hysteroscopy fails because of a stenosed cervical 
canal, an endometrial biopsy would be very likely to also fail.  
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Table 8.9 Diagnostic test success rate data 
Test Success rate Sensitivity analysis 
(range) 
Source 
Outpatient hysteroscopy 0.97  SR(205) 
 
Transvaginal ultrasound 
scan 
0.99*   SR (210) 
Endometrial pipelle biopsy 0.91 0.89- 0.93
†
 SR (150) 
 
Saline infusion sonogram 0.95 0.94-0.96
†
  SR(197) 
 
*reported as 0 but reduced to 0.99 as unlikely. †= 95% confidence interval,  SR= systematic review 
 
Test accuracy 
Outpatient hysteroscopy 
The accuracy data for hysteroscopy came from the two systematic reviews (see search in 
Appendix 7.5) used for test success and were identified by the outpatient hysteroscopy 
database searches (198;205). The first review looked at the accuracy of hysteroscopy for 
diagnosing intrauterine abnormalities in women presenting with abnormal uterine bleeding 
(pre and postmenopausal) using histopathology specimens as the reference standard. This 
study provided the data for polyps, submucous fibroids and dysfunctional uterine bleeding. 
This study has limitations as it has a mixed population and only 84% of procedures are 
specified as outpatient hysteroscopies. However, no other large data sets reporting accuracy 
exist. Data for the sensitivity and specificity of polyps (0.94 and 0.92) and submucous 
fibroids (0.87 and 0.95) are clearly reported in the paper and were combined to values for the 
combination group of polyps/submucous fibroids. Studies included in this large, systematic 
quantitative review of hysteroscopy report the accuracy of a test for diagnosing pathology 
rather than a normal cavity. Thus data for the accuracy of outpatient hysteroscopy in 
diagnosing dysfunctional uterine bleeding could not be identified, a reflection of the fact that 
DUB is considered a diagnosis of exclusion. Therefore the data values from the review were 
reversed i.e. used the proportion not diagnosed as abnormal and assigned these women as 
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DUB. In practice this results in the sensitivity and specificity being reversed. The sensitivity 
and specificity reported for diagnosing abnormalities were 0.94 and 0.89 respectively, so for 
diagnosing ‘no’ abnormality the values reverse and the sensitivity becomes 0.89 and 
specificity 0.94. 
  
The data regarding the accuracy of outpatient hysteroscopy for diagnosis of endometrial 
disease comes from the second identified review (198) which specifically looks at this 
question in a mixed population with 29% of the women specified as postmenopausal. This 
large systematic review meta-analysed data from 65 studies (26,346 women) that compared 
outpatient hysteroscopy to endometrial histology results and reported that the sensitivity for 
diagnosis of endometrial disease (cancer and hyperplasia) was 0.78 and that specificity was 
0.96, hence these  values were used in the decision tree. 
 
Transvaginal ultrasound 
The search for transvaginal ultrasound accuracy data included terms for abnormal uterine 
bleeding and yielded 420 studies once duplicates had been removed (Appendix 7.6). Thirty-
seven studies were selected for further assessment regarding accuracy of transvaginal scan. 
Only one of the selected papers was a systematic review (199) but as the studies included 
were heterogeneous, no meta-analysis was performed and no useful data could be extracted. 
The thirty-seven studies identified were assessed for quality and accuracy data were extracted 
for the different pathologies.  
 
A prospective comparative study was selected as the highest quality paper reporting the 
accuracy of TVS for diagnosing polyps and submucous fibroids (211). The study compared 
the TVS diagnosis to hysteroscopic diagnosis. The tests were performed by different 
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clinicians and each one was blinded to the other result. The tests were performed within 24 
hours of each other and the majority of women included in the study were premenopausal. 
The sensitivity and specificity of TVS for diagnosing polyps and submucous fibroids were 
reported as 0.45 (95% CI 0.32-0.58) and 0.78 (0.62-0.89), and these data were used to 
populate the decision tree. Data from the same study were used for accuracy of TVS for 
diagnosing endometrial disease reported as sensitivity 0.57 (95% CI 0.19-0.90) and specificity 
0.66 (0.55-0.76).  
 
Only one study was identified which reported the accuracy of TVS for diagnosing intramural 
or subserosal fibroids. The study aimed to assess the accuracy of TVS for diagnosing 
adenomyomas and fibroids and its ability to distinguish between the two pathologies by 
comparing the scan results to hysterectomy specimens (212). The mean age of women 
included in the study was 46.7 (range 35.7-51.8) years and 172 of the 206 women had 
menorrhagia or dysmenorrhoea. The sensitivity and specificity of TVS for diagnosing fibroids 
were reported as 95.1% and of 82.0% and were used as the accuracy values for TVS diagnosis 
of fibroids. 
 
As with outpatient hysteroscopy, no studies reported the accuracy of TVS for diagnosing a 
normal uterus, so this had to be derived indirectly. The largest high quality study (7 points) 
that reported the accuracy of TVS for diagnosing abnormality (213) was selected and the 
sensitivity and specificity were reversed. This study evaluated 770 women with HMB to 
establish the accuracy of TVS for diagnosing a composite of all pathologies labelled 
‘intrauterine disease’ by comparing the scan results to the results of hysteroscopy. As the 
reported sensitivity and specificity for abnormality were 0.96 (95% CI 0.934 to 0.972) and 
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0.86 (95% CI 0.823 to 0.898) they were reversed and 0.86 (95% CI 0.823 to 0.898) was used 
as the sensitivity and 0.96 (95% CI 0.934 to 0.972) as the specificity. 
 
Saline infusion sonography 
Searches for the accuracy of saline infusion scan identified 157 studies of saline scan for 
menorrhagia (Appendix 7.7). Forty-one papers were selected and assessed for quality and any 
reported accuracy data were extracted. Two systematic reviews were identified (199) (197), 
one of which was the study with no meta-analysis (199) identified during the TVS searches. 
The second was a systematic review and meta-analysis of diagnostic studies that compared 
SIS to either hysteroscopy or histopathology obtained at hysteroscopy or hysterectomy and 
reported the accuracy of the test for diagnosing intrauterine abnormalities (197). The analysis 
included twenty-four studies and more than 50% of the population were premenopausal. The 
accuracy of saline infusion sonography for diagnosing endometrial polyps and submucous 
fibroids was reported as a secondary outcome after meta-analysis of fifteen homogenous 
studies. These values were combined and weighted to calculate a value for the two 
pathologies combined. Once again data for a normal cavity were not available and so the 
sensitivity and specificity data for abnormalities were reversed.  
 
The accuracy of SIS for diagnosing endometrial disease was not reported in the systematic 
reviews. Of the thirty-nine remaining studies, four reported the accuracy of SIS for diagnosis 
of endometrial disease (hyperplasia and or cancer). When the quality was assessed, two of the 
studies scored 6 points (211;214) but the values that they reported for sensitivity were very 
different with one reporting a sensitivity for endometrial hyperplasia as 0.94 (214) and the 
second reporting sensitivity for endometrial hyperplasia and cancer as 0.29 (211). The study 
sizes were very similar, as were the proportions of premenopausal women, however one of 
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the studies had a much higher prevalence of endometrial disease (17%) than would be 
expected in a mainly premenopausal population (214) and the interval between the SIS and 
the reference test was up to fourteen days when in the second study it was just 24 hours (211). 
The first study (214) used a cut-off threshold for women of reproductive age of 8mm for 
diagnosing abnormality. Using an endometrial thickness cut-off level is crude and more 
applicable to a postmenopausal population where endometrial thickness is constant rather than 
changeable according to the menstrual cycle  In contrast, the second study diagnosed 
abnormalities based upon clinical features seen at SIS rather than defining abnormalities 
(211). The culmination of these factors resulted in the decision to use data from the second 
study (211) to populate the decision tree. 
 
Endometrial biopsy 
Searches for accuracy data of endometrial biopsy identified four studies with data regarding 
accuracy of the test. One of the studies was an RCT which looked at the use of three 
diagnostic tests, including endometrial biopsy, in groups of women at a specified risk of 
endometrial cancer (155). The population included pre and postmenopausal women and only 
reported the accuracy of pipelle for diagnosing endometrial cancer. Two of the remaining 
selected studies were systematic reviews one of which looked at diagnosis of endometrial 
hyperplasia (150) and a second which looked at endometrial cancer (151). Both studies used 
histopathology samples as the reference standard. These studies were limited in that they had 
mixed populations of pre and postmenopausal women. As postmenopausal women have an 
atrophic endometrium, focal lesion are more likely to be sampled and thus the effect of the 
postmenopausal women within these three studies may increase the sensitivity of the test 
above what may be expected in a purely premenopausal population.  As systematic reviews 
with meta-analysis were rated as higher quality evidence than RCT data the values from the 
160 
 
systematic reviews (150;151) were used for accuracy of diagnosing endometrial disease. In 
these papers, likelihood ratios were reported, but in order to populate the model, the 
sensitivities and specificities were used which had been reported in the thesis from which the 
papers were taken (Clark TJ 2004; PERSONAL COMMUNICATION).  
 
The fourth study reported the accuracy of endometrial biopsy for diagnosis of endometrial 
polyps (215). One hundred and seventy-six consecutive patients (77% premenopausal) who 
were scheduled for dilatation and curettage underwent transvaginal ultrasound and 
endometrial pipelle® biopsy prior to their surgery. The biopsy samples and the curettings 
were examined by different pathologists who were blinded to the other result. The paper 
reports these results in a cross-tabulated fashion enabling calculation of the sensitivity and 
specificity of endometrial biopsy for the diagnosis of endometrial polyps (216) as 0.997 (95% 
CI 0.973-1) and 0.003 (95% CI 0-0.027) respectively. These values were converted to the true 
positive and false positive values which were used in the decision tree. The some cross 
tabulation data were used to calculate the accuracy for diagnosis of dysfunctional uterine 
bleeding by looking at the accuracy for benign endometrium (excluding endometrial polyps 
and hyperplasia). The sensitivity was calculated as 0.953 (95% CI 0.895 to 0.98) and 
specificity as 0.971 (95% CI 0.902 to 0.992) and the corresponding true and false positive 
values used accordingly. 
 
No studies reported the use of endometrial biopsy for diagnosis of submucous fibroids so 
further searches were performed that did not include ‘heavy menstrual bleeding‘ or its 
associated terms. One study of 330 postmenopausal women was identified that reported the 
accuracy of endometrial biopsy for diagnosis of submucous fibroids. This prospective study 
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compared Novak catheter samples to histopathology samples obtained during surgery to 
establish accuracy of the blind biopsy. The reported sensitivity and specificity of the Novak 
catheter were 13% and 100%. The specificity was reduced to 99% (no ‘perfect’ values were 
deemed to be plausible) and the values were converted accordingly for use in the decision 
tree. 
 
The accuracy estimates, along with ranges for use in sensitivity analyses and data sources are 
summarised in Table 8.10.  
Table 8.10 Test sensitivity for specific pathologies 
Variable Baseline 
sensitivity 
Sensitivity 
analysis (range) 
Source 
    
OPH polyps 0.94  0.92-0.96
†
 SR (205) 
 
OPH submucous fibroids 0.87  0.81-0.92
†
 SR (205) 
 
OPH polyps / SMF 0.91  0.87-0.94
†
 Composite of polyp and 
SMF values 
 
OPH endometrial disease 0.78  0.76-0.80
†
 SR (198) 
 
OPH DUB 0.89  0.87-0.90
†
 SR (205) values reversed 
so for no pathology 
    
TVS polyps / SMF 0.45  0.32-0.58
†
 Prospective comparative 
study(211) 
 
TVS intramural fibroids 0.95  Prospective 
observational(212) 
 
TVS endometrial disease 0.57 0.19-0.90
†
 Prospective comparative 
study (211) 
 
TVS DUB 0.86 0.82- 0.90
†
 Prospective observational 
study (213)values 
reversed so for no 
pathology 
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Table 8.10 continued    
Variable Baseline 
sensitivity 
Sensitivity 
analysis (range) 
Source 
    
EBx polyps 0.41 0.14-0.76
†
 
 
Observational 
prospective cohort (215) 
 
EBx SMF 0.13 - Prospective comparative 
study (217) NB PMB 
 
EBx polyp / SMF 0.27 0.14-0.76 
†
 Composite of polyp and 
SMF values 
 
EBx endometrial 
hyperplasia 
0.66  0.47-0.81
†
 SR (150) 
 
EBx cancer / atypia 0.94  0.84-0.99
†
 SR (151) 
 
EBx endometrial disease 0.78  0.62-0.88
†
 Composite of hyperplasia 
and cancer / atypia values 
 
EBx DUB 0.95 0.90-0.98
†
 Observational 
prospective cohort (215) 
2x2 created and benign 
data used to calculate 
 
    
SIS polyps 0.86 0.81-0.91
†
 SR (197) 
 
SIS SMF 0.87 0.79-0.92
†
 SR (197) 
 
SIS polyps / SMF 0.87 0.80-0.92
†
 Composite of polyp and 
SMF values 
 
SIS endometrial disease 0.29  0.05–0.71† Prospective comparative 
study(211) 
 
SIS DUB 0.88 0.85-0.92
†
 SR (197) values reversed 
so for no pathology 
 
OPH= outpatient hysteroscopy; TVS = transvaginal scan; EBx= endometrial biopsy; SIS= saline infusion sonography; SMF= 
submucous fibroid; DUB= dysfunctional uterine bleeding; SR= systematic review; † = 95% confidence interval 
 
False positive rates 
Although the false positive rates were calculated from the specificity data (1-specificity = 
false positive rate) the derived values could not always be used in their pure form within the 
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decision model. This is because where a false diagnosis is made there are several possible 
erroneous options. However, the branches from one stem in the tree have to sum to one. This 
meant that all of the possible false diagnoses needed false positive rates which added up to 
one. To overcome this, if one of the erroneous diagnoses was DUB (i.e. normal) the FPR’s for 
the other pathologies would be used and the value remaining would become the FPR for 
DUB. When DUB was not a possible false diagnosis each FPR was divided by the sum of 
them together to weight the respective values appropriately: 
 
Example 1:- 1.If it is assumed that for TVS the possible false diagnoses were 
polyp/SMF (FPR=0.22), endometrial disease (FPR=0.34) and normal (FPR = 0.04). 
The only value which changes is the value for normal (i.e.  DUB) which becomes 1-
(0.34+0.22) = 1-0.56 = 0.44. 
 
Example 2:- If it is assumed that for TVS the possible false diagnoses are polyp/SMF 
(FPR= 0.22) or fibroids <12 weeks size (FPR= 0.18). Both values are then divided by 
the combined FPRs [(0.22+0.18) = 0.40] to weight them so that the sum of the two 
values equals one e.g. 0.22/0.40= 0.55 and 0.18/0.40= 0.45. 
 
This rule was used consistently throughout the decision tree. Weighting the values meant that 
the reported confidence intervals could not be used in subsequent sensitivity analyses so beta 
distributions were used to calculate appropriate confidence intervals. Table 8.11 details the 
false positive rates that were used within the tree as well as explanations as to how they were 
derived. 
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Table 8.11 Manipulation of false positive rates and their use within the decision tree 
Test True diagnosis False diagnosis Value Why 
 
     
TVS Polyp/SMF Fibroids <12wk 0.18 TVS FPR for intramural fibroids 
  Endometrial disease 0.34 TVS FPR for endometrial disease 
  Normal 0.48 Remaining 
     
 Fibroids <12wk Polyp/SMF 0.22 TVS FPR for polyp / SMF 
  Endometrial disease 0.34 TVS FPR for endometrial disease 
  Normal 0.44 Remaining 
     
 Fibroids >12wk Polyp/SMF 0.55 Unconditional FPR s weighted to add to 1 
  Fibroids <12wk 0.45 
     
 Endometrial disease Polyp/ SMF 0.22 TVS FPR for polyp / SMF 
  Fibroids <12wk 0.18 TVS FPR for Intramural fibroids 
  Normal 0.60 Remaining 
     
 DUB Polyp /SMF  0.30 Unconditional FPR s weighted to add to 1 
  Fibroids <12wk  0.24 
  Endometrial disease  0.46 
     
OPH Polyp / SMF Endometrial disease 0.04 OPH FPR for endometrial disease 
  Normal 0.96 Remaining 
     
 Fibroids <12wk Polyp/SMF 0.6 Unconditional FPR s weighted to add to 1* 
  Endometrial disease 0.4 
     
 Fibroids >12wk Polyp/SMF 0.6 Unconditional FPR s weighted to add to 1 
  Endometrial disease 0.4 
     
 Endometrial disease Polyp/SMF 0.06 OPH FPR for polyp/SMF 
  Normal 0.94 Remaining 
     
 DUB Polyp/SMF 0.6 FPR s weighted* 
  Endometrial disease 0.4 
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Table 8.11 continued    
Test True diagnosis False diagnosis Value Why 
 
      
EBx Polyp/SMF Normal 0.95 Remaining 
  Comp hyp 0.05 EBx FPR comp hyp 
     
 Fibroids <12wk Polyp/SMF 0.038 Unconditional FPR s weighted to add to 1 
  Comp hyp 0.962 
     
 Fibroids >12wk Polyp/SMF 0.038 Unconditional FPR s weighted to add to 1 
  Comp hyp 0.962 
     
 Endometrial disease Polyp/SMF 0.002 EBx FPR for polyp/SMF 
  Normal 0.998 Remaining 
     
 DUB Polyp 1  As no alternative disease 
     
SIS Polyp/SMF Fibroids <12wk 0.18 TVS FPR for intramural fibroids 
  Endometrial disease 0.02 SIS FPR for endometrial disease 
  Normal 0.80 Remaining 
     
 Fibroids <12wk Polyp/SMF 0.13 SIS FPR for polyp/SMF 
  Endometrial disease 0.02 SIS FPR for endometrial disease 
  Normal 0.85 Remaining 
     
 Fibroids >12wk Polyp/SMF 0.42 Unconditional FPR s weighted to add to 1 
  Fibroids <12wk 0.58 
     
 Endometrial disease Polyp/SMF 0.13 SIS FPR for polyp/SMF 
  Fibroids <12wk 0.18 TVS FPR for intra fib 
  Normal 0.69 Remaining 
     
 DUB Polyp/SMF 0.39 Unconditional FPR s weighted to add to 1 
  Fibroids <12wk 0.55 
  Endometrial disease 0.06 
OPH= outpatient hysteroscopy; TVS = transvaginal scan; EBx= endometrial biopsy; SIS= saline infusion sonography; SMF= submucous fibroid; DUB= dysfunctional uterine bleeding; 
SR= systematic review; FPR= false positive rate  
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Test combinations 
As the test combination trees display tests in series, no new values needed to be calculated for 
data accuracy for the combination trees.  
 
Treatment satisfaction data 
Levonorgestrel intrauterine device 
The medical database searches identified 2987 studies using the terms ‘levonorgestrel 
intrauterine device’, ‘heavy menstrual bleeding’ and their associated phrases. Eighty-two 
studies reported data regarding the effectiveness of the LNG-IUS. They were selected based 
on whether they reported effectiveness data for the LNG-IUS in any form for any pathology. 
The highest quality data for each pathology were then selected and used within the analysis 
(Appendix 7.9). The LNG-IUS works optimally when used to treat DUB and so data that 
reported patient satisfaction when used in women with DUB as their underlying pathology 
were identified and used as a reference. One of the selected studies was a systematic review 
with individual patient data (IPD) meta-analysis which looked at the relative effectiveness of 
hysterectomy, endometrial destruction and levonorgestrel intrauterine devices (LNG-IUS) 
(184). The review used 12 month follow up data to report rates of dissatisfaction when 
comparing the different treatments. The dissatisfaction reported for LNG-IUS overall at 12 
months was 17% (22/128). This was converted  to a satisfaction rate of 83% and confidence 
intervals were calculated from the data so that the values used for satisfaction with LNG-IUS 
when used to treat DUB were 0.83 (95% CI 0.76-0.89). 
  
No suitable studies were identified that reported the satisfaction level of premenopausal 
women with polyps, fibroids, endometrial hyperplasia or cancer if they were treated with an 
LNG-IUS. Any studies reporting this outcome were either very small (< 50 patients) or had a 
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mainly postmenopausal population. One study reported predictors of outcome for LNG-IUS 
and stated that small fibroids were not predictive of outcome (161), therefore an extrapolation 
was made from this and the same date were used for fibroids less than twelve weeks size as 
was used for DUB from the IPD study(184). For polyps / SMFs and for fibroids greater than 
twelve weeks size no studies were identified that reported patient satisfaction associated with 
the use of the LNG-IUS so the panel of gynaecologists were asked to estimate how effective 
the device would be in women with theses pathologies. The values of presumed treatment 
satisfaction for polyps/SMFs were inconsistent ranging from 20% to 85% with a median 
value of 40%. For fibroids > 12 weeks size the range was similarly imprecise varying from 
10% to 75% with a median value of 29%. The median values formed the point estimates and 
the ranges were used in the sensitivity analysis.  
 
One study was identified that reported the regression of endometrial disease with the use of 
the LNG-IUS (162), however only 37 of the women were premenopausal. The study reported 
that at 12 months 69/80 (86%) with complex hyperplasia had regressed and that 6/9 (66%) 
with atypical hyperplasia had regressed. This study was reported from data collected at BWH 
in 2008, however the database continued to be updated and so up-to-date data were used to 
produce values for endometrial hyperplasia and cancer. The database records follow-up data 
for women who have been diagnosed with endometrial hyperplasia with and without atypia, 
who are being treated with systemic or local progestogens. Women who were being treated 
with a LNG-IUS for endometrial disease were identified and their 6 and 12 month follow-up 
data examined. If they were still using the LNG-IUS at 12 months it was assumed that they 
were satisfied with it. If they had undergone hysterectomy or had the IUS removed they were 
counted as unsatisfied. One-hundred and one premenopausal women, 95 with complex 
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hyperplasia and 6 with complex hyperplasia with atypia were identified in the database. 
Thirteen of the women with complex hyperplasia had undergone a hysterectomy before 12 
months so 82/95 (86%) women were considered satisfied. This value is consistent with the 
original study (162). However this treatment success rate is greater than the aforementioned 
literature derived estimates for successful treatment outcomes in women without uterine 
pathology (DUB). This was considered highly unlikely so the value for the satisfaction rate of 
treatment with LNG-IUS in women with endometrial hyperplasia was reduced to 83% to 
make it the same value as for the DUB population. Confidence intervals were calculated for 
the original data but they were varied around a point estimate of 0.83 instead of 0.86. Of the 
six women who were treated for complex endometrial hyperplasia with atypia, three had 
undergone hysterectomy by twelve months, giving a satisfaction rate of 50%.  
 
It was assumed that the patients whose underlying disease was endometrial cancer would not 
be satisfied with the LNG-IUS treatment as the inappropriate treatment would mean 
persistence or worsening of their symptoms. In the database the ratio of pre-menopausal 
women with atypical endometrial hyperplasia to premenopausal women with endometrial 
cancer was 0.59: 0.41 so each was multiplied by the satisfaction value to produce a composite 
‘satisfaction’ value for the group ‘atypia/cancer’: 
 
Atypical hyperplasia   satisfaction rate= 0.50  prevalence= 0.59 
Endometrial cancer   satisfaction rate= 0.00  prevalence= 0.41 
 
Overall composite satisfaction rate is (0.50 x 0.59) + (0 x 0.41) = 0.295 
Value used for treatment satisfaction = 0.3 
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Similarly, the value for complex hyperplasia was used proportionally with the value for 
‘atypia/cancer’ to produce an overall satisfaction value for ‘endometrial disease’. 
 
Complex hyperplasia  satisfaction rate= 0.83  prevalence= 0.60 
Atypia/cancer   satisfaction rate= 0.30  prevalence= 0.40 
 
Overall composite satisfaction rate (0.60 x 0.83) + (0.30 x 0.40) = 0.44 
Value used for treatment satisfaction = 0.44 
 
Endometrial ablation 
To populate the decision tree, values were needed for satisfaction after endometrial ablation 
for DUB and for fibroid uteri. As endometrial ablation requires women to undergo an 
endometrial biopsy and either a TVS, SIS or OPH prior to the procedure it was assumed that 
any intrauterine pathology would be picked up by one of these pre-ablation tests and then 
treated appropriately. Thus outcome data for polyps/SMF and endometrial disease were not 
required. Searches for endometrial ablation identified 319 relevant studies, 8 of which were 
systematic reviews, with 4 containing meta-analysis (184;193;194;218) (Appendix 7.10a-
7.10b). Three of these studies appeared to be updated versions of the same Cochrane review 
and the fourth study was the IPD meta-analysis used for satisfaction with LNG-IUS (184). 
The most recent Cochrane review (193) and the IPD meta-analysis (184) were evaluated 
further. The IPD study was found to include 12 month satisfaction data from a larger overall 
population of women. It also had the benefit of using IPD data, so was selected as the 
preferable study. The reported dissatisfaction rates for second generation endometrial ablation 
110/1034 were converted to satisfaction rates which were then used to calculate confidence 
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intervals (0.893, 95% CI 0.874-0.912).  These values were used in the economic analysis for 
satisfaction after endometrial ablation for DUB. 
 
An electronic database search was performed (Appendix 7.10c-7.10d) to identify studies that 
reported outcome after endometrial ablation in the presence of fibroids. Once duplicates had 
been removed 315 studies were identified of which 17 were selected for further evaluation 
because they reported the use of endometrial ablation in the presence of fibroids. None of the 
studies reported satisfaction after second generation endometrial ablation in the presence of 
intramural or subserosal fibroids, however one study reported that the presence of a small 
fibroid uterus did not increase the hysterectomy rate (219). Once again this was extrapolated 
and the same data were used for small fibroid uteri as for satisfaction after second generation 
endometrial ablation for DUB. In the absence of published data for large fibroid uteri, the 
gynaecologist panel were asked for their estimation of satisfaction rates, 1 year post 
endometrial ablation. The median value of 0.575 was used as the point estimate and the range 
of values as the data for sensitivity analysis (0.075-0.85)  
 
Hysterectomy 
The IPD meta-analysis for treatment satisfaction data following the use of a LNG-IUS and 
after an endometrial ablation also reported data for hysterectomy so these values were used 
for satisfaction after hysterectomy for DUB (184). The rates reported were 409/432 patients 
satisfied which equates to a value of 0.95 and confidence intervals of 0.93 to 0.97. The studies 
included in this IPD looked at heavy menstrual bleeding and included women with polyps and 
fibroids. Only three studies supplied data regarding treatment outcome in the presence of 
focal uterine pathology. The presence of endometrial polyps and fibroids were found not to be 
statistically significant indicators of outcome. Thus it was assumed that satisfaction would be 
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the same whether hysterectomy was performed for DUB, polyps/SMFs or fibroids less than 
12 weeks size.  
 
For large fibroids (> 12 weeks uterine size), database searches were performed to identify 
studies reporting satisfaction after hysterectomy for fibroids. No systematic reviews were 
identified that examined this outcome directly. However a study of 397 women, that 
retrospectively followed up women who had either had hysterectomy or uterine artery 
embolisation reported that 88% of women who had undergone hysterectomy felt that their 
symptoms were better and that 70% would recommend their treatment to a friend (220). A 
disadvantage of this study was that the mean follow up time was 8.6 years. By scrutinising the 
reference list of this study, two similar studies (195;221) were identified. The first was a 
randomised trial of uterine artery embolisation (UAE) versus hysterectomy, with 51 women 
in the hysterectomy arm (195). Women were included if they had fibroids of at least 2cm in 
diameter (no upper limit), which caused symptoms and which a clinician thought justified 
surgical treatment. At 12 months 93% of women would recommend their treatment to a 
friend. The second study randomly allocated women with uterine fibroids up to 10cm in size 
and menorrhagia, to two groups. The women in group 1 were offered UAE as an alternative to 
hysterectomy for their fibroids and the women in group 2 were not offered the alternative and 
all had hysterectomy (221). In total 17 women underwent hysterectomy and at 6 months 88% 
reported that they would have the same treatment again, suggesting that they were satisfied 
with the surgery (221). After evaluating the data from these studies 0.88 was chosen as the 
satisfaction level as this was reported in the large retrospective study (220) and supported by 
the smaller randomised study (221). For the sensitivity analysis, the proportion of women 
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who would recommend their treatment to a friend from the two separate studies was used 
(0.70 and 0.93) (195;220).  
 
No studies were identified that reported satisfaction rates after hysterectomy for endometrial 
disease in premenopausal women. It was assumed that women having hysterectomy for 
atypical hyperplasia or cancer would be 100% satisfied because they would be prevented from 
developing cancer or treated for their cancer. For sensitivity analysis the lowest hysterectomy 
satisfaction value (i.e. 0.88 for fibroids) and the highest satisfaction value (1.0 for cancer) 
were used. For complex endometrial hyperplasia the same values as for DUB was used 
because complex hyperplasia is a benign condition so can be grouped with other benign 
causes of HMB without organic pathology i.e. DUB. Secondly, treatment satisfaction after 
LNG-IUS was the same for complex hyperplasia as for DUB and so this extrapolation 
regarding hysterectomy does not seem unreasonable. For endometrial disease overall, a 
composite value of the atypia/cancer value and the hyperplasia value was calculated as 0.97. 
For sensitivity analysis the lowest and highest satisfaction rates from the two categories were 
used i.e. 0.95 for hyperplasia to 1.0 for cancer.   
 
Polyp/SMF removal 
Satisfaction after removal of endometrial polyps and submucous fibroids was calculated as a 
composite of values for the two pathologies. For endometrial polyps two systematic reviews 
were selected (166;167)  from the 216 studies identified by database searches.  Neither 
systematic review included any meta-analysis because of the heterogeneity of the studies. The 
more recent review (167) identified all of the studies used in the older one (166) as well as 
more recently conducted studies. Satisfaction with polyp removal for abnormal uterine 
bleeding was reported as 75-100% so he high quality studies were examined for the most 
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appropriate data. Three studies were prospectively conducted (117;222;223). The first study 
was a cohort-controlled study comparing the effectiveness of outpatient and day case 
endometrial polypectomy which included 58 women, predominantly postmenopausal. At 6 
months, 34 women responded to a follow-up questionnaire that asked them about satisfaction 
with the treatment. 78% of women in the outpatient group and 88% women from the inpatient 
group were satisfied with their treatment, which equates to an 82% satisfaction rate overall 
(117). The second trial was a cohort study which looked at 21 women with abnormal 
menstrual bleeding and evaluated the change in their symptoms following endometrial 
polypectomy (222). At 6 months there was a statistically significant reduction in menstrual 
blood loss (p<0.001). Thirteen of the women had HMB, which persisted in 10 (77%) of them 
at 6 months although they had a statistically significant reduction in pictorial blood loss 
assessment chart (PBAC) scores (p=0.001). Overall, 86% of the women felt that they were 
cured or that their symptoms had been relieved by endometrial polypectomy (222). The third 
study randomised 150 premenopausal women with abnormal uterine bleeding to polypectomy 
or conservative management and found no difference in PBAC scores at 6 months. There was 
a significant difference between the groups for some of the secondary outcome measures 
including mean periodic blood loss measured by visual analogue scale (p=0.02) and 
occurrence of gynaecological symptoms (intermenstrual bleeding, pain), however, satisfaction 
was not reported and so could not be used (223). As the two comparative studies reporting 
satisfaction were small, the populations were combined and meta-analysed using Excel and 
RevMan to calculate a satisfaction value of 0.86. 
 
For satisfaction with transcervical resection of submucous fibroids (TCRF), 32 studies were 
identified by medical database searches. Nine studies reported satisfaction after transcervical 
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myomectomy but seven were rejected because they had fewer than forty patients (5;224) or 
reported satisfaction data from more than 3 years after treatment (170;225-228). The two 
remaining studies (168;171) were both prospectively conducted and had populations of over 
100 women, with more than 90% being premenopausal. The first study examined resection of 
submucous fibroids using a resectoscope under general anaesthesia (90%) or local anaesthesia 
with sedation. The average follow-up period was 2.3 years. Satisfaction with treatment was 
reported as 71.4% (168). The second study examined removal of fibroids using a bipolar 
intrauterine operating system and performed 38% of them under local anaesthesia. The 
average follow-up period was 2.6 years. Satisfaction with treatment was reported as 86% 
(171). In the decision tree resection as day-case surgery, under general anaesthesia was used 
for submucosal fibroid removal as it is the gold standard. Therefore the satisfaction rate from 
the first study was chosen as it appeared to be most appropriate for the analysis (168).  
 
The data from the polypectomy meta-analysis and the selected submucous fibroid resection 
study were used to create a value for the combined diagnostic group ‘polyps/SMF’ weighting 
the data according to the disease prevalence within the group (50% polyps, 50% SMFs). The 
value calculated was 0.79 and was used as the satisfaction value for removal of polyps and 
submucosal fibroids. 
 
To account for removal of erroneously diagnosed focal pathology (i.e. when no intrauterine 
pathology was present so normal endometrium is being resected) a satisfaction rate for 
dilatation and curettage was sought as the patients will essentially be having normal 
endometrial tissue removed. 274 studies were identified form database searches but none 
reported patient satisfaction following the procedure. One study was identified  which 
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reported relief of HMB after D&C and stated that the menstrual blood loss was reduced for 
the first month but returned to pre-operative levels after that (229). This does seem plausible 
as D&C is primarily a diagnostic procedure and removing the superficial endometrium will 
only be therapeutic until it grows back. As no additional data were available this value was 
used and allocated a satisfaction score of zero for satisfaction following ‘virtual removal’ 
when no intrauterine lesion was present. 
 
Myomectomy and uterine artery embolisation 
The alternative analysis which looked at treating women who wished to preserve their fertility 
included UAE and myomectomy as treatment options. Searches were performed to look at 
patient satisfaction after both treatments at 1 year (Appendix 7.14-7.15). For myomectomy 
one systematic review (230) was identified and selected from 120 studies and for UAE one 
systematic review (231) was identified and selected from 169 studies. Both systematic 
reviews compared UAE to surgical treatments (hysterectomy and myomectomy) (230;231) 
and both found no difference in patient satisfaction or quality of life between UAE, 
hysterectomy and myomectomy. Therefore the same value for satisfaction after hysterectomy 
was used for UAE and myomectomy (0.88).  
 
Costs 
 
Cost values were mainly taken from Healthcare Resource Group (HRG) codes for 2009 -
2010. The ‘national average unit cost’ was used as the cost for each intervention. The 
diagnostic and treatment codes for hysteroscopy include the cost of the consultation as well as 
any diagnostic or therapeutic procedures but the other diagnostic test codes equated to just the 
cost of the test. Within the decision tree patients could undergo multiple diagnostic tests and 
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treatments at one appointment. However, if the relevant HRG code costs were then used for 
each aspect the cost of the consultation would be included multiple times. In order to give an 
accurate reflection of the additional costs of multiple tests including hysteroscopic treatment, 
cost of consultation was removed from the diagnostic hysteroscopy costs and also from the 
therapeutic hysteroscopy codes. The cost of consultation and diagnostic hysteroscopy were 
subtracted so that the value remaining was the additional cost of performing the therapeutic 
hysteroscopic procedure alone. The relevant costs could then be added up depending upon the 
tests and treatments that the patients had undergone. For example, 
 
Cost of new gynaecology consultation     £  139 
Cost of outpatient hysteroscopy (consultation+ diagnostic OPH)  £  216 
Cost of outpatient hysteroscopic polypectomy     £  263 
(consultation+ diagnostic OPH+ polypectomy) 
Cost of transcervical resection of fibroid     £1344 
Cost of transvaginal ultrasound (test only)     £    55 
Cost of GnRH analogues       £  226 
 
So the cost of the diagnostic hysteroscopy is actually £216 - £139 =  £ 77 
And the additional cost of hysteroscopic polypectomy is £263 - £216 = £ 47 
 
If a woman (assigned to the TVS diagnostic pathway) comes to clinic and has a diagnosis of 
‘polyp/SMF’ made by TVS and then goes on to have removal of the lesion, the costs will 
equate to all the women having a consultation and a scan, half of them having an outpatient 
hysteroscopic polypectomy (ratio of polyps to submucous fibroids 50:50) and half of them 
177 
 
returning at a later date for a scheduled transcervical resection of fibroid (with 70% of these 
women having endometrial pre-treatment with GnRH analogues. 
 
 cGynaeNew + cTVS  + (0.5*cOPH) + (0.5*cPolypectomy) + (0.5*cTCRF) + (0.35*cGnRH) 
=       £139   +   £55    +  (0.5 x £77)  +      (0.5 x £47)         + (0.5 x £1344) + (0.35 x £226) 
= £139 + £55 + £38.50 + £23.50 + £672 + £79.10 
= £1007.10 
 
However, if the HRG code was used for hysteroscopic polypectomy alone the cost would be 
considered as £263 or if the code for TCRF was used it would be £1344. For the cost of LNG-
IUS and GnRH-a costs were taken from the British National Formulary (BNF) (25) The cost 
of uterine artery embolisation could not be identified in the HRG codes so the value used in 
the decision tree came from the REST study (195) as reported and used by NICE in an 
economic analysis for treatment of fibroids in their HMB guideline (142). Although this cost 
was published in 2007, the cost stated for hysterectomy was comparable to the cost stated in 
the HRG codes 2009-2010 (£2,566 vs. £2961) which are used in this economic analysis 
therefore no adjustment was made for inflation. For the cost of a GP appointment, data were 
taken from the Personal Social Services Research Unit (PSSRU (232)). Table 8.12 details all 
of the costs, ranges and sources of data.
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Table 8.12 Costs for investigation and treatment of women presenting with HMB 
Variable Decision tree name Cost (£) Lower 
quartile 
Upper 
quartile 
 
Explanation 
      
Consultations      
GP visit cGP_visit 36   Personal Social Services Research Unit. (PSSRU) 
http://www.pssru.ac.uk/uc/uc2010contents.htm 11min 
appt. Inc direct staff 
 
New gynaecology 
outpatient appointment 
 
cGynaeNew 139 111 161 502 HRG consultant service code 
Follow-up gynaecology 
outpatient appointment 
cGynaeFU 97 73 109 502 HRG consultant service code 
 
      
Diagnostic tests      
Diagnostic outpatient 
hysteroscopy 
 
cOPH 77 43 111 MA10Z HRG less cost of new gynaecology outpatient 
appointment  
Transvaginal ultrasound 
 
cTVS 55 40 66 HRG code RA23Z 
Endometrial biopsy cEBx 34 16 34 HRG code DAP824 
 
Saline infusion scan 
 
cSIS 71 54 83 HRG code RA24Z 
Confirmatory test cConfirmatory_test 115.72 77.56 130.66 (0.91*cEBx)+(0.09*cDandC) 
      
Treatments      
LNG-IUS fitting 
 
cLngIUS_fitted 85.66    
Endometrial polypectomy 
 
cPolypectomy 47 0 120 MA12Z HRG less the cost of diagnostic hysteroscopy 
MA10Z. 
Transcervical resection of 
fibroid with D+C cost 
cTCRF 1344 981 1541 HRG code MA09Z 
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Table 8.12continued      
Variable Decision tree name Cost (£) Lower 
quartile 
Upper 
quartile 
 
Explanation 
      
Transcervical resection of 
fibroid without D+C cost 
 
cTCRF_noDandC 401 281 433 HRG code MA09Z less the cost of D&C MA10Z 
Use of GnRH-a analogue 
 
cGnRHanalogue 225.73   BNF(25) 
Hysterectomy for benign 
disease 
 
cHysterectomy 2961 2346 3406 HRG code MA07D  
Hysterectomy for malignant 
disease 
 
cHysterectomy_malignant 3898 3052 4464 HRG code MA06Z 
Second laparotomy after 
cancer diagnosis to remove 
ovaries, lymph nodes etc. 
cReturn_for_BSO 3898 3052 4464 HRG code MA06Z 
Endometrial ablation 
 
cEndoAblation 896 697 1024 HRG code MA12Z 
Dilatation and curettage 
 
cDandC 942 700 1108 HRG code MA10Z 
Rescue treatment 
 
cRescue_Treatment 3136 2493 3606 cGP_visit + cGynaeNew + cHysterectomy 
Myomectomy 
 
cMyomectomy 2961 2346 3406 HRG code MA07D  
UAE cUAE 1685 1465 1905 REST study (195) 
MA09Z Upper Genital Tract Laparoscopic / Endoscopic Intermediate Procedures    MA10Z Upper Genital Tract Laparoscopic / Endoscopic Minor Procedures 
MA11Z Upper Genital Tract Intermediate Procedures     MA12Z Resection and ablation procedures for intra-uterine lesions 
MA06Z Open Major Upper and Lower Genital Tract Procedures with malignancy  MA07D Upper Genital Tract Major Procedures without Major CC 
RA 23Z Ultrasound Scan less than 20 minutes      RA 24Z Ultrasound Scan more than 20 minutes 
DAP824 Histology / Histopathology       502 Face to face, non-admission gynaecology consultant appointment  
 
OPH= outpatient hysteroscopy; TVS = transvaginal scan; EBx= endometrial biopsy; SIS= saline infusion sonography; SMF= submucous fibroid; DUB= dysfunctional uterine bleeding; 
LNG-IUS= levonorgestrel intrauterine system; TCRF= transcervical resection of fibroid; D&C= dilatation and curettage; BSO= bilateral salpingo-oophorectomy; UAE= uterine artery 
embolisation; GnRH-a= Gonadatrophin releasing hormone analogue; BNF= British National Formulary; GP= general practitioner; SR= systematic review; CI= confidence interval; 
HRG= health resource group. 
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Methods for the cost-effectiveness analysis 
(The following explanation of the methods for the economic analysis was written with Dr P. Barton, Reader 
in Health Economics. This section is essential for understanding the figures displayed in the results section 
and therefore is included within this thesis.)  
 
A decision tree was constructed using TreeAge Pro 2009. Model inputs included probabilities 
and costs. Effectiveness was measured in terms of patient satisfaction. Therefore each branch 
of the tree had an effectiveness outcome of 1 for a positive outcome and 0 if otherwise. Costs 
were unit costs for the various tests and treatments and were therefore treated as known with 
certainty, while probabilities depended on data and were treated as uncertain, to be varied in 
probabilistic sensitivity analysis. Note that the uncertainty in overall effectiveness for a given 
strategy is fully accounted for in the uncertainty in the probabilities, so there is no need to 
vary the outcome parameters. 
 
The model was first run using the point estimates of the branch probabilities. The results, 
known as “base case” results, are shown in terms of mean costs and effectiveness (overall 
proportion of positive outcomes) for each strategy modelled. These are tabulated and shown 
in a cost-effectiveness plane, with the mean cost shown on the vertical axis and the mean 
effectiveness shown on the horizontal axis. In some cases, a further plot was made of selected 
strategies to show more clearly the relationship between points that were close together on the 
first graph. 
 
Any strategy which has greater cost and worse effectiveness than some other strategy is said 
to be simply dominated. Such a strategy can be excluded from consideration. An incremental 
cost-effectiveness ratio (ICER) can be calculated between any two non-dominated strategies. 
The ICER is calculated by dividing the difference in cost by the difference in effectiveness. If 
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the ICER is less than the maximum willingness to pay for an additional positive outcome, 
then the more effective strategy can be said to be cost-effective relative to the other strategy. 
 
There is a further reason for excluding strategies known as extended dominance. This can 
only apply when there are three or more non-dominated strategies. In this case, two different 
strategies (incorporating a cheaper but less effective strategy and a more effective, more 
costly strategy relative to a third strategy) can be mixed together, with a proportion of patients 
getting one or other of the strategies such that the third strategy now becomes dominated (i.e. 
is more expensive and less effective) than the blended strategies Suppose that A, B and C are 
non-dominated strategies in order of increasing cost. Since they are non-dominated, they must 
also be in order of increasing effectiveness. Now suppose that the ICER of B over A is higher 
than the ICER of C over A. Then, if B is cost-effective compared to A, so also must C be 
cost-effective compared to A and B. In such a case, there is no value of willingness to pay per 
positive outcome at which B will be the preferred strategy, and the strategy B can be excluded 
by extended dominance. Extended dominance can be seen on a cost-effectiveness plane. The 
point for strategy B will be above the straight line joining the points for strategies A and C. 
 
Once all dominated strategies have been excluded, whether for simple or extended 
dominance, the remaining strategies are potentially cost-effective. Which will be preferred 
depends on the willingness to pay for an additional positive outcome. 
To test for the effect of uncertainty in the model inputs, two types of sensitivity analysis were 
used: probabilistic and deterministic. 
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In probabilistic sensitivity analysis, probability distributions are placed around the point 
estimate for each model parameter. If there is correlation between the uncertainties, joint or 
conditional distributions may be used. Beta distributions were used to represent the 
uncertainty around the branch probabilities in this model. The beta distribution is the standard 
distribution for a proportion. It has two parameters a and b, with mean a/(a+b) and variance 
essentially decreasing as a and b increase. 
For individual parameters of the models, the information available was in the form of a point 
estimate and a 95% confidence interval. In all cases, the beta distribution was selected with 
mean equal to the point estimate. Usually the distribution also matched the width of the 
confidence interval, but there were two main exceptions to this: 
 
 If the point estimate is either 0 or 1, then it is not possible to find a beta distribution 
with that mean. While it can be argued that the true mean estimate of the probability 
should be strictly between 0 and 1, taking any actual numerical value would risk 
overcompensating. Accordingly, it was decided to treat such probabilities as fixed, 
thereby preserving the mean but slightly underestimating the uncertainty in the model. 
 If either parameter a or b is less than 2, the beta distribution gives an unreasonably 
high proportion of values very close to the extreme values 0 or 1. To avoid this, in 
such cases the values of a and b were increased to preserve the mean of the 
distribution but ensure that both values were at least 2. Again, this slightly 
underestimates the overall uncertainty. 
 
In some cases, only a point estimate was available. In such cases, it is not appropriate to 
assume that the value is fixed. Instead the widest possible uncertainty was modelled subject to 
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the constraint that both parameters a and b should be at least 2, for the reasons given in the 
previous paragraph. 
 
In the analysis of SIS for detecting fibroids, point estimates of TPR and FPR were assumed to 
be the same as for TVS. In these cases, independent samples were taken from Beta 
distributions with the same parameters a and b. 
 
Since the costs in the model are all unit costs of specific procedures, these were treated as 
fixed, and the only parameters to be varied were the probabilities in the tree, which are 
proportions of patients expected to follow each branch.  
  
When the model was run for probabilistic sensitivity analysis (PSA), 1000 replications were 
made, sampling from distributions for all branch probabilities simultaneously. It is generally 
accepted that 1000 replications are sufficient to give a clear picture of the uncertainty. 
The parameters for this Beta distribution used for the probabilistic sensitivity analysis of the 
HMB tree are shown in Table 8.13. 
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Table 8.13 Beta distribution parameters for analysis of the base case decision tree for 
investigating women with heavy menstrual bleeding 
Parameter a* b* Low High 
Prevalence of disease 
    EndometrialDisease 5 95 0.02 0.10 
FibroidLarge 6 94 0.02 0.11 
FibroidSmall 19 81 0.12 0.27 
PolyporSMF 38 62 0.29 0.48 
     Success rates 
    EBx 728 72 0.89 0.93 
OPH 67.9 2.1 0.92 1.00 
SIS 1520 80 0.94 0.96 
TVS 198 2 0.97 1.00 
     True Positive Rates 
    ED_EBx 28.86 8.14 0.64 0.90 
ED_OPH 1248 352 0.76 0.80 
ED_SIS 2.03 4.97 0.05 0.65 
ED_TVS 3.249 2.451 0.19 0.90 
Fibroids_SIS 38 2 0.87 0.99 
Fibroids_TVS 38 2 0.87 0.99 
Normal_EBx 95 5 0.90 0.98 
Normal_OPH 1424 176 0.87 0.90 
Normal_SIS 264 36 0.84 0.91 
Normal_TVS 258 42 0.82 0.90 
PolyporSMF_EBx 2.16 5.84 0.04 0.60 
PolypsorSMF_OPH 227.5 22.5 0.87 0.94 
PolypsorSMF_SIS 104.4 15.6 0.80 0.92 
PolypsorSMF_TVS 22.5 27.5 0.32 0.59 
     False Positive Rates 
    CompHyp_EBx 7.5 142.5 0.02 0.09 
ED_OPH 1000 24000 0.04 0.04 
ED_SIS 2 98 0.00 0.05 
ED_TVS 27.2 52.8 0.24 0.45 
Fibroids_SIS 2.16 9.84 0.03 0.43 
Fibroids_TVS 2.16 9.84 0.03 0.43 
PolypSMF_EBx 2 998 0.00 0.01 
PolypSMF_OPH 33 517 0.04 0.08 
PolypSMF_SIS 3.9 26.1 0.04 0.27 
PolypSMF_TVS 7.7 27.3 0.10 0.37 
pExDetectsFibroids 8 2 0.52 0.97 
pHyperplasia 3 2 0.19 0.93 
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Table 8.13 continued 
    Parameter a* b* Low High 
Probability of being satisfied 
EA_DUB 924 110 0.87 0.91 
EA_Fibroids 2.76 2.04 0.17 0.92 
Hysterectomy_AtypCa parameter fixed at value 1 
Hysterectomy_ED 164.9 5.1 0.94 0.99 
Hysterectomy_Fibroids 24.64 3.36 0.74 0.97 
Hysterectomy_HMB 380 20 0.93 0.97 
Hysterectomy_Hyperpl 380 20 0.93 0.97 
LngIUS_DUB 107.9 22.1 0.76 0.89 
LngIUS_ED 9.68 12.32 0.24 0.65 
LngIUS_Fibroids 2.03 4.97 0.05 0.65 
LngIUS_Hyperplasia 91.3 18.7 0.75 0.89 
LngIUS_PolypSMF 420 580 0.39 0.45 
Removal 11 3 0.55 0.95 
Removal_CavityNormal parameter fixed at value 0 
  a, b: Parameters of Beta distribution. Low, High: 2.5 and 97.5 percentiles respectively of fitted distribution, corresponding to 
lower and higher limits of 95% confidence interval. All parameters sampled independently except for the prevalence 
parameters, which were sampled together from a Dirichlet distribution (see text). OPH= outpatient hysteroscopy; TVS = 
transvaginal scan; EBx= endometrial biopsy; SIS= saline infusion sonography; SMF= submucous fibroid; DUB= 
dysfunctional uterine bleeding 
*Please read ‘Methods for the cost-effectiveness analysis', for explanation regarding the parameters a and b 
 
For models (such as Markov models) in which there is a non-linear relationship between 
model inputs and outputs it is appropriate to give a table of mean results from the probabilistic 
sensitivity analysis, as the Bayesian viewpoint is that the mean results from the PSA are the 
appropriate basis for decision making. However, in the case of the models presented here, 
these results would be statistically equivalent to the base case results and therefore there is no 
need to produce such a table. Results that have been shown are as follows: 
 
A cost-effectiveness scattergraph: This shows, on a single graph, the uncertainty in the 
absolute expected cost and effectiveness for each option separately. For each option, the 
results of the 1000 replications of the model were shown each as a single point. In practice, 
the printed symbols used merge to form a “cloud” giving the general range of uncertainty in 
the results. The vertical spread of this cloud reflects the uncertainty in the overall cost and the 
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horizontal spread the uncertainty in overall effectiveness, while the centre of the cloud, where 
the points are most densely packed, indicates the most likely cost and effectiveness. 
 
A cost-effectiveness acceptability frontier (CEAF): At any given willingness to pay, the 
preferred option is determined by the mean outcomes, which in the case of the models here 
are the same as the base case results described earlier. The CEAF shows the proportion of 
model replications for which this option remained the preferred strategy, as a function of the 
willingness to pay for an additional positive outcome. 
 
While the graphs described above are the only convenient ways of showing results comparing 
all the modelled options, they are applicable only to a decision in which exactly those options 
are included. For other purposes, it is helpful to look at pairwise comparisons between 
strategies. The results shown from a pairwise comparison are helpful to any decision problem 
in which both those strategies are included. Pairwise comparisons were made between 
successive non-dominated options (in order of increasing cost or effectiveness), and others 
where a dominated option was close to another option. 
 
For pairwise comparisons, the incremental cost-effectiveness scattergraph was shown. In this 
type of graph, there is a single point for each of the 1000 replications of the model, showing 
the difference in cost and effectiveness between the two strategies. If the “clouds” shown in 
the cost-effectiveness scattergraph for the two strategies overlap, it may be for two possible 
reasons. First, it may be because there is genuine uncertainty as to which is the more costly 
and/or more effective strategy. Second, it may be that one strategy is consistently more costly 
and/or more effective than the other, but this consistent difference is small compared to the 
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uncertainty in the absolute costs and/or effectiveness. The incremental cost-effectiveness 
scattergraph distinguishes between these two cases and shows the relevant uncertainty for a 
decision maker. 
 
The other graph plotted for the pairwise comparisons was the cost-effectiveness acceptability 
curve (CEAC). This shows the proportion of model replications in which one of the strategies 
is cost-effective compared to the other, across a range of values of willingness to pay per 
additional positive outcome. 
 
In deterministic sensitivity analysis, one or more model inputs are varied systematically and 
the effect on the model outcomes is noted. This was used to test the effect of reducing the 
prevalence of polyps and submucous fibroids and increasing the prevalence of dysfunctional 
uterine bleeding and also to examine the effect when the unit cost of saline infusion 
sonography was reduced. For prevalence of the various pathologies, a Dirichlet distribution 
was used. This is the generalisation of the Beta distribution for more than two options. Given 
that the prevalence data came from different sources, it was necessary to take a compromise 
between the effective sample sizes indicated by those sources. An effective sample size of 100 
was assumed. The distribution of any prevalence parameter on its own then follows a Beta 
distribution 
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CHAPTER 9 
 
RESULTS OF THE ECONOMIC ANALYSIS OF DIAGNOSTIC 
STRATEGIES FOR THE INVESTIGATION OF HEAVY 
MENSTRUAL BLEEDING 
 
Deterministic results: Base case 
 
The current recommended first line treatment for HMB in women not desiring immediate 
fertility, is the levonorgestrel intrauterine system treatment (LNG-IUS) otherwise known as 
the Mirena® coil (Bayer  HealthCare Pharmaceuticals Inc. Wayne, USA) (142). The majority 
of women with HMB have no uterine pathology (known as dysfunctional uterine bleeding) or 
benign uterine pathologies such as small uterine fibroids or endometrial hyperplasia and all 
these conditions respond well in general to the LNG-IUS (161;162).  
 
Thus, given the negligible chance of life-threatening disease, lack of recommendations 
stipulating the need for routine diagnostic testing and the known effectiveness and 
applicability of the LNG-IUS in HMB, the strategy using LNG-IUS without any preliminary 
diagnostic testing was chosen as the reference strategy. The costs and effects of the other 
diagnostic testing strategies were compared against this reference strategy. In addition, a 
recent cost-effectiveness analysis informed by IPD analysis of published trials for treatment 
of HMB suggested that surgical treatment with hysterectomy was more cost-effective than the 
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LNG-IUS(136) so a strategy of hysterectomy without diagnostic work up was also 
considered. 
  
Table 9.1 reports the deterministic results, referencing all other diagnostic or treatment 
strategies to the LNG-IUS treatment alone base-case strategy.  
 
Table 9.1 Determinist analysis results for the investigation of women with heavy 
menstrual bleeding 
Strategy Cost (£) Effectiveness 
(satisfaction) 
   
LNG-IUS alone 1067 0.9333 
OPH alone 1078 0.9641 
SIS alone 1083 0.9629 
TVS alone 1085 0.9551 
TVS + OPH 1139 0.9644 
OPH and Ebx 1149 0.9674 
SIS + OPH 1170 0.9645 
EBx alone 1209 0.9460 
SIS + Ebx 1223 0.9643 
TVS+ OPH+Ebx 1227 0.9649 
TVS + Ebx 1231 0.9539 
SIS +OPH +Ebx 1256 0.9650 
Hysterectomy alone 3182 0.9335 
EBx = endometrial biopsy; OPH = outpatient hysteroscopy; SIS = saline infusion sonography; TVS = transvaginal ultrasound 
scan; LNG-IUS = levonorgestrel intrauterine system. 
 
Outcomes 
Direct treatment without preliminary diagnostic testing was less effective than treatment 
instigated after diagnostic testing. The least effective approach was the base case strategy of 
LNG-IUS treatment alone followed closely by surgical treatment with hysterectomy, both 
approaches resulting in satisfaction rates around 93.3-93.4%. The effectiveness of HMB 
management was similar across all testing strategies ranging from 94.6% to 96.7% rates of 
190 
 
satisfaction. The most effective strategy was combination testing with outpatient hysteroscopy 
and endometrial biopsy.  
  
Costs 
The LNG-IUS treatment alone base case strategy was the cheapest costing £1067 per woman 
treated for HMB in a secondary care setting and the strategy of hysterectomy for all women 
was the most expensive at £3182 per woman treated i.e. £2116 more than the approach of 
LNG-IUS treatment alone. The cheapest of the nine diagnostic testing strategies was the use 
of outpatient hysteroscopy alone, costing £1078 for every woman treated, i.e. £11 more than 
universal LNG-IUS treatment.  
 
Cost-effectiveness and dominance 
Only the testing strategies outpatient hysteroscopy (OPH) alone and outpatient hysteroscopy 
combined with endometrial biopsy (OPH + EBx) remain non-dominated by alternative 
empirical treatment or diagnostic testing strategies. It is clear from the analysis that the 
strategy OPH alone dominates the testing strategies SIS alone and TVS alone. The 
combination testing strategy TVS and OPH is excluded by extended dominance between OPH 
alone and OPH + EBx. The remaining seven alternate strategies are dominated by OPH + 
EBx. Table 9.2 presents the deterministic analysis restricted to the non-dominated competing 
strategies. 
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Table 9.2 Deterministic results for the non-dominated strategies for investigation of 
women with heavy menstrual bleeding 
Strategy 
 
Total 
Cost 
(£) 
Incremental 
Cost (£) 
Effectiveness 
(satisfaction) 
Incremental  
effectiveness 
ICER 
 
      
LNG-IUS 
alone 1067 
 
0.9333 
  OPH alone 1078 11 0.9641 0.0308 359 
OPH and 
EBx 1149 71 0.9674 0.0033 21500 
Apparent anomalies with subtraction are due to rounding effects 
EBx = endometrial biopsy; ICER = incremental cost-effectiveness ratio; LNG-IUS = levonorgestrel intrauterine system; 
OPH= outpatient hysteroscopy 
 
The cheapest strategy is the base-case scenario of no testing and universal treatment with the 
LNG-IUS alone. The most effective strategy is the combination of initial testing with OPH + 
EBx, but this comes at a greater cost, generating an ICER of  £21,500 i.e. the strategy requires 
an investment of £21,500 to gain an extra woman satisfied  following treatment for HMB 
compared with investigation with OPH alone. The single test strategy of OPH is slightly less 
effective than the strategy of OPH with the addition of EBx, but is substantially less costly. 
The ICER for OPH is £359, i.e. an additional financial outlay of £360 is necessary to acquire 
an extra woman satisfied following treatment for HMB.  
 
Figure 9.1 shows the total costs and effectiveness of alternative strategies for the diagnosis 
and treatment of HMB in secondary care. The line presented graphically joins the non-
dominated strategies (OPH alone and OPH+EBx). Any strategy plotted above this line is not 
considered cost-effective in relation to the non-dominated strategies. 
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Figure 9.1 Cost-effectiveness plane showing the results of deterministic analysis of the 
strategies for investigation of women with heavy menstrual bleeding 
 
LNG-IUS = levonorgestrel intrauterine system; EBx = endometrial biopsy; OPH = outpatient hysteroscopy; SIS = saline 
infusion sonography; TVS= transvaginal ultrasound scan  
 
It is clear that direct treatment with hysterectomy is the least cost-effective strategy. 
Replicating the figure and excluding the hysterectomy strategy reduces the scale of the y axis 
allowing closer examination of the remaining testing strategies.  
 
Figure  9.2 reveals that the options "TVS alone" and "SIS alone" are sufficiently close to the 
boundary of dominance that it is worth checking for the uncertainty between these dominated 
alternatives in addition to the non-dominated options “OPH” and “OPH + EBx” through 
sensitivity analyses.  
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Figure 9.2 Cost-effectiveness plane showing the results of deterministic analysis of the 
strategies for investigation of women with heavy menstrual bleeding- hysterectomy 
excluded 
 
LNG-IUS = levonorgestrel intrauterine system; EBx = endometrial biopsy; OPH = outpatient hysteroscopy; TVS= 
transvaginal scan; SIS= saline infusion sonography 
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Probabilistic sensitivity analysis results: Base case 
Figure 9.3 demonstrates the uncertainty surrounding the absolute expected cost and 
effectiveness of each of the strategies, with the true value lying somewhere within the ‘cloud’ 
of plotted points, probably where they are most densely clustered. It shows that hysterectomy 
is too expensive to be a competitive option but that there is overlap between the remaining 
strategies. 
Figure 9.3 Scatterplot showing the uncertainty in costs and effectiveness within the 
model for each of the individual strategies for investigation of women with heavy 
menstrual bleeding 
 
LNG-IUS = levonorgestrel intrauterine system; EBx = endometrial biopsy; OPH = outpatient hysteroscopy; TVS= 
transvaginal scan; SIS= saline infusion sonography 
 
Figure 9.4 illustrates the overall uncertainty related to the optimal decision across a range of 
plausible willingness to pay (WTP) values, where the willingness to pay is measured in £ per 
additional case satisfied. When a model is linear in all parameters and they are sampled 
independently, the mean of the probabilistic results will be the same as the deterministic 
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result. This is true for the current model, as the only parameters which are not independently 
sampled are the prevalences, and these do not interact in the calculation of the model results. 
The cost-effectiveness acceptability frontier (CEAF) (Figure 9.4) is generated as follows. 
First, for any willingness to pay, the optimal option is determined based on the mean results. 
Then the proportion of model replications for which that was the optimal option is found and 
plotted. For example, considering a WTP of £10,000 per case satisfied, the preferred option 
based on the mean results is OPH alone, and this was optimal in around 60% of the model 
replications. Thus there is an estimated probability of 40% that there is a better option than 
OPH at that WTP. By definition, only the options which are not dominated in the mean results 
can appear on the CEAF. Sometimes the probability shown will be lower than 50%. It will 
often be the case that the option preferred on mean values is also the preferred option in the 
highest proportion of model replications, but this not always so. As the willingness to pay 
crosses the ICER between two non-dominated options, the choice of optimal option changes, 
and there will usually be a discontinuity in the curve. 
 
Figure 9.4 Cost-effectiveness acceptability frontier showing the optimal investigative 
strategy across a range of willingness to pay thresholds for the sensitivity analysis of 
stratgies to investigate women with heavy menstrual bleeding 
 
LNG-IUS = levonorgestrel intrauterine system; EBx = endometrial biopsy; OPH = outpatient hysteroscopy 
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For the current model, the CEAF shows the same range of preferred options already shown in 
Table 9.2, but indicates that there is appreciable uncertainty about the preferred option across 
the whole range of WTP values plotted. To explore the uncertainty more fully, it is helpful to 
consider a range of appropriate pair wise comparisons between the different options. 
Comparisons are shown between adjacent non-dominated options. There are also options that 
are dominated on mean values, but whose mean values are close to the non-dominance lines 
shown on Figure 9.2. These options are compared to relevant non-dominated options. 
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Outpatient hysteroscopy versus levonorgestrel releasing intrauterine system 
The cost-effectiveness plane (Figure 9.5a) shows the modelled uncertainty in the difference in 
costs between OPH alone and LNG-IUS alone. It shows that OPH alone is consistently more 
effective than LNG-IUS alone, and is likely (but not certain) to be more costly. The cost-
effectiveness acceptability curve (CEAC) (Figure 9.5b) shows the proportion of model 
replications for which OPH alone is preferred to LNG-IUS alone at any given WTP. OPH is 
the preferred option at any willingness to pay over £360 per additional case satisfied, but there 
is considerable uncertainty when the WTP is just above this figure. However, by the time the 
WTP exceeds £8,000 per additional case satisfied, it is almost certain that OPH is preferred to 
LNG-IUS. 
Figure 9.5 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
Outpatient hysteroscopy alone strategy relative to the LNG-IUS alone strategy 
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Outpatient hysteroscopy and endometrial biopsy versus outpatient hysteroscopy  
The graph (Figure 9.6a) shows the modelled uncertainty in the difference in costs between 
"OPH and EBx" and OPH alone. It shows that adding EBx to OPH increases the cost and is 
very likely to increase the effectiveness. The CEAC (Figure 9.6b) shows the proportion of 
model replications for which OPH and EB is preferred to OPH alone at any given willingness 
to pay per additional case satisfied. It is more likely than not that OPH + EBx is cost-effective 
compared to OPH above a WTP threshold of around £23,000. However, there is considerable 
uncertainty throughout the range of WTP values shown. About 30% of replications favour 
OPH alone even if the WTP is as high as £40,000 per additional case satisfied. 
 
Figure 9.6 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
Outpatient hysteroscopy and endometrial biopsy strategy relative to the outpatient 
hysteroscopy alone strategy 
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Assessment of potentially cost-effective competing strategies 
In addition to the non-dominated testing strategies “OPH” and “OPH + EBx”, the single 
testing strategies TVS and SIS were sufficiently close to the boundary of dominance to  
 
explore the level of uncertainty within the model pertaining to these two dominated strategies. 
 
Transvaginal ultrasound scan versus levonorgestrel releasing intrauterine system 
The graph (Figure 9.7a) shows the modelled uncertainty in the difference in costs between 
TVS alone and LNG-IUS alone. It shows that TVS alone is consistently more effective than 
LNG-IUS alone, and is likely (but not certain) to be more costly. The CEAC (Figure 9.7b) 
shows that it is more likely than not that TVS is cost-effective compared to LNG-IUS above a 
WTP threshold of around £1000 and this is almost certain at WTP thresholds beyond £9000. 
 
Figure 9.7 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
Transvaginal ultrasound scan alone strategy relative to the LNG-IUS alone strategy 
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Saline infusion sonography versus levonorgestrel releasing intrauterine system 
The graph (Figure 9.8a) shows the modelled uncertainty in the difference in costs between 
SIS alone and LNG-IUS alone. It shows that SIS alone is consistently more effective than 
LNG-IUS alone, and is likely (but not certain) to be more costly. The CEAC (Figure 9.8b) 
shows that the likelihood is that SIS is cost-effective compared to LNG-IUS above a WTP 
threshold of around £800. This is almost certainly the case at WTP thresholds beyond £8000.   
 
Figure 9.8 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b):  
Saline infusion sonography alone strategy relative to the LNG-IUS alone strategy 
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Outpatient hysteroscopy versus transvaginal ultrasound scan  
The graph (Figure 9.9a) shows the modelled uncertainty in the difference in costs between 
OPH alone and TVS alone. It shows that OPH alone is almost certainly more effective than 
TVS alone but it is unclear whether it is more costly. The CEAC (Figure 9.9b) shows the 
proportion of model replications for which OPH alone is preferred to TVS alone at any given 
willingness to pay per additional case satisfied. The likelihood is that OPH is cost-effective 
compared to TVS above any WTP threshold and this is almost certain at WTP thresholds 
beyond £9000.  
Figure 9.9 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
Outpatient hysteroscopy alone strategy relative to the transvaginal ultrasound scan 
alone strategy 
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Outpatient hysteroscopy versus saline infusion sonography 
The graph (Figure 9.10a) shows the modelled uncertainty in the difference in costs between 
OPH alone and SIS alone. It shows that OPH alone is likely to be more effective than SIS 
alone, and there is considerable uncertainty as to which is more costly. The CEAC (Figure 
9.10b) shows the proportion of model replications for which OPH alone is preferred to SIS 
alone at any given willingness to pay per additional case satisfied. The likelihood is that OPH 
is cost-effective compared to SIS above any WTP threshold although there is considerable 
uncertainty throughout. Even at a WTP of £40,000 per additional case satisfied, SIS is 
preferred in 20% of model replications. 
 
Figure 9.10 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
Outpatient hysteroscopy alone strategy relative to the saline infusion sonography alone 
strategy 
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Deterministic sensitivity analysis results 
 
Assessment of the impact of reducing the cost of saline infusion sonography 
The probabilistic sensitivity analyses show uncertainty around whether OPH or SIS is the 
most cost-effective investigative strategy. To assess this uncertainty further, deterministic 
sensitivity analysis was performed to reduce the cost of SIS and determine at what cost it 
would become more cost-effective than OPH. Table 9.3 details the ICER values when the cost 
of SIS is reduced.   
 
Table 9.3 Incremental cost-effectiveness ratio value for saline infusion sonography when 
the cost is varied 
SIS cost £ 
 
ICER 
65      76 
60  4006 
55  7937 
53  9509 
52 10295 
50 11867 
45 15797 
35 23658 
SIS= saline infusion scan; ICER= incremental cost-effectiveness ratio 
 
In this analysis, the unit cost for SIS was reduced from £71 (base case cost), keeping all other 
variables fixed. When the cost was reduced to £65, the strategy "SIS alone" was no longer 
dominated by "OPH alone". However, the modelled ICER was £76 per additional case 
satisfied, suggesting that OPH alone is still highly cost-effective compared to SIS alone.  As 
the cost of SIS reduces further, the ICER increases (see Figure 9.11). Considering an 
illustrative willingness to pay of £10,000 per case satisfied, the ICER goes above this figure 
when the cost of SIS drops to £52. In that case, OPH is no longer cost-effective compared to 
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SIS, and SIS becomes the preferred strategy (of the two) on cost-effectiveness grounds. It 
should also be noted that at a unit cost for SIS of £53 or lower, the strategy "SIS alone" 
becomes less costly, as well as remaining more effective, than LNG-IUS alone.  
 
Figure 9.11 Incremental cost-effectiveness ratios between outpatient hysteroscopy and 
saline infusion sonography when the cost of saline infusion sonography is varied 
 
SIS= saline infusion scan; ICER= incremental cost-effectiveness ratio 
 
 
Assessment of the impact of the prevalence of focal uterine pathology 
A high prevalence of intracavity focal endometrial lesions will favour outpatient hysteroscopy 
over the imaging technologies TVS and SIS because it is more likely to diagnose the lesions 
and treatment can be initiated with only a small additional cost during the diagnostic 
procedure (the so called ‘see & treat’ approach). If the prevalence of endometrial polyps and 
submucous fibroids is over-estimated within the decision tree, OPH will falsely appear the 
most cost-effective. Similarly the prevalence of DUB may be an underestimate. To assess the 
effect of prevalence on the analysis the prevalence of polyps / SMF’s was varied, keeping the 
prevalence of fibroids and endometrial disease fixed. The prevalence of dysfunctional uterine 
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bleeding was changed inversely to compensate for the change in prevalence of polyp or SMF. 
All other variables in the model were fixed at their point estimates. Figure 9.12 shows the 
preferred option at a range of values of willingness to pay per additional case satisfied, 
varying the prevalence of polyp or SMF. For example, at a prevalence of 30%, the 
combination of OPH and EBx is preferred if the willingness to pay per additional case 
satisfied is more than about £27,000, while OPH alone is preferred if this willingness to pay is 
between £2000 and £27,000. Only at a willingness to pay below £2000 per case satisfied is 
LNG-IUS alone preferred. For this prevalence, other options are dominated and so not 
preferred at any willingness to pay value. It is only at a prevalence of polyps/SMFs of 27% 
that SIS becomes a non-dominated option and at 24% when TVS becomes non-dominated. 
 
Figure 9.12 Incremental cost-effectiveness ratios between non-dominated options at a 
variety of prevalence values for polyps / submucous fibroids and dysfunctional uterine 
bleeding 
 
OPH = outpatient hysteroscopy; SIS = saline infusion sonography; TVS = transvaginal ultrasound scan; LNG-IUS = 
levonorgestrel intrauterine system, SMF= submucous fibroid 
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Deterministic results: Women being managed during multiple clinic 
appointments 
 
To reflect ‘traditional’ investigation and treatment of patients, over the course of multiple 
clinic appointments, the base case tree was adapted and the results of the deterministic 
analysis are displayed in Table 9.4 below. 
 
Table 9.4 Deterministic results of cost-effectiveness analysis for women with heavy 
menstrual bleeding managed over multiple clinic appointments 
 
LNG-IUS = levonorgestrel intrauterine system; EBx = endometrial biopsy; OPH = outpatient hysteroscopy; SIS = saline 
infusion sonography; TVS – transvaginal ultrasound scan  
 
Outcomes 
As with the base case analysis, the ‘no investigation’ strategies were the least effective 
strategies for managing women. The most effective strategy for investigating women using a 
multiple clinic attendance as opposed to a ‘one-stop’ approach was the combination of OPH 
+EBx. 
 
Strategy 
 
Cost(£) 
 
Effectiveness 
(Satisfaction) 
   
LNG-IUS alone 1067 0.9333 
TVS alone 1204 0.9551 
EBx alone 1214 0.9460 
SIS alone 1217 0.9629 
TVS + Ebx 1266 0.9540 
SIS + EBx 1274 0.9643 
OPH alone 1288 0.9641 
TVS + OPH 1315 0.9644 
OPH +EBx 1317 0.9674 
SIS + OPH 1343 0.9644 
TVS+ OPH+EBx 1391 0.9649 
SIS +OPH +EBx 1418 0.9650 
Hysterectomy alone 3182 0.9335 
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Costs 
Costs for the ’no investigation’ strategies (LNG-IUS alone and hysterectomy alone) remained 
unchanged. The costs of the investigative strategies however increased due to the additional 
appointments required with the costs for the investigation strategies ranging from £1204 to 
£1418 in this alternative analysis compared to £1078 to £1256 in the base case analysis. 
 
Cost-effectiveness and dominance 
The strategies "EBx alone", "TVS + EBx", "OPH alone", "SIS + OPH", "TVS + OPH + 
EBx", "SIS + OPH + EBx", and "Hysterectomy alone" are excluded by simple dominance and 
the strategies  "TVS alone",  "SIS + EBx" and "TVS + OPH" are excluded by extended 
dominance. The remaining three strategies are not dominated. In contrast to the base case 
analysis the strategy SIS alone is no longer dominated whereas "OPH alone" is. Table 9.5 
displays the non-dominated strategies from deterministic analysis.  
 
Table 9.5 Non-dominated strategies from the analysis of women presenting with heavy 
menstrual bleeding managed over multiple clinic appointments 
Strategy  
Cost 
(£) 
Incremental 
Cost (£) Effectiveness 
Incremental 
Effectiveness ICER 
      
LNG-IUS alone 1067 
 
0.9333 
  SIS alone 1217 150 0.9629 0.0296 5070 
OPH + EBx 1317 100 0.9674 0.0045 22100 
EBx = endometrial biopsy; OPH = outpatient hysteroscopy; SIS = saline infusion sonography; LNG-IUS = levonorgestrel 
intrauterine system 
 
Using SIS to investigate women in this strategy costs an additional £5070 to make an extra 
women satisfied compared to not investigating and giving all women a LNG-IUS. OPH and 
EBx costs an additional £22,100 to the cost of SIS to gain a further satisfied patient. OPH 
alone does not appear as a non-dominated option in this analysis. The line on the cost-
effectiveness plane in Figure 9.13 links the non-dominated strategies. 
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Figure 9.13 Cost-effectiveness plane showing the results of deterministic analysis for 
strategies to investigate women presenting with heavy menstrual bleeding managed over 
multiple clinic appointments. (Hysterectomy removed). 
 
 
EBx = endometrial biopsy; OPH = outpatient hysteroscopy; SIS = saline infusion sonography; TVS = transvaginal ultrasound 
scan; LNG-IUS = levonorgestrel intrauterine system 
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Probabilistic sensitivity analysis results: Women being managed during 
multiple clinic appointments 
 
In the cost-effectiveness scatterplot below (Figure 9.14) it is clear from the degree of overlap 
of the diagnostic strategies that there is uncertainty regarding which one might be considered 
most cost-effective when a range of values is sampled from the distributions of the data 
values.  
 
Figure 9.14 Scatterplot showing the uncertainty in costs and effectiveness within the 
model for each of the individual strategies for investigating women with heavy 
menstrual bleeding managed over multiple clinic appointments 
  
 
LNG-IUS = levonorgestrel intrauterine system; EBx = endometrial biopsy; OPH = outpatient hysteroscopy; SIS = saline 
infusion sonography; TVS = transvaginal ultrasound scan  
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The CEAF (Figure 9.15) illustrates the overall uncertainty related to the optimal decision 
across a range of plausible willingness to pay (WTP) values and shows that up to a WTP 
value of approximately £5000 LNG-IUS alone is cost-effective. However between £5000 and 
£20,000 SIS alone may be preferable although there is reasonable uncertainty as to whether 
this really is the optimal strategy with the probability lying between 40 and 60%. Above 
£20,000 OPH and EBx becomes the preferred strategy. 
 
Figure 9.15 Cost-effectiveness acceptability frontier showing the optimal investigative 
strategies for women with heavy menstrual bleeding managed over multiple clinic 
appointments 
 
 
LNG-IUS = levonorgestrel intrauterine system; EBx = endometrial biopsy; OPH = outpatient hysteroscopy 
 
Probabilistic pair wise comparisons were made between the non-dominated strategies to 
explore the uncertainty between them. TVS was also compared to SIS alone because of its 
proximity to the line of non-dominance.  
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Transvaginal scan versus levonorgestrel intra-uterine system: Women with HMB 
managed over multiple clinic appointments 
The scatterplot below (Figure 9.16a) shows that the strategy TVS alone is more effective than 
LNG-IUS alone and is very likely to be more costly per patient satisfied. The CEAC (Figure 
9.16b) shows that above a WTP of £8000 TVS is probably a more cost effective option than 
LNG-IUS alone per woman satisfied but it is only at WTP above £20,000 that this is almost 
certain (p>0.9). 
 
Figure 9.16 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
transvaginal ultrasound scan alone strategy relative to the LNG-IUS alone strategy for 
women with heavy menstrual bleeding managed over multiple clinic appointments 
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Saline infusion sonography versus levonorgestrel intra-uterine system: Women with 
HMB managed over multiple clinic appointments 
The scatterplot depicted in Figure 9.17a shows that saline infusion scan is more effective than 
LNG-IUS alone but it is also probably more expensive. The CEAC (Figure 9.17b) shows that 
at a WTP of around £10,000 it is probable that SIS is the most cost-effective option and this 
becomes almost certain at a WTP of £20,000. 
 
Figure 9.17 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
saline infusion sonography alone strategy relative to the LNG-IUS alone strategy for 
women with heavy menstrual bleeding managed over multiple clinic appointments 
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Outpatient hysteroscopy versus saline infusion sonography: Women with HMB 
managed over multiple clinic appointments 
Figure 9.18a suggests that there is uncertainty between SIS and OPH but that OPH may be 
more effective than SIS. It also suggests that OPH is more expensive than SIS. The CEAC 
(Figure 9.18b) shows that even at a WTP of £40,000, OPH is unlikely to be the most cost-
effective strategy (p<0.3). 
 
Figure 9.18 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
outpatient hysteroscopy alone strategy relative to the saline infusion sonography alone 
strategy for women with heavy menstrual bleeding managed over multiple clinic 
appointments 
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Outpatient hysteroscopy and endometrial biopsy versus outpatient hysteroscopy: 
Women with HMB managed over multiple clinic appointments 
Figure 9.19 shows that OPH and EBx is probably more effective and more expensive than 
OPH alone but that it is only becomes likely to be the most cost-effective of the two strategies 
at WTP values of above £20,000 and that even at WTP of £40,000 the probability of it being 
the most cost-effective strategy is only just above 0.7.  
 
Figure 9.19 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
outpatient hysteroscopy with endometrial biopsy strategy relative to the outpatient 
hysteroscopy alone strategy for women with heavy menstrual bleeding managed over 
multiple clinic appointments. 
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Saline infusion sonography versus transvaginal scan: Women with HMB managed over 
multiple clinic appointments 
The scatterplot below (Figure 9.20a) shows that SIS is more effective than TVS although it is 
probably a more expensive strategy. The CEAC (Figure 9.20b) shows that SIS is likely to be 
the most cost-effective strategy at a WTP of approximately £3000 but this becomes almost 
certain (p>0.9) at just over £10,000. 
 
Figure 9.20 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
saline infusion sonography alone strategy relative to the transvaginal scan alone strategy 
for women with heavy menstrual bleeding managed over multiple clinic appointments. 
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Saline infusion sonography and endometrial biopsy versus saline infusion sonography: 
Women with HMB managed over multiple clinic appointments 
Figure 9.21a shows that SIS + EBx is more effective and more expensive than SIS alone. 
Figure 9.21b shows that SIS + EBx is unlikely to be cost-effective at WTP values acceptable 
to health service providers.  
 
Figure 9.21 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
saline infusion sonography with endometrial biopsy strategy relative to the saline 
infusion sonography alone strategy for women with heavy menstrual bleeding managed 
over multiple clinic appointments. 
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Outpatient hysteroscopy and endometrial biopsy versus saline infusion sonography and 
endometrial biopsy: Women with HMB managed over multiple clinic appointments 
The cost-effectiveness plane in Figure 9.22a shows that OPH+EBx is more effective and more 
expensive than SIS+EBx. The CEAC (Figure 9.22b) suggests that above £15,000 OPH and 
EBx is likely to be the most cost-effective test and that as the WTP increases so does the 
certainty. 
 
Figure 9.22 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
outpatient hysteroscopy with endometrial biopsy strategy relative to the saline infusion 
sonography with endometrial biopsy strategy for women with heavy menstrual bleeding 
managed over multiple clinic appointments. 
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Outpatient hysteroscopy and endometrial biopsy versus saline infusion sonography: 
Women with HMB managed over multiple clinic appointments 
The scatterplot below (Figure 9.23a) shows that OPH and EBx is probably more effective and 
more expensive than SIS. The CEAC (Figure 9.23b) shows that above a WTP threshold of 
£25,000 OPH and EBx is likely to be the most cost-effective strategy, although the probability 
of this is till only 0.7 at a WTP of £40.000. 
 
Figure 9.23 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
outpatient hysteroscopy with endometrial biopsy strategy relative to the saline infusion 
sonography alone strategy for women with heavy menstrual bleeding managed over 
multiple clinic appointments. 
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Deterministic results: Prior treatment with the LNG-IUS 
 
The base case economic analysis assumed that the women presenting to the gynaecologist 
with HMB had not had any treatment in primary care. NICE recommend that women with 
HMB should be treated with a LNG-IUS in primary care and only be referred to a 
gynaecologist if symptoms persist, structural abnormality is expected or contraindications 
exist (142). In practice only around 25% of women referred from primary care have received 
prior treatment with the LNG-IUS (233). An alternative analysis was performed to examine 
the ‘ideal’ scenario, when women have already tried a LNG-IUS, and assess whether the 
preferred cost-effective investigative strategies are altered. Disease prevalence was adjusted to 
reflect the fact that women treated appropriately with a LNG-IUS in primary care (i.e. without 
intracavity pathology, endometrial cancer or large fibroids) were less likely to have persistent 
symptoms and need referral to a gynaecologist. It was assumed that fertility was not desired in 
this analysis, as in the base case analysis. The strategy LNG-IUS alone could no longer be 
used as the reference strategy (now being redundant) and was replaced by a strategy of ‘no 
further intervention’ i.e. attending clinic with a LNG-IUS in situ, seeing a gynaecologist but 
deciding not to have any further intervention.  
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Table 9.6 Deterministic results of cost-effectiveness analysis for women with heavy 
menstrual bleeding with a LNG-IUS in situ 
Strategy Cost (£) Effectiveness 
(satisfaction) 
   
No further intervention 1355 0.9039 
OPH alone 1681 0.9633 
SIS alone 1711 0.9633 
TVS + OPH 1746 0.9633 
SIS + OPH 1775 0.9633 
TVS alone 1785 0.9633 
OPH and EBx 1796 0.9628 
TVS+ OPH+EBx 1840 0.9628 
SIS + EBx 1846 0.9628 
SIS +OPH +EBx 1864 0.9629 
EBx alone 1942 0.9628 
TVS + Ebx 1980 0.9639 
Hysterectomy alone 3218 0.9378 
LNG-IUS = levonorgestrel intrauterine system; EBx = endometrial biopsy; OPH = outpatient hysteroscopy; SIS = saline 
infusion sonography; TVS= transvaginal ultrasound scan  
 
Outcomes 
As before, the diagnostic strategies were more effective than the treatment only strategies. 
The most effective strategy was combination testing with transvaginal scan and endometrial 
biopsy however the difference between all of the diagnostic strategies was minimal, ranging 
from 96.28% to 96.39%. 
 
Costs 
The results presented in Table 9.6 show that all costs have increased compared with the base 
case analysis, reflecting the increased prevalence of organic uterine pathology requiring more 
expensive treatments. Adopting no further treatment and persevering with the LNG-IUS 
treatment alone (reference strategy) was the cheapest option, costing £1355 per woman 
treated for HMB in a secondary care setting. The strategy of hysterectomy for all women was 
the most expensive at £3218 per woman treated i.e. £1863 more than the approach of LNG-
221 
 
IUS treatment alone. The cheapest diagnostic testing strategy was the use of outpatient 
hysteroscopy alone, costing £1681 for every woman treated, i.e. £326 more than continuation 
with LNG-IUS treatment.  
 
Cost-effectiveness & dominance 
The testing strategies outpatient hysteroscopy (OPH) alone and transvaginal scan combined 
with endometrial biopsy (TVS + EBx) remain non-dominated by alternative empirical 
treatment or diagnostic testing strategies. The remaining strategies are all dominated by OPH 
alone except for hysterectomy which is dominated by TVS+EBx. Table 9.7 presents the 
deterministic analysis restricted to the non-dominated competing strategies. 
  
Table 9.7 Non-dominated strategies from the analysis of women presenting with heavy 
menstrual bleeding with a LNG-IUS in situ 
Strategy  
Cost 
(£) 
Incremental 
Cost (£) Effectiveness 
Incremental 
Effectiveness ICER 
      
No further 
intervention 1355 
 
0.9039 
  OPH alone 1681 326 0.9633 0.0594 5480 
TVS + EBx 1980 299 0.9639 0.0006 516000 
Apparent anomalies with subtraction are due to rounding effects. 
EBx = endometrial biopsy; OPH = outpatient hysteroscopy; TVS=– transvaginal ultrasound scan ; ICER= incremental cost-
effectiveness ratio 
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Figure 9.24 Cost-effectiveness plane showing the results of deterministic analysis for 
strategies to investigate women with heavy menstrual bleeding with a LNG-IUS in situ 
 
 
 
 
LNG-IUS = levonorgestrel intrauterine system; EBx = endometrial biopsy; OPH = outpatient hysteroscopy; SIS = saline 
infusion sonography; TVS= transvaginal ultrasound scan  
 
The line on the graph in Figure 9.24 joins the non-dominated strategies, LNG-IUS only, OPH 
alone and TVS and EBx. When LNG-IUS and hysterectomy are removed the relationship of 
the other strategies to the line of non-dominance is clearer (Figure 9.25). 
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Figure 9.25 Cost-effectiveness plane showing the results of deterministic analysis for 
strategies to investigate women with heavy menstrual bleeding with a LNG-IUS in situ. 
(Hysterectomy alone and LNG-IUS alone not shown) 
 
 
 
LNG-IUS = levonorgestrel intrauterine system; EBx = endometrial biopsy; OPH = outpatient hysteroscopy; SIS = saline 
infusion sonography; TVS – transvaginal ultrasound scan  
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Probabilistic sensitivity analysis results: Prior treatment with the LNG-IUS  
 
In the cost-effectiveness scatterplot below (Figure 9.26) it is clear from the degree of overlap 
of the diagnostic strategies that there is uncertainty regarding which one might be considered 
most cost-effective when a range of values is sampled from the distributions of the data 
values.  
Figure 9.26 Scatterplot showing the uncertainty in costs and effectiveness within the 
model for each of the individual strategies for investigating women with heavy 
menstrual bleeding with a LNG-IUS in situ 
 
LNG-IUS = levonorgestrel intrauterine system; EBx = endometrial biopsy; OPH = outpatient hysteroscopy; SIS = saline 
infusion sonography; TVS= transvaginal ultrasound scan  
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around £20,000. It can be seen that OPH is the preferred option at lower WTP values but that 
there is considerable uncertainty as WTP falls below £10,000.  
Figure 9.27 Cost-effectiveness acceptability frontier showing the optimal investigative 
strategies for women with heavy menstrual bleeding with a LNG-IUS in situ 
 
 
LNG-IUS = levonorgestrel intrauterine system; OPH = outpatient hysteroscopy 
 
Probabilistic pair wise comparisons were made between the non-dominated strategies to 
explore the uncertainty between them. SIS was also compared to OPH alone because of its 
proximity to the line of non-dominance.  
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Outpatient hysteroscopy versus levonorgestrel intra-uterine system: Prior treatment 
with the LNG-IUS 
The scatterplot below (Figure 9.28a) shows that OPH is almost certain to be more effective 
than LNG-IUS alone but it will be more costly per patient satisfied. The CEAC (Figure 9.28b) 
shows that above a WTP of £6000 OPH is probably a more cost effective option than LNG-
IUS alone per woman satisfied. At a WTP above £15,000 this is almost certain (p>0.9). 
 
Figure 9.28 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
Outpatient hysteroscopy alone strategy relative to the LNG-IUS alone strategy for 
women with heavy menstrual bleeding with a LNG-IUS in situ 
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Transvaginal ultrasound scan and endometrial biopsy versus outpatient hysteroscopy: 
Prior treatment with the LNG-IUS 
The cost-effectiveness plane, Figure 9.29a shows that there is considerable overlap between 
‘TVS and EBx’ and ‘OPH alone’. It certainly is not clear which is the most effective strategy 
but TVS and EBx is the more costly of the two. For all WTP values between £0 and £40,000 
per extra woman satisfied, OPH alone is almost definitely the most cost-effective option when 
compared to TVS and EBx (p>0.98) as displayed in the CEAC below (Figure 9.29b) 
 
Figure 9.29 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
Transvaginal scan and endometrial biopsy strategy relative to the outpatient 
hysteroscopy alone strategy for women with heavy menstrual bleeding with a LNG-IUS 
in situ 
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Saline infusion sonography versus outpatient hysteroscopy: Prior treatment with the 
LNG-IUS 
SIS falls close to the line of non-dominance in the deterministic analysis therefore a 
comparison was made between SIS and the most cost-effective, non-dominated strategy, OPH 
alone. The graph, Figure 9.30a, shows that although there is likely to be little difference in 
effectiveness between the two strategies, SIS is almost certain to be the more costly strategy. 
The CEAC (Figure 9.30b) comparing SIS and OPH shows that SIS is extremely unlikely to be 
the most cost-effective option even at a WTP of £40,000 per additional woman satisfied. 
 
Figure 9.30 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
Saline infusion scan alone strategy relative to the outpatient hysteroscopy alone strategy 
for women with heavy menstrual bleeding with a LNG-IUS in situ 
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Deterministic analysis: Women wishing to preserve their fertility 
 
Table 9.8 shows the deterministic analysis of the twelve strategies following re-configuration 
of the decision trees to reflect women who would not have a hysterectomy or an endometrial 
ablation to treat their HMB because they wished to maintain their long term fertility.  
Table 9.8 Deterministic results of cost-effectiveness analysis for women with heavy 
menstrual bleeding who wish to preserve their fertility 
Strategy 
 
Cost (£) 
 
Effectiveness 
(satisfaction) 
   
LNG-IUS alone 421 0.6557 
SIS alone 800 0.8467 
OPH alone 844 0.8629 
SIS + OPH 944 0.8649 
TVS alone 740 0.8033 
EBx alone 754 0.7419 
TVS + Ebx 870 0.8020 
TVS + OPH 913 0.8389 
OPH and EBx 914 0.8618 
SIS + EBx 971 0.8473 
TVS+ OPH+EBx 971 0.8572 
SIS +OPH +EBx 1003 0.8584 
LNG-IUS = levonorgestrel intrauterine system; EBx = endometrial biopsy; OPH = outpatient hysteroscopy; SIS = saline 
infusion sonography; TVS=  transvaginal ultrasound scan  
 
Outcomes 
Satisfaction rates are reduced when compared to the original analysis as optimal surgical 
interventions precluding future fertility are not available for women with large fibroids or 
those resistant to the LNG-IUS. This is reflected by the lower satisfaction rate of 65.6% for 
this analysis compared with 93.33% in the original when women receive LNG-IUS without 
any investigation. Satisfaction rates for the investigative strategies range from 74.19% for 
TVS to 86.49% for SIS and OPH. There is greater variation between the satisfaction rates in 
this analysis than in the base case when values varied marginally between 94.6% and 96.7%.    
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Costs 
It should be noted that the costs decreased when compared to the original analysis. Cost is 
decreased because the more expensive treatments tend to be the surgical options (endometrial 
ablation and hysterectomy) which are contraindicated in women desiring preservation of their 
fertility. The cost of LNG-IUS alone has decreased to £421 from £1066 in the base case 
analysis because the women identified to have large fibroids do not undergo a hysterectomy 
and women who are dissatisfied with the LNG-IUS cannot be offered any further treatment. 
The cheapest investigative strategy in this analysis is TVS alone, costing £740 per patient. 
The most expensive strategy is the combination of SIS, OPH and EBx costing £1003 per 
patient.  
 
Cost-effectiveness and dominance 
The strategy of EBx alone is dominated by TVS alone ,which in turn is dominated by 
extended dominance due to a blend of LNG-IUS alone and SIS alone. The remaining 
strategies are dominated by either OPH alone or SIS and OPH together. Once the dominated 
strategies were removed the testing strategies which remained were SIS alone, OPH alone and 
SIS and OPH together. This can be more clearly appreciated in Table 9.9. In contrast to the 
base case analysis, a combination strategy of OPH + EBx is not potentially cost-effective. 
Moreover, SIS alone or in combination with OPH is non-dominated whereas in women 
without the need to preserve their fertility (base case), SIS and related strategies were not 
cost-effective. 
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Table 9.9 Non-dominated strategies from the analysis of women presenting with heavy 
menstrual bleeding who wish to preserve their fertility 
Strategy 
 
Cost  
(£) 
Incremental 
cost (£) 
Effectiveness 
(satisfaction) 
Incremental 
effectiveness ICER  
      
LNG-IUS 
alone 421 
 
0.6557 
  SIS alone 800 378 0.8467 0.1910 1980 
OPH alone 844 44 0.8629 0.0162 2720 
SIS + OPH 955 100 0.8649 0.0020 50300 
Apparent anomalies with subtraction are due to rounding effects. 
LNG-IUS = levonorgestrel intrauterine system; OPH = outpatient hysteroscopy; SIS = saline infusion sonography; ICER= 
incremental cost-effectiveness ratio. 
 
 
 
Figure 9.31 Total costs and effectiveness of the alternative strategies for the diagnostic 
work up of HMB for women wishing to preserve their fertility. (Hysterectomy has been 
excluded). 
 
LNG-IUS = levonorgestrel intrauterine system; EBx = endometrial biopsy; OPH = outpatient hysteroscopy; SIS = saline 
infusion sonography; TVS= transvaginal ultrasound scan  
 
The line on the cost-effectiveness plane (Figure 9.31) joins the non-dominated strategies, 
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and OPH. TVS lies close to this line and therefore when exploring the results TVS was 
included to see whether analysing the spread of results might suggest that TVS could become 
cost-effective when values are varied around their point estimates. 
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Probabilistic sensitivity analysis results: Women wishing to preserve their 
fertility 
 
Figure 9.32 shows the uncertainty around the absolute cost and effectiveness values for each 
of the strategies. Hysterectomy alone has been removed as it is too expensive to be a 
competing strategy and removing it allows clearer presentation of the other strategies. There 
is overlap between strategies. 
Figure 9.32 Scatterplot showing the uncertainty in costs and effectiveness within the 
model for each of the individual strategies for investigating women with heavy 
menstrual bleeding who wish to preserve their fertility 
 
LNG-IUS = levonorgestrel intrauterine system; EBx = endometrial biopsy; OPH = outpatient hysteroscopy; SIS = saline 
infusion sonography; TVS – transvaginal ultrasound scan  
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The acceptability frontier in Figure 9.33 shows how likely the non-dominated strategies are to 
be the most cost-effective option at a range of WTP thresholds. The strategy SIS and OPH is 
not plotted on the CEAF because it only becomes cost-effective at a WTP too high to be 
acceptable to the NHS. 
 
Figure 9.33 Cost-effectiveness acceptability frontier showing the preferred diagnostic 
strategy over a range of WTP thresholds for women who wish to preserve their fertility 
 
 
 
LNG-IUS = levonorgestrel intrauterine system; SIS = saline infusion sonography OPH = outpatient hysteroscopy. 
 
The uncertainty represented in the CEAF is explored by considering pair wise comparisons 
between the adjacent non-dominated options. TVS is also explored because its mean is close 
to the non-dominance line. 
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SIS alone vs. LNG-IUS alone: Women wishing to preserve their fertility 
Figure 9.34 shows that SIS is definitely more effective and more costly than LNG-IUS alone. 
The CEAC (Figure 9.34b) shows that at above a WTP of £2700 SIS is definitely (p=1) a more 
cost-effective option than using LNG-IUS alone. 
 
Figure 9.34 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
Saline infusion sonography alone strategy relative to the LNG-IUS alone strategy for 
women wishing to preserve their fertility 
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Outpatient hysteroscopy versus saline infusion: Women wishing to preserve their 
fertility 
Figure 9.35a shows that outpatient hysteroscopy is likely to be more effective and more 
expensive than saline infusion scan for investigating women with HMB who want to preserve 
their fertility. The CEAC (Figure 9.35b) shows that above a WTP of approximately £2500 to 
make one extra woman satisfied, OPH becomes likely to be the most cost effective strategy 
(p>0.5) and that at a WTP just above £5000 it has a greater than 90% chance of being the 
most cost-effective strategy when compared to SIS. 
 
Figure 9.35 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
Outpatient hysteroscopy alone strategy relative to the saline infusion sonography alone 
strategy for women wishing to preserve their fertility 
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Saline infusion sonography and outpatient hysteroscopy versus outpatient hysteroscopy: 
Women wishing to preserve their fertility 
Figure 9.36a shows the cost-effectiveness plane comparing OPH with SIS to OPH alone. It 
shows that SIS with OPH is more costly than OPH alone and that this extra cost is almost 
certainly between £100 and £120. The two test combination is also probably but not 
definitely, the more effective strategy. The CEAC (Figure 9.36b) shows the proportion of 
model replications for which saline infusion scan and outpatient hysteroscopy is preferred to 
outpatient hysteroscopy alone at any given willingness to pay per additional case satisfied. It 
shows that even at a WTP of £40,000 there is considerable uncertainty that SIS and OPH is a 
more-cost-effective strategy than OPH alone (p=0.2). 
 
Figure 9.36 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
Saline infusion sonography and outpatient hysteroscopy strategy relative to the 
outpatient hysteroscopy alone strategy for women wishing to preserve their fertility 
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Transvaginal ultrasound scan versus levonorgestrel intra-uterine system: Women 
wishing to preserve their fertility their fertility  
The graph (Figure 9.37a) shows the modelled uncertainty in the difference in costs between 
TVS alone and LNG-IUS. It shows that TVS is more effective and more costly than giving all 
women an LNG-IUS without investigation. The CEAC (Figure 9.37b) shows the proportion 
of model replications for which transvaginal scan is preferred to LNG-IUS alone at any given 
willingness to pay per additional case satisfied. It shows that above a WTP of £3,000 TVS is 
definitely the most cost-effective option (p=1). 
 
Figure 9.37 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
Transvaginal ultrasound scan alone strategy relative to the LNG-IUS alone strategy for 
women wishing to preserve their fertility 
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Saline infusion sonography versus transvaginal ultrasound scan: Women wishing to 
preserve their fertility 
The graph (Figure 9.38a) shows the modelled uncertainty in the difference in costs between 
SIS alone and TVS alone. It shows that SIS is probably more effective and more costly that 
TVS alone. The CEAC (Figure 9.38b) shows the proportion of model replications for which 
SIS is preferred to TVS alone at any given willingness to pay per additional case satisfied. It 
shows that above a WTP of approximately £4000 SIS alone is definitely the most cost-
effective option when compared to TVS. 
 
Figure 9.38 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b): 
Saline infusion sonography alone strategy relative to the transvaginal ultrasound scan 
alone strategy for women wishing to preserve their fertility 
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CHAPTER 10 
 
DISCUSSION OF THE ECONOMIC ANALYSIS OF 
DIAGNOSTIC STRATEGIES FOR THE INVESTIGATION OF 
HEAVY MENSTRUAL BLEEDING 
 
Discussion of the main findings 
 
The objective of this economic analysis was to evaluate the cost-effectiveness of diagnostic 
testing strategies for HMB. Universal treatment with the LNG-IUS without any preliminary 
investigation was chosen as the reference strategy to compare testing options against. This 
was because (i) not investigating or treating is an unacceptable alternative; (ii) the LNG-IUS 
is recommended by NICE as first line treatment of HMB. Treating all women with a LNG-
IUS without preliminary testing resulted in high levels of satisfaction (93%) which were 
increased by approximately 4% if some form of currently available diagnostic testing was 
undertaken to guide treatment.  
 
Base Case 
The economic model which adopted a ‘one-stop’ setting for the base-case analysis reflects 
contemporary practice and will remain relevant as services evolve.  
Two potentially cost-effective investigation strategies were identified; initial testing with 
outpatient hysteroscopy alone (OPH) or a combination strategy incorporating outpatient 
hysteroscopy with endometrial biopsy (OPH + EBx). Although the strategy OPH +EBx was 
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marginally more effective, the incremental cost-effectiveness ratio (ICER) was approximately 
£21,000 to gain one more satisfied patient compared to OPH, while OPH has an ICER of 
under £400 per additional case satisfied compared to LNG-IUS alone. Thus for relatively little 
additional investment by the NHS, the adoption of OPH in place of LNS-IUS alone will 
improve outcomes for women presenting with HMB. This improvement can be increased 
further if combination testing with OPH + EBx is introduced. This additional cost is 
contentious, but it can be tested by comparison to the £20,000-£30,000 per QALY NICE 
threshold at which interventions are considered cost-effective to implement within the NHS. 
Due to paucity of HRQL data, QALYs could not be used for the cost effectiveness analysis 
however an estimation can be made to give an approximate cost per QALY. It has been 
estimated that a woman’s quality of life is reduced by 0.5 for the one week per month of 
heavy menses (234). This means that HMB is associated with a reduction of 0.125 QALY in 
any year, as the reduction of 0.5 applies for one quarter of the time overall. Considering a 45 
year old woman with seven symptomatic years until menopause, future years need to be 
discounted at 3.5%, so that the annual QALY loss must be multiplied by [1 + (1/1.035) + 
(1/1.035)
2
 + (1/1.035)
3
 + ...  + (1/1.035)
6
 ] or approximately 6.3 to give a total QALY loss of 
approximately 0.8 QALY. This means that an ICER of £21,000 per case satisfied is 
approximately equivalent to an ICER of £26,500/QALY, which falls within the £20,000-
£30,000 per QALY threshold range used by NICE. Therefore, the strategy OPH+EBx is of 
borderline cost-effectiveness compared to initial investigation with OPH in isolation.  
The certainty of the base-case results was assessed by probabilistic sensitivity analysis. 
Outpatient hysteroscopy remained the more cost-effective strategy even at relatively low 
willingness to pay thresholds. Outpatient hysteroscopy with EBx also remained stable 
however, to be at least 70% certain that it was a more cost-effective alternative than OPH 
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alone, the WTP threshold would need to be increased to around £40,000 per patient satisfied 
(~ £50,000 / QALY). Endometrial biopsy is most useful for diagnosing endometrial disease 
but the prevalence of endometrial hyperplasia and carcinoma is low in a premenopausal 
population estimated at around 5%. In populations of women where higher rates of 
endometrial disease are observed (e.g. epidemics of obesity), the benefit of EBx will have 
more influence on overall cost-effectiveness. However, substantially higher estimates of 
endometrial disease in an HMB population are unlikely.  
 
Ultrasound is a convenient, minimally invasive, portable test that allows assessment of both 
the uterus and ovaries. It is universally available and can be incorporated easily into standard 
gynaecological examination. In view of the popularity of pelvic scanning and the fact that two 
scanning strategies came close to the boundary of dominance when the cost-effectiveness 
analysis was performed, further exploratory analyses were undertaken. Sensitivity analysis 
was performed to examine transvaginal ultrasound (TVS) and saline infusion sonography 
(SIS) to see whether there was uncertainty regarding them when compared to the most cost-
effective strategy of OPH alone. However when compared to OPH, TVS was found to be 
almost certainly less effective and there was also a chance of it being more costly too 
therefore ruling it out as a primary diagnostic test. When SIS was compared to OPH there was 
significant doubt regarding which was the most effective approach. By increasing the 
willingness to pay threshold from £0 to £40,000, the likelihood that OPH was more cost 
effective than SIS increased further from 60% to 80%. Thus, at WTP levels acceptable to the 
NHS, OPH appears preferable to SIS as a first-line diagnostic test in HMB. However, 
clinicians who currently use SIS for first line investigation of HMB and are able to easily 
integrate SIS into their practice at low cost, may have less to gain by changing to OPH.  
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Furthermore, patients receive added  reassurance from knowing that their ovaries have been 
examined as well as the uterine cavity, a benefit of scanning that is neglected by OPH.  
 
In sensitivity analysis, the cost of SIS needed to be reduced from £71 to £52 to make it more 
cost-effective than OPH. This reduction in costs is unrealistic as SIS would have to cost less 
than the £55 which is the cost of a standard 2D transvaginal scan which is unfeasible given 
that it requires additional equipment (instillation catheter) and takes longer to perform; costs 
which have been estimated to be an extra 35% on top of transvaginal scan in a Dutch study 
(156). 
 
Prevalence of focal uterine pathology  
Sensitivity analyses were conducted to investigate whether the prevalence of polyps/SMFs 
could have biased the results towards OPH. The prevalence was reduced sequentially to 
determine at what prevalence an alternative option may be favoured. This analysis suggested 
that even if the estimate of polyps/SMFs was 10% less than had been stated in the base case 
(i.e. 28% instead of 38%), OPH would still remain the preferred option. The prevalence of 
polyps and submucous fibroids reported in the better quality prevalence studies used in the 
model reported values for both pathologies of around 20% (202;205), which approximates to 
the 40% prevalence quoted by NICE in their HMB guideline (30% submucous fibroids and 
10% endometrial polyps) (142), so if 40% is a true reflection of disease then OPH is for 
certain the most cost-effective option. Even in different HMB populations it seems unlikely 
that the combined prevalence of endometrial polyps and submucous fibroids would be lower 
than 28%, thus there is reasonable certainty that OPH is the most cost-effective diagnostic 
strategy in HMB, even in populations with focal uterine pathology prevalence rates at the 
lower end of the plausible range. 
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Women managed over multiple clinic appointments 
Whilst one-stop services are being increasingly developed, the traditional multi-stop model of 
care remains embedded in much of the NHS, therefore an adapted version of the model 
investigated the multi-stop approach to investigation and treatment of women with HMB. 
This analysis suggested that SIS alone, at an added cost of £5070 per additional patient 
satisfied or OPH and EBx at an added cost of £22,100 were the most cost effective strategies. 
OPH alone was not considered a cost-effective option in this analysis, however, costs were 
applied to OPH that made it less competitive than the other tests by dictating that concomitant 
treatment of polyps and fibroids could not be performed at the time of diagnostic 
hysteroscopy. This approach is practised at some centres across the UK to try and avoid 
delays in clinic running time, so this ‘worst-case scenario’ was used in the multi-stop analysis. 
OPH become relatively expensive because it required an additional consultant appointment 
whereas TVS and SIS were performed in the scan department by a sonographer and 
endometrial biopsy was performed at the initial consultant GOPD appointment. Interestingly, 
in the pairwise comparison between OPH and SIS, OPH was probably more effective than 
SIS but it was more expensive under the assumptions of the multi-stop model of care to a 
degree that OPH was no longer cost-effective compared with SIS. In both the one-stop base 
case model of care and the multi-stop reanalysis, the testing strategy of OPH combined with 
EBx was a non-dominated strategy. If the same QALY rules are applied to this strategy as to 
the base case results (see the discussion under ‘Base case’ above) the cost per QALY for 
OPH+EBx was £27,625 which falls within the NICE threshold of £20,000 to £30,000. Thus, 
an initial testing approach for women presenting with HMB using OPH with EBx is 
potentially cost-effective regardless of the model of care. However, those able to provide a 
contemporary ‘one-stop’ service would need to weigh up the additional costs associated with 
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OPH+EBx over simply OPH alone to gain a further health benefit. Similarly, those Units 
utilising a traditional multi-stop set up would need to consider the much reduced costs of 
initial testing with SIS against the reduction in health benefit when compared to a 
combination of OPH + EBx.  
 
It seems likely that the drive to provide outpatient testing and where possible simple 
concomitant treatments will continue in light of the convenience for patients and their doctors 
as well as the on-going improvement in health technologies. Therefore, because the base case 
analysis based upon the premise of a one-stop service, indicated that OPH was the optimal 
strategy (regardless of wish for fertility or prior treatment with LNG-IUS (see below)), it may 
be consistent to employ combination testing from the outset with OPH and EBx in hospitals 
that don’t yet have ‘one-stop’ facilities in place. This would allow the services in these centres 
to evolve until they were able to offer ‘one-stop’ care based upon initial testing with OPH in 
women presenting with HMB. The alternative for these hospitals would be to adopt SIS as the 
first line test for investigating HMB, training doctors, nurses and sonographers in the 
technique. However, future re-investment in equipment and training to establish one-stop 
services based upon initial testing with OPH may become necessary if such service models 
become embedded. 
 
Fertility preservation 
Heavy menstrual bleeding is most common in parous women in their fifth decade of life 
(186). Thus, the majority of women presenting to secondary care have completed their 
families. However, some women with HMB do want to retain their fertility potential and to 
take account of this and to test the generalisability of the base case findings an additional 
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model was produced for women wishing to preserve their fertility which precluded certain 
surgical treatment options. The findings of this additional analysis were consistent with the 
base case scenario with OPH remaining the most cost-effective first line diagnostic test of 
choice. SIS was the closest, viable competing testing option. Adopting OPH rather than SIS, 
costs an additional £2720 to achieve an extra woman satisfied but this is likely to be 
considered affordable and worthwhile by health services. Moreover, at willingness to pay 
(WTP) thresholds of around £5000, there is a greater than 90% certainty of OPH being the 
most cost-effective option. Indeed, SIS only appeared to be cost-effective over a very narrow 
range of WTP values and even then there was considerable observed uncertainty.   
 
Universal LNG-IUS treatment prior to referral 
A further analysis using a modified decision model, was based upon the situation envisaged 
by NICE in their 2007 report into the management of HMB (142) where all women referred 
from primary care with HMB have received prior treatment with a LNG-IUS. Even in this 
scenario, OPH continued to be the favoured, cost-effective option with an ICER of £5480 for 
each additional woman  satisfied and increasing certainty of cost-effectiveness with 
increasing, but viable, WTP levels.  Although the combination of TVS and EBx was a more 
effective approach, it’s ICER of over £500,000 prohibits its use as a sensible diagnostic 
strategy for adoption by the NHS.  
 
 ‘See and Treat’ 
Outpatient hysteroscopy is consistently the preferred first line testing strategy for women with 
HMB irrespective of their desire for future fertility and regardless of pre-referral treatment 
with the LNG-IUS. One consideration driving the economic benefits of OPH over other tests 
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is that the modality allows treatment for most pathology to be initiated at the same time as the 
diagnosis, thereby reducing the number of patient attendances and costs. This contemporary 
’see & treat’ ambulatory approach in gynaecological practice is increasingly being adopted. 
There are also additional benefits of embracing this philosophy not accounted for in the 
analysis e.g. improved safety, lowered infection risks, convenience, rapid discharge and 
recovery (6). Only 30% of women in the model required a further appointment in order to 
return for treatment at a later stage in the OPH testing strategy. This was because all women 
presenting with polyps or pathology suitable for treatment with a LNG-IUS could be treated 
at their first appointment if diagnosed correctly. For scanning modalities, concomitant 
treatment was still possible for the same proportion of women, however the cost is elevated 
slightly because of the additional cost of hysteroscopy and polypectomy for the 19% of 
women with endometrial polyps. Furthermore, the accuracy of TVS for the diagnosis of focal 
pathology is reduced compared with OPH. This consideration combined with the additional 
costs of the OPH needed to perform the polypectomy for both TVS and SIS scanning 
approaches, contributes to their reduced cost-effectiveness compared with OPH. This was 
even more apparent for strategic testing approaches utilising EBx from the outset where no 
simultaneous treatment was possible because of the necessity to await the EBx result before 
making a diagnosis and instituting therapy. ‘Real time’ bedside testing can be seen to confer 
an advantage in the efficiency of delivering care. Thus, it is the ability to concomitantly treat 
as well as diagnose intrauterine pathology with a high degree of accuracy that leads to OPH 
being the most cost-effective strategy testing strategy in HMB. 
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Strengths and limitations  
 
The economic evaluation was based upon the construction of comprehensive, contemporary 
and clinically informed decision trees. All available testing strategies were modelled and a 
modern, ‘one-stop’ clinical environment for testing assumed. Test accuracy and performance 
data were mainly obtained from high quality systematic quantitative reviews of the literature. 
Other clinical parameter inputs, including treatment effectiveness and disease prevalence were 
obtained following systematic searches and selection based upon a rigorous evaluation of data 
quality. Data for the prevalence of fibroids were taken from a database of women from 
Birmingham and the surrounding area. It should be recognised that this may not be a true 
reflection of the UK prevalence of fibroids due to the large number of women from ethnic 
minorities. Producing a comprehensive series of reviews was not the aim of the economic 
modelling study so although data were identified using a systematic approach, ‘systematic 
reviews’ per se were not conducted for each clinical question. When data were not available 
in the published literature or there was uncertainty regarding the assumed diagnosis or need 
for further testing, a panel of senior gynaecologists was consulted.  
 
The economic evaluation took the UK NHS as its perspective. This meant that only costs 
incurred by the NHS were included, and benefits were measured in patient satisfaction. The 
prime aim of testing in chronic benign conditions like HMB is to improve patient 
symptomatic outcomes. Thus the approach of evaluating effectiveness in terms of patient 
satisfaction within the HMB analysis was relevant. Patient satisfaction was chosen in order to 
(i) ensure consistency with previous research trials undertaken in the field (136) and (ii) 
because patient satisfaction is deemed to be the co-primary measure of importance (together 
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with menstrual bleeding) by the Cochrane Menstrual Disorders & Subfertility Group for 
reviews of interventions for heavy menstrual bleeding (193).  Inevitably, this perspective will 
have excluded other potentially important costs and benefits. For example, the scarcity of 
HRQL data in AUB precluded a cost-utility analysis and comparison by health care decision 
makers with competing health care interventions. Whilst feasibility of testing was taken into 
account, the morbidity (anxiety, discomfort, complications) and psychological implications 
for women and their families was not. Similarly patient preference for testing was not 
incorporated into the models or the added value of individual tests outside of the focus of 
uterine assessment e.g. simultaneous assessment of the ovaries.  
 
The findings of this analysis appear generalisable to modern practice in the UK because a 
contemporary, one-stop clinical setting was used and it was assumed that minor therapeutic 
interventions were implemented during the initial visit; when appropriate. Costs were derived 
from up-to-date HRG data (235); the cost of individual tests were derived and added to the 
cost of a standard new consultation. This method allowed different strategies to be compared 
fairly by breaking down the different aspects of each appointment. However, whilst this 
approach allowed costs in a contemporary ‘one stop’ clinical setting to be applied, the costs 
may not accurately reflect the true cost to the NHS. It is unlikely that the HRG codes 
precisely take account of costs from the clinician’s perspective i.e. the additional time and 
disruption associated with combination testing either from the outset or conditional on 
preceding tests. For example, the ‘one stop’ diagnostic testing philosophy combined with the 
ability to provide concomitant treatment (‘see & treat’) is certainly convenient and efficient 
but the additional time required (which is somewhat unpredictable) necessitates the allocation 
of fewer appointment slots within such clinics. In sensitivity analysis the base case model was 
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adapted to reflect multi-stop diagnostic and treatment pathways to help inform health 
providers currently using traditional service models. 
 
Whilst it is certainly the case that a one-stop approach is efficient, obviating the need for 
further appointments, the UK NHS perspective of this economic analysis may have 
underestimated the total cost savings of the one-stop service. If a wider social perspective was 
adopted, the economic benefits of minimising interference to women’s lives by avoiding 
unnecessary follow up appointments and the consequent travel and waiting times, would 
probably have been substantial. If the costs of absence from paid work and household 
activities had been quantifiable in monetary units, they may not have been insignificant. Thus 
it is probable that a one-stop setting for investigation of HMB from a societal viewpoint 
would have been even more cost-effective compared with traditional multi-stop models of 
service delivery. 
 
A variety of different benign pathologies underlie HMB and each pathology has its optimal 
first-line treatment. However, some pathologies e.g. DUB and endometrial hyperplasia, share 
the same ‘optimal’ first-line treatment i.e. the LNG-IUS. Moreover, erroneously diagnosed 
pathologies given ‘incorrect’ treatment, will generally, still respond to several treatments 
albeit to a suboptimal degree. Thus, the fact that HMB is usually of benign origin and often 
responds to treatment with the LNG-IUS to some degree, regardless of pathology,  has raised 
uncertainty over the cost-effectiveness of any testing in HMB. It was for this reason that ‘no 
investigation’ but LNG-IUS treatment for all was used as the reference strategy against which 
all other testing options could be compared. However, the universal prescription of the LNG-
IUS in secondary care to treat HMB is unlikely to be acceptable to either women who require 
251 
 
an explanation for their symptoms (and may not want a LNG-IUS although the model did not 
account for patient preferences) or clinicians who are aware that more effective, tailored 
treatments are available according to the underlying diagnosis. In primary care the situation is 
different with NICE recommending LNG-IUS as a first-line treatment without stipulating the 
need for diagnostic testing (142). In view of this, a scenario was modelled where all women 
with HMB referred to secondary care were refractory to treatment with the LNG-IUS. The 
inference from this alternate analysis, that investigation should be based upon first-line testing 
with OPH, was unchanged. Thus, given the data available, the model is comprehensive, 
pragmatic and relevant to current clinical practice.  
 
Extensive probabilistic sensitivity analyses were conducted to allow for uncertainty, 
manipulating parameter inputs for clinical assumptions (disease prevalence, test performance, 
accuracy, and consequences of false diagnoses and effectiveness of treatments) and costs. 
Acceptability frontiers were drawn to aid assessment and interpretation. The most cost-
effective testing strategies remained stable following sensitivity analyses increasing 
confidence in the conclusions To further evaluate the stability and also transferability of the 
findings in HMB, alternative models were produced to embrace scenarios where referral to 
secondary care is restricted to women who remain refractory to effective medical treatment 
(142) and where preservation of fertility is required. 
 
Simplifications  
The aim was to develop economic models that accurately and explicitly mirrored clinical 
practice. Some simplifications were necessary, driven by a desire to keep the extensive and 
comprehensive decision trees workable. One problem was how to account for failed testing 
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and discordance of tests within combination strategies. The accuracy of individual outpatient 
tests varies according to which pathology is under scrutiny.  However, this does not mean that 
combination testing will be more cost-effective. The model comprehensively evaluated tests 
used in isolation (with additional testing conditional on the test outcome) and in combination 
from the outset (again with any further testing being conditional on the combination testing 
outcome). However, when combination testing was incomplete due to tests within the 
combination failing, clinicians would then face a dilemma as to what to do next .It was 
decided to simplify the model with the aim of maintaining consistency and minimising 
potential bias. Thus the approach used was that any test or tests that failed within a 
combination testing strategy were assumed to have not allowed a diagnosis to be arrived at 
(i.e. the testing strategy has failed) and recourse to hysteroscopy, D&C was the result. The 
limitation of this approach, is its clinical validity and relevance. Undoubtedly many clinicians 
would consider examination under anaesthesia with hysteroscopy D&C as the ‘gold standard’ 
test whereas others may pragmatically arrive at a diagnosis based upon the information 
provided by the successful tests within the combination strategy. However, there are a huge 
amount of potential test combinations and failure possibilities to consider. Moreover, it was 
hard to arrive at any consensus from the expert panel as to what subsequent testing or 
management decisions would then arise. Therefore the simplification of the model, such that a 
combination testing strategy was considered incomplete necessitating recourse to D&C, was 
reasonable in order to maintain consistency and minimise bias. Moreover, the failure rates of 
tests are generally low and so the impact of this model simplification should have been 
minimal. 
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Subtle differences between testing strategies may have been overlooked, for example it was 
assumed that women could only have one underlying pathology whereas in practice they may 
co-exist. The most common pathologies underlying HMB were accounted for in the model; 
DUB, polyps/SMFs, small and large fibroids and significant endometrial disease. 
Adenomyosis, a condition of the myometrium (uterine muscle) where ectopic endometrial 
tissue is found, can be associated with HMB but was excluded from the model as it tends to 
present with pain rather than HMB. 
 
All relevant, widely employed testing modalities were modelled. Endometrial tissue sampling 
was assumed to be by outpatient EBx and inpatient D&C in failed cases. Endometrial biopsy 
can however be performed under direct vision by passing miniature forceps down the working 
channel of an outpatient hysteroscope. This method was not included as it is not widely used 
and is less likely to provide an adequate tissue sample for histological assessment compared 
with simpler, cheaper and universal outpatient EBx. Furthermore, OPH and SIS are accurate 
tests for the diagnosis of focal pathology without recourse to histological confirmation. In 
addition, focal endometrial disease (cancer and hyperplasia) necessitating a directed biopsy is 
rare with most endometrial conditions being global hormonally induced phenomena allowing 
‘blind’ sampling technologies to obtain representative, diagnostic samples with a high level of 
accuracy (150;151).  
 
Testing with magnetic resonance imaging was not examined because NICE recommend that it 
should not be used for diagnosis in women with HMB on the basis that there are no studies 
examining its use (142). One study compared MRI to TVS for identification of adenomyosis 
and found no significant difference between them (236). In addition, MRI is not suitable for 
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real time outpatient (‘office’) testing and is expensive and rarely used in the diagnosis of 
HMB unless there are concerns over the nature of uterine fibroids (an infrequent situation) or 
when suitability for uterine artery embolisation is being assessed.  
 
Assumptions  
As with all economic modelling exercises, assumptions had to be made when contentious 
clinical decision making or paucity of clinical data were encountered and these assumptions 
were ultimately endorsed by the expert clinical panel. One such area pertained to disease 
prevalence, estimates of which came from a variety of sources and this meant that to make 
them sum to one,  the prevalence of one ‘disease’, DUB,  needed to be a flexible value. The 
assigned value of 0.32 (32%) may not accurately reflect the true prevalence. However, 
published data and the expert panel considered this a reasonable estimate. As with the 
precision of all assumptions, they were subject to sensitivity analyses. In this particular case, 
the inferences of the base case analysis were not affected with varied, plausible estimates of 
DUB prevalence. A similar problem was encountered for some accuracy data such that the 
reciprocal false positive rate estimates, which had originated from diverse data sources, had to 
be manipulated to total one and these were tested in sensitivity analysis. 
 
The selected outcome measure was satisfaction with treatment at one year because this is one 
of the most common outcomes measured in RCTs of interventions for HMB (184) and is 
clinically relevant. Moreover, the availability of other patient reported outcome measures e.g. 
health related quality of life data, (and especially their application to the specific scenarios 
that arose from the construction of the comprehensive decision trees) are scarce. 
Approximating data from published studies was decided to be an inaccurate method for 
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producing QALYs and so ‘cost per patient satisfied’ was used alone. In addition, the cyclical 
and intermittent nature of HMB makes it somewhat problematic to calculate QALY’s 
particularly as women are only affected by the condition for approximately 25% of the year 
and symptoms will naturally resolve in time once the menopause is reached. Systematic 
searching and quality appraisal were used to try and identify the optimal data, but with some 
of the interventions used for particular underlying diagnoses, satisfaction data were not 
explicitly available. In these cases it was assumed that the outcomes reported (e.g. “reduced 
bleeding”, “would recommend the treatment”, “cured of cancer”) were indirect measures of 
satisfaction. 
 
Occasionally, satisfaction data were not reported at one year in which case the data collected 
closest to one year were used. Using ‘one year’, whilst reasonable in terms of evaluating 
medium term response, may favour conservative, ‘uterine-sparing’ procedures (the LNG-IUS, 
endometrial ablation and myomectomy) because their effectiveness reduces over time (136). 
In contrast, more invasive but definitive hysterectomy is not associated with recurrence of 
HMB symptoms. Thus, longer term outcome assessment may have made the option of 
‘hysterectomy without diagnostic testing’ a more viable option. However, the objective and 
emphasis of the analysis was to estimate the cost-effectiveness of diagnostic testing. Thus, as 
long as the treatment options were appropriate and consistently applied according to the 
diagnosed pathology, the most cost-effective testing strategies should have been delineated. 
The base case analysis assumed included women to be 45 years old as this is the modal age 
for presentation to secondary care with HMB. Thus they could be expected to have an average 
of a further seven years of menstruation before the menopause. 
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The ability of OPH to facilitate the removal of uterine polyps in addition to simply providing 
a diagnosis has been highlighted. However, this presumed cost-efficient benefit may be 
blunted if uterine polyps are not causative of HMB, but simply an incidental finding. NICE 
were unable to find any data to link uterine polyps and HMB (142) although clinicians do 
assume some link (172;237). Two systematic reviews of generally low quality, observational 
studies do however, support the notion of polyp treatment being associated with a 75-100% 
improvement in HMB complaints (166;167). Even if polyps don’t cause HMB they may 
negatively affect treatment (e.g. impairing the effectiveness of the LNG-IUS) and ultimately 
cause dissatisfaction (238;239). This may also be a psychological effect given that most 
women and their clinicians are unwilling to accept conservative management of detected 
uterine polyps (240). In addition to hysteroscopic surgical interventions such as polypectomy 
and myomectomy, other uterine sparing therapeutic interventions such as fitting of LNG-IUS 
or endometrial ablation, may not be successfully completed. For the purposes of the model it 
was assumed that all treatments were successfully performed given that the objective of the 
economic analysis was to examine the cost-effectiveness of diagnostic testing based upon test 
performance and accuracy, rather than an assessment of treatment efficacy.  
 
Despite the need for assumptions arising in response to the ‘holes’ in the evidence base, the 
analytic modelling methodology allowed an extensive, comprehensive, contemporary and 
clinically relevant evaluation to be produced. An all-embracing randomised controlled trial, 
assessing the wide range of diagnostic strategies defined in the models would be a huge, 
impractical and ultimately futile undertaking. 
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Comparisons with existing guidance  
 
Current NICE guidance published in 2007 for the management of HMB (142) recommends 
that TVS should be the diagnostic modality of choice when testing is considered and OPH 
employed if TVS is inconclusive. This advice was based upon a cost-effectiveness analysis, 
limited to the assessment of three single testing options; TVS, SIS and OPH. The outcome 
‘cost per correct diagnosis’ did not take into account the range of pathologies under 
consideration for HMB, and the optimal treatments upon knowledge of the underlying 
diagnosis. A fuller evaluation is necessary in order to consider the consequences of erroneous 
diagnosis given that the raison d’etre of formulating a diagnosis is to inform and optimise 
clinical management. Women may serendipitously receive appropriate treatment following a 
false diagnosis, but more often than not, misdiagnosis results in misallocation of resources 
and consequent morbidity attributable to unnecessary procedures. In contrast, the 
comprehensive analysis performed in this thesis reflects the reality of diagnostic evaluation in 
day to day clinical practice in the UK. 
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CHAPTER 11 
 
CONCLUSIONS 
 
Summary of the findings of the systematic reviews of outpatient 
hysteroscopy 
 
The systematic reviews of outpatient hysteroscopy showed that by making small adjustments 
to the way the procedure is carried out can affect the pain experienced by the patient. The 
reviews suggest that women attending for an outpatient hysteroscopy should take a non-
steroidal anti-inflammatory prior to arriving in clinic to try and reduce pain post-operatively. 
When considering the effect on pain, the clinician performing the procedure may choose to 
use a flexible hysteroscope, as this was shown to be less painful. However, there were more 
failed procedures with flexible scopes and they are more expensive to maintain thus the 
clinician may decide that the benefits of using a rigid hysteroscope outweigh the increased 
level of pain, particularly when the pain scores were generally low overall (1.2-4.0). Although 
there was no difference between carbon dioxide and normal saline in terms of pain scores, 
normal saline has many other advantages (quicker procedure, reduced shoulder tip pain, acts 
as a lavage to wash away blood and bubbles and it can be used during bipolar operative 
procedures) that may prompt clinicians to favour it. Although injectable local anaesthetics 
were shown to reduce pain, it was unclear how clinically significant this finding was, 
especially when it was found that using the vaginoscopic technique reduces pain when 
compared to the traditional procedure. The vaginoscopic technique should be the default 
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method for conducting outpatient hysteroscopy. Finally, the use of cervical preparation was 
shown to not affect dilatation of the cervix or reduce pain during the procedure. Furthermore, 
although the systematic review in this thesis found no significant increase in side effects with 
the use of misoprostol, other meta-analyses of its use in inpatient procedures have found an 
association with genital tract bleeding and gastrointestinal symptoms (24;106;107).These 
findings led to the conclusion that  routine cervical preparation with misoprostol prior to 
outpatient hysteroscopy should be avoided.  
 
An important consideration when interpreting the results of the systematic reviews is that the 
primary studies tended to use hysteroscopes of 5.5mm in diameter which is much larger than 
the outpatient hysteroscopes being used today (approximately 3mm). Thus the findings of the 
reviews of local anaesthetic, cervical preparation and scope type may have even less clinical 
significance than was suggested by the results.  
 
Ultimately, using a small hysteroscope, via a vaginoscopic approach with normal saline is 
likely to be acceptable to the majority of women who attend for outpatient hysteroscopy. 
Local anaesthetic and cervical preparation should not routinely be used, however, future 
research should investigate whether certain populations might benefit from these interventions 
(postmenopausal or nulliparous women).  
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Summary of the comparison of the SIGN and GRADE methods for 
assessing evidence quality 
 
The comparison of the SIGN and GRADE methods for grading evidence quality in clinical 
guidelines found that SIGN gives higher gradings of evidence quality than GRADE. This may 
be because GRADE underestimates the quality but it seems more likely that this is due to 
SIGN overestimating the quality due to its less rigorous assessment of methodology. GRADE 
was found to be difficult to use because of the complex method of assessment and although 
the intention is that GRADE is standardised, there are numerous opportunities for subjectivity 
to be introduced.  Neither GRADE nor SIGN appear to be the ideal method for classifying 
and displaying evidence quality. A hybrid version which performs an in-depth assessment but 
displays this data graphically rather than in tabulated form may result in more ‘user-friendly’ 
clinical guidance. 
 
Summary of findings of the economic analysis of HMB 
 
The economic analysis identified two potentially cost-effective testing strategies for the 
investigation of women with HMB. These were initial testing with OPH alone or in 
combination with EBx. To adopt a strategy of OPH, £360 needs to be invested to gain one 
more woman satisfied at one year compared to a strategy of empirical treatment with a LNG-
IUS. Although a testing strategy of OPH +EBx is marginally more effective, the ICER is 
approximately £21,000 to gain one more satisfied patient compared to OPH. This 
approximates to around £26,500 per QALY which falls within the £20,000-£30,000 per 
QALY threshold. These findings were stable during sensitivity analyses, varying model 
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inputs including disease prevalence, test feasibility and accuracy, with OPH remaining more 
cost-effective than the LNG-IUS reference strategy even at relatively low willingness to pay 
thresholds. In women wishing to preserve their fertility, therapy with endometrial ablation and 
hysterectomy are contra-indicated. SIS was cost-effective in this situation, with an ICER of 
approximately £2000, but for an additional financial outlay of £2720, testing instead with 
OPH produces a further satisfied patient, which is likely to be considered affordable and 
worthwhile by the NHS. Sensitivity analysis also showed SIS to be a cost-effective testing 
option along with the combination testing strategy of OPH + EBx within the context of 
traditional multi-stop pathways, although such service models are likely to diminish over time 
with the on-going improvement and increasing availability of portable diagnostic health 
technologies. Outpatient hysteroscopy remains the most cost-effective testing option if a 
scenario is envisaged where only women with HMB refractory to the LNG-IUS, 
recommended first line treatment in general practice (142), are referred to secondary care for 
investigation. In this situation, it was estimated that £5480 extra funding is necessary for each 
additional woman satisfied. No other testing strategies fell within plausible willingness to pay 
ranges.  
 
Therefore, the data are consistent in supporting OPH as the diagnostic testing strategy of 
choice for women referred to secondary care with HMB irrespective of their desire for future 
fertility and regardless of pre-referral treatment with the LNG-IUS. A combination strategy of 
OPH+EBx may be cost-effective at the upper NICE willingness to pay threshold, in women 
without a desire to retain their fertility who have not undergone pre-referral treatment with the 
LNG-IUS or in women investigated through a traditional multi-visit pathway. 
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Summary of the role of outpatient hysteroscopy as investigated by this 
thesis 
 
Outpatient hysteroscopy is clearly an important intervention in gynaecological care not only 
as a diagnostic test but also as an operative procedure (111;241). However, there was no 
consensus on how to best perform the procedure until the systematic reviews and meta-
analyses in this thesis were produced. The results led to development of a clinical guideline 
which is now available from the RCOG (website http://www.rcog.org.uk/womens-
health/clinical-guidance/hysteroscopy-best-practice-outpatient-green-top-59) and is 
influencing patient care.  
The economic analysis confirmed that outpatient hysteroscopy is not only cost-effective when 
compared to other outpatient diagnostic test but that it is likely to be the most cost-effective 
test for investigating women with HMB when used in a contemporary setting. 
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APPENDIX 1 
 
A1.1 Search strategy for systematic review and meta-analysis of local 
anaesthesia for pain control during outpatient hysteroscopy 
 
1.1a Medline (1950- September 2008) 
1. HYSTEROSCOPY/ 
2. Hysteroscopy.ti,ab 
3. 1 OR 2 
4. Vaginoscopy. Ti,ab 
5. 3 OR 4 
6. ANAESTHETICS, LOCAL/ OR LIDOCAINE/ OR BUPIVICAINE/ OR 
ANAESTHESIA, LOCAL/ OR PROCAINE 
7. “local anaesthetic”.ti,ab 
8. (local AND anaesthe*).ti,ab 
9. 6 OR 7 OR 8 
10. 5 AND 9 
 
1.1b EMBASE (1980 to September 2008) 
1. HYSTEROSCOPY/ 
2. Hysteroscopy.ti,ab 
3. 1 OR 2 
4. VAGINOSCOPY/ 
5. Vaginoscopy.ti,ab 
6. 4 OR 5 
7. 3 OR 6 
8. LOCAL ANESTHTEIC AGENT/ OR LOCAL ANESTHESIA/ OR 
BUPIVICAINE/ OR LIDOCAINE/ OR MEPIVICAINE/ OR ROPIVICAINE/ OR 
PRILOCAINE/ OR LEVOBUPIVICAINE/ OR TETRACAINE/ 
9. “local anaesthetic”.ti,ab 
10. 8 OR 9 
11. 7 AND 10 
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1.1c CINAHL (1981 to September 2008) 
1. HYSTEROSCOPY/ 
2. Hysteroscopy.ti,ab 
3. Vaginoscopy.ti,ab 
4. 1 OR 2 OR 3 
5. ANESTHESIA, LOCAL/ OR ANESTHTICS, LOCAL/ 
6. “local anaesthetic”.ti,ab 
7. 5 OR 6 
8. 4 AND 7 
 
1.1d The Cochrane Library (Cochrane Central Register of Controlled Trials) 
1. hysteroscopy AND anaesthetic 
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A1.2 Search strategy for the systematic review of analgesia for pain control 
during outpatient hysteroscopy 
 
1.2a Medline (1950- September 2008) 
1. HYSTEROSCOPY/ 
2. Hysteroscopy.ti,ab 
3. 1 OR 2 
4. Vaginoscopy. Ti,ab 
5. 3 OR 4 
6. ANALGEISA/ 
7. ANALGESICS/ OR ANALGESICS, NON-NARCOTIC/ OR ANALGESICS, 
OPIOID/ 
8. Analges*.ti,ab 
9. 6 OR 7 OR 8 
10. 5 AND 9 
 
1.2b EMBASE (1980 to September 2008) 
1. HYSTEROSCOPY/ 
2. Hysteroscopy.ti,ab 
3. 1 OR 2 
4. VAGINOSCOPY/ 
5. Vaginoscopy.ti,ab 
6. 4 OR 5 
7. 3 OR 6 
8. ANALGESIA/ 
9. ANALGESIC AGENT/ 
10. Analges*.ti,ab 
11. 8 OR 9 OR 10 
12. 7 AND 11 
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1.2c CINAHL (1981 to September 2008) 
1. HYSTEROSCOPY/ 
2. Hysteroscopy.ti,ab 
3. Vaginoscopy.ti,ab 
4. 1 OR 2 OR 3 
5. ANALGESIA/ 
6. analgesia.ti,ab 
7. analges*.ti,ab 
8. ANALGESICS/ OR ANALGESICS, OPIOID/ OR ANALGESICS, 
NONNARCOTIC/ OR NARCOTICS/ OR TRAMADOL/ OR 
ANTIINFLAMMATORY AGENTS, NON-STEROIDAL/ 
9. 5 OR 6 OR 7 OR 8 
10. 4 AND 9 
 
1.2d The Cochrane Library (Cochrane Central Register of Controlled Trials) 
1. hysteroscopy AND analgesia 
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A1.3 Search strategy for the systematic review of conscious sedation for 
pain control during outpatient hysteroscopy 
 
1.3a Medline (1950- September 2008) 
1. HYSTEROSCOPY/ 
2. Hysteroscopy.ti,ab 
3. 1 OR 2 
4. Vaginoscopy. Ti,ab 
5. 3 OR 4 
6. CONSCIOUS SEDATION/ 
7. “conscious sedation”.ti,ab 
8. 6 OR 7 
9. HYPNOTICS AND SEDATIVES/ 
10. Sedative.ti,ab 
11. 9 OR 10 
12. 8 OR 11 
13. 5 AND 12 
 
1.3b EMBASE (1980 to September 2008) 
1. HYSTEROSCOPY/ 
2. Hysteroscopy.ti,ab 
3. 1 OR 2 
4. VAGINOSCOPY/ 
5. Vaginoscopy.ti,ab 
6. 4 OR 5 
7. 3 OR 6 
8. CONSCIOUS SEDATION/ 
9. “conscious sedation”.ti,ab 
10. SEDATIVE AGENT/ 
11. Sedative.ti,ab 
12. 8 OR 9 OR 10 OR 11 
13. 7 AND 12 
 
  
268 
 
1.3c CINAHL (1981 to September 2008) 
1. HYSTEROSCOPY/ 
2. Hysteroscopy.ti,ab 
3. Vaginoscopy.ti,ab 
4. 1 OR 2 OR 3 
5. CONSCIOUS SEDATION/ 
6. “conscious sedation”.ti,ab 
7. HYPNOTICS AND SEDATIVES/ OR SEDATIVES, BARBITURATE/ OR 
SEDATIVES, NONBARBITURATE/ 
8. Sedate*.ti,ab 
9. 5 OR 6 OR 7 OR 8 
10. 4 AND 9 
 
1.3d The Cochrane Library (Cochrane Central Register of Controlled Trials) 
1. hysteroscopy AND sedation 
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A1.4 Search strategy for the systematic review of cervical preparation for 
pain control during outpatient hysteroscopy 
 
1.4a Medline (1950- February 2010) 
1. HYSTEROSCOPY/ 
2. Hysteroscopy.ti,ab 
3. 1 OR 2 
4. Vaginoscopy. Ti,ab 
5. 3 OR 4 
6. MISOPROSTOL/ OR DINOPROSTONE  
7. LAMINARIA/  
8. PROSTAGLANDINS/ OR PROSTAGLANDINS, SYNTHETIC/  
9. ESTROGENS/ 
10. (oestrogen OR estrogen).ti,ab  
11. PROGESTERONE/  
12. PROGESTINS/  
13. CERVICAL RIPENING/  
14. "cervical preparation".ti,ab  
15. laminaria.ti,ab 
16. prostaglan*.ti,ab 
17. progest*.ti,ab 
18. "cervical ripening".ti,ab 
19. 6 AND 7 AND 8 AND 9 AND 10 AND 11 AND 12 AND 13 AND 14 AND 15 
AND 16 AND 17 AND 18 
20. 5 AND 20 
 
  
270 
 
1.4b EMBASE (1980 to February 2010) 
1. HYSTEROSCOPY/ 
2. Hysteroscopy.ti,ab 
3. 1 OR 2 
4. VAGINOSCOPY/ 
5. Vaginoscopy.ti,ab 
6. 4 OR 5 
7. 3 OR 6 
8. MISOPROSTOL/ OR GEMEPROST/ OR PROSTAGLANDIN E2/ OR 
MIFEPRISTONE/ OR DILAPAN/ OR PROSTAGLANDIN/ OR UTERINE 
CERVIX DILATATION/  
9. UTERINE CERVIX RIPENING/  
10. 8 OR 9  
11. "cervical ripening".ti,ab  
12. 10 OR 11  
13. LAMINARIA/  
14. laminaria.ti,ab  
15. 13 OR 14  
16. 12 OR 15  
17. 7 AND 16  
 
1.4c CINAHL  (1981 to February 2010) 
1. HYSTEROSCOPY/ 
2. Hysteroscopy.ti,ab 
3. Vaginoscopy.ti,ab 
4. 1 OR 2 OR 3 
5. MISOPROSTOL.ti,ab  
6. Laminaria.ti,ab  
7. prostaglandins.ti,ab  
8. (oestrogen OR estrogen).ti,ab  
9. progest*.ti,ab  
10. "cervical ripening".ti,ab  
11. "cervical prep*".ti,ab  
12. MISOPROSTOL/  
13. PROSTAGLANDINS/  
14. ESTROGENS/  
15. PROGESTERONE/  
16. CERVIX DILATATION AND EFFACEMENT/  
17. 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16  
18. 4 AND 17  
 
1.4d The Cochrane Library (Cochrane Central Register of Controlled Trials) 
1. hysteroscopy AND cervical  
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A1.5 Search strategy for the systematic review of the effect of the 
vaginoscopic approach to outpatient hysteroscopy on pain 
 
1.5a Medline (1950- February 2009) 
1. HYSTEROSCOPY/ae,mt [ae=Adverse Effects, mt=Methods]  
2. hysteroscopy.ti,ab 
3. Vaginoscopy.ti,ab 
4. “no touch”.ti,ab 
5. HYSTEROSCOPY/ 
6. Vaginoscop*.ti,ab 
7. 2 OR 5 
8. 1 OR 3 OR 4 OR 6 
9. 7 AND 8 
 
1.5b EMBASE (1980 to February 2009) 
1. exp HYSTEROSCOPY/ 
2. hysteroscopy.ti,ab 
3. 1 OR 2 
4. VAGINOSCOPY/ 
5. Vaginoscopy.ti,ab 
6. “no touch”.ti,ab 
7. 1 OR 2 
8. 3 OR 4 OR 5 
9. Vaginoscop*.ti,ab 
10. 7 OR 9 
11. 6 AND 10 
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1.5c CINAHL (1981 to February 2009) 
1. Hysteroscopy.ti,ab 
2. HYSTEROSCOPY/AE,MT,AE,MT [AE=Adverse Effects, MT=Methods, 
AE=Adverse Effects, MT=Methods]  
3. Vaginoscopy.ti,ab 
4. “no touch”.ti,ab 
5. 2 OR 3 OR 4 
6. 1 AND 5 
7. Vaginoscop*.ti,ab 
8. 5 OR 7 
9. HYSTEROSCOPY/ 
10. 1 OR 9 
11. 8 AND 10  
 
1.5d The Cochrane Library (Cochrane Central Register of Controlled Trials) 
1. hysteroscopy AND (vaginoscopy OR vaginoscopic OR "no-touch") 
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A1.6 Search strategy for the systematic review of the effect of distension 
media on pain during outpatient hysteroscopy 
 
1.6a Medline (1950- February 2009) 
1. HYSTEROSCOPY/ 
2. Hysteroscopy.ti,ab 
3. 1 OR 2 
4. Vaginoscopy. Ti,ab 
5. 3 OR 4 
6. DEXTRANS/ OR SODIUM CHLORIDE/ OR MANNITOL/ OR SORBITOL/  
7. “distension media”.ti,ab 
8. (uter* AND disten*).ti,ab 
9. CARBON DIOXIDE 
10. “carbon dioxide”.ti,ab 
11. 6 OR 7 OR 8 OR 9 OR 10 
12. 5 AND 11 
 
1.6b EMBASE (1980 to February 2009) 
1. HYSTEROSCOPY/ 
2. Hysteroscopy.ti,ab 
3. 1 OR 2 
4. VAGINOSCOPY/ 
5. Vaginoscopy.ti,ab 
6. 4 OR 5 
7. 3 OR 6 
8. (uter* AND disten*).ti,ab 
9. “distension media”.ti,ab 
10. SODIUM CHLORIDE/ OR CARBON DIOXIDE/ 
11. 8 OR 9 OR 10 
12. 7 AND 11 
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1.6c CINAHL (1981 to February 2009) 
1. HYSTEROSCOPY/ 
2. Hysteroscopy.ti,ab 
3. Vaginoscopy.ti,ab 
4. 1 OR 2 OR 3 
5. “distension media”.ti,ab 
6. NORMAL SALINE/ OR SALINE SOLUTION, HYPERTONIC/ OR SODIUM 
CHLORIDE/  
7. DEXTRANS/ 
8. Dextrans.ti,ab 
9. MANNITOL/ 
10. Mannitol.ti,ab 
11. CARBON DIOXIDE/ 
12. “carbon dioxide”.ti,ab 
13. (uter* AND disten*).ti,ab 
14. 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 Or 14 OR 15 
15. 4 AND 14 
 
1.6d The Cochrane Library (Cochrane Central Register of Controlled Trials) 
1. hysteroscopy AND distension 
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A1.7 Search strategy for systematic review of the effect on pain of the type 
of hysteroscope used for outpatient hysteroscopy 
 
1.7a Medline (1950- February 2009) 
1. HYSTEROSCOPY/ 
2. Hysteroscopy.ti,ab 
3. vaginoscopy. Ti,ab 
4. flexible.ti,ab 
5. flex*.ti,ab 
6. rigid.ti,ab 
7. rigid*.ti,ab 
8. 1 OR 2 OR 3 
9. 4 OR 5 OR 6 OR 7 
10. 8 AND 9  
 
1.7b EMBASE (1980 to February 2009) 
1. HYSTEROSCOPY/ 
2. Hysteroscopy.ti,ab 
3. VAGINOSCOPY/ 
4. Vaginoscopy.ti,ab 
5. Flex*.ti,ab 
6. Rigid.to,ab 
7. Rigid*.ti,ab 
8. Flexible.ti,ab 
9. 5 OR 6 OR 7 OR 8 
10. 1 OR 2 OR 3 OR 4 
11. 9 AND 10 
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1.7c CINAHL  (1981 to February 2009) 
1. HYSTEROSCOPY/ 
2. Hysteroscopy.ti,ab 
3. Vaginoscopy.ti,ab 
4. Flexible.ti,ab 
5. Flex*.ti,ab 
6. Rigid.ti,ab 
7. Rigid*.ti,ab 
8. 4 OR 5 OR 6 OR 7 
9. 1 OR 2 OR 3 
10. 8 AND 9 
 
1.7d The Cochrane Library (Cochrane Central Register of Controlled Trials) 
 
1. hysteroscopy AND (flexible OR rigid) 
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APPENDIX 2 
 
Data retrieval form for systematic review and meta-analysis of local 
anaesthesia for pain control during outpatient hysteroscopy 
 
The following form was used for data extraction from studies selected for use in the 
systematic review of local anaesthesia. The data extraction forms used for the other 
systematic reviews were adapted to evaluate the different interventions by changing the 
selection criteria and the secondary outcomes. 
 
Reviewer ……………. Paper No. ……….. Name of 1st author & year…………  
 
 
Ring the appropriate category(ies) 
i) population – women undergoing out-patient hysteroscopy    yes / no 
ii) intervention –  use of local anaesthetic     yes / no 
iii) outcome –  patient experience i.e. pain / feasibility    yes / no 
 
Select this study (i-iii inclusive)       yes / no 
 if no reject & specify reason 
…………………………………………………………………………………………….. 
 
 
 
Selection criteria (therapy study): 
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Study Design:  
(1) Study Design   RCT    Yes [  ]  No [  ] 
(2) Was the study described as randomized (this includes the use of words such as 
randomly, random, and randomization)? 
        Yes [  ]  No [  ] 
Was the method to generate the sequence of randomization described?  
        Yes [  ]  No [  ] 
If yes was it: 
appropriate (table of random numbers, computer generated etc)?   [  ] 
or 
Inappropriate (patients were allocated alternately, or according to DOB etc.) [  ] 
(3) Was the study described as blinded? Double [  ]   Single [  ]   Not blinded [  ]  NR [  ] 
If double blind was the method: 
 Appropriate (identical placebo, active placebo, dummy, etc.).  [  ] 
Or 
 Inappropriate (e.g. comparison of pill v. injection without double dummy). [  ] 
(4) Was there a description of withdrawals and dropouts?       Yes [  ]  No [  ] 
(Participants who were included in the study but did not complete the observation period or 
who were not included in the analysis must be described. The number and the reasons for 
withdrawal in each group must be stated. If there were no withdrawals, it should be stated in 
the article. If there is no statement on withdrawals, this item must be given no points.) 
 
Population: 
(1) Type of patient   Premenopausal  [   ]  Postmenopausal   [   ]  Both   [   ] 
Data Retrieval: 
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(2) No. patients recruited  A original population   n=…… 
B Pre-enrolment /randomisation n=…… 
 exclusions (reasons e.g. pop characteristics) 
……………………………………………………. 
C actually recruited (A-B) n=……  
D post-enrolment /randomisation n=…… 
exclusions (reasons e.g. missing data, drop-outs)           
…………………….………………………………..… 
E analysable data (C-D)  n=…… 
(3) Type of procedure   Diagnostic [  ]   Operative [  ]   
 Speculum used   Yes [  ] No [  ]  Sometimes [  ] 
 Scope type and size......................................................................................................  
 Distension medium used ......................................………………............................. 
 Pipelle sample taken  Yes [  ]  No [  ]  Sometimes [  ] 
 
Intervention: 
(1) Type & nature of anaesthesia 
No in intervention group……………………………………………….....…….......………. 
What anaesthetic? 
…………………………………….…Dose……..…………….....…….……....………… 
Method of administration (e.g. Direct cervical / paracervical)…………………………… 
When administered?……………..……………………….………………………………. 
No. in control group ……………………………….…………………….……………….. 
Control method (e.g. placebo used etc.)......…………………………………………….. 
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(2) Description of technique (i.e. could we reproduce it)  Adequate / Inadequate 
 
Outcome: 
(1) Method of assessing pain e.g. pain scores, VAS, use of post op analgesia, BP 
measurements, cortisol  
…………………………………………………………………………………………………
………………………………………………………………………………………………… 
(2) Was pain relief / assessment defined?      yes / no 
If so, how....................................................................................................................................... 
 (3) Pain results 
 
(4) Completeness of Follow up (%) >90 / 81-90 / <81 % 
Secondary outcomes: 
(1) Fail to perform procedure NR inter grp. n=……control grp n= ................. 
(2) Need for post-op analgesia NR  inter grp. n=….… control grp. n=…......... 
(3) Complication rate   NR  inter grp. n=….… control grp. n=…......... 
(4) Vasovagal reactions    NR  inter grp. n=….… control grp. n=…......... 
 Has ‘vasovagal’ been defined? yes / no 
 If so, how?.........................................................................................................................      
................................................................................................................................................... 
 Intervention group Control group 
Number in group   
Values (e.g. mean, sd)   
Pain scores 
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(5) Patient admitted    NR  inter grp. n=….… control grp. n=…......... 
 (6) Other (e.g. patient satisfaction) NR  inter grp. n=….… control grp. n=…......... 
 
2x2 Contingency tables (RCT / controlled studies only): 
Local Anaesthetic  
Outcome 
Intervention 
Pain No / acceptable pain Total 
Anaesthetic    
Control / Comparison    
Total    
 
Vasovagal episodes  
Outcome 
Intervention 
Outcome present  Outcome absent Total 
Surgery    
Control / Comparison    
Total    
 
Other 
Outcome 
Intervention 
Outcome present  Outcome absent Total 
Surgery    
Control / Comparison    
Total    
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APPENDIX 3 
 
Jadad method for scoring the Quality of Randomised Controlled Trials (50) 
 
1. Was the study described as randomized (this includes the use of words such as 
randomly, random, and randomisation)? 
2. Was the study described as double blind? 
3. Was there a description of withdrawals and dropouts? 
Scoring the items: 
 
Either give a score of 1 point for each ”yes” or 0 points for each “no.” There are no in-
between marks. 
 
Give 1 additional point if:  
For question 1, the method to generate the sequence of 
randomisation was described and it was appropriate 
(table of random numbers, computer generated, etc.). 
and/or: 
If for question 2 the method of double blinding was 
described and it was appropriate (identical placebo, 
active placebo, dummy, etc.). 
 
Deduct 1 point if: For question 1, the method to generate the sequence of 
randomization was described and it was inappropriate 
(patients were allocated alternately, or according to date 
of birth, hospital number, etc.) 
and/or: 
For question 2, the study was described as double blind 
but the method of blinding was inappropriate (e.g., 
comparison of tablet vs. injection with no double 
dummy). 
 
Guidelines for Assessment 
 
1. Randomisation 
A method to generate the sequence of randomisation will be regarded as appropriate if it 
allowed each study participant to have the same chance of receiving each intervention and 
the investigators could not predict which treatment was next. Methods of allocation using 
date of birth, date of admission, hospital numbers, or alternation should be not regarded as 
appropriate. 
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2. Double blinding 
A study must be regarded as double blind if the word “double blind” is used. The method 
will be regarded as appropriate if it is stated that neither the person doing the assessments 
nor the study participant could identify the intervention being assessed, or if in the 
absence of such a statement the use of active placebos, identical placebos, or dummies is 
mentioned. 
 
 
3. Withdrawals and dropouts 
Participants who were included in the study but did not complete the observation period or 
who were not included in the analysis must be described. The number and the reasons for 
withdrawal in each group must be stated. If there were no withdrawals, it should be stated 
in the article. If there is no statement on withdrawals, this item must be given no points. 
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APPENDIX 4 
‘Best Practice in Outpatient Hysteroscopy’ Guideline 
Reproduced from: Royal College of Obstetricians and Gynaecologists. Best Practice in 
Outpatient Hysteroscopy. Green-top Guideline No. 59. London: RCOG; 2011, with the 
permission of the Royal College of Obstetricians and Gynaecologists.  
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APPENDIX 5 
GRADE tables for ‘Best Practice in Hysteroscopy’ Guideline recommendations with corresponding SIGN 
gradings 
A5.1 Analgesia 
 
Do analgesics given prior to diagnostic hysteroscopy reduce the pain felt during the procedure? 
 
Routine use of opiate analgesia prior to outpatient hysteroscopy should be avoided as it may cause adverse side effects 
Question: Should tramadol be used for pain relief prior to outpatient hysteroscopy? 
Quality assessment No of patients Effect 
Quality Importance 
No of 
studies 
Design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Tramadol Control 
Relative 
(95% 
CI) 
Absolute 
Pain with im tramadol (measured with: Visual analogue scale; range of scores: 0-20; Better indicated by lower values) 
1 randomised 
trials 
very 
serious
1
 
no serious 
inconsistency 
no serious 
indirectness 
serious
2
 reporting bias
3
 40 40 - MD 3.3 lower (4.96 to 1.64 
lower) 
 
VERY 
LOW 
CRITICAL 
Pain with iv tramadol (measured with: Visual analogue scale; range of scores: 0-10; Better indicated by lower values) 
1 randomised 
trials 
serious
4
 no serious 
inconsistency 
no serious 
indirectness 
serious
2
 reporting bias
3
 25 25 -   
VERY 
LOW 
CRITICAL 
Side effects with iv tramadol 
1 randomised 
trials 
serious
5
 no serious 
inconsistency 
no serious 
indirectness 
serious
2
 reporting bias
3
 4/25  
(16%) 
2/25  
(8%) 
- 80 fewer per 1000 (from 80 
fewer to 80 fewer) 
 
VERY 
LOW 
CRITICAL 
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1
 Randomisation not described and no blinding. Unclear who assessed the pain scores but likely to be the surgeons. 
2
 Only one small study. 
3
 This is the only study identified. 
4
 The study does not accurately report the point estimate and confidence intervals it displays them on a graph that cannot be reliably read.  
Reports that the result is significant p<0.012 and p<0.008. 
5
 Not clear whether the study was blinded. 
Question: Should sublingual buprenorphine be used for pain relief prior to outpatient hysteroscopy? 
Quality assessment No of patients Effect 
Quality Importance 
No of 
studies 
Design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Sublingual 
buprenorphine 
Control 
Relative 
(95% CI) 
Absolute 
Pain (measured with: Visual analogue scale; range of scores: 0-10; Better indicated by lower values) 
1 randomised 
trials 
serious
1
 no serious 
inconsistency 
serious
2
 serious
3
 reporting bias
4
 80 84 - MD 0.1 higher 
(0.27 lower to 0.47 
higher) 
 
VERY 
LOW 
CRITICAL 
Presence of side effects associated with buprenorphine 
1 randomised 
trials 
serious
1
 no serious 
inconsistency 
no serious 
indirectness 
very 
serious
3,5
 
reporting bias
4
 31/80  
(38.8%) 
0% OR 107.55 
(6.44 to 
1796.46) 
-  
VERY 
LOW 
IMPORTANT 
1
 Not clear whether the study was blinded.  
2
 Pain was assessed by a nurse who was observing the facial expressions of the patients and not the patients themselves. 
3
 This is single study with a small population. 
4
 This was the only study identified. 
5
 The confidence interval is very wide. 
 
SIGN grading: B 
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Patients, without contra-indications, should be advised to consider taking standard doses of non-steroidal anti-inflammatory agents 
around one hour before their scheduled outpatient hysteroscopy appointment with the aim of reducing pain in the immediate post-
operative period. 
Question: Should non-steroidal anti-inflammatory drugs (NSAIDs) be used for pain relief prior to outpatient hysteroscopy? 
Quality assessment No of patients Effect 
Quality Importance 
No of 
studies 
Design Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
NSAIDs Control 
Relative 
(95% 
CI) 
Absolute 
Visual analogue scale pain score with oral diclofenac (range of scores: 0-10; Better indicated by lower values) 
1 randomised 
trials 
no serious risk 
of bias 
no serious 
inconsistency 
no serious 
indirectness 
serious reporting bias 92 89 - MD 0 higher (0.79 lower 
to 0.79 higher) 
 
LOW 
CRITICAL 
Visual analogue scale pain score with im ketorolac (range of scores: 0-10; Better indicated by lower values) 
1 randomised 
trials 
serious
1
 no serious 
inconsistency 
no serious 
indirectness 
serious
2
 reporting bias
3
 12 12 - MD 1.1 lower (3.35 lower 
to 1.16 higher) 
 
VERY 
LOW 
CRITICAL 
Visual analogue scale pain score with oral mefenamic acid (range of scores: 0-10; Better indicated by lower values) 
1 randomised 
trials 
no serious risk 
of bias 
no serious 
inconsistency 
no serious 
indirectness 
serious
4
 reporting bias
5
 49 46 - MD 0 higher (0 to 0 
higher) 
 
LOW 
CRITICAL 
1
 There is no description of randomisation and the study is not blinded. 
2
 This is a single study with a very small population. 
3
 This was the only study identified. 
4
 This is only one small study. 
5
 This is the only identified study. 
 
SIGN grading: B 
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A5.2 Cervical Preparation 
 
Does cervical preparation reduce uterine trauma, failure to access the uterine cavity or pain associated with outpatient 
hysteroscopy? 
 
Cervical preparation prior to outpatient hysteroscopy should not be used in the absence of any evidence of benefit in terms of reduction 
in pain, rates of failure or uterine trauma. 
Question: Should Vaginal Prostaglandins be used in women undergoing outpatient hysteroscopy? 
Quality assessment No of patients Effect 
Quality Importance 
No of 
studies 
Design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Vaginal 
Prostaglandins 
Control 
Relative 
(95% CI) 
Absolute 
Premenopausal women: pain score during dilatation (range of scores: 0-10; Better indicated by lower values) 
1 randomised 
trials 
very 
serious
1
 
no serious 
inconsistency 
no serious 
indirectness 
very serious
2
 reporting bias
3
 22 21 - 0 higher (0 to 0 
higher) 
 
VERY LOW 
CRITICAL 
Premenopausal: pain reduction during hysteroscopy 
1 randomised 
trials 
serious
4
 no serious 
inconsistency 
no serious 
indirectness 
very serious
5
 reporting bias
3
 6/13  
(46.2%) 
12/23  
(52.2%) 
RR 0.88 
(0.44 to 
1.79) 
63 fewer per 1000 
(from 292 more to 
412 more) 
 
VERY LOW 
CRITICAL 
Postmenopausal: pain reduction during the procedure (measured with: visual analogue scale; Better indicated by lower values) 
1 randomised 
trials 
serious
6
 serious
7
 no serious 
indirectness 
no serious 
imprecision 
reporting bias
3
 60 60 - 0 higher (0 to 0 
higher) 
 
VERY LOW 
CRITICAL 
Mixed population: pain (measured with: Visual analogue scale; range of scores: 0-10; Better indicated by lower values) 
1 randomised 
trials 
very 
serious
8
 
no serious 
inconsistency 
no serious 
indirectness 
serious
9
 reporting bias
3
 50 50 - 0 higher (0 to 0 
higher) 
 
VERY LOW 
CRITICAL 
Mixed population: pain after dilatation (measured with: Visual analogue scale; range of scores: 0-100; Better indicated by lower values) 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
serious
9,10
 reporting bias
3
 50 51 - MD 12.3 lower 
(13.69 to 10.91 
lower) 
 
LOW 
CRITICAL 
Premenopausal: adequate dilatation 
1 randomised 
trials 
very 
serious
11
 
no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
reporting bias
3
 20/22  
(90.9%) 
6/21  
(28.6%) 
OR 25 (4.41 
to 141.68) 
623 more per 1000 
(from 352 more to 
697 more) 
 
VERY LOW 
IMPORTANT 
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Postmenopausal- need for dilatation 
1 randomised 
trials 
serious
12
 no serious 
inconsistency 
no serious 
indirectness 
serious
13
 reporting bias
3
 10/58  
(17.2%) 
12/59  
(20.3%) 
OR 0.82 
(0.32 to 
2.06) 
30 fewer per 1000 
(from 128 fewer to 
141 more) 
 
VERY LOW 
IMPORTANT 
Needs dilatation- mixed population 
1 randomised 
trials 
very 
serious
8
 
no serious 
inconsistency 
no serious 
indirectness 
serious
2
 reporting bias
3
 15/50  
(30%) 
11/50  
(22%) 
OR 1.52 
(0.62 to 
3.74) 
80 more per 1000 
(from 71 fewer to 
293 more) 
 
VERY LOW 
IMPORTANT 
Force needed to dilate at 6mm- mixed population (Better indicated by lower values) 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
reporting bias
3
 50 51 - SMD 0.48 lower 
(0.88 to 0.09 lower) 
 
MODERATE 
IMPORTANT 
Misoprostol in postmenopausal women- failed hysteroscopies 
1 randomised 
trials 
serious
12
 no serious 
inconsistency 
no serious 
indirectness 
serious
14
 reporting bias
3
 4/60  
(6.7%) 
4/60  
(6.7%) 
OR 1 (0.24 
to 4.2) 
0 fewer per 1000 
(from 50 fewer to 
164 more) 
 
VERY LOW 
IMPORTANT 
Misoprostol in premenopausal women- failed hysteroscopies 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
very serious
15
 reporting bias
3
 7/20  
(35%) 
1/24  
(4.2%) 
OR 12.38 
(1.37 to 
112.1) 
308 more per 1000 
(from 15 more to 
788 more) 
 
VERY LOW 
IMPORTANT 
Cervical lacerations 
3 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
serious
14
 reporting bias
16
 8/125  
(6.4%) 
13/131  
(9.9%) 
OR 0.59 
(0.22 to 
1.55) 
38 fewer per 1000 
(from 76 fewer to 47 
more) 
 
LOW 
CRITICAL 
Cervical Bleeding 
4 randomised 
trials 
no serious 
risk of bias 
serious
17
 no serious 
indirectness 
serious
13
 reporting bias
18
 21/135  
(15.6%) 
12/141  
(8.5%) 
OR 1.32 
(0.52 to 3.4) 
24 more per 1000 
(from 39 fewer to 
155 more) 
 
VERY LOW 
CRITICAL 
1
 Randomisation not described and not blinded. 
2
 Only one study with a very small population and a large effect so results are less likely to be accurate. 
3
 Only a single study was identified. 
4
 33% of the women randomised to misoprostol did not undergo hysteroscopy and therefore could not be assessed. 
5
 The population size is very small. The confidence interval includes 'no effect'.  
6
 Probable reporting bias as multiple evaluations of pain are reported. Blinding suggested but unclear. 
7
 Results are confusing with no clear evidence of effect. 
8
 No blinding as compared to nothing rather than placebo. 
9
 Only one study with a small population so results less likely to be accurate. 
10
 Single study with population size that was calculated based on the outcome 'dilatation' and not pain. 
11
 Randomisation not described and study not blinded. 
12
 Blinding suggested but unclear. 
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13
 The confidence interval contains no effect. 
14
 Confidence interval includes 'no effect'. Also a small number of events. 
15
 A single study with a small population and wide confidence intervals. 
16
 Only three small trials. 
17
 Significant heterogeneity which can only be partially explained by different administration times and doses. 
18
 Only four small trials. 
Question: Should Mifepristone be used in women undergoing outpatient hysteroscopy? 
Quality assessment No of patients Effect 
Quality Importance 
No of 
studies 
Design Risk of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
Mifepristone  Control 
Relative 
(95% 
CI) 
Absolute 
Pain after cervical dilatation (measured with: Visual analogue scale; range of scores: 0-100; Better indicated by lower values) 
1 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency 
no serious 
indirectness 
serious
1
 reporting bias
2
 28 30 - MD 3.6 lower (17.42 
lower to 10.22 higher) 
 
LOW 
CRITICAL 
1
 Results are from one small study with a wide confidence interval. 
2
 Only one study identified. 
 
SIGN grading: A 
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A5.3 Type of Hysteroscope 
 
Should rigid or flexible hysteroscopes be used routinely in the outpatient setting? 
 
Flexible hysteroscopes are associated with less pain during outpatient hysteroscopy compared with rigid hysteroscopes. However, rigid 
hysteroscopes may provide better images, fewer failed procedures, quicker examination time and reduced cost Thus there is insufficient 
evidence to recommend preferential use of rigid or flexible hysteroscopes for diagnostic, outpatient procedures and choice of 
hysteroscope should be left to the discretion of the operator 
Question: What type of hysteroscope should be used for outpatient hysteroscopy? 
Quality assessment No of patients Effect 
Quality Importance 
No of 
studies 
Design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Flexible 
hysteroscopes 
Rigid 
hysteroscopes 
Relative 
(95% CI) 
Absolute 
Pain score (measured with: Visual analogue scale; range of scores: 0-10; Better indicated by lower values) 
2 randomised 
trials 
no serious 
risk of bias
1
 
no serious 
inconsistency 
no serious 
indirectness 
serious
2
 reporting bias
3
 110 115 - not 
pooled 
 
LOW 
IMPORTANT 
Failures (assessed with: Occurrence vs. non-occurrence) 
2 randomised 
trials 
no serious 
risk of bias
1
 
no serious 
inconsistency 
no serious 
indirectness 
serious
2,4
 reporting bias
3
 5/112  
(4.5%) 
0/115  
(0%) 
OR 11.81 
(0.64 to 
217.75) 
-  
LOW 
IMPORTANT 
1
 The only limitation is that the studies were not double blinded however this would be impossible to do. 
2
 Small sample sizes encourage imprecision. 
3
 Only two small studies. Likely that studies finding no advantage of one hysteroscope over the other are not published. 
4
 Small number of events. 
 
SIGN grading: B 
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A5.4 Distension Media 
Which uterine distension medium should be used during outpatient hysteroscopy? 
 
The choice of distension media, for routine outpatient hysteroscopy, between carbon dioxide and normal saline should be left to the 
discretion of the operator as neither is superior in reducing pain, although uterine distension with normal saline appears to reduce the 
incidence of vasovagal episodes. 
Uterine distension with Normal saline allows outpatient diagnostic hysteroscopy to be completed more quickly compared with carbon 
dioxide. 
 
Question: Which is the best distension medium for outpatient hysteroscopy? 
Quality assessment No of patients Effect 
Quality Importance 
No of 
studies 
Design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Normal 
saline 
Carbon 
dioxide 
Relative 
(95% CI) 
Absolute 
Pain score (Better indicated by lower values) 
6 randomised 
trials 
very 
serious
1
 
serious
2
 no serious 
indirectness 
no serious 
imprecision 
none 540 569 - SMD 0.34 higher (0.12 
lower to 0.8 higher) 
 
VERY 
LOW 
CRITICAL 
Shoulder tip pain 
5 randomised 
trials 
very 
serious
1
 
no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 9/472  
(1.9%) 
55/448  
(12.3%) 
OR 0.19 
(0.09 to 0.4) 
97 fewer per 1000 
(from 70 fewer to 110 
fewer) 
 
LOW 
CRITICAL 
Vasovagal episodes 
3 randomised 
trials 
very 
serious
1
 
no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
reporting bias
3
 5/210  
(2.4%) 
18/210  
(8.6%) 
OR 0.31 
(0.12 to 0.82) 
57 fewer per 1000 
(from 14 fewer to 75 
fewer) 
 
VERY 
LOW 
IMPORTANT 
Procedure time (Better indicated by lower values) 
4 randomised 
trials 
very 
serious
1
 
no serious 
inconsistency
4
 
no serious 
indirectness 
no serious 
imprecision 
none 434 401 - SMD 1.32 lower (1.48 
to 1.17 lower) 
 
LOW 
IMPORTANT 
Unsatisfactory hysteroscopic view  
1 randomised 
trials 
very 
serious
1
 
no serious 
inconsistency 
no serious 
indirectness 
serious
5
 reporting bias
6
 4/100  
(4%) 
19/100  
(19%) 
RR 4.75 
(1.61 to 16.4) 
712 more per 1000 
(from 116 more to 1000 
more) 
 
VERY 
LOW 
CRITICAL 
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1
 Poor randomisation methods (quasi-randomised in some cases) and lack of allocation concealment in most studies. Neither patient nor 
operator was blinded but this would not be possible. 
2
 High heterogeneity that cannot be explained by differences in technique. 
3
 Outcome reported in just three of the six identified trials. 
4
 High heterogeneity but all studies in favour of normal saline and heterogeneity can be explained by the two studies that don't using a 
speculum showing the largest effect size. 
5
 Single study therefore imprecise. 
6
 This is the only study that reports a difference. 
 
SIGN grading: A 
 
 
  
314 
 
A5.5 Local anaesthesia and cervical dilatation 
 
Should topical local anaesthetic be administered prior to outpatient hysteroscopy? 
 
Injection of local anaesthetic into the cervical canal does not reduce pain during diagnostic outpatient hysteroscopy  
 
Should injectable local anaesthetic be administered to the cervix and / or para-cervix prior to outpatient hysteroscopy? 
 
Injection of local anaesthetic into or around the cervix is associated with reduction in pain experienced during outpatient diagnostic 
hysteroscopy.  However, it is unclear how clinically significant this reduction in pain is. Consideration should be given to the routine 
administration of intracervical or paracervical local anaesthetic, particularly in postmenopausal women. 
 
Routine administration of intracervical or paracervical local anaesthetic is not indicated to reduce the incidence of vasovagal reaction. 
 
Question: Should local anaesthetic be used in women undergoing outpatient hysteroscopy? 
Quality assessment No of patients Effect 
Quality Importance 
No of 
studies 
Design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Local 
anaesthetic 
Control 
Relative 
(95% CI) 
Absolute 
pain score with topical local anaesthetic (Better indicated by lower values) 
2 randomised 
trials 
no serious 
risk of bias 
no serious 
inconsistency
1
 
no serious 
indirectness 
serious
2
 reporting bias
3
 312 306 - SMD 0.32 lower 
(0.97 lower to 0.33 
higher) 
 
LOW 
CRITICAL 
pain score with transcervical anaesthetic (measured with: Visual analogue scale; range of scores: 0-10; Better indicated by lower values) 
5 randomised 
trials 
serious
4
 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
none 276 270 - SMD 0.11 lower 
(0.31 lower to 0.1 
higher) 
 
MODERATE 
CRITICAL 
Pain score with intracervical anaesthetic block (Better indicated by lower values) 
3 randomised 
trials 
serious
5
 no serious 
inconsistency 
no serious 
indirectness 
serious
6
 reporting bias
7
 123 116 - SMD 0.36 lower 
(0.61 to 0.1 lower) 
 
VERY LOW 
CRITICAL 
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pain with paracervical anaesthetic block (Better indicated by lower values) 
5 randomised 
trials 
very 
serious
8
 
serious
9
 no serious 
indirectness 
serious
10
 none 335 337 - SMD 1.28 lower 
(2.22 to 0.35 lower) 
 
VERY LOW 
CRITICAL 
Vasovagal attacks 
9 randomised 
trials 
serious
8
 serious
11
 no serious 
indirectness 
no serious 
imprecision 
none 40/635  
(6.3%) 
56/629  
(8.9%) 
OR 0.69 
(0.45 to 
1.05) 
26 fewer per 1000 
(from 47 fewer to 4 
more) 
 
LOW 
IMPORTANT 
1
 Studies use different strengths of lignocaine which may explain the heterogeneity. However, stratifying for strength of anaesthetic agent 
would result in multiple, small sub-groups. 
2
 Wide confidence intervals with a small effect size. 
3
 Only two studies included. 
4
 Poor allocation concealment. 
5
 Details of randomisation and allocation concealment are unclear. 
6
 Small population size. 
7
 Only 3 small studies identified. 
8
 Poor allocation concealment. Details of randomisation unclear and some studies not blinded. 
9
 Heterogeneity is high. When the study with greatest effect size is removed I2 is still 90%. Two studies do not overlap with any of the 
other studies. 
10
 Wide confidence intervals. 
11
 Heterogeneous. The studies use different methods and use different administration of local anaesthetic. 
 
SIGN grading: A 
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A5.6 Conscious sedation 
Should conscious sedation be used to reduce pain associated with outpatient hysteroscopic procedures? 
 
Conscious sedation should not be routinely used in outpatient hysteroscopic procedures, as it confers no advantage in terms of pain 
control and patient satisfaction over local anaesthesia. 
Question: Does conscious sedation reduce pain during outpatient hysteroscopy? 
Quality assessment No of patients Effect 
Quality Importance 
No of 
studies 
Design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Conscious sedation 
versus intracervical 
block 
Control 
Relative 
(95% 
CI) 
Absolute 
Pain score  (Better indicated by lower values) 
1 randomised 
trials 
serious
1
 no serious 
inconsistency 
no serious 
indirectness 
serious
2
 reporting bias
3
 84 82 - MD 0.2 lower (0.43 
lower to 0.03 
higher) 
 
VERY 
LOW 
CRITICAL 
1
 Allocation concealment not clear. Not blinded.  
2
 Single study and small population therefore imprecise. 
3
 Only a single study identified. 
 
SIGN grading: A 
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A5.7 Vaginoscopy 
 
Does a vaginoscopic approach to outpatient hysteroscopy reduce pain and increase the feasibility of the procedure? 
 
Vaginoscopy reduces pain during diagnostic rigid outpatient hysteroscopy. 
 
Question: Should the vaginoscopic technique be used for outpatient hysteroscopy? 
Quality assessment No of patients Effect 
Quality Importance 
No of 
studies 
Design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Vaginoscopy Control 
Relative 
(95% CI) 
Absolute 
Pain score (Better indicated by lower values) 
4 randomised 
trials 
serious
1
 no serious 
inconsistency
2
 
no serious 
indirectness 
no serious 
imprecision 
reporting bias
3
 472 439 - SMD 0.44 lower (0.65 
to 0.22 lower) 
 
LOW 
CRITICAL 
Failed procedures 
5 randomised 
trials 
serious
1
 no serious 
inconsistency 
no serious 
indirectness 
serious
4
 reporting bias
3
 39/584  
(6.7%) 
25/550  
(4.5%) 
OR 1.28 
(0.74 to 2.24) 
12 more per 1000 
(from 11 fewer to 51 
more) 
 
VERY 
LOW 
IMPORTANT 
1
 Poor allocation concealment. 
2
 Heterogeneity can be explained by the fact that the traditional technique varied between studies. 
3
 Only a small number of trials and they mainly have positive results. 
4
 Wide confidence interval. 
 
SIGN grading: A 
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APPENDIX 6 
Decision trees for the economic analysis of heavy menstrual bleeding 
 
The heavy menstrual bleeding decision trees are too large to be displayed in their entirety therefore an expanded branch from the outpatient 
hysteroscopy tree is shown below. Table 3.2 shows the diagnosis made and the treatments given for all branches within the decision tree. 
A6.1 Expanded branch from the outpatient hysteroscopy strategy for investigation of HMB 
 
Satisfied
pSatisfied_Removal
Satisfied
pSatisfied_LngIUS_DUB
Not satisfied
#
LNG-IUSNot satisfied
#
RemoveShows polyp /SMF
pTPR_PolypsorSMF_OPH
Satisfied
pSatisfied_LngIUS_PolypSMF
Satisfied
pSatisfied_Removal
Not satisfied
#
Remove
EA but not done as
hysteroscopy shows
polyp/SMFNot satisfied
#
LNG-IUSShows polyp/SMFConfirmatory test
Shows endometrial
disease
pFPR_ED_OPH
Satisfied
pSatisfied_LngIUS_PolypSMF
Satisfied
pSatisfied_Removal
Not satisfied
#
Remove
EA but not done as
hysteroscopy shows
polyp/SMFNot satisfied
#
LNG-IUS
No intracavity 
pathology/ DUB
#
Doesn't show
polyp /SMF
#
Succeed
pSuccessful_OPH
Satisfied
pSatisfied_Removal
Satisfied
pSatisfied_LngIUS_DUB
Not satisfied
#
LNG-IUSNot satisfied
#
Remove Shows polyp / SMFHyst D+C Fail
#
OPH
Resectable intrauterine
pathology (polyp/SMF)
pPolyporSMF
Fibroids <12/40
pFibroidSmall  [+] 
Fibroids >12/40
pFibroidLarge  [+] 
Endometrial disease
pEndometrialDisease  [+] 
Dysfunctional
uterine bleeding
#  [+] 
OPH alone
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A6.2 Diagnosis and treatments from the decision tree for investigation of women with HMB 
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
LNG-IUS only Polyp / SMF     LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
 Fibroids <12     LNG-IUS EA 
 Fibroids >12     LNG-IUS EA 
      Hysterectomy if 
bimanual exam 
suggests >12 weeks size 
GP appt 
 ED     LNG-IUS Hysterectomy 
 DUB     LNG-IUS EA 
        
Hysterectomy 
only 
Polyp / SMF     Hysterectomy GP appt 
 Fibroids <12     Hysterectomy GP appt 
 Fibroids >12     Hysterectomy GP appt 
 ED     Hysterectomy GP appt 
 DUB     Hysterectomy GP appt 
        
OPH alone Polyp / SMF Polyp / SMF    Resection LNG-IUS 
  Endometrial 
disease 
Polyp / SMF   LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
  DUB    LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
 Fibroids < 12 Normal cavity    LNG-IUS EA 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
  Polyp / SMF    Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
  ED Normal 
endometrium 
  LNG-IUS EA 
 Fibroids >12 Normal cavity >12 by 
bimanual exam 
  Hysterectomy GP appt 
   <12 by 
bimanual exam 
  LNG-IUS  
  Polyp / SMF >12 by 
bimanual exam 
  Hysterectomy GP appt 
   <12 by 
bimanual exam 
  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
  ED >12 by 
bimanual exam 
Normal endometrium  Hysterectomy GP appt 
   <12 by 
bimanual exam 
Normal endometrium  LNG-IUS EA 
 ED ED Hyperplasia   LNG-IUS Hysterectomy 
   Cancer   Hysterectomy GP appt 
  Polyp / SMF    Resection- histology 
shows hyperplasia / 
cancer so get LNG-IUS/ 
hysterectomy 
Hysterectomy / 
GP visit 
  DUB    LNG-IUS Hysterectomy as 
EBx prior to EA 
shows ED 
 DUB DUB    LNG-IUS EA 
  Polyp / SMF    Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
TVS alone 
and 
SIS alone 
Polyp / SMF Polyp / SMF    Resection LNG-IUS 
  Fibroids <12    LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
  ED Polyp / SMF   Resection LNG-IUS 
  DUB    LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
 Fibroids <12 Fibroids < 12    LNG-IUS EA 
  Polyp / SMF    Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
  ED Normal 
endometrium 
  LNG-IUS EA 
  DUB    LNG-IUS EA 
        
 Fibroids >12 Fibroids >12 >12 by 
bimanual exam 
  Hysterectomy GP appt 
   <12 by 
bimanual exam 
  LNG-IUS EA 
  Polyp / SMF >12 by 
bimanual exam 
  Hysterectomy GP appt 
   <12 by 
bimanual exam 
  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
  Fibroids <12 >12 by 
bimanual exam 
  Hysterectomy GP appt 
   <12 by 
bimanual exam 
  LNG-IUS EA 
 ED ED Hyperplasia   LNG-IUS Hysterectomy 
   Cancer   Hysterectomy GP appt 
  Polyp / SMF    Resection- histology 
shows hyperplasia / 
cancer so get LNG-IUS/ 
hysterectomy 
Hysterectomy / 
GP visit 
  Fibroids <12    LNG-IUS Hysterectomy as 
EBx prior to EA 
shows ED 
  DUB    LNG-IUS Hysterectomy as 
EBx prior to EA 
shows ED 
 DUB DUB    LNG-IUS EA 
  Polyp / SMF    Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
  Fibroids <12    LNG-IUS EA 
  ED Normal 
endometrium 
  LNG-IUS EA 
        
EBx alone Polyp / SMF Polyp / SMF    Resection LNG-IUS 
  DUB    LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
  Complex 
hyperplasia 
   LNG-IUS Hysterectomy 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
 Fibroids <12 Normal cavity    LNG-IUS EA 
  Polyp / SMF    Resection but no lesion 
seen so LNG-IUS 
inserted 
EA 
  Complex 
hyperplasia 
   LNG-IUS Hysterectomy 
 Fibroids > 12 Normal cavity >12 by 
bimanual exam 
  Hysterectomy  GP appt 
   <12 by 
bimanual exam 
  LNG-IUS EA 
  Polyp / SMF >12 by 
bimanual exam 
  Hysterectomy  GP appt 
   <12 by 
bimanual exam 
  Resection but no lesion 
seen so LNG-IUS 
inserted 
EA 
  Complex 
hyperplasia 
>12 by 
bimanual exam 
  Hysterectomy  GP appt 
   <12 by 
bimanual exam 
  LNG-IUS Hysterectomy 
 ED Complex 
hyperplasia 
   LNG-IUS Hysterectomy 
  Atypia / 
cancer 
   Hysterectomy  GP appt 
  Polyp / SMF    Resection- histology 
shows hyperplasia / 
cancer so get LNG-IUS/ 
hysterectomy 
Hysterectomy / 
GP visit 
  DUB    LNG-IUS Hysterectomy as 
BX prior to EA 
shows ED 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
 DUB Normal cavity    LNG-IUS EA 
  Polyp / SMF    Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
        
OPH and EBx Polyp / SMF Polyp / SMF Polyp / SMF   Resection LNG-IUS 
   DUB   Resection LNG-IUS 
   Complex 
hyperplasia 
  Resection followed by 
LNG-IUS 
Hysterectomy 
  ED Polyp / SMF   LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
   DUB   LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
   Complex 
hyperplasia 
  LNG-IUS Hysterectomy 
  Normal cavity Polyp / SMF   LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
   DUB   LNG-IUS EA 
   Complex 
hyperplasia 
  LNG-IUS Hysterectomy 
 Fibroids <12 DUB DUB   LNG-IUS EA 
   Polyp / SMF   LNG-IUS EA 
   Complex 
hyperplasia 
  LNG-IUS Hysterectomy 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
  Polyp / SMF DUB   Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   Polyp / SMF   Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   Complex 
hyperplasia 
  Resection followed by 
LNG-IUS 
Hysterectomy 
  ED DUB   LNG-IUS EA 
   Polyp / SMF   LNG-IUS EA 
   Complex 
hyperplasia 
  LNG-IUS Hysterectomy 
 Fibroids >12 DUB DUB >12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  LNG-IUS EA 
   Polyp / SMF >12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  LNG-IUS EA 
   Complex 
Hyperplasia 
>12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  LNG-IUS Hysterectomy 
  Polyp / SMF DUB >12 by bimanual exam Hysterectomy GP appt 
    <12 by bimanual exam Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   Polyp / SMF >12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   Complex 
Hyperplasia 
>12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  Resection followed by 
LNG-IUS 
Hysterectomy 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
  ED DUB >12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  LNG-IUS EA 
   Polyp / SMF >12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  LNG-IUS EA 
   Complex 
Hyperplasia 
>12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  LNG-IUS Hysterectomy 
 ED ED Complex 
hyperplasia 
  LNG-IUS Hysterectomy 
   Cancer / atypia   Hysterectomy GP appt 
   Polyp /SMF   LNG-IUS Hysterectomy as 
pre ablation EBx 
shows ED 
   DUB   LNG-IUS Hysterectomy as 
pre ablation EBx 
shows ED 
  Polyp / SMF Complex 
hyperplasia 
  Resection followed by 
LNG-IUS 
Hysterectomy 
   Cancer / atypia   Hysterectomy GP appt 
   Polyp /SMF   Resection but histology 
shows complex 
hyperplasia / cancer so 
LNG-IUS/hysterectomy 
Hysterectomy / 
GP appt 
   DUB   Resection but histology 
shows complex 
hyperplasia / cancer so 
LNG-IUS/hysterectomy 
Hysterectomy / 
GP appt 
  DUB Complex 
hyperplasia 
  LNG-IUS Hysterectomy 
   Cancer / atypia   Hysterectomy GP appt 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
   Polyp /SMF   LNG-IUS Hysterectomy as 
pre ablation EBx 
shows ED 
   DUB   LNG-IUS Hysterectomy as 
pre ablation EBx 
shows ED 
 DUB DUB DUB   LNG-IUS EA 
   Polyp /SMF   LNG-IUS EA 
  Polyp/SMF DUB   Resection followed by 
LNG-IUS 
EA 
   Polyp /SMF   Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
  ED DUB   LNG-IUS EA 
   Polyp /SMF   LNG-IUS EA 
        
SIS and EBx 
and 
TVS and EBx 
Polyp/SMF Polyp/SMF Polyp/SMF   Resection LNG-IUS 
   DUB   Resection LNG-IUS 
   Complex 
hyperplasia 
  Resection followed by 
LNG-IUS 
Hysterectomy 
  Fibroids <12 Polyp/SMF   Resection LNG-IUS 
   DUB   LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
   Complex 
hyperplasia 
  LNG-IUS Hysterectomy 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
  ED Polyp/SMF   Resection LNG-IUS 
   DUB   LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
   Complex 
hyperplasia 
  LNG-IUS Hysterectomy 
  DUB Polyp/SMF   LNG IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
LNG-IUS 
   DUB   LNG-IUS Resection- lesion 
diagnosed at pre-
ablation  
   Complex 
hyperplasia 
  LNG-IUS Hysterectomy 
 Fibroids <12 Fibroids <12 DUB   LNG-IUS EA 
   Polyp/SMF   Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   Complex 
hyperplasia 
  LNG-IUS Hysterectomy 
  Polyp / SMF DUB   Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   Polyp/SMF   Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
   Complex 
hyperplasia 
  Resection but as normal 
endometrium LNG-IUS 
inserted 
Hysterectomy 
  ED DUB   LNG-IUS EA 
   Polyp/SMF   Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   Complex 
hyperplasia 
  LNG-IUS Hysterectomy 
  DUB DUB   LNG-IUS EA 
   Polyp/SMF   LNG-IUS EA 
   Complex 
hyperplasia 
  LNG-IUS Hysterectomy 
 Fibroids >12 Fibroid >12 DUB >12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  LNG-IUS EA 
   Polyp/SMF >12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   Complex 
hyperplasia 
>12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  LNG-IUS Hysterectomy 
  Polyp / SMF DUB >12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   Polyp/SMF >12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
   Complex 
hyperplasia 
>12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  Resection followed by 
LNG-IUS  
Hysterectomy 
  Fibroid  <12 DUB >12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  LNG-IUS EA 
   Polyp/SMF >12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   Complex 
hyperplasia 
>12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  LNG-IUS Hysterectomy 
 ED ED Complex 
hyperplasia 
  LNG-IUS Hysterectomy 
   Cancer / atypia   Hysterectomy GP appt 
   Polyp / SMF   Resection but histology 
shows complex 
hyperplasia / cancer so 
LNG-IUS/hysterectomy 
Hysterectomy / 
GP appt 
   DUB   LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
  Polyp / SMF Complex 
hyperplasia 
  Resection followed by 
LNG-IUS 
Hysterectomy 
   Cancer / atypia   Resection followed by 
hysterectomy 
GP appt 
   Polyp / SMF   Resection but histology 
shows complex 
hyperplasia / cancer so 
LNG-IUS/hysterectomy 
Hysterectomy / 
GP appt 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
   DUB   Resection but histology 
shows complex 
hyperplasia / cancer so 
LNG-IUS/hysterectomy 
Hysterectomy / 
GP appt 
  Fibroids < 12 Complex 
hyperplasia 
  LNG-IUS Hysterectomy 
   Cancer / atypia   Hysterectomy GP appt 
   Polyp / SMF   Resection but histology 
shows complex 
hyperplasia / cancer so 
LNG-IUS/hysterectomy 
Hysterectomy / 
GP appt 
   DUB   LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
  DUB Complex 
hyperplasia 
  LNG-IUS Hysterectomy 
   Cancer / atypia   Hysterectomy GP appt 
   Polyp / SMF   LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
   DUB   LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
 DUB DUB DUB   LNG-IUS EA 
   Polyp / SMF   LNG-IUS EA 
  Polyps / SMF DUB   Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   Polyp / SMF   Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
  Fibroids < 12 DUB   LNG-IUS EA 
   Polyp / SMF   Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
  ED DUB   LNG-IUS EA 
   Polyp / SMF   Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
        
SIS and OPH 
and 
TVS and OPH 
Polyp / SMF Polyp / SMF Polyp / SMF   Resection LNG-IUS 
   ED Polyp/SMF  LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
   DUB   LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
  Fibroid <12 Polyp / SMF   Resection LNG-IUS 
   ED Polyp / SMF  LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy  
   DUB   LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
  ED Polyp / SMF   Resection LNG-IUS 
   ED Polyp / SMF  LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
   DUB   LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
  DUB Polyp / SMF   Resection LNH-IUS 
   ED Polyp / SMF  LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
   DUB   LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
 Fibroids <12 Fibroids  <12 DUB   LNG-IUS EA 
   Polyp / SMF   Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   ED Normal endometrium  LNG-IUS EA 
  Polyp / SMF DUB   LNG-IUS EA 
   Polyp / SMF   Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   ED Normal endometrium  LNG-IUS EA 
  ED DUB Normal endometrium  LNG-IUS EA 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
   Polyp / SMF   Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   ED Normal endometrium  LNG-IUS EA 
  DUB DUB   LNG-IUS EA 
   Polyp / SMF   Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   ED Normal endometrium  LNG-IUS EA 
 Fibroids >12 Fibroids > 12 DUB >12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  LNG-IUS EA 
   Polyp / SMF >12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   ED >12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam Normal 
endometrium 
LNG-IUS EA 
  Polyp / SMF DUB >12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  LNG-IUS EA 
   Polyp / SMF >12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   ED >12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam Normal 
endometrium 
LNG-IUS EA 
  Fibroid <12 DUB >12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  LNG-IUS EA 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
   Polyp / SMF >12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   ED >12 by bimanual exam  Hysterectomy GP appt 
    <12 by bimanual exam Normal 
endometrium 
LNG-IUS EA 
 ED ED ED Complex hyperplasia  LNG-IUS Hysterectomy 
    Cancer / atypia  Hysterectomy GP appt 
   Polyp / SMF   Resection but histology 
shows complex 
hyperplasia / cancer so 
LNG-IUS/hysterectomy 
Hysterectomy / 
GP appt 
   DUB Complex hyperplasia  LNG-IUS Hysterectomy 
    Cancer / atypia  Hysterectomy GP appt 
  Polyp / SMF ED Complex hyperplasia  LNG-IUS Hysterectomy 
    Cancer / atypia  Hysterectomy GP appt 
   Polyp / SMF   Resection but histology 
shows complex 
hyperplasia / cancer so 
LNG-IUS/hysterectomy 
Hysterectomy / 
GP appt 
   DUB   LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
  Fibroid  <12 ED Complex hyperplasia  LNG-IUS Hysterectomy 
    Cancer / atypia  Hysterectomy GP appt 
   Polyp / SMF   Resection but histology 
shows complex 
hyperplasia / cancer so 
LNG-IUS/hysterectomy 
Hysterectomy / 
GP appt 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
   DUB   LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
  DUB ED Complex hyperplasia  LNG-IUS Hysterectomy 
    Cancer / atypia  Hysterectomy GP appt 
   Polyp / SMF   Resection but histology 
shows complex 
hyperplasia / cancer so 
LNG-IUS/hysterectomy 
Hysterectomy / 
GP appt 
   DUB   LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
 DUB DUB DUB   LNG-IUS EA 
   Polyp / SMF   Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   ED Normal endometrium  LNG-IUS EA 
  Polyp / SMF DUB   LNG-IUS EA 
   Polyp / SMF   Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   ED Normal endometrium  LNG-IUS EA 
  Fibroids <12 DUB   LNG-IUS 
   Polyp / SMF   Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   ED Normal endometrium  LNG-IUS EA 
  ED DUB Normal endometrium  LNG-IUS EA 
   Polyp / SMF   Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   ED Normal endometrium  LNG-IUS EA 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
SIS and OPH 
and EBx 
and 
TVS and OPH 
and EBx 
Polyp / SMF Polyp / SMF Polyp / SMF Polyp / SMF  Resection LNG-IUS 
    DUB  Resection LNG-IUS 
    Complex hyperplasia  Resection followed by 
LNG-IUS 
Hysterectomy 
   ED Polyp / SMF  LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
    DUB  LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
    Complex hyperplasia  LNG-IUS Hysterectomy 
   DUB Polyp / SMF  LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
    DUB  LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
    Complex hyperplasia  LNG-IUS Hysterectomy 
  Fibroids <12 Polyp / SMF Polyp / SMF  Resection LNG-IUS 
    DUB  Resection LNG-IUS 
    Complex hyperplasia  Resection followed by 
LNG-IUS 
Hysterectomy 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
   ED Polyp / SMF  LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
    DUB  LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
    Complex hyperplasia  LNG-IUS Hysterectomy 
   DUB Polyp / SMF  LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
    DUB  LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
    Complex hyperplasia  LNG-IUS Hysterectomy 
  ED Polyp / SMF Polyp / SMF  Resection LNG-IUS 
    DUB  Resection LNG-IUS 
    Complex hyperplasia  Resection followed by 
LNG-IUS 
Hysterectomy 
   ED Polyp / SMF  LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
    DUB  LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
    Complex hyperplasia  LNG-IUS Hysterectomy 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
   DUB Polyp / SMF  LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
    DUB  LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
    Complex hyperplasia  LNG-IUS Hysterectomy 
  DUB Polyp / SMF Polyp / SMF  Resection LNG-IUS 
    DUB  Resection LNG-IUS 
    Complex hyperplasia  Resection followed by 
LNG-IUS 
Hysterectomy 
   ED Polyp / SMF  LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
    DUB  LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
    Complex hyperplasia  LNG-IUS Hysterectomy 
   DUB Polyp / SMF  LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
    DUB  LNG-IUS Resection- lesion 
diagnosed at pre-
ablation 
hysteroscopy 
    Complex hyperplasia  LNG-IUS Hysterectomy 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
    Polyp / SMF  LNG-IUS EA 
    Complex hyperplasia  LNG-IUS Hysterectomy 
   Polyp / SMF DUB  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
    Polyp / SMF  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
    Complex hyperplasia  Resection followed by 
LNG-IUS 
Hysterectomy 
   ED DUB  LNG-IUS EA 
    Polyp / SMF  LNG-IUS EA 
    Complex hyperplasia  LNG-IUS Hysterectomy 
  Polyp / SMF DUB DUB  LNG-IUS EA 
    Polyp / SMF  LNG-IUS EA 
    Complex hyperplasia  LNG-IUS Hysterectomy 
   Polyp / SMF DUB  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
    Polyp / SMF  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
    Complex hyperplasia  Resection followed by 
LNG-IUS 
Hysterectomy 
   ED DUB  LNG-IUS EA 
    Polyp / SMF  LNG-IUS EA 
    Complex hyperplasia  LNG-IUS Hysterectomy 
  ED DUB DUB  LNG-IUS EA 
    Polyp / SMF  LNG-IUS EA 
    Complex hyperplasia  LNG-IUS Hysterectomy 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
   Polyp / SMF DUB  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
    Polyp / SMF  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
    Complex hyperplasia  Resection followed by 
LNG-IUS 
Hysterectomy 
   ED DUB  LNG-IUS EA 
    Polyp / SMF  LNG-IUS EA 
    Complex hyperplasia  LNG-IUS Hysterectomy 
  DUB DUB DUB  LNG-IUS EA 
    Polyp / SMF  LNG-IUS EA 
    Complex hyperplasia  LNG-IUS Hysterectomy 
   Polyp / SMF DUB  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
    Polyp / SMF  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
    Complex hyperplasia  Resection followed by 
LNG-IUS 
Hysterectomy 
   ED DUB  LNG-IUS EA 
    Polyp / SMF  LNG-IUS EA 
    Complex hyperplasia  LNG-IUS Hysterectomy 
 Fibroids > 12 Fibroids > 12 DUB DUB >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
LNG-IUS EA 
    Polyp / SMF >12 by 
bimanual exam 
Hysterectomy  GP appt 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
     <12 by 
bimanual exam 
LNG-IUS EA 
    Complex hyperplasia >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
LNG-IUS Hysterectomy 
   Polyp / SMF DUB >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
    Polyp / SMF >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
    Complex hyperplasia >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
Resection followed by 
LNG-IUS 
Hysterectomy 
   ED DUB >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
LNG-IUS EA 
    Polyp / SMF >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
LNG-IUS EA 
    Complex hyperplasia >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
LNG-IUS Hysterectomy 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
  Polyp / SMF DUB DUB >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
LNG-IUS EA 
    Polyp / SMF >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
LNG-IUS EA 
    Complex hyperplasia >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
LNG-IUS Hysterectomy 
   Polyp / SMF DUB >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
Resection but as 
normal endometrium 
LNG-IUS inserted 
EA 
    Polyp / SMF >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
    Complex hyperplasia >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
Resection followed by 
LNG-IUS 
Hysterectomy 
   ED DUB >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
LNG-IUS EA 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
    Polyp / SMF >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
LNG-IUS EA 
    Complex hyperplasia >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
LNG-IUS Hysterectomy 
  Fibroids < 12  DUB DUB >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
LNG-IUS EA 
    Polyp / SMF >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
LNG-IUS EA 
    Complex hyperplasia >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
LNG-IUS Hysterectomy 
   Polyp / SMF DUB >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
    Polyp / SMF >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
    Complex hyperplasia >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
Resection followed by 
LNG-IUS 
Hysterectomy 
   ED DUB >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
LNG-IUS EA 
    Polyp / SMF >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
LNG-IUS EA 
    Complex hyperplasia >12 by 
bimanual exam 
Hysterectomy  GP appt 
     <12 by 
bimanual exam 
LNG-IUS Hysterectomy 
 ED ED ED Complex hyperplasia  LNG-IUS Hysterectomy 
    Cancer / atypia  Hysterectomy  GP appt 
    Polyp / SMF  LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
    DUB  LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
   Polyp / SMF Complex hyperplasia  Removal followed by 
LNG-IUS 
Hysterectomy 
    Cancer / atypia  Removal followed by 
hysterectomy 
GP appt 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
    Polyp / SMF  Resection but histology 
shows complex 
hyperplasia / cancer so 
LNG-IUS/hysterectomy 
Hysterectomy / 
GP appt 
    DUB  Resection but histology 
shows complex 
hyperplasia / cancer so 
LNG-IUS/hysterectomy 
Hysterectomy / 
GP appt 
   DUB Complex hyperplasia  LNG-IUS Hysterectomy 
    Cancer / atypia  Hysterectomy  GP appt 
    Polyp / SMF  LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
    DUB  LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
  Polyp / SMF ED Complex hyperplasia  LNG-IUS Hysterectomy 
    Cancer / atypia  Hysterectomy  GP appt 
    Polyp / SMF  LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
    DUB  LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
   Polyp / SMF Complex hyperplasia  LNG-IUS Hysterectomy 
    Cancer / atypia  Hysterectomy  GP appt 
    Polyp / SMF  Resection but histology 
shows complex 
hyperplasia / cancer so 
LNG-IUS/hysterectomy 
Hysterectomy / 
GP appt 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
    DUB  Resection but histology 
shows complex 
hyperplasia / cancer so 
LNG-IUS/hysterectomy 
Hysterectomy / 
GP appt 
   DUB Complex hyperplasia  LNG-IUS Hysterectomy 
    Cancer / atypia  Hysterectomy  GP appt 
    Polyp / SMF  LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
    DUB  LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
  Fibroids <12 ED Complex hyperplasia  LNG-IUS Hysterectomy 
    Cancer / atypia  Hysterectomy  GP appt 
    Polyp / SMF  LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
    DUB  LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
   Polyp / SMF Complex hyperplasia  Removal followed by 
LNG-IUS 
Hysterectomy 
    Cancer / atypia  Removal followed by 
hysterectomy  
GP appt 
    Polyp / SMF  Resection but histology 
shows complex 
hyperplasia / cancer so 
LNG-IUS/hysterectomy 
Hysterectomy / 
GP appt 
        
348 
 
A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
    DUB  Resection but histology 
shows complex 
hyperplasia / cancer so 
LNG-IUS/hysterectomy 
Hysterectomy / 
GP appt 
   DUB Complex hyperplasia  LNG-IUS Hysterectomy 
    Cancer / atypia  Hysterectomy  GP appt 
    Polyp / SMF  LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
    DUB  LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
  DUB ED Complex hyperplasia  LNG-IUS Hysterectomy 
    Cancer / atypia  Hysterectomy  GP appt 
    Polyp / SMF  LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
    DUB  LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
   Polyp / SMF Complex hyperplasia  LNG-IUS Hysterectomy 
    Cancer / atypia  Hysterectomy  GP appt 
    Polyp / SMF  Resection but histology 
shows complex 
hyperplasia / cancer so 
LNG-IUS/hysterectomy 
Hysterectomy / 
GP appt 
    DUB  Resection but histology 
shows complex 
hyperplasia / cancer so 
LNG-IUS/hysterectomy 
Hysterectomy / 
GP appt 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
   DUB Complex hyperplasia  LNG-IUS Hysterectomy 
    Cancer / atypia  Hysterectomy  GP appt 
    Polyp / SMF  LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
    DUB  LNG-IUS Hysterectomy as 
pre-ablation 
testing shows ED 
 DUB DUB DUB DUB  LNG-IUS EA 
    Polyp / SMF  LNG-IUS EA 
   Polyp / SMF DUB  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
    Polyp / SMF  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   ED DUB  LNG-IUS EA 
    Polyp / SMF  LNG-IUS EA 
  Polyp / SMF DUB DUB  LNG-IUS EA 
    Polyp / SMF  LNG-IUS EA 
   Polyp / SMF DUB  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
    Polyp / SMF  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   ED DUB  LNG-IUS EA 
    Polyp / SMF  LNG-IUS EA 
  Fibroid <12 DUB DUB  LNG-IUS EA 
    Polyp / SMF  LNG-IUS EA 
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A6.2 continued       
Strategy True 
pathology 
Diagnosis 
from test 1 
Diagnosis 
from test 2 
Diagnosis from test 3  First Treatment Second treatment 
        
   Polyp / SMF DUB  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
    Polyp / SMF  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   ED DUB  LNG-IUS EA 
    Polyp / SMF  LNG-IUS EA 
  ED DUB DUB  LNG-IUS EA 
    Polyp / SMF  LNG-IUS EA 
   Polyp / SMF DUB  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
    Polyp / SMF  Resection but as normal 
endometrium LNG-IUS 
inserted 
EA 
   ED DUB  LNG-IUS EA 
    Polyp / SMF  LNG-IUS EA 
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APPENDIX 7 
Search strategies for collection of data to populate the decision trees for the 
economic analysis of heavy menstrual bleeding 
 
A7.1a Medline search strategy for prevalence of endometrial polyps 
1 endometrial.ti,ab  
2 endometr*.ti,ab  
3 uterine.ti,ab  
4 uter*.ti,ab  
5 exp UTERINE DISEASES/  
6 uterus.ti,ab  
7 exp UTERUS/  
8 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7  
9 polyp.ti,ab  
10 polyp*.ti,ab  
11 exp POLYPS/  
12 9 OR 10 OR 11  
13 8 AND 12  
14 hysteroscopy.ti,ab  
15 exp HYSTEROSCOPY/  
16 hysteroscop*.ti,ab  
17 14 OR 15 OR 16  
18 sensitiv*.ti,ab  
19 exp "SENSITIVITY AND SPECIFICITY"/  
20 diagnos*.ti,ab  
21 DIAGNOSIS/  
22 diagnostic*.ti,ab  
23 DIAGNOSIS, DIFFERENTIAL/  
24 *DIAGNOSIS/  
25 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24  
26 13 AND 17 AND 25  
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A7.1b Embase search strategy for prevalence of endometrial polyps 
1 endometrial.ti,ab  
2 endometr*.ti,ab  
3 exp ENDOMETRIAL DISEASE/  
4 uter*.ti,ab  
5 uterine.ti,ab  
6 exp UTERUS/  
7 uterus.ti,ab  
8 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7  
9 polyp.ti,ab  
10 polyp*.ti,ab  
11 exp POLYP/ OR exp ENDOMETRIUM POLYP/  
12 9 OR 10 OR 11  
18 8 AND 12  
19 hysteroscopy.ti,ab  
20 exp HYSTEROSCOPY/  
21 hysteroscop*.ti,ab  
22 19 OR 20 OR 21  
23 18 AND 22  
24 sensitiv*.ti,ab  
25 exp "SENSITIVITY AND SPECIFICITY"/  
26 diagnos*.ti,ab  
27 DIAGNOSIS/  
28 DIFFERENTIAL DIAGNOSIS/  
29 DIAGNOSTIC TEST/  
30 24 OR 25 OR 26 OR 27 OR 28 OR 29  
31 18 AND 30  
32 22 AND 31  
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A7.2a Medline search strategy for prevalence of fibroids 
1 prevalence.ti,ab  
2 exp PREVALENCE/  
3 1 OR 2  
4 exp LEIOMYOMA/  
5 fibroid.ti,ab  
6 leiomyoma.ti,ab  
7 exp MYOMA/  
8 fibromyoma.ti,ab  
9 leiofibromyoma.ti,ab  
10 fibroleiomyoma.ti,ab  
11 fibroma.ti,ab  
12 exp FIBROMA/  
13 myoma*.ti,ab  
14 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13  
15 sonogr*.ti,ab  
16 hysterosonogr*.ti,ab  
17 ultrasound.ti,ab  
18 exp ULTRASONOGRAPHY/  
19 ((transvaginal scan)).ti,ab  
20 hysterosco*.ti,ab  
21 exp HYSTEROSCOPY/  
22 sonohyster*.ti,ab  
23 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22  
24 3 AND 14 AND 23  
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A7.2b Embase search strategy for prevalence of fibroids 
1 prevalence.ti,ab  
2 exp PREVALENCE/  
3 fibroid*.ti,ab  
4 exp LEIOMYOMA/ OR exp UTERUS MYOMA/  
5 leiomyoma.ti,ab  
6 myoma*.ti,ab  
7 exp MYOMA/  
8 fibromyoma.ti,ab  
9 leiofibromyoma.ti,ab  
10 fibroleiomyoma.ti,ab  
11 fibroma.ti,ab  
12 exp FIBROMA/  
13 1 OR 2  
14 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12  
15 sonogra*.ti,ab  
16 hysterosonogra*.ti,ab  
17 sonohyster*.ti,ab  
18 ultrasound.ti,ab  
19 exp ULTRASOUND/  
20 ((transvaginal scan)).ti,ab  
21 hysterosco*.ti,ab  
22 exp HYSTEROSCOPY/  
23 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22  
24 13 AND 14 AND 23  
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A7.3a Medline search strategy for the prevalence of endometrial hyperplasia 
1 exp HEMORRHAGE/  
2 bleeding.ti,ab  
3 exp BLOOD/  
4 blood.ti,ab  
5 exp MENORRHAGIA/  
6 menorrhagia.ti,ab  
7 menstr*.ti,ab  
8 exp MENSTRUAL CYCLE/  
9 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8  
10 prevalence.ti,ab  
11 exp PREVALENCE/  
12 10 OR 11  
24 uterine.ti,ab  
25 uterus.ti,ab  
26 exp UTERUS/  
27 uter*.ti,ab  
28 endometrial.ti,ab  
29 exp ENDOMETRIAL HYPERPLASIA/  
30 endometr*.ti,ab  
31 hyperplas*.ti,ab  
32 hyperplasia.ti,ab  
33 exp HYPERPLASIA/  
34 24 OR 25 OR 26 OR 27 OR 28 OR 30  
35 29 OR 31 OR 32 OR 33  
37 9 AND 12 AND 34 AND 35  
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A7.3b Embase search strategy for the prevalence of endometrial hyperplasia 
1 hemorrhage.ti,ab  
2 exp BLEEDING/  
3 bleed*.ti,ab  
4 blood*.ti,ab  
5 exp BLOOD/  
6 bleeding.ti,ab  
7 exp MENORRHAGIA/  
8 menorrhagia.ti,ab  
9 menstr*.ti,ab  
10 exp MENSTRUAL CYCLE/  
11 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10  
12 prevalence.ti,ab  
13 exp PREVALENCE/  
14 12 OR 13  
15 uterus.ti,ab  
16 exp UTERUS/  
17 uter*.ti,ab  
18 uterine.ti,ab  
19 endometrial.ti,ab  
20 exp ENDOMETRIAL DISEASE/  
21 endometr*.ti,ab  
22 hyperplas*.ti,ab  
23 exp HYPERPLASIA/ OR exp ENDOMETRIUM HYPERPLASIA/  
24 15 OR 16 OR 17 OR 18 OR 19 OR 21  
25 20 OR 22 OR 23  
26 24 AND 25 
27 11 AND 15 AND 27  
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A7.4a Medline search strategy for the prevalence of endometrial cancer 
1 exp HEMORRHAGE/  
2 bleeding.ti,ab  
3 exp BLOOD/  
4 blood.ti,ab  
5 exp MENORRHAGIA/  
6 menorrhagia.ti,ab  
7 menstr*.ti,ab  
8 exp MENSTRUAL CYCLE/  
9 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13  
10 prevalence.ti,ab  
11 exp PREVALENCE/  
12 15 OR 16  
13 uterine.ti,ab  
14 uterus.ti,ab  
15 exp UTERUS/  
16 uter*.ti,ab  
17 endometrial.ti,ab  
19 endometr*.ti,ab  
20 cancer.ti,ab  
21 exp NEOPLASMS/  
22 malignan*.ti,ab  
23 ((Endometrial cancer)).ti,ab  
24 exp ENDOMETRIAL NEOPLASMS/  
25 13 OR 14 OR 15 OR 16 OR 17 OR 19  
26 20 OR 21 OR 22 OR 23 OR 24  
27 9 AND 12 AND 25 AND 26  
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A7.4b Embase search strategy for the prevalence of endometrial cancer 
1 hemorrhage.ti,ab  
2 exp BLEEDING/  
3 bleed*.ti,ab  
4 blood*.ti,ab  
5 exp BLOOD/  
6 bleeding.ti,ab  
7 exp MENORRHAGIA/  
8 menorrhagia.ti,ab  
9 menstr*.ti,ab  
10 exp MENSTRUAL CYCLE/  
11 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10  
12 prevalence.ti,ab  
13 exp PREVALENCE/  
14 12 OR 13 
15 uterus.ti,ab  
16 exp UTERUS/  
17 uter*.ti,ab  
18 uterine.ti,ab  
19 cancer.ti,ab  
20 exp NEOPLASM/  
21 malignan*.ti,ab  
22 (endometrial AND cancer).ti,ab  
23 endometrial.ti,ab  
24 exp ENDOMETRIAL DISEASE/  
25 endometr*.ti,ab  
26 15 OR 16 OR 17 OR 18 OR 23 OR 24 OR 25  
27 19 OR 20 OR 21  
28 26 AND 27 
29 22 OR 28  
30 11 AND 14 AND 29  
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A7.5a Medline search strategy for reviews of outpatient hysteroscopy 
1 exp HYSTEROSCOPY/  
2 hysteroscopy.ti,ab  
3 hysteroscop*.ti,ab  
4 1 OR 2 OR 3  
5 4 [Limit to: Review Articles]  
 
 
A7.5b Embase search strategy for reviews of outpatient hysteroscopy 
1 exp HYSTEROSCOPY/  
2 hysteroscopy.ti,ab  
3 hysteroscop*.ti,ab  
4 1 OR 2 OR 3  
5 4 [Limit to: (Publication Types Review)]  
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A7.6a Medline search strategy for studies of transvaginal ultrasound and heavy 
menstrual bleeding 
1 (transvaginal AND ultrasound).ti,ab  
2 exp ULTRASONOGRAPHY/  
3 sonogra*.ti,ab  
4 transvaginal.ti,ab  
5 vaginal.ti,ab  
6 2 OR 3  
7 4 OR 5  
8 6 AND 7  
9 1 OR 8  
10 "abnormal uterine bleeding".ti,ab  
11 exp METRORRHAGIA/ OR exp MENORRHAGIA/  
12 menorrhagia.ti,ab  
13 10 OR 11 OR 12  
14 9 AND 13  
 
A7.6b Embase search strategy for studies of transvaginal ultrasound and heavy 
menstrual bleeding 
1 (transvaginal AND ultrasound).ti,ab  
2 exp ULTRASOUND/  
3 sonogra*.ti,ab  
4 transvaginal.ti,ab  
5 vaginal.ti,ab  
6 4 OR 5  
7 2 OR 3  
8 6 AND 7  
9 1 OR 8  
10 exp MENORRHAGIA/ OR exp UTERUS BLEEDING/  
11 "abnormal uterine bleeding".ti,ab  
12 menorrhagia.ti,ab  
13 10 OR 11 OR 12  
14 9 AND 13  
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A7.7a Medline search strategy for studies of saline infusion sonography and heavy 
menstrual bleeding 
1 exp MENORRHAGIA/  
2 menorrhagia.ti,ab  
3 hypermenorrhea.ti,ab  
4 (heavy ADJ menstrual ADJ bleeding).ti,ab  
5 (heavy ADJ menstrua*).ti,ab  
6 "abnormal uterine bleeding".ti,ab  
7 1 OR 2 OR 3 OR 4 OR 5 OR 6  
8 exp SODIUM CHLORIDE/ AND exp ULTRASONOGRAPHY/  
9 (saline AND infusion AND sonography).ti,ab  
10 (sono AND hysterosonography).ti,ab  
11 (saline AND hysterosonography).ti,ab  
12 (saline AND hysterography).ti,ab  
13 sonohysterography.ti,ab  
14 8 OR 9 OR 10 OR 11 OR 12 OR 13  
15 7 AND 14  
 
A7.7b Embase search strategy for studies of saline infusion sonography and heavy 
menstrual bleeding 
1 exp MENORRHAGIA/  
2 menorrhagia.ti,ab  
3 hypermenorrhea.ti,ab  
4 (heavy ADJ menstrual ADJ bleeding).ti,ab  
5 (heavy ADJ menstrua*).ti,ab  
6 "abnormal uterine bleeding".ti,ab  
7 1 OR 2 OR 3 OR 4 OR 5 OR 6  
8 exp SODIUM CHLORIDE/ AND exp ULTRASONOGRAPHY/  
9 (saline AND infusion AND sonography).ti,ab  
10 (sono AND hysterosonography).ti,ab  
11 (saline AND hysterosonography).ti,ab  
12 (saline AND hysterography).ti,ab  
13 sonohysterography.ti,ab  
14 8 OR 9 OR 10 OR 11 OR 12 OR 13  
15 7 AND 14  
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A7.8a Medline search strategy for reviews of endometrial biopsy 
1 (endometrial AND biopsy).ti,ab  
2 exp ENDOMETRIUM/  
3 endometr*.ti,ab  
4 exp BIOPSY/  
5 biopsy.ti,ab  
6 sampling.ti,ab  
7 2 OR 3  
8 4 OR 5 OR 6  
9 7 AND 8  
10 1 OR 9  
11 10 [Limit to: Review Articles]  
 
A7.8b Embase search strategy for reviews of endometrial biopsy 
1 (endometrial AND biopsy).ti,ab  
2 exp ENDOMETRIUM BIOPSY/  
3 exp ENDOMETRIUM/  
4 endometr*.ti,ab  
5 biopsy.ti,ab  
6 exp BIOPSY/  
7 sampling.ti,ab  
8 exp SAMPLING/  
9 5 OR 6 OR 7 OR 8  
10 3 OR 4  
11 9 AND 10  
12 1 OR 2 OR 11  
13 12 [Limit to: (Publication Types Review)]  
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A7.9a Medline search strategy for studies of LNG-IUS for heavy menstrual bleeding 
1 menorrhag*.ti,ab  
2 exp MENORRHAGIA/  
3 "heavy menstrual blee*".ti,ab  
4 menometrorrhagia.ti,ab  
5 METRORRHAGIA/  
6 hypermenorrh*.ti,ab  
7 1 OR 2 OR 3 OR 4 OR 5 OR 6  
8 mirena.ti,ab  
9 exp LEVONORGESTREL/  
10 "intrauterine device".ti,ab  
11 "intrauterine system".ti,ab  
12 INTRAUTERINE DEVICES, MEDICATED/ OR INTRAUTERINE 
DEVICES/  
13 IUS.ti,ab  
14 IUD.ti,ab  
15 LNG-IUS.ti,ab  
16 levonorgestrel-releasing.ti,ab  
17 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16  
18 7 AND 17  
 
A7.9b Embase search strategy for studies of LNG-IUS for heavy menstrual bleeding 
1 menorrhag*.ti,ab  
2 exp MENORRHAGIA/  
3 "heavy menstrual bleed*".ti,ab  
4 exp MENSTRUATION DISORDER/  
5 menometorrhagia.ti,ab  
6 hypermenorrh*.ti,ab  
7 1 OR 2 OR 3 OR 4 OR 5 OR 6  
8 mirena.ti,ab  
9 exp LEVONORGESTREL/  
10 "intrauterine system".ti,ab  
11 IUS.ti,ab  
12 LNG-IUS.ti,ab  
13 IUD.ti,ab  
14 "intrauterine device".ti,ab  
15 levonorgestrel-releasing.ti,ab  
16 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15  
17 7 AND 16  
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A7.10a Medline search strategy for patient satisfaction after endometrial ablation 
1 "endometrial ablation".ti,ab  
2 exp ENDOMETRIAL ABLATION TECHNIQUES/  
3 satisfaction.ti,ab  
4 exp PATIENT SATISFACTION/  
5 1 OR 2  
6 3 OR 4  
7 5 AND 6  
 
A7.10b Embase search strategy for patient satisfaction after endometrial ablation 
1 "endometrial ablation".ti,ab  
2 exp ENDOMETRIUM ABLATION/  
3 satisfaction.ti,ab  
4 exp PATIENT SATISFACTION/ OR exp SATISFACTION/  
5 3 OR 4  
6 1 OR 2  
7 5 AND 6  
 
 
A7.10c Medline search for endometrial ablation and fibroids 
1 fibroid*.ti,ab  
2 UTERUS MYOMA/ OR LEIOMYOMA/  
3 myoma.ti,ab  
4 leiomyoma.ti,ab  
5 1 OR 2 OR 3 OR 4  
6 (endometrial AND ablation).ti,ab  
7 exp ENDOMETRIAL ABLATION TECHNIQUES/  
7 6 OR 7  
9 5 AND 8  
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A7.10d Embase search for endometrial ablation and fibroids 
1 ((endometrial ablation)).ti,ab  
2 exp ENDOMETRIUM ABLATION/  
3 1 OR 2  
4 fibroid*.ti,ab  
5 UTERUS MYOMA/ OR LEIOMYOMA/  
6 myoma.ti,ab  
7 leiomyoma.ti,ab  
8 4 OR 5 OR 6 OR 7  
9 3 AND 8  
 
A7.11a Medline search strategy for satisfaction with hysterectomy as a treatment for 
fibroids 
1 exp HYSTERECTOMY/  
2 exp LEIOMYOMA/  
3 exp PERSONAL SATISFACTION/  
4 satisfaction.ti,ab  
5 3 OR 4  
6 1 AND 2 AND 5  
 
A7.11b Embase search strategy for satisfaction with hysterectomy as a treatment for 
fibroids 
1 exp HYSTERECTOMY/  
2 exp LEIOMYOMA/  
3 satisfaction.ti,ab  
4 exp SATISFACTION/  
5 3 OR 4  
6 1 AND 2 AND 5  
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A7.12a Medline search strategy for satisfaction after endometrial polypectomy 
1 polypectomy.ti,ab  
2 (endometrial AND polyp).ti,ab  
3 exp POLYPS/ AND exp ENDOMETRIUM/  
4 removal.ti,ab  
5 1 OR 4  
6 2 OR 3  
7 5 AND 6  
 
A7.12b Embase search strategy for satisfaction after endometrial polypectomy 
 
A7.12c Medline search strategy for satisfaction after transcervical resection of a fibroid 
1 (transcervical AND resection AND fibroid).ti,ab  
2 exp LEIOMYOMA/  
3 (hysteroscopic AND removal).ti,ab  
4 myomectomy.ti,ab  
5 exp GYNECOLOGIC SURGICAL PROCEDURES/  
6 fibroid.ti,ab  
7 (submucosal AND fibroid).ti,ab  
8 submuc*.ti,ab  
9 6 AND 8  
10 2 AND 8  
11 1 OR 3 OR 4 OR 5  
12 7 OR 9 OR 10  
13 11 AND 12  
14 satisf*.ti,ab  
15 satisfaction.ti,ab  
16 14 OR 15  
17 13 AND 16  
 
1 polypectomy.ti,ab  
2 exp POLYPECTOMY/  
3 (endometrial AND polyp).ti,ab  
4 exp ENDOMETRIUM POLYP/  
5 removal.ti,ab  
6 1 OR 2 OR 5  
7 3 OR 4  
8 6 AND 7  
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A7.12d Embase search strategy for satisfaction after transcervical resection of a fibroid 
1 (transcervical AND resection AND fibroid).ti,ab  
2 fibroid.ti,ab  
3 exp UTERUS MYOMA/ OR exp LEIOMYOMA/  
4 (hysteroscopic AND removal).ti,ab  
5 myomectomy.ti,ab  
6 exp MYOMECTOMY/  
7 submuc*.ti,ab  
8 (submucosal AND fibroid).ti,ab  
9 2 OR 3  
10 7 AND 9  
11 8 OR 10  
12 1 OR 4 OR 5 OR 6  
13 11 AND 12  
14 satisf*.ti,ab  
15 satisfaction.ti,ab  
16 exp SATISFACTION/ OR exp PATIENT SATISFACTION/  
17 14 OR 15 OR 16  
18 13 AND 17  
 
 
A7.13a Medline search strategy for satisfaction after dilatation and curettage 
1 D+C.ti,ab  
2 exp "DILATATION AND CURETTAGE"/  
3 curettage.ti,ab  
4 CURETTAGE/  
5 ((heavy menstrual bleeding)).ti,ab  
6 exp MENORRHAGIA/  
7 5 OR 6  
8 1 OR 2 OR 3 OR 4  
9 7 AND 8  
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A7.13b Embase search strategy for satisfaction after dilatation and curettage 
1 D+C.ti,ab  
2 exp "DILATATION AND CURETTAGE"/  
3 curettage.ti,ab  
4 CURETTAGE/  
5 ((heavy menstrual bleeding)).ti,ab  
6 exp MENORRHAGIA/  
7 5 OR 6  
8 1 OR 2 OR 3 OR 4  
9 7 AND 8  
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A7.14a Medline search strategy for satisfaction after uterine artery embolisation 
1 "uterine artery embolis*".ti,ab  
2 "uterine artery emboliz*".ti,ab  
3 UAE.ti,ab  
4 exp UTERINE ARTERY EMBOLIZATION/  
5 1 OR 2 OR 3 OR 4  
6 satisfaction.ti,ab  
7 satisf*.ti,ab  
8 6 OR 7  
9 5 AND 8  
 
A7.14b Embase search strategy for satisfaction after uterine artery embolisation 
1 "uterine artery embolis*".ti,ab  
2 "uterine artery emboliz*".ti,ab  
3 UAE.ti,ab  
4 exp UTERINE ARTERY EMBOLIZATION/  
5 1 OR 2 OR 3 OR 4  
6 satisfaction.ti,ab  
7 exp SATISFACTION/ OR exp PATIENT SATISFACTION/  
8 satisf*.ti,ab  
9 6 OR 7 OR 8  
10 5 AND 9  
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A7.15a Medline search strategy for satisfaction after myomectomy 
1 myomectomy.ti,ab  
2 satisf*.ti,ab  
3 2 AND 3  
 
A7.15b Embase search strategy for satisfaction after myomectomy 
1 myomectomy.ti,ab  
2 satisf*.ti,ab  
3 2 AND 3  
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